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Abstract 
 
Striatal medium spiny neurons (MSNs) are the main output from the striatum, a 
subcortical part of the forebrain, which is the main input of the basal ganglia (BG) 
system. 96% of the striatum is composed of MSNs. Huntington’s disease (HD) is 
caused by a progressive loss of MSNs in the striatum. It is caused by polyglutamine 
expansion in the Huntingtin protein (HTT). This impairs cerebral cortex function and 
deregulates several genes that play a role in subpallium development. 
The identification and use of transcription factors (TFs) to direct the 
differentiation of stem cells to MSNs is described. Microarray data analysis of MSNs, 
from data in NCBIs Gene Expression Omnibus (GEO), was performed to detect gene 
expression profiles involved in telencephalon development and striatum maturation. 
The genes Dlx2, Gsx2, Mash1, Pax6, Sox4 and Foxp1 were found to play roles in 
neurogenesis, forebrain neuron fate commitment, cell proliferation, anatomical 
structure morphology, maturation of MSNs and transcriptional activation and 
repression. 
A differentiation protocol was developed in which three TFs, DLX2, GSX2 and 
MASH1, were selected and cloned into expression vectors, in different combinations, 
to direct the differentiation of stem cells into naïve rosette neural progenitor cells 
(nrNPCs). These were then terminally differentiated into striatal MSNs. 
Expression of DLX2, GSX2 and MASH1 in human embryonic stem cell (hESC) 
and induced pluripotent stem cell (iPSC) lines successfully directed their differentiation 
into nrNPCs. iPSC-derived nrNPCs were successfully terminally differentiated into 
DARPP-32+ve MSNs. However, only overexpression of DLX2 and MASH1 in iPSC-
derived nrNPCs yielded functionally active MSNs that expressed DARPP-32, CTIP2, 
FOXP1, EBF1, DRD1, DRD2, GAD2 and CALBIN-1. It was successful and, therefore, 
could provide a new cell source for disease modeling in vitro, transplantation studies 
and drug discovery approaches. 
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In Huntington’s disease (HD), medium spiny neurons (MSNs) in the striatum are 
the population of neurons most affected by the disease, and they are subsequently 
lost. The development of a direct differentiation protocol, to derive MSNs from human 
pluripotent stem cells (hPSCs) would result in the production of unlimited numbers of 
MSNs that can be used for disease modeling and cell transplantation in HD studies in 
order to achieve neural network repair. Therefore, the development of a differentiation 
protocol to derive MSNs from hPSCs is of significant importance. Currently, no efficient 
protocol for directing differentiation of hPSCs into MSNs in vitro or in vivo is available. 
Here, hPSCs (human embryonic stem cells (hESCs) and induced pluripotent stem cells 
(iPSCs)) were used to develop a model for direct differentiation into striatal MSNs. This 
thesis describes the identification and cloning of the transcription factors (TFs) required 
for ventral telencephalon commitment and specification towards lateral ganglionic 
eminence (LGE), the striatum primordium. These were then used to transform hPSCs 
in order to produce mature striatal MSNs.  
 
1.1 Human pluripotent stem cells (hPSCs)  
 
The first hESCs line was derived in 1998, 17 years after the derivation of mouse 
embryonic stem cells (mESCs) (Evans and Kaufman 1981; Martin 1981; Thomson et 
al. 1998). hPSCs, which include hESCs derived from the inner-cell mass (ICM) of a 
blastocyst, and iPSCs, which are reprogrammed from somatic cells, have the ability to 
differentiate into thousands of cell types of the three germ lines (ectoderm, mesoderm 
and endoderm) and preserve their capability of self-renewal (Martin 1981; Evans and 
Kaufman 1981; Thomson et al. 1998; Takahashi and Yamanaka 2006; Takahashi et al. 
2007). Both of these cell types are discussed in the following sections. 
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1.1.1 hESCs 
 
hESCs are derived from pre-implantation embryos and propagated in vitro. The 
important use of hESCs lies in their three fundamental properties, namely their 
unlimited proliferation capacity, the ability to be genetically manipulated and 
differentiated into functional specialised cell types. These characteristics of hESCs 
make them an attractive tool for tissue engineering and repair, or disease modeling, 
which would allow a detailed understanding of underlying disease mechanisms (Chang 
and Cotsarelis 2007).  
 
1.1.2 iPSCs 
 
Human fibroblast cells and a number of other somatic cells can be genetically 
induced into a stem cell-like state. This was first done by the ectopic expression of four 
defined transcription factors (TFs), namely OCT3/4, SOX2, C-MYC and KLF4. These 
reprogrammed cells were termed induced pluripotent stem cells (iPSCs) and can be 
generated by several methods, as shown in Figure 1.1 (Takahashi and Yamanaka 
2006; Takahashi et al. 2007). This successful technology opened new possibilities in 
pluripotent stem cell research, such as establishment of disease-specific iPSCs lines 
for disease modeling, cell-based therapies and tissue engineering.  
While iPSCs and hESCs share key properties, such as morphological 
appearance, unlimited proliferation potential and differentiation capacity (Gao et al. 
2012; Chang and Cotsarelis 2007), iPSCs are ethically more acceptable as the 
procedure for generating iPSCs does not involve the destruction of a human embryo 
(Gao et al. 2012). There is some evidence that iPSCs retain the memory of their parent 
cells (i.e. the somatic cells from which they were generated) and display some of the 
non-CG methylation characteristic of somatic cells in the regions of the centromeres 
and telomeres, resulting in changes in gene expression (Gao et al. 2012; Lister et al. 
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2011). As one example, human iPSCs carrying the mutant Huntington (mHTT) gene 
have been derived and used for cell modelling (Section 1.2.1.1). 
 
Figure 1.1: The established models for generating iPSCs through expression of TFs 
Oct3/4, Sox2, C-Mys and Klf4. 
There are several ways to generate iPSCs from human somatic cells, such as (1) retroviral 
transduction, (2) plasmid transfection, (3) direct programming, (4) mRNA transfection, (5) 
piggyback vectors, (6) the Cre/Loxp system and (7) Minicircle vectors. 
 
1.2 Huntington’s disease (HD): symptoms and pathology 
 
HD is an autosomal dominant inherited neurodegenerative disorder. The 
prevalence of HD is approximately 10 per 100 thousand in the UK (Ross and Tabrizi 
2011). It is characterised by expansion of a tri-nucleotide repeat sequence (cytosine 
adenine guanine-CAGn that encodes polyglutamine) in the Huntington (HTT) gene. 
Mutation occurs in the first exon of the Huntington gene (IT15), which encodes a 350 
kDA HTT protein (Kelly et al. 2009; Connor 2011; Tauber et al. 2011; Benraiss and 
Goldman 2011). Clinically, this disorder is characterised by unconscious movement, 
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cognitive impairment and psychological abnormalities (Walker 2007). Pathologically, it 
is characterised by loss of cortical neurons and striatal MSNs of the caudate nucleus 
and putamen, and abnormal growth of the ventricles and shrinkage of the overlying 
cortex (Figure 1.2) (Walker 2007; Kelly et al. 2009; Tauber et al. 2011; Benraiss and 
Goldman 2011). In the general population, the number of CAG tri-nucleotide repeats in 
the HTT gene is between 6 and 35. However, patients with HD have more than 35 
CAG repeats (Tauber et al. 2011). The number of CAG repeats is linked to the age of 
disease onset. For example, in HD patients with 36 to 60 CAG repeats, the symptoms 
of HD manifest after the age of 35 years, whereas when the number of CAG repeats is 
more than 60, the symptoms of HD become apparent at a much younger age (Benraiss 
and Goldman 2011). In addition, when unaffected mothers and fathers have high 
numbers of CAG repeats, their offspring could be affected, as the CAG repeat is 
unstable on transmission (Ranen et al. 1995). Presently, there is no cure for HD. 
Current treatments are restricted to medications that decrease the symptoms of HD, 
such as, muscle relaxants, antidepressants and anticonvulsants (Ross and Tabrizi 
2011). 
 
Figure 1.2: Comparison between a normal brain and HD brain. 
Frontal section across a human brain, showing the normal adult brain (A), and the HD brain with 
deteriorate in the striatum (caudate nucleus and putamen) and the cerebral cortex (B) Figure 
taken from Benraiss and Goldman 2011. 
 
The HTT protein is essential for normal brain function (Zheng and Diamond 
2012). It undergoes post-translational modifications, such as acetylation and 
A) B) 
Caudate nucleus 
        Putamen Striatum 
Cerebral cortex 
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phosphorylation (Ross and Tabrizi 2011; Zheng and Diamond 2012). Although the 
exact function of HTT protein is still not fully known (Zheng and Diamond 2012), there 
is an increasing body of evidence describing its neuroprotective properties (Rigamonti 
et al. 2000; Cattaneo et al. 2005). The HTT protein can regulate RNA trafficking, gene 
transcription, intracellular trafficking, including membrane recycling, clathrin-mediated 
endocytosis, neuronal transport and postsynaptic signalling (Gutekunst et al. 1995; 
Ross and Tabrizi 2011; Sari 2011). However, the loss of function seen with wild-type 
HTT and the toxic gain of function with mHTT (which has neurotoxic properties) both 
contribute to HD pathogenesis (Cattaneo et al. 2001; Cattaneo et al. 2005). A large 
amount of evidence from both human HD (post-mortem) and animal HD models has 
revealed the different dysfunctional aspects of mHTT, including mitochondrial 
dysfunction (Cui et al. 2006; Kim et al. 2011), impaired axonal transport (Trushina et al. 
2004), altered synaptic transmission, altered protein-protein interaction, glutamate- and 
dopamine-mediated excitotoxicity (Zeron et al. 2002), and most importantly, altered 
expression of transcription factors (Thomas et al. 2011). Such dysfunctional processes 
eventually lead to neuronal death or degeneration in HD (Johri and Beal 2012). Having 
said that a comprehensive understanding of the pathogenic mechanisms, with the aim 
of developing an effective therapy, is still emerging. In this respect, the development of 
cell and gene therapy is being considered as a new therapeutic approach to curing 
diseases such as HD (Zuccato et al. 2010). Therefore, it is of importance to advance 
our knowledge of the cellular and molecular pathophysiology of HD, which becomes 
feasible through the establishment of human HD modelling using HD patient cells. This 
could consequently enhance future development of a cure. 
 
1.2.1 Disease modeling of HD 
 
Disease modeling can shed light on our understanding of the cellular and 
molecular pathogenesis resulting in clinical manifestation of HD. Importantly, better 
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understanding of the disease mechanisms can facilitate the development of a potential 
cell-based therapy and also aid therapeutic drug screening. 
Animal models of HD have been established by expressing whole mHTT or the 
N-terminal fragment that contains expanded polyglutamine (Sipione and Cattaneo 
2001). Several animal models exist including, Caenorhabditis elegans, Drosophila 
melanogaster, mice, rats, sheep, pigs and monkeys (Sipione and Cattaneo 2001). In 
the past few decades, research on animal models of HD has added valuable 
information about HD pathogenesis. Nevertheless, animal models of HD have failed to 
provide a full understanding of HD pathogenesis, and hence it may not be possible to 
use those models to develop therapeutic approaches, which would prevent or slow 
down the HD progression in human subjects; therefore, cell-based models of HD could 
be preferable. 
Several cellular models have been used previously as disease models to mimic 
the aspects of HD in vitro. The first approaches involved using transient expression of 
mHTT in Human Embryonic Kidney 293 (HEK293) or monkey kidney cells (Martindale 
et al. 1998). Later, models were developed that relied on neural–like cells rather than 
non-neuronal cells for long-term analysis. These include pheochromocytoma 12 
(PC12), neuroblatoma-glioma hybrid cell (NG108-15) and embryoid striatum with 
variation of temperature sensitive large antigen named T (ST14A cell) (Li et al. 1999; 
Lunkes and Mandel 1998; Ehrlich et al. 2001). PC12 cells can be induced to 
differentiate into neuronal like cells by the presence of neuron growth factor. NG108-15 
cells have the ability to differentiate into neuronal like cells, and ST14A cells are 
derived from E14 rat striatum and can display some characteristics of MSN subtype 
(Sipione and Cattaneo 2001; Ehrlich et al. 2001). From these HD cellular models, it 
was found that expansion of CAG repeats caused the HTT exon 1 protein to 
accumulate in the nucleus. This affected gene expression and resulted in abnormal cell 
morphology, a high rate of apoptosis and a deficiency in the development of neurites 
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(Li et al. 1999). In addition, the localisation of the mHTT in the nucleus occurs in a 
time- and CAG repeat unit number-dependent manner (Lunkes and Mandel 1998). 
Although these neurons were shown to mimic mechanisms of human cells in HD in 
vitro, more sophisticated models were required to recapitulate some characteristics of 
HD. Therefore, in vitro models of HD using disease-specific hPSCs were developed to 
fully recapitulate the pathogenesis of HD. 
In 2009, two novel HD-hESCs were generated that carried mutant genes with 37 
and 51 glutamate repeats, cell lines SI-186 and SI-187, respectively (Niclis et al. 2009). 
The cell lines with mutant alleles were derived from affected in vitro fertilization (IVF) 
embryos that were identified by pre-implantation genetic diagnosis (PGD) (Niclis et al. 
2009). It was shown that the mutant HTT was expressed at the transcriptional and 
protein levels (Niclis et al. 2009). Therefore, both HD-hESC lines carrying the genetic 
mutation have the potential to exhibit HD pathology in vitro. In addition, it was 
demonstrated that HD-hESCs could be differentiated into the primary neurons and 
astrocytes that are associated with the pathology of HD, and were immunopositive to 
β-III Tubulin and GFAP, respectively (Niclis et al. 2009). The HD-hESC-derived primary 
neurons and astrocytes were frequently similar to those to HD-negative control hESC 
lines (HES2/HES3) (Niclis et al. 2009). The two HD lines were able to successfully 
differentiate into primary neurons and astrocytes (Niclis et al. 2009). 
Although disease-specific hESCs provide a valuable knowledge of HD pathology, 
ethical and technical considerations make this a time-consuming and challenging 
disease model. The recent establishment of iPSCs in 2006 opened a new avenue for 
the generation and development of more sophisticated cell models to investigate and 
establish human therapies for complex diseases, such as HD, Parkinson’s disease 
(PD) and Alzheimer diseases (AD). 
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1.2.1.1 Human-cell modeling in vitro using iPSCs 
 
Reprogramming of a patient’s somatic cells, such as fibroblasts into iPSCs and 
their subsequent differentiation into target cells (neuronal cells in case of 
neurodegenerative disorders), would provide a wealth of information on disease 
pathology and potentially provide an unlimited source for autologous cell replacement 
therapy. The major advantage of iPSCs is their plasticity, the ability to acquire the 
morphological and functional properties of a wide range of cell types.  
To date, modeling pathogenesis using disease-specific iPSCs has been 
established in diseases characterised by a single gene defect such as familial 
dysautonomia and autism spectrum disorders (ASD) (Lee et al. 2009; Marchetto et al. 
2010), and rapid disease development in infants such as spinal muscular atrophy 
(Ebert et al. 2009; Gao et al. 2012). 
Recently, direct reprogramming of monkey skin cells from HD monkey into 
iPSCs was successfully achieved by ectopic expression of the transcription factors 
Oct4, Kif4 and Sox2 (Chan et al. 2010). In addition, the first iPSCs derived from human 
HD patients were successfully produced by Park and colleagues in 2008. The HD-
iPSCs were capable of differentiating into cells of the three germ layers, including 
neural cell types that demonstrated features of HD (Park et al. 2008). 
In 2010 a human HD cell model was established. HD-iPSCs were successfully 
generated and induced to differentiate into neural stem cells (HD-NSCs) followed by 
differentiation into striatal neuronal precursors. The HD-NSCs were cultured with sonic 
hedgehog (SHH), dickkopf WNT signaling inhibitor-1 (DKK1) and brain-derived 
neurotrophic factor (BDNF) for 8-10 days, followed by treatment with BDNF, cAMP, 
valproic acid and Rho-associated kinase (ROCK) inhibitor (Y-27632), to prevent 
apoptosis. Further differentiation resulted in 10% of the cell population being positive 
for the most important MSN marker DARPP-32 (the dopamine and adenosine 3’, 5’-
cyclic monophosphate cAMP-regulated phosphoprotein of 32 kDa). In addition, the 
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CAG repeat was stable and there was an increase in caspase 3/7 activity, which is one 
characteristic of HD pathology; hence this human HD-cell model has the potential to 
use for drug screening (Zhang et al. 2010). 
Camnasio and colleagues established HD-specific iPSCs using lentiviral 
technology to create an in vitro model of HD. A number of cell lines were derived from 
three patients, and three of these cell lines (two with a homozygous and one with a 
heterozygous genotype) were compared with wild type-iPSCs (WT-iPSCs) (Camnasio 
et al. 2012). The neural differentiation protocol used in this study is shown in 
Figure1.3. It was reported that the CAG repeats were stable in both HD and WT-
iPSCs, and the caspase activity was the same in both HD and WT-iPSCs (Camnasio et 
al. 2012). Whereas, in the study of HD mouse models and HD patient brains, the CAG 
repeats were unstable (Gao et al. 2012). Hence, HD-iPSCs and HD-iPSC-derived 
neurons can reach maturation state and could be used as cell replacement therapy 
(Gao et al. 2012). Interestingly, the authors stated that the lysosomal activity in HD-
iPSCs was four times greater than those in WT-iPSCs. They also suggest that the HD-
iPSCs were capable of clearing out the mutant proteins using autophagosome-like 
structures (Camnasio et al. 2012).  
 
Figure 1.3: The neural differentiation protocol used by Camnasio and collaborators 
in 2012. 
  
Neural differntiation used in Camnasio, S., et al, 2012 
  
  
     D0                      D3                                             D15      
     hESCs                       hESCs medium                     replate on Laminin (3µg/ml) 
     hES medium              with Noggin (500ng/ml)         N2 medium with BDNF (30ng/ml)  
     with10ng/ml bfgf2       and SB435425 (5µM)           and 50x B27  
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From Day (D)0 to D3, the hESCs were cultured with 10 ng/ml bfgf2, and between D3 and 
D15, the cells were neurally  differentiated in culture media with 500 ng/ml Noggin and 5 
µM SB435425. After D15, the cells were further differentiated with N2 media with 30 ng/ml 
BDNF and 50x B27.  
 
Joen et al. induced HD-iPSCs from an HD juvenile patient with 75 CAG repeats 
(HD75-h-iPSCs) and differentiated them into neurons by co-culture with PA6 stromal 
cells (Jeon et al. 2012; Jeon et al. 2014). The properties of HD75-iPSCs derived neural 
progenitors were examined and then transplanted into QA-Lesioned rat (Jeon et al. 
2012) or YAC128 transgenic mice with 128 CAG repeats (Jeon et al. 2014) in order to 
investigate the role of HD75-h-iPSCs in vivo and analyse the motor behavior. Results 
showed that, a large proportion (75%) of the differentiated neurons derived from the 
HD75-h-iPSCs were immunopositive for striatal MSNs markers and exhibited the 
properties of functional GABAergic neurons (Jeon et al. 2012; Jeon et al. 2014). The 
HD75-h-iPSCs neural differentiation were transplanted into different models and 
showed similar outcomes. It was shown that the motor performance initiated to improve 
from 3 weeks following transplantation. At 12 weeks, the grafted cells were 
immunopositive for NESTIN and MAP2. It was also observed that the human cells 
differentiated into GABAergic MSNs that were DARPP-32+ve, GABA+ve, GAD6+ve and 
SVP38+ve (synaptic vesicle protein synaptophysin). The expression of SVP38 
evidenced the ability of synapse formation in the human cells (grafted cells). In 
addition, the expression of aggregated mHTT protein (EM48) was not detected in the 
grafted cells, whereas it was expressed in the host cells. According to the double 
staining analysis at 12 weeks, the DARPP-32+ve MSNs were affected by the 
immunopositive EM48, and hence it was suggested that the HD pathology was not 
developed in human cells or transmitted from host cells to the human cells (Jeon et al. 
2014). However, at later cellular stages, the aggregates formation was detected (Jeon 
et al. 2012), as it would be expected to form in the transplanted YAC128 mice with 
HD75-h-iPSCs at later cellular stages (Jeon et al. 2014). 
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These data illustrate that HD cell models have the ability to differentiate into striatal 
MSNs and to have their HD phenotype corrected by genetic manipulation. However, 
the current protocols also generate non-specified neurons and the differentiated cells 
are not affected by HD to the same extent as the diseased cells (MSNs). Therefore, 
more reproducible and efficient protocols for MSN differentiation in vitro are required in 
order to investigate HD dysfunction at the cellular level.  
 
1.3 Basal ganglia 
 
The basal ganglion consists of the lateral ganglionic eminence (LGE), which 
gives rise to the striatum, the dorsal region, and the medial ganglionic eminence 
(MGE), which gives rise to the ventral region, the globus pallidus (GP) (Figure 1.4 A, B 
& C) (Pauly et al. 2013). Neocortical neurons migrate from the MGE through the LGE 
to their final targets (Sussel et al. 1999). For example, GABAergic (γ-aminobutyric acid) 
neurons, which are produced in the ventricular (VZ) and subventricular (SVZ) zones of 
the LGE and MGE, migrate throughout the SVZ to the cerebral cortex, olfactory bulb 
and hippocampus (Tamamaki et al. 1999; Wichterle et al. 1999). 
Nkx2.1 and Gsx2 are two of the transcription factors that play a role in 
controlling and patterning the basal telencephalon, while Dlx1, Dlx2 and Mash1 have a 
role in differentiation. The interplay of these transcription factors regulates cortical 
GABAergic neuron output (Anderson 1997; Anderson et al. 1997; Szucsik et al. 1997; 
Casarosa et al. 1999; Horton et al. 1999; Sussel et al. 1999; Fode et al. 2000; 
Anderson et al. 2001; Pauly et al. 2013).  
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Figure 1.4: Structure of basal ganglion. 
Human brain showing the structure of the basal ganglia. The basal ganglia consist of 
the LGE (striatum) and MGE (globus pallidus) (A). Coronal sections of human brain 
showing the basal ganglion components: striatum (caudate nucleus and putamen), 
globus pallidus (GPe and GPi) (B), SN and STN (C). Figure taken from Joseph 2011. 
Abbreviations: LGE: Lateral ganglionic eminence, MGE: Medial ganglionic 
eminence, GPe: External segment of globus pallidus, GPi: Internal segment of globus 
pallidus. SN: Substantia nigra; STN: subthalamic nucleus. 
 
  
A) 
B) C) 
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1.3.1 Striatum  
 
The striatum, known as the caudoputamen, is a complex of caudate nucleus 
and the putamen (Figure 1.4 A & B). The striatum forms a major part of the basal 
ganglia along with the substantia nigra (SN), subthalamic nucleus (STN) and GP. It is 
organised into the striosome (patch) and matrix domains. The patch and matrix 
neurons receive input from deep and superficial parts of the neocortical layer, 
respectively. The patch cells pass their output to the SN pars compacta (SNc), 
whereas the matrix cells pass their output to the SN pars reticulata (SNr) (Gerfen 1992; 
Anderson et al. 1997; Feyder et al. 2011). 
The functions of the striatum are to process information from the cerebral 
cortex, thalamus and SNc, and to send GABAergic outputs to the internal part of the 
GP (GPi) and SNr relating to voluntary movement, learning and cognition (Figure 1.5) 
(Gerfen 1992; Feyder et al. 2011).  
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Figure 1.5: Medium spiny projection neurons in the basal ganglia. 
This diagram shows the projection neurons of striatal MSN. Striatal MSN with DRD1 project 
neurons to GPi then to thalamus and go back to motor cortex (A) This pathway activates the 
motor activity (B). Striatal MSN with DRD2 project to GPe and STN then to GPi and thalamus 
then project back to the motor cortex (A). This pathway is indirect and decreases the motor 
activity (B). The red arrows indicate the dopaminergic pathway that acts as a positive feedback 
loop for the direct pathway and negative feedback loop for the indirect pathway to thalamus and 
then back to the cerebral cortex. 
Abbreviations: GPe: external segment of globus pallidus, GPi: internal segment of globus 
pallidus, STN: the subthalamic nucleus, SNc: the pars compacta of substantia nigra, SNr: the 
pars reticulata substantia nigra, DRD1: dopamine D1-like receptors; DRD2: dopamine D2-like 
receptors.  
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1.3.2 Medium Spiny Neurons (MSNs) 
 
The striatum's primary neurons are GABAergic medium-sized spiny neurons 
(Figure 1.6) that constitute around 90-95% of the striatal neurons in rats and over 85% 
in humans (Chang et al. 1982; Chang and Kitai 1985; Wictorin 1992; Kelly et al. 2009). 
These neurons originate from the LGE, while the small percentage of interstriatal 
neurons originate from the MGE (Olsson et al. 1998; Marin et al. 2000; Toresson and 
Campbell 2001; Arlotta et al. 2008). MSNs are characterised by complex dendritic 
arborisation and large dendritic spines receiving excitatory glutamatergic and 
modulatory dopaminergic inputs (Feyder et al. 2011; Penrod et al. 2011). 
 
 
 
Figure 1.6: Morphology of medium-
sized spiny neurons. 
A Medium-sized spiny neuron with spiny 
dendrites. Figure taken from Churchill et 
al. 2004. 
 
The MSNs in the striatum receive excitatory glutamatergic inputs from the 
cerebral cortex and dopaminergic input from the SNc. MSNs activity is regulated by 
dopamine, glutamate and acetylcholine (Ach). MSNs express two dopamine receptors, 
dopamine D1-like receptors (DRD1) and dopamine D2-like receptors (DRD2). These 
two groups of receptors have different expression patterns in the two projection 
pathways that connect the striatum toward the output of basal ganglion nuclei. For 
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example, the MSNs with DRD1 project directly to the GPi and to the SNr, which then 
projects to the thalamus and sends signals back to the cortex (Figure 1.5 A). Whereas 
the MSNs with DRD2 project indirectly to the GPi via a path along the external part of 
the globus pallidus (GPe) and the STN. The STN also receives input from the cortex 
and projects to the GPi which then sends signals to the thalamus and back to the 
cortex (Figure 1.5 A) (Nicola et al. 2000; Gong et al. 2003; Valjent et al. 2009).  
The direct projection neuron pathway (striatonigral), with DRD1 MSNs, 
activates motor activity through disinhibition of thalamocortical neurons. Whereas 
activation of the indirect pathway (striatopallidal), with DRD2 from MSNs, decreases 
motor activity by increasing inhibition of thalamocortical neurons (Figure 1.5 B) 
(Feyder et al. 2011). 
The MSNs can be distinguished by their expression of DARPP-32. DARPP-32 
is enriched in the striatum and is the most commonly used marker of MSNs in the adult 
striatum, as it has been reported that more than 90% of MSNs express DARPP-32 
(Anderson and Reiner 1991; Ouimet et al. 1984). Currently, DARPP-32 is the only 
available marker to distinguish MSNs from the other striatal neurons. The transcription 
factor COUP TF1-interacting protein 2 (CTIP2) was shown to be expressed in MSNs 
(Arlotta et al. 2008). It was observed that all the DARPP-32+ve neurons expressed 
CTIP2 in the mouse striatum (Arlotta et al. 2008). Furthermore, it was confirmed that 
the CTIP2+ve neurons co-expressed the TF forkhead box protein P1 (FOXP1). FOXP1 
was detected in the developing mouse striatum from E13.5 by in situ hybridization and 
immunocytochemistry (IHC) and was expressed in the striatal projection neurons but 
not in the interneurons of the striatum (Tamura et al. 2004). It was also found that 
FOXP1 mRNA was expressed in the developing basal ganglia but not in the GP 
(Ferland et al. 2003; Tamura et al. 2004). 
The DARPP-32 protein was first detected at E14 in the caudate nucleus of 
embryonic rat in a small percentage of cells by IHC (Foster et al. 1987). Over the next 
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few days, the number of DARPP-32+ve cells increased rapidly. By postnatal day 0 (P0), 
the developmental pattern of immunoreactivity of DARPP-32 was seen to be similar to 
that obtained in the adult striatum (Foster et al. 1987).  
According to Ehrlich et al. (1990), Darpp-32 mRNA of was not detectable at E14 
in the mouse brain. However, at P0, both Darpp-32 mRNA and protein were expressed 
in small amounts, and at postnatal weeks 3-4, Darpp-32 expression increased rapidly 
at both the transcriptional and protein levels. However, compared to mRNA, protein 
levels of DARPP-32 were decreased in the adult (Ehrlich et al. 1990). Moreover, it was 
suggested that the expression of Darpp-32 at transcriptional level occurs mostly during 
the last week of gestation, and subsequently Darpp-32 is present at P0. The induction 
of MSNs reaches its peak at E15 and is nearly complete by P1-2 in the rat and mouse 
(Marchand and Lajoie 1986; Ehrlich et al. 1990; Sturrock 1980). The MSNs originate 
from LGE (subpallium) and then migrate to the neocortex (NCX) (pallium) via the 
preventricular proliferation zone for motor activity. 
 
1.3.3 Cerebral cortex 
 
The cerebral cortex develops from the dorsal telencephalon. The projection 
neurones originate from the ventral telencephalon of the LGE and MGE in the cerebral 
cortex. Recently, it has been found that cerebral projection neurons originate from 
different proliferation zones. While some are derived from the cortical ventricular zone 
and then migrate into the cortical mantle, most of the interneurons and projection 
neurons of the cerebral cortex derive from the basal telencephalon and then transfer 
into the developing cortex (Anderson et al. 2001). In the early period of neurogenesis, 
at E11.5 to E14.5, cortical neurons cells migrate from the MGE through the piriform 
cortex (paleocortex–PCX) into the cerebral cortex. In the later stages of neurogenesis, 
at E.14.5 to E16.5, cells transfer from both the LGE and MGE via the preventricular 
proliferation zone (PZ) into the neocortex (NCX) (Figure 1.7) (Anderson et al. 2001). 
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Figure 1.7: Cortical neuron migration 
from the MGE and LGE in the earlier 
and later stages of neurogenesis. 
The red arrows show cortical neuron cell 
migration from the MGE into the 
neocortex (NCX) via the piriform cortex 
(PCX), in the early period of 
neurogenesis (E11.5 to E14.5). In the 
later period of neurogenesis (at E14.5 to 
E16.5), cortical cells migrate from the 
MGE and LGE into the NCX via the 
preventricular proliferation zone (blue 
arrows). Figure taken from Anderson et 
al. 2001. 
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1.4 Neural (brain) development 
 
An efficient and reproducible protocol for directing the differentiation of hPSCs 
into MSNs in vitro is an important approach for disease modeling and drug screening. 
In order to establish an efficient method for direct differentiation of MSNs from hPSCs, 
an understanding of the TFs and signaling pathways that are essential in MSN 
development in vivo is fundamental. In this section, neural development, with a focus 
on forebrain (telencephalon) development, is reviewed. 
In the first week of human embryonic development after fertilization, cleavage of 
the zygote, as it passes along the uterine tube, results in formation of the morula 
(Moore et al. 2011). The morula (12 to 16 cell stage) reaches the uterus 3-4 days after 
fertilization, and hence the formation of blastocyst occurs in the uterus (Figure 1.8). 
The size of the developing embryo does not increase, although the number of 
blastomeres increases during the process of zygote cleavage, they are smaller than 
the parent cells. The zona pellucida is no longer present at the late stage of the 
blastocyst development (Figure 1.8); hence the blastocyst starts to enlarge 
substantially. At day 6 after fertilization, the blastocyst attaches to the uterine 
endometrium, endometrial epithelium. At this stage the outer layer of the blastocyst, 
the trophoblast, starts to proliferate and differentiates into two layers, regulated by 
transforming growth factor-β (TGF-β). At day 7 after fertilization, the blastocyst is 
completely implanted in the endometrial epithelium. After implantation, the morphology 
of the ICM, known as the embryoblast, is changed and forms the bilaminar embryonic 
disc (BED), which consists of the epiblast and hypoblast. Extraembryonic structures, 
such as the yolk sac (umbilical vesicle), chorionic sac, amniotic cavity and amnion, 
start to form at the second week of human embryogenesis. The BED is located 
between the amniotic cavity and yolk sac and produces the germ layers, which form all 
the embryo cells, tissues and organs. Both the yolk sac and amniotic cavity produce 
morphogens for cell movements of the BED.  
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Figure 1.8: Formation of late blastocyst.  
When the sperm (A) contacts the plasma membrane of secondary oocyte (B), the 
zygote (fertilized egg) is produced where the first mitotic division occurs containing 
the maternal and paternal chromosomes (C). This is followed by the cleavage 
stage of the zygote (D to E) as it travels along the uterine tube, and the formation 
of early blastocyst (F). When this reaches the uterus, the zona pellucida (zp) 
disappears and this is now known as the late blastocyst (G). The blastocyst 
enlarges considerably after the degeneration of zp. 
 
The primitive streak (PS), notochord development and gastrulation take place 
during the third week of human embryogenesis (Moore et al. 2011). Gastrulation is the 
formation of the three germ layers, namely ectoderm, mesoderm and endoderm, and 
establishment of axial orientation. Each of the layers is responsible for production of 
particular cell types (Figure 1.9). At the gastrulation stage, the BED is transformed into 
a trilaminal embryonic disc (TED). Morphogenesis starts in the third week of human 
embryonic development, driven by morphogens such as bone morphogenetic protein 
(BMP), fibroblast growth factors (FGFs), SHH and WNTs. The first step of 
morphogenesis results in the appearance of the PS located on the epiblast surface of 
the TED. The PS is established through proliferation and migration of the cells of the 
epiblast caudally to the middle level of the dorsal TED. Once it is formed, the 
craniocaudal (CrCd) and dorsoventral (DV) surface axes of the embryo are defined. 
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The mesenchymal cells are produced by PS and are located between the epiblast and 
hypoblast. The epiblast produces the embryonic ectoderm, the hypoblast produces the 
embryonic endoderm and the mesenchyme produces the embryonic mesoderm.  
 
 
 
Figure 1.9: the three germ layers and their derivatives.  
The inner cell mass (ICM), or embryoblast, gives rise to the embryo and forms 
the bilaminar embryonic disc (BED) which is transformed to the trilaminar 
embryonic disc (TED) at gastrulation stage. TED consists of endoderm, 
mesoderm and ectoderm. This diagram shows the derivatives of each layer in 
TED. Figure taken from Moore et al. 2011. 
 
Following gastrulation, mesenchymal cells form between the ectoderm and 
endoderm form the notochord (Moore et al. 2011). The notochord promotes the 
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thickening of the embryonic ectoderm by endogenous signals to form the neural plate. 
The neural plate folds and forms a central neural groove flanked by neural folds 
(Figure 1.10). The neural folds fuse to form the neural tube in a process called 
neurulation (Figure 1.10). The neural tube develops into the central nervous system 
(CNS).  
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Figure 1.10: Neurulation stage.  
This diagram shows the dorsal section of an embryo at 21 days of gestation (A), and the 
formation of the neural fold, neural groove, neural tube, neural crest and developing epidermis 
(B to F). Figure adapted from Moore et al. 2011. 
 
The CNS in vertebrates comprises a large assortment of neurons and glial cells 
that are produced at specific times and in specific positions in the embryonic neural 
tube. The CNS is composed of three main cell types: neurons, astroglia and 
oligodendroglia. It consists of the brain (cranial end of neural tube) and spinal cord 
(caudal end of neural tube). During neural tube development, the tube differentiates 
into three parts: prosencephalon (forebrain), mesencephalon (midbrain) and 
rhombencephalon (hindbrain) (Figure 1.11). Each of prosencephalon and 
rhombencephalon subdivides into two regions. The prosencephalon subdivides into the 
telencephalon and diencephalon, while the rhombencephalon divides into the 
metencephalon and myelencephalon, (Lumsden and Keynes 1989; Qiu et al. 1995; 
Rubenstein et al. 1998; Lumsden et al. 1991). The forebrain is the most rostral part of 
the neural tube; the telencephalon is the anterior part of the forebrain and is known as 
the most subdivided region of the CNS (Figure 1.11). In the forebrain, there are 
several TFs that are expressed in limited patterns. These TFs are homeobox genes, 25 
of which are found to be expressed in the forebrain (Rubenstein and Puelles 1994). 
These TFs include members of the Dlx, Emx, Otx and other families (Qiu et al. 1995). 
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Figure 1.11: The neural tube differentiates 
into three parts. 
Once the neural tube is formed, it 
differentiates into three domains. These are 
the prosencephalon (forebrain) consisting of 
the telencephalon and the diencephalon, the 
mesencephalon (midbrain) and the 
rhombencephalon (hindbrain). Figure taken 
from Evans et al. 2012. 
 
During development, the brain is patterned by morphogens FGFs and retinoic 
acid (RA) along the anterior-posterior axis to form the forebrain (FB), midbrain (MB), 
hindbrain (HB), and spinal cord (SC). Each of these is further subdivided into several 
domains along the dorsal-ventral axis by specific morphogens such as WNTs, SHHs 
and BMPs (Figure 1.12 A).  
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Figure 1.12: Patterning of brain according to the morphogenesis.  
In the development of brain, NT, which differentiates into CNS, is patterned 
by morphogenesis of FGFs and retinoic acid (RA) along anterior to posterior 
axis to form forebrain (FB), midbrain (MB), hindbrain (HB), and spinal cord 
(SC), and each part of those are subdivided into several domains by dorsal 
to ventral axis by specific morphogenesis such as WNTs, BMPs (dorsal 
patterning) and SHHs (ventral patterning) (A). The structure of telencephalon 
that consists of pallium “Cortex” expressing the dorsal marker Pax6 and 
subpallium “basal ganglion: LGE and MGE” expressing the ventral markers 
Nkx2.1, Dlx2 and Gsx2 (B). The morphogenesis WNT and SHH have a role 
in the telencephalon patterning (B).   
Abbreviations: NT: Neural tube, RP: Roof plate, FP: Floor plate, Epi: 
Epidermal development, NC: Notochord, SHH: Sonic hedgehog signaling, 
WNT/BMP: WNT and bone morphogenetic protein signaling, RA: Retinoic 
acid, FGF: Fibroblast growth factor, D: Dorsal, V: Ventral. LGE: Lateral 
ganglion eminence, MGE: Medial ganglion eminence; Cx: Cortex. 
 
The telencephalon is subdivided into dorsoventral domains. The dorsal 
telencephalon, called “the pallium”, develops into the cerebral cortex, and the ventral 
telencephalon, known as “the subpallium”, develops into the basal ganglia. The 
homeobox genes, such as Pax6 and Emx2, play a significant role in the regulation of 
patterning and the proliferation of progenitor cells in the dorsal telencephalon (Warren 
et al. 1999; Bishop et al. 2003; Quinn et al. 2007; Pauly et al. 2013), whereas NKX2.1, 
Dlx2 and GSX2 have a role in the ventral telencephalon (Pauly et al. 2013; Carri et al. 
2013) (Figure 1.12 B). 
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In the following section, several factors that play an essential role in 
telencephalon development are discussed. 
 
1.4.1 Factors involved in the development of telencephalon  
 
Concerning the patterning of embryonic telencephalon, there are at least three 
patterning centres that are located in the developing telencephalon and provide definite 
signals, which have a role in the regulation of telencephalic morphogenesis and 
regional specification (Ohkubo et al. 2002; Storm et al. 2006; Crossley et al. 2001). The 
first patterning centre is the rostral patterning centre, which expresses certain genes of 
FGF family including FGF8, FGF18, FGF17 and FGF15 (Figure 1.13) (Storm et al. 
2006). The second is the dorsal patterning centre, which expresses genes from WNT 
and BMP families (Figure 1.13) (Storm et al. 2006). Finally, the ventral patterning 
centre which expresses SHH (Figure 1.13) (Storm et al. 2006). During gastrulation, 
neurulation and rostral forebrain morphogenesis, FGF, SHH and BMP are located in 
the midline of the neural plate (Crossley et al. 2001; Storm et al. 2006). In addition, 
there is cross-regulation between them which regulates the patterning in the early 
development of embryonic telencephalon (Storm et al. 2006).   
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Figure 1.13: Schematic of patterning centers in the mouse telencephalon 
(frontolateral view).  
This diagram shows the location of the three patterning centers in the telencephalon. It 
expresses the genes Bmp4/Wnt3a (green area), Fgf family (blue area) and SHH (red 
area). The cross regulation between the genes is also shown. Fgf family and SHH 
have a positive interaction, whereas Fgf family and Bmp4/Wnt3a have a negative 
interaction. Figure adapted from Storm et al. 2006. 
Abbreviations: Cx: Cortex, LGE: Lateral ganglionic eminence, MGE: Medial 
ganglionic eminence, S: Septum, CP: Commissural plate, LT: Lamina terminalis, OC: 
Optic chiasm, HT: Hypothalamus; MB: Midbrain.  
 
Numerous growth factors participate in the patterning of forebrain. One of them 
is FGF8 which has been shown to be expressed in the anterior neural ridge (ANR) and 
next to the tissues that express SHH and Bmp4 (Crossley et al. 2001; Storm et al. 
2006). FGF8 has a function in cell proliferation, patterning of anterior-posterior (A-P) 
neural tube and regulating Foxg1 (forebrain marker) expression, which in turn 
promotes regionalisation and cell proliferation of telencephalic and optic vesicles 
(Shimamura and Rubenstein 1997; Storm et al. 2006). In a study of loss-of-function of 
FGF8, it was shown that the structure of LGE and MGE was lost and the expression of 
ventral genes Dlx2 and Nkx2.1 were reduced with an increase of dorsal gene 
expression Pax6 (Storm et al. 2006). It was therefore suggested that FGF8 has a role 
in fate commitment of telencephalon ventralisation (Storm et al. 2006).  
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The expression of FGF8 is maintained by the morphogen SHH (Ohkubo et al. 
2002). SHH is produced from the notochord, located under the posterior area of the 
brain and prechordal plate, which in turn is located under the telencephalon domain in 
along a ventral to dorsal gradient (Rubenstein et al. 1998). SHH has a role in the 
patterning of the ventral neural tube, in embryonic development and in telencephalon 
development (Jessell 2000). It has been demonstrated that the concentration and 
duration of SHH signalling are essential for the fate commitment of ventral neural tube 
(Stamataki et al. 2005). According to Jessell (2000), SHH evokes its effect in a 
concentration-dependent manner. It was shown that in spinal cord patterning, SHH 
gradients generated five different classes of ventral neurons from ventral progenitor 
cells (four classes of ventral interneurons and one class of motor neurons) (Jessell 
2000). 
In the developing brain, it has been observed that SHH is expressed in the 
ventral area of telencephalon from E11.5 (Kohtz et al. 1998). It has a fundamental 
function in forebrain patterning, in particular the specification of ventral neuronal cell 
fate. It can also induce the expression of ventral markers in the telencephalon, such as 
Nkx2.1, Dlx and Islet-1/2 (Chiang et al. 1996; Ericson et al. 1995; Kohtz et al. 1998; 
Rallu et al. 2002). In a study of SHH knock out mice, it was observed that the structure 
of the ventral forebrain was lost with dorsalisation of the ventral telencephalon (Chiang 
et al. 1996). Conversely, another study showed that with overexpression of SHH, the 
expression domains of ventral definite genes, such as Nkx2.1, were expanded dorsally 
of the neural tube (Goodrich 1997). In addition, it was observed that when the 
telencephalon explant cultures were exposed to SHH, the ventral forebrain marker 
Nkx2.1 was expressed (Ericson et al. 1995). Furthermore, in a study of SHH 
misexpression in the cortex, it was found that ventral markers such as Nkx2.1 and Dlx2 
were expressed ectopically (Kohtz et al. 1998). 
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The primary receptors for SHH are patched and smoothened. In the absence of 
SHH, patched inhibits downstream signalling from smoothened, whereas in the 
presence of SHH, it binds patched and blocks patched inhibition, and hence signalling 
from smoothened is activated. This activates glioma-associated oncogene homologs 
(Gli) 1, 2 and 3 (Gli1, Gli2 and Gli3), which translocate to the nucleus and induce 
transcriptional activation of target genes (Figure 1.14).  
 
Figure 1.14 The SHH pathway of gene expression. 
In the absence of SHH (A) patched inhibits downstream signaling from smoothened. However, 
in the presence of SHH (B) patched inhibition is blocked, and smoothened is free to activate Gli. 
Activated Gli is free to translocate to the nucleus and activates the transcriptional target gene 
expression. 
 
It was shown that the SHH–dependent gene expression is regulated by the 
three members of Gli family of transcription factors, Gli1, Gli2 and Gli3 (Gulacsi and 
Anderson 2006). According to Stamataki and collaborators (2005), different 
concentration levels of SHH generate a gradient of Gli activity. It was generally 
accepted that Gli1 and Gli2 proteins stimulate the patterning of ventral telencephalon in 
response to SHH signalling. At a low concentration of SHH, the Gli3 protein is 
transformed from an activator form into a repressor form (Gli3R), which stimulates the 
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patterning of dorsal telencephalon. Subsequently, in the patterning of telencephalon, 
the main function of SHH is to inhibit the formation of Gli3R and indirectly up-regulate 
expression of the ventral gene Nkx2.1, and the lateral ventral genes Dlx2 and Gsx2 
(Figure 1.15 A & B). In the study of double mutants of Gli1/Gli2, a normal patterning of 
telencephalon was observed (Figure 1.15 C). Furthermore, in the study of double 
homozygous mutants SHH/Gli3 and Gli3-/-, the patterning of ventral telencephalon was 
largely preserved with Nkx2.1 gene expression (Figure 1.15 C) (Gulacsi and Anderson 
2006; Rallu et al. 2002).  
 
Figure 1.15: Role of SHH and Gli3R in patterning of mouse telencephalon.  
A diagram of a coronal section of mouse telencephalon (A) highlighting the three deferent 
domains via the dorso-ventral axis, which are cortex (ctx) (blue), LGE (green) and MGE 
(red). The homoedomain genes are shown on the left side of the diagram and colour-coded 
to indicate their expression in these domains and their fundamental role in the telencephalic 
patterning. The gradient of SHH and Gli3R are shown on the right of this figure. The SHH 
has a role in the telencephalic patterning by inhibition of Gli3R activity and promotes the 
expression of Nkx2.1, Dlx2 and Gsx2 indirectly (B). The gene regulation of Nkx2.1 is shown 
to be different from Dlx2 and Gsx2 gene expressions as it was expressed normally in the 
Gli3-/- mouse model (C) Gli3R promotes the dorsal telencephalon patterning (A, B) and 
expression of dorsal markers such as Pax6. The boundary of Pax6 and Gsx2 expression 
repress each other, where the Pax6 expression represses the expression of Gsx2 which is 
regulated by Gli3 as it was shown that, in the mouse model of Gli3-/-, the expression of Pax6 
was down-regulated whereas the expression of Gsx2 was expanded dorsally (C).    
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BMPs are a member of the secreted growth factor superfamily of TGFβ. BMPs 
are expressed from the roof plate (RP) of the neural tube and spread ventrally to 
promote the fate commitment of dorsal neurons in a concentration-dependant gradient 
(Dale and Wardle 1999). In neural induction of the neural tube, FGF signalling is 
required to repress the expression of BMP (Wilson and Houart 2004). It was observed 
that in the gain of function of BMP4, the expression of SHH and FGF8 were reduced in 
the telencephalon (Ohkubo et al. 2002). Moreover, in a culture of a telencephalon 
explant in the presence of BMPs, it was shown that the specification of forebrain was 
inhibited because the expression of Foxg1 was repressed as well as the expression of 
ventral expression markers, such as Nkx2.1 and Dlx2 (Furuta et al. 1997; Ohkubo et al. 
2002). 
In the BMP pathway, BMP ligands bind to their heterotetrameric receptors. 
These receptors consist of BMP receptor type I (BMPRI) and BMP receptor type II 
(BMPRII). BMPRI is an inactive domain whereas BMPRII is a phosphorylated and 
constitutively active receptor. Binding of the ligand to the transmembrane receptors 
triggers intracellular signalling. The BMPRI is transphosphorylated and becomes active 
hence phosphorylating the receptor-associated Smad proteins (R-Smads), consisting 
of Smad 1,2,3,5 and 8, which bind to common-partner Smad, Smad4 (Smad4). The 
phosphorylated R-Smad/Smad4 complex translocates to the nucleus and activates the 
transcriptional process with cofactors (Figure 1.16).  
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Figure 1.16: TGT-β/Samd signalling pathway 
When TGT-β ligands, such as BMPs, bind to the BMP receptors, which include BMPRI and 
BMPRII, BMPRI is recruited and transphosphorylated. BMPRI becomes active and 
phosphorylates R-Smad, which includes Smad 1-2/5/8. The phosphorylated R-Smad binds to 
the Co-Smad and then translocates to the nucleus and activates transcription of target genes. 
Abbreviations: TGT-β: Transforming growth factor-β, BMPs: Bone morphogenetic protein, 
TGF-βRI: Type I TGF-β receptor, TGF-βRII: Type II TGF-β receptor, BMPRI= Type I BMP 
receptor, BMPRII: Type II BMP receptor, P: Phosphorylated, R-Smad: Receptor associated 
Smad protein; Co-Smad: Common partner Smad protein.  
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Retinoic acid (RA) is the biologically active (bioactive) form of vitamin A. During 
forebrain development, RA has roles in cell survival, proliferation, differentiation and 
specification during development of the forebrain (Haskell and LaMantia 2005). RA is 
produced in the retina by the retinal aldehyde dehydrogenase enzyme (Figure 1.17) 
(Liao et al. 2005). It carries out its function via two receptors: RA receptors (RARs) and 
retinoid X receptors (RXRs). Each of these have α, β and γ subtypes, which can be 
recognised in the developing striatum (Liao et al. 2005). Both of RARβ and RXRγ are 
expressed selectively and mainly in the LGE domain. RXRγ is expressed at low levels 
in the MGE domain but it is not present in the CTX domain (Liao et al. 2005). In a study 
of a RXRγ homozygous mutant, expression of the choline acetyltransferase (ChAT) 
gene was reduced in the striatum region; however, GABA gene expression was not 
affected (Saga et al. 1999). Furthermore, in a study of RARβ-/- mice, striatal enriched 
tyrosine phosphatase mRNA, which is regulated by RA, was found to be reduced, (Liao 
et al. 2005). The number of Darpp-32+ve neuron cells in the dorsal part of the striatum 
was also reduced (Liao et al. 2008). 
 
Figure 1.17: The RA synthetic pathway 
Retinal is produced from retinol by the enzyme Retinol 
dehydrogenase. RA is then generated through further processing 
by retinal dehydrogenase. Two enzymes: CRBP and CRABP, 
block the formation of retinal and RA respectively.   
Dietary vitamin A 
(Retinol) 
Retinal 
Retinoic Acids 
(Bioactive form) 
By Retinol 
dehydrogenase 
By Retinal 
dehydrogenase 
Cellular retinal 
binding protein 
(CRBP) 
Cellular RA 
binding protein 
(CRABP) 
                                                                                                      Chapter 1: General introduction 
 36 
It has been reported that RA is essential for development of the forebrain 
(Schneider et al. 2001). In the adult, RA expression is conserved in the domain of 
forebrain (Haskell and LaMantia 2005). In addition, it was found that retinoid signalling 
maintains expression of FGF8 and SHH in the forebrain (Haskell and LaMantia 2005; 
Schneider et al. 2001). When retinoid signalling is not present, loss of FGF8 and SHH 
expression was observed (Schneider et al. 2001). 
In a study of Gsx2-/- mice, it was observed that forebrain development was 
disturbed and Darpp-32 expression was reduced when the RA synthesis enzyme 
levels in LGE were reduced. However, it was reported that when the exogenous RA 
was added to the mutant mice, the expression of Darpp-32 increased. Consequently, it 
has been suggested that RA plays a role in regulation of DARPP-32 gene expression 
in the developing forebrain (Waclaw et al. 2004).  
The wingless (WNT) protein ligand family is a large group of secreted 
glycoproteins that play a role in embryogenesis. WNT regulates the activity of β-
catenin, thereby regulating the target gene expression (Huelsken and Behrens 2002). 
There are three WNT intracellular signalling pathways: (i) the canonical pathway that 
regulates the activity of β-catenin, (ii) the non-canonical planner cell polarity pathway 
that regulates the c-jun N-terminal kinase (JNK), and (iii) the non-canonical 
WNT/calcium pathway that regulates calcineurin (Huelsken and Behrens 2002). The 
canonical pathway is that which is involved in the development of telencephalon. 
In the WNT canonical signalling pathway (Figure 1.18), the WNT- protein ligand 
binds to the seven-transmembrane receptor Frizzled that activates intracellular 
signalling, leading to phosphorylation of Dishevelled (Dsh) (Huelsken and Behrens 
2002; Moore et al. 2011). The phosphorylated Dsh blocks formation of a multiprotein 
complex of axin, glycogen synthase kinase 3β (GSK-3β) and adenomatous polyposis 
coli (APC) as well as phosphorylation of GSK-3β. The phosphorylated GSK-3β 
becomes inactive and subsequently cannot phosphorylate the cytoplasmic β-catenin, 
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therefore preventing degradation of β-catenin. Hence, β-catenin accumulates in the 
cytoplasm and is subsequently translocated into the nucleus where it activates WNT 
target gene expression with T-cell factor (TCF). In the absence of WNT, the formation 
of multiprotein complex is initiated so that GSK-3β can phosphorylate the cytoplasmic 
β-catenin leading to its degradation. Consequently, the accumulation of β-catenin in the 
cytoplasm and its translocation to the nucleus is prevented and the TCF represses the 
target gene of WNT.  
 
Figure 1.18: WNT/β-Catenin signaling pathway 
When WNT is absent, the multiprotein complex is formed and GSK-3 phosphorylates the 
cytoplasmic β-Catenin, which is then degraded in the cytoplasm. TCF in the nucleus represses 
transcription of the target gene (A). When WNT is present, it binds to the seven-transmembrane 
frizzled receptor and co-receptor LRP5/6 is recruited and activates the intracellular signaling. 
Dsh is phosphorylated and blocks the formation of the complex such that GSK-3 cannot 
phosphorylate β-Catenin. Subsequently, β-Catenin accumulates in the cytoplasm and freely 
translocates to the nucleus where it activates the transcription of the target gene with the 
transcription factor TCF. 
Abbreviations: LRP5/6: Low density lipoprotein receptors-related protein 5/6 co-receptors, 
APC: Adenomatous polyposis coli, GSK-3: Glycogen synthase kinase-3, Dsh: Dishevelled; TCF: 
T-Cell factor.   
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During murine development, canonical WNT signalling was observed in the 
dorsal telencephalon but not in the ventral domain at E11.5 and E16.5. This was 
demonstrated using a reporter line with the expression of lacZ gene under the control 
of responsive elements of β-catenin and TCF (Maretto et al. 2003; Backman et al. 
2005). It was reported that inhibition of the WNT pathway is essential for generation of 
the telencephalon (Houart et al. 2002). Using a Cre-loxP system, Backman and 
colleagues examined the influence of canonical WNT signals before and after the 
onset of neurogenesis (Backman et al. 2005). Before neurogenesis, it was observed 
that the inactivation of β-catenin in the dorsal mouse telencephalon down-regulates the 
expression of dorsal markers such as Emx1/2 and Nng2, with expansion of ventral 
markers such as Dlx2, Mash1 and Gsx2. Conversely, when β-catenin was activated in 
the ventral mouse telencephalon, the ventral expression markers were down-regulated 
and the dorsal markers were expressed in the ventral telencephalon. However, after 
neurogenesis, it was observed that the canonical WNT signalling has no role in the 
dorsoventral fate commitment shift (Backman et al. 2005). Consequently, it was 
suggested that the role of canonical WNT is to specify the telencephalic cells by 
repressing expression of the ventral markers (Backman et al. 2005). 
It is, therefore, clear that the exact levels of the certain factors in specific 
sections are essential in neural development. The specification of cells according to 
their position determines the appropriate phenotype through differentiation.  
There are numerous classes of TFs that play a role in different stages of 
neuronal differentiation and the determination of different neuronal subtypes (Helms et 
al. 2005; Guillemot 2007). These include patterning proteins, progenitor proteins, 
proneural proteins, neuronal differentiation basic helix-loop-helix (bHLH) proteins, 
neuronal homeodomain proteins and inhibitory HLH proteins, which repress the 
expression of proneural genes (Guillemot 2007). 
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1.4.2 The TF expression of FOXG1 in the telencephalon development  
 
Foxg1 was formally known as brain factor 1 (BF1) and was the first 
telencephalon marker to be identified (Tao and Lai 1992). Foxg1 is an evolutionarily 
conserved TF of the forkhead–box (Fox) (also known as winged–helix) family, and is 
expressed in the forebrain (Hanashima et al. 2002). In mammals, Foxg1 was first 
detected in the developing rat brain, and its expression was restricted to the 
telencephalon domain of the forebrain during embryogenesis (Tao and Lai 1992). In a 
study of rat forebrain development, it was observed that the expression of Foxg1 was 
at high level in the telencephalon domains from E10, and absent in the adjacent 
diencephalon domains as shown by in situ hybridization (Tao and Lai 1992). It was 
therefore concluded that Foxg1 has a role in development of the telencephalon and 
formation of the boundaries between the telencephalon and diencephalon. 
A mouse model with a null mutation of Foxg1 was produced by replacing the 
majority of the coding sequence of Foxg1 with a LacZ gene and neomycin antibiotic 
resistance cassette (Xuan et al. 1995). The expression of the enzyme β-galactosidase 
(β-Gal) was controlled by the Foxg1 promoter (Xuan et al. 1995). The expression of 
Foxg1 was detected by X-Gal histochemistry in the neural tube from E8.5 and E9, and 
there was no difference between the wild type and the homozygous mutant mice 
(Foxg1-/-). However, the differences between them emerged from E10.5, the size of the 
telencephalon was tremendously reduced and even further impaired in E12.5 Foxg1 
null embryos (Xuan et al. 1995; Martynoga et al. 2005).  
A study of Foxg1-/- mice revealed that the subpallium of telencephalon was 
more affected than the pallium of telencephalon compared to the wild type mice (Xuan 
et al. 1995). At E12.5, the Foxg1-/- mice expressed the pallium markers, Pax6, Emx1 
and Emx2; however, the subpallium markers Dlx1 and Dlx2, were not detected (Xuan 
et al. 1995). Moreover, morphological changes were observed; the structure of 
ganglionic eminences failed to form at E12.5 in the Foxg1-/- mice (Martynoga et al. 
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2005). A similar outcome was observed in the study of mouse telencephalon, when the 
ventral telencephalon markers, such as Nkx2.1 and Mash1, were absent in the Foxg1-/- 
mutant mice compared with the wild type mice at E9.5, as was the TF Gsx2 at E10.5 
(Martynoga et al. 2005). Furthermore, the dorsal marker Pax3 was overexpressed in 
the Foxg1-/- mutant compared with the wild type. The dorsal marker Pax6, which is 
normally expressed in the pallium telencephalon, was also overexpressed throughout 
the telencephalon (Martynoga et al. 2005).  
In another study, cell proliferation in the Foxg1-/- mouse model was analysed by 
bromodeoxyuridine (BrdU) labeling. It was found that while the precursor cells in the 
dorsal telencephalon were actively proliferating, the ventral telencephalic precursors 
cells were not (Xuan et al. 1995). Therefore, the ventral telencephalon failed to develop 
in the Foxg1-/- mutant because the precursor cells were not proliferating (Xuan et al. 
1995). In a more recent study, cells were double labelled with BrdU and 
iododeoxyuridine (IddU) in order to estimate the duration of the S phase in the cell 
cycle and the entire cell cycle. It was observed that the duration of cell cycle increased 
in the Foxg1-/- telencephalon but remained unchanged in the ventral telencephalon 
domain (Martynoga et al. 2005). In addition, the rate of proliferation was reduced in the 
Foxg1-/- mutant, consistent with results from the earlier study (Xuan et al. 1995). 
Recently, it was shown that the TF Foxg1 coordinates the signaling pathway of 
SHH, which is independently essential for the development of subpallium 
telencephalon, and WNT/β-catenin, which is independently essential for the 
development of pallium telencephalon (Danesin et al. 2009). It has been established 
that Foxg1 represses the identity of the dorsal telencephalon by inhibition of the activity 
of WNT/β-catenin, confirming Foxg1 requirement for the induction of ventral 
telencephalon. However, SHH and Foxg1 independently play a role in the induction of 
the ventral telencephalon (Danesin et al. 2009). 
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1.4.3 The organisation of Dorsoventral (DV) pattern in the developing 
telencephalon  
 
As mentioned earlier, the telencephalon is subdivided into two domains: the 
dorsal telencephalon that develops into cortex and the ventral telencephalon that 
develops into LGE and MGE. In terms of gene expression, there are well-defined 
boundaries between the DV domains and between the two subdivisions of the ventral 
telencephalon (Figure 1.19). The TFs Pax6, Emx1/2 and Ngn1/2 are expressed in the 
dorsal telencephalon, while the TFs Mash1, Gsx2, Dlx1/2 and Nkx2.1 are expressed in 
the ventral telencephalon. The TF Nkx2.1 is specific to the MGE region while Mash1, 
Gsx2 and Dlx1/2 are expressed mainly (but not exclusively) in the LGE. 
Figure 1.19: Schematic coronal section of the developing telencephalon at 
E12.5. 
The pallium and subpallium telencephalon are shown and defined by specific gene 
expression patterns. The pallium telencephalon expresses the TFs Pax6, Emx1/2 and 
Ngn1/2, while the subpallium telencephalon expresses the TFs Mash1, Dlx1/2 and 
Gsx2 mainly in LGE domain and the TF Nkx2.1 specifically in the MGE region. Figure 
adapted from Schuurmans and Guillemot 2002.  
Abbreviations: DP: Dorsal pallium, VP: Ventral pallium, MP: Medial pallium, LP: 
Lateral pallium, dLGE: Dorsal LGE; vLGE: Ventral LGE.  
dLGE 
VP 
LP 
DP 
MGE 
(Pallidum) 
vLGE 
(Striatum) 
MP 
PAX6 
EMX
1/2 
NGN
1/2 
MASH1 
DLX1/2 
GSX2 
GSX1 
NKX2.1 
Pallium 
Subpallium 
                                                                                                      Chapter 1: General introduction 
 42 
The TF expression profile for the pallium telencephalon includes Pax6, Emx1/2 
and Ngn1/2. Pax6, a paired homeodomain gene, is essential for the proliferation of 
precursor cells in the developing cerebral cortex and for the development of cortical 
progenitors (Toresson et al. 2000). Another marker of the pallium telencephalon is 
Emx1. Its expression is restricted to the dorsal part of cortex and, therefore, it is absent 
in the ventral area of the cortex (Figure 1.19). Neurogenin1/2 (Ngn1/2) is known as 
neurogenic basic-helix-loop-helix (bHLH) TF and is expressed throughout the pallium 
alongside Pax6. It is essential for determining the phenotype of pallium telencephalon. 
The expression of Pax6 was observed at E8 in the developing forebrain (Stoykova 
and Gruss 1994). In Pax6-/- mutant mice, known as the small eye phenotype 
(Sey/Sey), it was observed that the patterning of forebrain and the development of 
cortex were defective. The pallial-subpallial boundary (PSB) was also shifted 
(Toresson et al. 2000). Moreover, it was observed that the expression of dorsal 
markers such as Ngn1/2 and Emx1/2 were down-regulated, whereas the LGE ventral 
markers such as Gsx2, Mash1 and Dlx1/2 were ectopically expressed throughout the 
pallium region of the mutant telencephalon. Nkx2.1 expression, which is normally 
restricted to the MGE domain, was expanded into the LGE domain, thereby shifting the 
boundary between LGE and MGE regions (Toresson et al. 2000; Stoykova et al. 2000). 
The TFs Pax6 and Gsx2 play a role in the dorsoventral patterning of telencephalon 
and the formation of the PSB (Yun et al. 2001; Toresson et al. 2000). The PSB is 
defined as the border of the ventral pallium and the dorsal LGE (dLGE) (Yun et al. 
2001). In the region of the dLGE, expression of both Pax6 and Gxs2 were overlapping 
at E10.5 of murine development (Yun et al. 2001). A previous study showed that the 
PSB is comprised of a subgroup of progenitor pools of olfactory bulb interneurons and 
cortical neurons. In addition to this, expression of both Pax6 and Gsx2 was required for 
specification of PSB progenitors (Carney et al. 2009).  
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In a study of Gsx2-/-, Sey/Sey and double mutant Gsx2/Sey mice models, it was 
shown that Gsx2 repressed the expression of Pax6 in the subpallium telencephalon 
and maintained expression of the ventral markers Mash1 and Dlx1/2. Meanwhile, Pax6 
inhibited the expression of Gsx2 in the pallium telencephalon and maintained the 
expression of the dorsal markers Emx1/2 and Ngn1/2 (Toresson et al. 2000). In 
addition, Gsx2 repressed the dorsal markers Emx1/2 and Ngn1/2, whereas Pax6 
inhibited the ventral markers Mash1 and Dlx1/2. According to Fode and colleagues, 
Ngn1/2 repressed the expression of Mash1 and Dlx1/2 in the developing pallium (Fode 
et al. 2000). It has, therefore, been suggested that Pax6 inhibits the expression of 
ventral markers Mash1 and Dlx1/2 via the expression of Ngn1/2 (Toresson et al. 2000). 
However, in mice model when Gsx2 was present, the expression of Mash1 and Dlx1/2 
was not required for the inhibition of Ngn1/2 (Toresson et al. 2000). Consequently, it 
was concluded that the function of Gsx2 in the development of telencephalon was 
essential to repress Pax6 and to maintain the identity of subpallium domain (Toresson 
et al. 2000). Pax6 and Gsx2 have complementary roles in generating the pallium-
subpallium boundary in the developing telencephalon and in specification of precursor 
cells in the cortex and striatum (Toresson et al. 2000).   
 
1.4.3.1 GSX2 (GS homeobox 2) 
 
The GSX2 gene is located on chromosome 4 at 4q12. It was formerly known as 
homeobox protein GSH-2 (GSH2) (Hsieh-Li et al. 1995). Gsx2 belongs to the 
homeobox TF family and is expressed beginning at E9 and E10 in the developing 
forebrain (Corbin et al. 2000). GSX2 and GSX1, another homeobox gene located on 
chromosome13q.2, are the earliest TFs expressed in the LGE progenitor cells (Pei et 
al. 2011).  
The homeobox Gsx genes are involved in the initial specification of the neural 
progenitors of the LGE (Pei et al. 2011). Gsx2 and Gsx1 have a similar function in LGE 
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patterning. However, they play different roles in the balance between proliferation and 
differentiation in LGE progenitor cells (Pei et al. 2011). Gsx2 expression controls 
maintenance of the undifferentiated phase of the neural progenitors of the LGE, while 
Gsx1 expression supports the maturation of the progenitor cells via down-regulation of 
Gsx2 (Pei et al. 2011). At embryonic day E12.5, Gsx2 is more highly expressed in the 
neuronal progenitors of dorsal LGE at the boundary of VZ, than in the ventral LGE and 
MGE, while Gsx1 is mainly expressed in the ventral LGE and MGE progenitor cells at 
the boundary of VZ and SVZ (Toresson et al. 2000; Yun et al. 2003; Pei et al. 2011). 
Recently, it has been found that Gsx1 is expressed in areas where the expression of 
Gsx2 is low, such as in ventricular LGE and MGE. In the Gsx1 mutant mice, during the 
late phases of neurogenesis, the expression of Gsx2 is increased in the ventral LGE. 
Also, when Gsx1 is overexpressed, the expression of Gsx2 ceases. Therefore, it was 
suggested that Gsx1 could be a repressor of Gsx2 expression (Pei et al. 2011). 
Consequently, the Gsx2 gene expression gradient along the dorsal to ventral axis of 
telencephalic LGE goes from high (dorsal) to low (ventral), and is thought to be 
controlled by Gsx1 expression (Pei et al. 2011). 
Furthermore, the homeobox Gsx genes have a role in the development of 
striatal pyramidal neurons and interneurons of the olfactory bulb (Toresson et al. 2000; 
Yun et al. 2003). In the early stages of neurogenesis, Gsx2 is highly expressed in the 
progenitor cells of the ventral LGE, whereas in later stages it is highly expressed in 
progenitor cells of the dorsal LGE (Waclaw et al. 2009). During LGE neurogenesis, 
Gsx2 plays a fundamental role in cell fate commitment of striatal projection neurons 
and olfactory bulb interneurons at distinct time points. In the early stages of 
telencephalic development, Gsx2 is highly expressed and specifies ventral LGE and its 
main derivatives, namely the striatum, and the dorsal LGE and its derivatives, such as 
the olfactory bulb (Waclaw et al. 2009).  
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Following the loss of Gsx2, both ventral and dorsal LGE and their derivatives 
are acutely reduced (Yun et al. 2001; Yun et al. 2003; Waclaw et al. 2004; Waclaw et 
al. 2006). When Gsx2 is mutated in the early stages of telencephalon development, the 
number of striatal projection neurons is reduced. Whereas, when the mutation of Gsx2 
is delayed, the olfactory interneurons are defective (Waclaw et al. 2009). Therefore, 
development of the striatum depends on the early expression of Gsx2, and vice versa 
for the olfactory bulb. 
Interestingly, knocking out Gsx2 in mice leads to misspecification of the 
neuronal progenitors of the LGE and its derivatives, but only in early precursor cells. 
However, when Gsx2 is knocked out at a later stage, it is compensated for as the 
expression of Gsx1 is increased in Gsx2 mutant LGE (Toresson and Campbell 2001). 
However, the resulting striatum is less than half of the size of the striatum in wild type 
LGE (Pei et al. 2011). The double homozygous mutants Gsx2/Gsx1 have a more acute 
misspecification of LGE than the Gsx2 single mutant. Overexpression of Gsx2 causes 
a reduction in telencephalon progenitor cell maturation (neurogenesis) both in vivo and 
in vitro (Pei et al. 2011). However, overexpression of both Gsx2 and Gsx1 has different 
effects on the maturation of neuronal progenitors (Pei et al. 2011). 
 
1.4.3.2 DLX2 (Distal-less homeobox) 
 
The Dlx gene family contains homeobox genes homologous to Drosophila 
Distal-less, which are expressed in the developing head and limbs. Dlx genes are 
present in the genome in three clusters with each pair sharing common enhancers 
(Stock et al. 1996; Eisenstat et al. 1999). Pairs Dlx1/2 and Dlx5/6 are expressed in the 
developing brain in the telencephalon and diencephalon (Poitras et al. 2007). In 
addition to having a definite role in ventral forebrain patterning and neuronal subtype 
specification, they have functions in craniofacial development (Panganiban and 
Rubenstein 2002).  
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Dlx gene expression in the telencephalon is confined to the differentiating γ-
aminobutyric acid (GABA)-expressing neurons (Stühmer et al. 2002b). Dlx expression 
in the MGE is associated with GABA interneuron development, whereas Dlx 
expression in LGE progenitors is associated with striatal and olfactory bulb GABA 
neurogenesis (Poitras et al. 2007). The expression of Dlx1 is localised to the VZ and 
the SVZ of the LGE and MGE; it is also expressed in the mantle zone (MZ) (Poitras et 
al. 2007). The expression of the Dlx2 is found in two zones of the telencephalon: the 
VZ and SVZ of mouse ventral telencephalon of embryos at E12.5 where early 
differentiation arises (Panganiban and Rubenstein 2002). Dlx5 and Dlx6 expression is 
restricted to migrating neurons that are further differentiated, and these are located in 
the SVZ and MZ (Poitras et al. 2007). 
Mice lacking Dlx1 and Dlx2 do not exhibit migration of the GABAergic 
interneurons from the telencephalon of the SVZ and the VZ of the LGE and MGE to the 
cerebral cortex. This leads to a fourfold reduction in the number of GABAergic 
expressing cells in the cerebral cortex, striatum and olfactory bulb, the final 
destinations of the GABAergic interneurons (Anderson 1997). In addition, the 
development of striatal SVZ and differentiation of late born striatal neurons is disrupted 
(Anderson et al. 1997; Anderson 1997; Marin et al. 2000). When both Dlx1 and Dlx2 
are knocked out in mice, there is a reduced expression of the bigene cluster Dlx5/Dlx6. 
In 2004, chromatin immunoprecipitation (CHIP) studies showed that the Dlx2 protein 
binds the Dlx5/Dlx6 intergenic enhancer known as the I56i (Zerucha et al. 2000). 
 
1.4.3.2.1 Cis-acting regulatory elements separate the two Dlx genes 
 
Transgenic and phylogenetic footprinting analyses have shown that there are a 
minimum of two cis-acting regulatory elements that separate the two Dlx genes in the 
intergenic region. For Dlx1 and Dlx2, these cis-acting regulatory elements are I12a and 
I12b (Ghanem et al. 2003; Park et al. 2004; Poitras et al. 2007). The I12b cis-acting 
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regulatory element was analysed to understand the genetic pathways that control Dlx 
gene family expression in the prosencephalon (forebrain). DNase I footprint analysis of 
the I12b enhancer followed by transgenic enhancer assays revealed that the Dlx 
proteins auto-regulate and cross-regulate the expression of DLX1/2 in the 
telencephalon and diencephalon. Furthermore, it was discovered that the expression of 
the DLX1/2 is regulated by the bHLH transcription factor ASCL1, also known as 
MASH1 (Poitras et al. 2007).  
In transgenic mice the I12b enhancer directs expression of reporter genes to 
the forebrain (Ghanem et al. 2003). I12b-lacZ reporter transgene expression is 
detectable in the diencephalon and basal telencephalon from E10, and in the VZ, SVZ 
and MZ of the LGE, the MGE, the anterior entopedunuclar area (AEP) of the 
telencephalon and the frontonasal prominence at E11.5 in a mouse embryo. The 
expression of I12b-lacZ reporter transgene was detectable in cells migrating to the 
dorsal telencephalon, or pallium which develops into the cerebral cortex. Moreover, 
after birth, expression of the I12b-lacZ reporter transgene was found in the neocortex, 
and at P25 was detected in the olfactory bulb that contains GABAergic neurons 
(Poitras et al. 2007). Therefore, it was concluded that the enhancer in the region of the 
Dlx1/2 has a role in differentiation of GABAergic interneurons and projection neurons 
(Poitras et al. 2007). 
 
1.4.3.3 ASCL1 (achaete-scute complex homologue 1 (Drosophila)) 
 
The ASCL1 gene, also known as MASH1, ASH1, HASH1 or bHLHA46, is a 
member of the TFs of the basic helix-loop-helix (bHLH) family. It activates transcription 
by binding to the E-box sequence, 5'-CANNTG-3'. For DNA binding, Mash1 is 
dimerized with other bHLH proteins (Ross et al. 2003; Poitras et al. 2007; Henke et al. 
2009). Moreover, Mash1 is one of the proneural transcription factors that regulates 
neurogenesis in the embryonic brain (Castro et al. 2011). It is expressed in the ventral 
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regions of the telencephalon, more specifically, the proliferation zones of the MGE and 
LGE, which determine GABAergic neural differentiation (Parras et al. 2004). It is highly 
expressed in the SVZ, VZ and MZ of the ventral telencephalon of the LGE and MGE at 
E12.5 (Castro et al. 2011). 
 
1.4.3.3.1 MASH1 activates Notch signaling 
 
The timing of cell fate specification and differentiation in the nervous system of 
vertebrates is regulated by a lateral inhibition process that is mediated by Notch 
signalling (Chitnis and Kintner 1996; Lewis 1996; Henrique et al. 1997). Mash1 
indirectly influences the activation of Notch signalling by controlling the expression of 
the Notch ligands Delta and Jagged (Dll1, Dll3, Dll4, Jag1 and Jag2) (Lindsell et al. 
1996; Castro et al. 2006; Henke et al. 2009). Notch-ligand binding results in cleavage 
of the intracellular domain of Notch (Notch-IC) and translocation of Notch-IC to the 
nucleus where it regulates the expression of neurogenic TFs. Notch signalling 
represses differentiation of neurons and inhibits proneural bHLH expression, including 
Mash1 (Artavanis-Tsakonas et al. 1995; de la Pompa et al. 1997; Robey 1997).  
It has been shown that while Mash1 gene expression is required in the early 
stages of neurogenesis, Dlx2 is required in the late stages of neurogenesis to down-
regulate Notch signalling during the specification and differentiation steps. Cell fate 
commitment is therefore regulated by the coordinated function of Mash1 and Dlx1/2, 
via their distinct influence of the Notch signalling pathway (Yun et al. 2002). 
 
1.4.3.3.2 MASH1 directly regulates DLX1/2 expression 
 
Several groups have demonstrated that Mash1 is an upstream regulator of Dlx2 
(Porteus et al. 1994; Casarosa et al. 1999; Fode et al. 2000; Letinic et al. 2002; Yun et 
al. 2002). CHIP and electromobility shift assay (EMSA) analysis have shown that 
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Mash1 binds to the E-box sequence at FP5, which is a functional bHLH binding site 
present in the I12b enhancer. This enhancer is located upstream of the bigene cluster 
Dlx1/2. Binding of Mash1 to the E-box site of the I12b enhancer, activates transcription, 
thereby regulating the Dlx1/2 bigene directly (Poitras et al. 2007). 
Both Dlx1/2 and Mash1 have common expression patterns in the ventral 
telencephalon region of the proliferation zone of the LGE and MGE (Porteus et al. 
1994). Further evidence comes from Mash1 knockout mice, which show a reduction in 
Dlx gene expression in the SVZ of the MGE and the LGE at E12.5 (Horton et al. 1999). 
Moreover, when Mash1 is ectopically expressed in neocortical neurons, Dlx1/2 
expression is up-regulated (Fode et al. 2000). 
 
1.4.3.3.3 MASH1 regulates a large number of other target genes which 
promote neurogenesis 
 
Mash1 plays a significant role in controlling neurogenesis by regulating neural 
progenitor processes including cell cycle progression, proliferation and differentiation. It 
also directly regulates the early and late phases of neurogenesis (Castro et al. 2011). 
Castro and colleagues performed a genome-wide study with CHIP on chip with an 
antibody against Mash1 to the microarrays promoter (chip) from the embryonic ventral 
telencephalon at E12.5, in order to understand the genetic programme that is activated 
by Mash1 in telencephalon development. Mash1 directly regulates a considerable 
number of genes that are associated with all the main phases of neurogenesis, 
including distinct biological processes, molecular functions and cellular processes. 
Biological processes of target genes activated by Mash1 include the early steps of 
inhibition processes (Notch signalling), cell fate specification, regulation of cell 
proliferation and neuronal differentiation (Castro et al. 2011). Several molecular 
processes are regulated by Mash1; for example, 48% of the target genes are involved 
in the regulation of transcription, 36% in signal transduction, 64% in nucleic acid 
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binding, and small percentages in kinase activity (19%), enzyme activity (13%), 
transporter activity (14%) and cytoskeletal activity (11%) (Castro et al. 2011). In 
addition to this, Mash1 directly regulates a number of positive cell cycle regulators that 
promote cell cycle exits (Castro et al. 2011).  
In Mash1 knock out mice, differentiation of the earlier stages of LGE and MGE 
is obstructed. Furthermore, there is evidence of a reduction in the number of cortical 
GABAergic neurons (Casarosa et al. 1999; Horton et al. 1999). As Mash1 regulates the 
expression of Dlx1/2, it can be concluded that Mash1 and Dlx1/2 direct the 
differentiation of GABAergic neurons (Petryniak et al. 2007; Long, Cobos, et al. 2009). 
Inhibition of Mash1 results in a reduction in the number of cell divisions, and a 
division failure in intermediate progenitor cells in the ventral telencephalon (Castro et 
al. 2011). In the adult telencephalon, deletion of Mash1 results in acute failure of 
dividing neural progenitors and stem cells in the proliferation zone of the SVZ in the 
telencephalon (Castro et al. 2011). 
When Mash1 is overexpressed in neural stem cells, it causes rapid differentiation 
of neuronal cells into operative neurons and it has an outstanding capability to control 
the entire sequence of phases of neurogenesis (Berninger, Guillemot, et al. 2007; 
Geoffroy et al. 2009; Vierbuchen et al. 2010). This is because, as a proneural TF, it 
promotes cell cycle exit and differentiates neurons into a distinct progenitor population 
(Bertrand et al. 2002; Ross et al. 2003). Moreover, most of the positive cell cycle 
regulators are up-regulated when Mash1 is overexpressed (Castro et al. 2011). On the 
other hand, loss of Mash1 results in acute failure of basal ganglia neurons in the 
telencephalon, as well as loss of cortical projection neurons (Casarosa et al. 1999; 
Horton et al. 1999; Marin et al. 2000; Yun et al. 2002; Castro et al. 2011). 
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1.5 Stages of striatal GABAergic neurons differentiation 
 
1.5.1 Direct differentiation of hPSCs into neural lineage 
 
In vitro mouse ESCs (mESCs) are maintained in their state of pluripotency and 
self-renewal by the presence of the cytokine leukaemia inhibitory factor (LIF), without 
LIF the mESCs start to differentiate and lose their pluripotent state. In vitro mESCs can 
be induced to differentiate into different lineages by changing the culture conditions 
(Bain et al. 1995). Differentiation of mESCs is promoted by culturing them in 
bacteriological non-adhesive substrate petri dishes where they proliferate, in 
suspension, as multicellular aggregates called embryoid bodies (EB) (Bain et al. 1995). 
Following 8-10 days of suspension culture, EBs are plated onto an adhesive substrate 
(Bain et al. 1995). 
There are some differences between the maintenance of mESCs and hESCs. 
To sustain the pluripotent state in vitro, mESCs require the presence of LIF and serum 
replacement. hESCs are unresponsive to LIF, and instead require a feeder layer, such 
as a mouse embryonic fibroblast (MEF) feeder layer, to maintain their multilineage 
differentiation capacities (Thomson et al. 1998). In spite of this, hESCs and mESCs 
share many similarities including high telomerase activity, expression of pluripotency 
marker Oct3/4 and the ability to form teratomas composed of the derivatives of the 
three germ layers (Thomson et al. 1998). The growth rate of hESCs is slower than that 
of mESCs, and they are more susceptible to apoptosis upon dissociation. This issue 
can be resolved by the application of ROCK inhibitor, which functions as an apoptosis 
inhibitor (Y-27632). Using this inhibitor, it was observed that the rate of apoptosis 
during dissociation of hESCs was significantly decreased compared to untreated 
hESCs (Watanabe et al. 2007).  
For neural induction of hESCs, a novel method was established that uses dual 
inhibitors of SMAD signaling, which is activated in the signaling pathway of BMP 
(Figure 1.16). This is achieved through treatment with SB431542 (10 µM) and noggin 
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(300 ng/ml) in adherent culture or SB431542 (10 µM) and Dorsomorphin (DM) under 
stromal cell co-culture and EB culture (Smith et al. 2008; Chambers et al. 2009; 
Morizane et al. 2011). Dual SMAD inhibition using SB431542 and noggin, was shown 
to achieve an increase in expression of neuroectoderm marker Pax6 (80%) and other 
neural markers, such as Foxg1, epiblast marker Otx2 and Sox1, by day seven, with a 
decline in expression of ES cell marker Oct-4 by day five (Chambers et al. 2009). The 
recombinant protein noggin was replaced with small molecule DM at different 
concentrations (the most optimal concentration was 2 µM); cell survival was 
determined by measuring the number of colonies formed (Morizane et al. 2011). Cells 
cultured with DM had increased cell survival, whereas cells cultured with noggin failed 
to proliferate and form colonies. Furthermore, it is important to consider the advantages 
of using small molecules; they are more stable and cost effective than recombinant 
proteins, and also pose a lower risk of infection (Morizane et al. 2011). However, a 
study by Surmacz and colleagues showed that DM above 5 µM was toxic to cells in 
culture. They also showed that replacement with small molecule LDN193189 (1 µM), 
with SB431542 (10 µM), was more efficient at inducing the expression of 
neuroectoderm marker Pax6 (Surmacz et al. 2012). Nevertheless, the neural induction 
protocol often generates heterogeneous culture (multiple cell lineages) that is not 
exclusively differentiated into neural cells. This is a matter of huge importance in the 
field of transplantation as the undifferentiated cells in culture have ability to form 
teratomas, and therefore, could be a risk to patients. However, this risk can be reduced 
by using techniques such as fluorescence activated cell sorting (FACS), magnetic 
activated cell sorting (MACS) and DNA plasmid integration linked to a specific gene 
carrying antibiotic resistance, which can be used for cell selection or increased 
differentiation of hESCs before transplantation to reduce or eliminate the 
undifferentiated cells. 
In neural patterning, regional commitment of anteroposterior (AP) identity and 
expansion specification of DV identity are dependent on the morphogenic factors WNT 
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and SHH, respectively. It was shown that in vitro WNT signaling inhibits neural 
induction of EBs (Aubert et al. 2002). However, for regional commitment, WNT 
signaling is both essential and sufficient for determining AP patterning of the neuraxis 
in a dose-dependent manner (Kiecker and Niehrs 2001; Houart et al. 2002; ten Berge 
et al. 2008; Paek et al. 2012). It was shown that exogenous WNT signaling initiated 
development of the characteristics of the posterior structure with the differentiation of 
mesendoderm. On the other hand, inhibition of WNT signals was required for 
establishment of anterior structure with the differentiation of neuroectoderm (ten Berge 
et al. 2008). 
In the patterning of DV, addition of SHH to serum-free suspension culture 
(SFSC) resulted in an increased expression of the ventral marker Nkx2.1 with 
decreased expression of the dorsal markers Pax6 and Emx1. Foxg1 expression was 
not affected (Watanabe et al. 2005). Consequently, SHH has an effect on the 
patterning of DV but not in AP identities in forebrain population. Meanwhile, inhibition of 
SHH, using SHH antagonist in chemically defined serum-free media, resulted in an 
increase in expression of Emx1 and Pax6 with reduced expression of the ventral 
telencephalon markers Dlx2, Gsx2 and Nkx2.1 (Gaspard et al. 2008). 
 
1.5.2 Differentiation into striatal medium spiny neurons  
 
Over the last 4 years, several studies have differentiated hPSCs into MSN-like 
cells and have used them for cell replacement therapy in the rodent brain (some of 
these studies are summarized in Table 1.1). The studies’ approach was to employ 
developmental cues (also called morphogens), such as SHH, to control and stimulate 
the transcriptional networks that regulate sequential neuron progenitor fate (Carri et al. 
2013; Nicoleau et al. 2013; Ma et al. 2012) This strategy generates a mixture of cell 
types, including LGE and MGE progenitor cells (reviewed in Soldner and Jaenisch 
2012), and so far, no-one has succeeded in generating a pure population of striatal 
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MSNs. The development of a protocol for inducing disease-specific cell types in vitro is 
a pressing need in order to produce iPSC-disease-specific cell types with high 
efficiency to be employed in potential cell replacement therapy. 
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Table 1.1: Sum
m
ary of published papers that differentiate hPSC
s into M
SN
-like cells and transplantation into rodent. 
A
uthors 
C
ell line 
N
euron 
differentiation 
protocol 
H
ost striatum
 
N
um
ber of 
cells 
transplant 
Sum
m
ary of outcom
es 
K
allur et al. 
2006 
H
um
an 
striatal 
N
S
C
s 
(6-9 
w
eeks post-
fertilization) 
E
xpanded in 
neurosphere cell 
culture w
ith:  
20ng/m
l E
G
F,  
10ng/m
l FG
F, and  
10ng/m
l LIF. 
• N
eonatal rat (2-3 postnatal days) 
• S
urvival at 4 and 16 w
eeks. 
• Im
m
une-suppression w
as not used. 
150,000 cells 
• 
In the early m
onths, few
 cells had survived.  
• 
S
om
e cells had m
igrated to the cortex, G
P
 and 
corpus callosum
, but the m
ajority of cells w
ere 
in the striatum
. 
• 
A
t 4 m
onths, the num
ber of positive N
E
S
TIN
 
cells 
had 
decreased, 
w
hile 
the 
num
ber 
of 
D
oublecortin 
(D
C
X
) 
and 
N
euN
 
cells 
had 
increased.  
• 
Few
 cells w
ere positive for astrocyte m
arkers, 
w
hile, 
m
ost 
of 
the 
cells 
w
ere 
parvalbum
in 
positive.  
• 
M
orphology: 
The 
grafted 
cells 
had 
m
ature 
neuron-like m
orphology, w
hile others had m
ore 
astrocyte/oligodendrocyte - like characteristics.  
S
ong et al. 
2007 
hE
S
C
s 
(M
iz-hE
S
1) 
C
o-culture w
ith P
A
6 
strom
al cells. 
• Q
A
-Lesioned rat 
• S
urvival at 3 w
eeks. 
• U
se im
m
une-suppression daily 
(C
yclosporine). 
20,000 cells 
• 
A
t 3 w
eeks, the grafted cells w
ere found in the 
striatum
 and cortex, even though the cells had 
been transplanted into the striatum
. 
• 
N
o form
ation of tum
ours occurred. 
• 
 C
ells 
in 
the 
cortex 
form
ed 
aggregates 
(N
E
S
TIN
+ve, N
euN
-ve and M
A
P
2
-ve). 
• 
The striatal cells w
ere D
C
X
+ve, G
A
D
6
+ve and 
D
A
R
P
P
-32
-ve and they m
igrated to the lesion 
core. 
• 
Few
 G
FA
P
+ve (astrocyte cells) w
ere found. 
A
ubry et al. 
2008 
hE
S
C
s (H
9, 
S
A
-01) 
200ng/m
l S
H
H
,  
100ng/m
l D
K
K
1, 
and  
20ng/m
l B
D
N
F  
(46-59 days). 
• Q
A
-Lesioned nude rat 
(A
) 
21-30 days of neural 
progenitors differentiation. 
(B
) 
46-59 days of striatal 
precursors differentiation. 
• S
urvival at 4-6 w
eeks. 
50,000-
200,000 cells 
• 
A
t A
: in the grafted cells, there w
as no D
A
R
P
P
-
32 expression w
as seen, and tetratom
as w
ere 
form
ed. 
• 
A
t B
: a cluster of D
A
R
P
P
-32 expression w
as 
found. 
• 
13-15 w
eeks after transplantation, overgrow
th 
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• Im
m
une-suppression w
as not used. 
of grafted cells w
as observed. 
• 
Functional phenotyping w
as not perform
ed. 
• 
M
orphology: bi-polar, m
edium
-sized cell bodies 
and expansive neurite outgrow
th. 
(Jeon et al. 
2012) 
H
D
75-h-
iP
S
C
s-
derived 
neural 
progenitors.  
C
o-culture w
ith P
A
6 
strom
al cells. 
• Q
A
-Lesioned rat. 
• S
urvival at 12 w
eeks. 
• U
se im
m
une-suppression daily 
(C
yclosporine). 
100,000 cells 
• 
B
ehavioural recovery started to im
prove after 3 
w
eeks, as seen using the R
otarod test. 
• 
A
t 12 w
eeks, no aggregates w
ere observed. 
• 
The 
grafted 
cells 
produced 
G
A
B
A
ergic 
neurons. 
• 
N
o H
D
 transm
ission from
 the m
ice cells to the 
hum
an grafted cells w
as observed, and H
D
 
pathology w
as not seen in hum
an cells. 
M
a et al. 
2012 
hE
S
C
s (H
9, 
H
1) 
200ng/m
l S
H
H
, or  
0.65µM
 
P
urm
orpham
ine 
(w
hich is in 
equivalence of 
200ng/m
l S
H
H
). 
• Q
A
-Lesioned m
ice 
(D
ay 40 of differentiation protocol) 
• S
urvival at 4 m
onths. 
• Im
m
une-suppression w
as not used. 
100,000 cells 
• 
The grafted cells w
ere D
A
R
P
P
-32
+ve, C
TIP
2
+ve, 
M
E
IS
2
+ve 
G
A
B
A
 
M
S
N
s, 
and 
enkephalin 
or 
substance P
+ve. 
• 
Few
 
populations 
w
ere 
found 
to 
express 
vG
LU
T1, C
H
A
T, 5-H
T, TH
 and C
A
LB
IN
D
IN
. 
• 
The neurons projected to the substantia nigra. 
• 
The 
neurons 
received 
dopam
inergic 
and 
glutam
atergic inputs. 
• 
C
orrect m
otor asym
m
etry w
as observed, as 
seen using Trendscan. 
C
arri et al. 
2013 
hE
S
C
s (H
9, 
H
540) 
200ng/m
l S
H
H
, and  
100ng/m
l D
K
K
1. 
• Q
A
-Lesioned rat 
(D
ay 38 of differentiation protocol). 
• S
urvival at 3, 6 and 9 w
eeks. 
• U
se im
m
une-suppression daily 
(C
yclosporine). 
500,000 cells 
• 
A
t 3 w
eeks, no striatal m
arkers w
ere present. 
• 
A
t 
6 
&
 
9 
w
eeks, 
the 
grafted 
cells 
w
ere 
O
TX
2
+ve, 
FO
X
G
1
+ve, 
M
A
P
2
+ve 
and 
β-Tubulin 
III +ve. 
• 
A
t 
9 
w
eeks, 
the 
cells 
w
ere 
FO
X
P
1
+ve, 
FO
X
P
2
+ve, D
A
R
P
P
-32
+ve, but expression w
as 
not quantified. 
• 
A
 projection of N
E
S
TIN
-positive fibers into the 
intact striatum
 w
as observed, illustrating an 
interaction betw
een the grafts and the rat host 
tissue. 
• 
A
 decline in m
otor abnorm
ality w
as observed. 
                                                                                                                                                                                                              C
hapter 1: G
eneral introduction 
 
57 
N
icoleau et 
al. 2013 
hE
S
C
s (H
9) 
50ng/m
l S
H
H
, and  
W
N
T antagonist 
(100ng/m
l D
K
K
1 or 
1µM
 X
A
V
-939). 
• Q
A
-Lesioned nude rat 
(D
ay 25 of differentiation protocol) 
• S
urvival at 5 m
onths. 
• Im
m
une-suppression w
as not used 
150,000 cells 
• 
A
t 5 m
onths, the grafted cells w
ere FO
X
G
1
+ve, 
FO
X
P
1
+ve, C
TIP
2
+ve and D
A
R
P
P
-32
+ve. 
• 
N
o behavioural recovery. 
(Jeon et al. 
2014) 
H
D
75-h-
iP
S
C
s-
derived 
neural 
progenitors.  
C
o-culture w
ith P
A
6 
strom
al cells. 
•  Y
A
C
128 transgenic m
ice w
ith 128 
C
A
G
 repeats (12 m
onths old). 
• S
urvival at 12 w
eeks 
• U
se im
m
une-suppression daily 
(C
yclosporine). 
100,000 cells 
• 
S
igns 
of 
H
D
 
pathology 
observed 
at 
later 
cellular 
age 
(33 
w
eeks). 
H
ow
ever, 
at 
early 
cellular 
age 
(12 
w
eeks), 
no 
aggregate 
form
ation w
as evident. 
• 
B
ehavioural 
tests 
w
ere 
perform
ed 
using 
stepping, staircase and apom
orphine-induced 
rotation tests. B
ehavioural recovery began at 
w
eek 4 for the stepping test and at w
eek 6 for 
the other tw
o tests. 
(A
rber et 
al. 2015) 
hE
S
C
s (H
7) 
A
C
TIV
IN
 A
. 
• Q
A
-Lesioned rat 
(D
ay 20 of differentiation protocol). 
• S
urvival at 4-16 w
eeks. 
• U
se im
m
une-suppression daily 
(C
yclosporine). 
500,000 cells 
• 
A
t 16 w
eeks, the grafted cells w
ere G
A
B
A
ergic 
neurons 
that 
w
ere 
FO
X
P
2
+ve, 
C
TIP
2
+ve,  
D
A
R
P
P
-32
+ve and C
A
LB
IN
D
IN
+ve. 
• 
There w
as not overgrow
th of the grafted cells. 
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1.5.3 Direct differentiation into a specific differentiated cell type by 
ectopic expression of transcription factors  
 
In 1988, the first direct differentiation strategy using TFs was used by Tapscott et 
al. (1988) using the protein of MyoD1 to direct reprogramed fibroblasts into myogenic 
cells. Recently, the forced expression of TFs was used to direct differentiate human 
and mouse fibroblasts into induced neural (iN) cells and neuron precursor cells (NPCs) 
that was summarized in Table1.2 as Group 1 and 2 respectively. Also, direct 
reprogramming into different cell types such as cardiomyocytes (Table1.2 Group 3), 
haematopoietic fate precursor cells (Table1.2 Group 4) and induced hepatocyte-like 
cells (Table1.2 Group 5).  
 
Table 1.2: Summary of some published papers used the direct reprogramming strategy 
to differentiate somatic cells into a specific cell type. 
 
 Cell line Direct differentiation into cell type 
Ectopic expression of 
TFs References 
Group 1: direct 
differentiation 
into iN 
Astroglia Functional iN cells Ngn2 & Mash1 Berninger et 
al. 2007 
Postnatal 
cerebral 
cortical 
astroglia 
Functional glutamatergic 
neurons or GABAergic 
neurons 
Ngn2 or Dlx2 Heinrich et al. 
2010 
mPSCs and 
postnatal 
fibroblast 
Functional iN cells Brn2, Mash1 & Myt1l Vierbuchen et 
al. 2010 
Human 
fibroblasts 
Functional iN cells or 
dopaminergic neurons 
BRN2, MASH1 & MYT1L 
or  
BRN2, MASH1, MYT1L, 
LMX1A & FOXA2 
Pfisterer et al. 
2011 
Adult human 
primary 
dermal 
fibroblasts 
Functional human iN 
cells 
miRNA-124, MYT1L & 
BRN2 
Ambasudhan 
et al. 2011 
Human and 
mouse 
fibroblasts 
Functional iDA cells Mash1, Nurr1 & Lmx1a Caiazzo et al. 
2011 
Human 
fibroblasts 
including 
neonatal 
Functional neuronal cells miRNA-9/9-124, 
NEUROD1, MASH1 & 
MYT1L 
Yoo et al. 
2011 
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adult dermal 
cells. 
Human and 
mouse 
fibroblasts 
Functional iMNs Brn2, Mash1, Myt1l, Lhx3, 
Isl1, Hb9 & Ngn2 
Son et al. 
2011 
Mouse 
hepatocytes 
Functional iN Brn2, Mash1 & Myt1l Marro et al. 
2011 
hPSCs Functional iN cells BRN2, MASH1 & MYT1L Pang et al. 
2012 
Mouse 
fibroblasts  
Functional iNSC Brn2, Sox2, Klf4, c-Myc & 
E47  
Han et al. 
2012 
Mouse 
fibroblasts  
Functional iNSC Sox2, Klf4 & c-Myc Thier et al. 
2012 
Human and 
mouse 
fibroblasts 
Functional multipotent 
iNSCs 
Sox2 Ring et al. 
2012 
Adipocyte 
precursor cells 
Functional iN cells Brn2, Mash1 & Myt1l Yang et al. 
2013 
hPSCs Functional iN cells NGN2 OR NEUROD1 Zhang et al. 
2013 
Human 
fibroblast 
Functional iN cells with 
high efficiency 
MASH1, BRN2 & MYT1L 
vector then GFP vector 
with 4x miRNA-124 target 
sequences 
Lau et al. 
2014 
Group 2: direct 
differentiation 
into iNPCs 
Mouse 
fibroblasts 
Functional midbrain iDA 
progenitors cells 
Pitx3, Nurr1, Lmx1a, 
Lmx1b, En1, Mash1, Myt1l, 
Brn2, Ngn2, Sox1 & Pax6 
Kim et al. 
2011 
Mouse 
fibroblasts  
1- Functional iNPCs with 
glia and neural 
morphologies 
2- Bi-potent iNPCs 
(differentiated into 
astrocyte and 
functional neurons), 
3-  tri-potent iNPCs (into 
astrocytes, neurons 
and 
oligodendrocytes) 
and 
4- tri-potent iNPCs (into 
astrocytes, 
oligodendrocytes and 
less mature neurons) 
1-11 TFs; Foxg1, Sox2, 
Brn2, Mash1, Lhx2, Dlx1, 
Zic1, Olig2, Pax6, ID4 & 
Rfx4, 
2-Foxg1 & Sox2, 
3-Foxg1, Sox2 & Brn2 and 
4-Foxg1 & Brn2 
Lujan et al. 
2012 
Group 3: direct 
differentiation 
into cardiac 
muscle cells 
Mouse 
fibroblasts 
Cardiomyocytes Oct4, Sox2, C-Myc & Klf4 Efe et al. 
2011 
Group 4: direct 
differentiation 
into blood cells 
Human 
fibroblasts 
Mature haematopoietic 
precursors cells  
Oct4 Szabo et al. 
2010 
Group 5: direct 
differentiation 
into liver cells 
Mouse 
fibroblasts  
Functional induced 
hepatocyte-like cells 
Gata4, Hnf1α, Foxa3 & 
p19Arf inactivation 
Huang et al. 
2011 
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Abbreviations: iN cells: induced neuronal cells, iMNs: induced motor neurons, iDA cells: induced 
dopaminergic (iDA) cells, miRNA: MicroRNA, iNSC: induced neural stem cells; iNPCs: Induced neural 
precursor cells. 
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1.6 Working hypothesis and aims 
 
Direct differentiation of mouse and human somatic cells into induced neuronal 
cells has been successfully achieved through the forced expression of TFs, that have a 
role in neurogenesis, such as MASH1, Sox2, NGN2 and DLX2 (see details in Table 
1.2 Group 1&2). Nonetheless, this strategy has not been performed yet, to direct 
differentiate hPSCs into the functional MSNs through forced expression of major TFs, 
with a specific role in ventral telencephalon development, such as MASH1, DLX2 and 
GSX2 (Pauly et al. 2013). However, indirect ectopic expression of morphogens, such 
as SHH, has been evaluated; this approach has resulted in low percentage of DARPP-
32+ve MSNs (Kallur et al. 2006; Aubry et al. 2008; Jeon et al. 2012;Carri et al. 2013; 
Nicoleau et al. 2013; Jeon et al. 2014; Arber et al. 2015). In fact, these studies have 
failed to generate a pure population of striatal MSNs. Only one study has observed in 
high yield of (up to 80%) DARPP-32+ve MSNs (Ma et al. 2012). Another disadvantage of 
some of these studies was the lack of comprehensive function analysis of striatal 
neurons using electrophysiology (Kallur et al. 2006;Aubry et al. 2008;Nicoleau et al. 
2013) Therefore, based on the above hypothesis, the aim of this study was to express 
the TFs ectopically, that have role in ventral telencephalon development into hPSCs to 
direct reprogram into specific neuron cell type, i.e. striatal GABAergic MSNs. In 
addition, a comprehensive approach was also employed to assess the phenotype and 
functionality of GABAergic MSNs in this project. 
 
1.7 Objectives of the project 
 
The main objectives of the project were to predict and confirm the desired TFs 
that have a role in the MSN development using existing microarray public database 
with the help of bioinformatics tool. Then, the identified TFs were used to express 
ectopically in the hPSCs-derived forebrain-like neural progenitors in order to directly 
differentiate them into MSNs-like cells. In addition, the reprogrammed cells were 
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characterized for the ectopic expression of nucleofected TFs, and further validated for 
differentiation into ventral forebrain commitment towards LGE neuronal progenitors, 
eventually towards functional GABAergic MSNs using ventral markers and 
electrophysiology, in vitro.  
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2.1 Introduction 
 
The striatum forms a major part of the basal ganglia that is located in the 
subpallium domain of telencephalon (Pauly et al. 2013). The striatum’s primary and 
major neurons are GABAergic medium-sized spiny neurons (MSNs), originating from 
the lateral ganglionic eminence (LGE) (Feyder et al. 2011). In Huntington’s disease 
(HD) patients, the most affected tissue is the striatum, where the degeneration of 
GABAergic MSNs takes place (Vonsattel et al. 1985). Several mechanisms have been 
identified to promote neurodegeneration in HD, including mitochondrial dysfunction 
(Cui et al. 2006), impaired axonal transport (Trushina et al. 2004), altered synaptic 
transmission, altered protein-protein interactions, glutamate- and dopamine-mediated 
excitotoxicity (Zeron et al. 2002) and, most importantly, altered transcription factor (TF) 
expression (Thomas et al. 2011). In HD, dysregulation of gene expression is based on 
a loss of function in Huntington protein (HTT)-mediated regulation of transcription 
(Gardian et al. 2005; Bithell et al. 2009; Soldati et al. 2013). A growing number of 
studies from both HD patients (post-mortem) and animal models have indicated a 
widespread changes in gene expression, which possibly trigger a cascade of several 
intracellular pathways and subsequently cause loss of neuronal identity and 
neurodegeneration (Augood et al. 1997; Gardian et al. 2005; Bithell et al. 2009; Soldati 
et al. 2013). More specifically, previous investigations using the HD model in mice have 
shown that mutant Huntington protein (mHTT) interacts with TFs and reduces histone 
acetylation such that TFs cannot access specific regions of DNA to initiate 
transcription, producing a TF impairment and contributing to HD pathogenesis (Gardian 
et al. 2005). Transcriptional changes in HD also involve transcriptional repressor 
dysregulation (Landles and Bates 2004; Hodges et al. 2006; Bithell et al. 2009). By 
way of example, disrupted interactions between mHTT and RE1 (repressor element 1)-
silencing transcription factor (REST) and neuron-restrictive silencing factor (NRSF), a 
TF repressor, in HD promotes migration of REST into the nucleus, resulting in aberrant 
repression of coding target genes and non-coding RNAs (Zuccato et al. 2001; Zuccato 
                                                                                                                    Chapter 2: Introduction 
 65 
et al. 2003). This reduced expression of coding genes, such as the brain-derived 
neurotrophic factor (BDNF) genes, leads to loss of neuronal trophic support and leaves 
striatal neurons vulnerable to degenerative changes in HD (Altar et al. 1997; Zuccato et 
al. 2001; Zuccato et al. 2003; Zuccato et al. 2007). On the other hand, the increase in 
nuclear REST consequences in repression of miRNA, e.g. mir-124, and in a 
concomitant increase of its target genes, driving the loss of neuronal identity (Wu and 
Sun 2006; Johnson et al. 2008).  
It is becoming increasingly essential to understand the molecular dysregulation of 
HD and its underlying pathogenic mechanism, the knowledge of which is still in its 
infancy. To achieve this goal, a human disease model derived from HD patients’ actual 
cells is required instead of using animal models. With this, the first step in establishing 
a human disease model is to successfully differentiate HD patient-derived stem cells to 
MSNs using the right combination of TFs to drive neurogenesis and MSN 
differentiation. To gain further insight into the TF network involved in normal forebrain 
neurogenesis and striatal differentiation, bioinformatics tools can be used to import 
genomic datasets from Gene Expression Omnibus (GEO) and analyze the statistical 
significance of candidate genes using GeneSpring software (Genetics 2003). 
Importantly, GeneSpring allows microarray data to be more easily understood relative 
to its biological function (Genetics 2003). Such an approach has been employed 
previously to explore the genetic circuits of Parkinson’s Disease (PD) (Hu 2011), where 
significant gene expression profiles were retrieved using two datasets, GSE6613 and 
GSE7621, from the GEO website (Genetics 2003).  
The aim of this study was to validate and identify TFs and their target genes that 
have fundamental roles in ventral telencephalic fate commitment, regulation of 
neurogenesis, and MSN differentiation and maturation. The only available microarray 
data from the NCBI that elucidates TF networks in brain development and 
neurogenesis are derived from B-cell lymphoma/leukemia 11B (BCL11B, also named 
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Ctip2) null mutant mice and Ctip2-/+ mutant mice (Arlotta et al. 2008). In the present 
work, the MSN microarray repository dataset analysed here were derived from the 
striatum of Ctip2-/- and Ctip2-/+ mutant mice at postnatal day 0 (P0), (series reference 
GSE9330) (Arlotta et al. 2008), obtained from the GEO datasets of the NCBI. Then, 
differentially expressed TFs and their target genes associated with neurogenesis 
identified using GeneSpring software could be manipulated to generate a gene pool of 
MSNs in vitro, which may then be used for the disease model of HD.  
 
 
                                                                                                   Chapter 2: Experimental Strategy 
 67 
2.2 Experimental Strategy 
 
Global transcriptome comparison was conducted between two different mouse 
models and the wild type. GeneSpring software was used to import experiment data 
sets from GEO and to generate expression datasets to assess statistically significant 
genes from a total of eight samples. The control datasets included three independent 
replicates. The test samples included datasets representing four independent 
replicates of the Ctip2-/- homozygous mouse and one dataset from the Ctip2-/+ 
heterozygous mouse with no replicates (Arlotta et al. 2008).  
Analysis of the microarray data sets using GeneSpring software involved four 
steps: importing the microarray datasets to the software; creating the experiment; 
quality control of the microarray data sets; and statistical analysis of the data. 
 
2.2.1 Importing the microarray data set to GeneSpring software  
 
Eight Affymetrix files were downloaded from the tools menu by selecting an 
option “imported NCBI GEO experiment”, as the datasets were originally from the GEO 
database. The experimental data were generated using an Affymetrix mouse 430-2 
chip. 
 
2.2.2 Creating the experiment 
 
The experiment was created using three steps as follows: (i) normalization of 
the datasets; (ii) definition of parameters; and (iii) interpretation. Firstly, the CEL 
scanned image files were converted into values, which represented intensity values 
associated with probes, and the values were grouped into probe sets. The MAS.5 
algorithm was then used to transform these probe sets into expression values. The 
advantage of the MAS.5 algorithm is that it defines the mismatch positions and counts 
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the number of nonspecific bindings for a given object. All samples were baseline 
normalised to a median. An example of mismatch (MM) and perfect match (PM) probes 
used in the Affymetrix platform is shown in Figure 2.1. The Affymetrix approach 
assembly probes into probe set pairs comprising a MM and a PM. The PM probe is a 
25 base oligonucleotide that is complementary to a transcript, and the MM probe has 
the same sequence as the PM; however, at the 13th base position is hybridized to the 
PM probe set (Figure 2.1) (Rouchka et al. 2008). The data generated from MM probes 
enables recognition of cross-hybridization. Whether or not to include a probe set is 
based on the ratio of the intensity values of the corresponding PM and MM. For 
example, in Figure 2.2, which shows the probe set 206055-at, the intensity values for 
the PM probes are higher than the corresponding MM probes, and hence this probe set 
is included (Rouchka et al. 2008). However, in Figure 2.2 for the probe set 219820-at, 
the MM probes have higher intensity values than the PM probes, which may be due to 
cross hybridization, and hence this probe set may be excluded (Rouchka et al. 2008). 
 
Figure 2.1:! An example of complementary of PM versus MM to the transcript in the 
Affymetrix platform. 
The diagram shows an example of hybridization of PM and MM to the transcript. At the 13th 
position, MM is cross-hybridize with the position in PM probe. 
 
 
Transcript 
 
 
PM 
 
 
MM 
Cross-
hybridization 
at 13th 
position 
A T C G A T C G A T C G A ---- To 25 Base 
T A C G T A G C T A G C T ---- To 25 Base 
T A C G T A G C T A G C A ---- To 25 Base 
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Figure 2.2:! An example of intensity levels for three Affymetrix probe set PM and MM 
pairs. 
Three different probe set pairs of PM/MM that show the intensity levels of PM and the 
corresponding MM that located directly below the PM probe. Each probe set represents eleven 
probe set pairs and a greyscale is used to depict intensity levels. Figure adapted from (Rouchka 
et al. 2008). 
Abbreviations: PM: Perfect match; MM: Mismatch. 
 
In the following step, a new parameter, such as tissue type (the control wild 
type mouse, Ctip2-/- homozygous mouse and Ctip2-/+ heterozygous mouse), was 
added. Importantly, the tissue type parameter was chosen as a predictor in this 
experiment. Following construction of the experiment, a list of probe set IDs were 
generated with additional information, such as the Gene Symbol, Entrez Gene and 
Gene Ontology, specifically the biological process, cellular components and molecular 
functions.  
PM 
 
MM 
 
PM 
 
MM 
 
PM 
 
MM 
 
Affymetrix ID: 206055-s-at 
Affymetrix ID: 208913_at 
Affymetrix ID: 219820_at 
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2.2.3 Quality control and statistical analysis of the data sets 
 
The MAS.5 algorithm was used to detect the hybridized genes and establish if 
they were present, marginal or absent. The data was then filtered using flags to 
determine if they were present, marginal or absent and below a condition of one out of 
eight, this being shown as 12.5%. Each gene had a signal value with a detection p-
value to indicate if the transcript was detected as present, marginal or absent. In 
addition, where the data flagged as present marginal or absent flags, additional filtering 
was performed via a differential expression using statistics (unpaired t-test) with a p-
value of less than or equal to 0.05, with correction for multiple comparisons using the 
Benjamini-Hochberg false discovery rate (FDR). An unpaired T-test was used for the 
three cultures, the control and the two mutant cultures with different replicates. The 
profiles of differentially expressed genes were then filtered again with a cut-off fold 
change (FC) of less than 1.3 in order to retrieve the differentially expressed genes with 
a large magnitude of FC. This meant that there were changes in expression between 
the mutant and control tissues which revealed the genes that passed the t-test with a 
p-value of less than 0.05 and also showed changes in expression of more than 1.3. 
Clustering of the data for the hierarchal gene tree was performed with entities of 
clusters; these had particular conditions (Ctip2-/- homozygous mouse, Ctip2-/+ 
heterozygous mouse and control). For this analysis, the metric distance of the 
differentiation and the linkage role were centroid.  
Finally, analysed data and figures were exported. Further data analysis utilized 
bioinformatics databases, including the David Bioinformatics Resources 6.7 (National 
Institute of Allergies and Infectious Diseases (NIAID), NIH), the GeneCards Human 
Gene Database v.3 (Weizmann Institute of Science), and the UniProtKG (Protein 
Knowledgebase, UniProt Consortium). The probe set IDs were pasted into the David 
Bioinformatics database under functional annotation clustering in order to retrieve more 
information about the biological role of the differentially expressed significant genes. 
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2.3 Results 
 
2.3.1 Differentially expressed genes identified in Ctip2-/-heterozygous, 
Ctip2-/+ heterozygous and wild-type mice  
 
A total of 45,101 genes were analysed for the Ctip2-/- homozygous, Ctip2-/+ 
heterozygous and control mice. In order to obtain a nearly complete knowledge about 
TFs association with forebrain development and specific striatal medium spiny neurons 
(MSNs) differentiation, all present, marginal, and absent genes detected were included 
in the analyses. The results showed 2,791 differentially expressed genes with a p-
value less than 0.05 and a fold change more than 1.3. The top 20 up-regulated and 
down-regulated genes with a wide range of functions are listed in Table 2.1. Next, 
Gene ontology (GO) analyses were performed to define only dysregulated genes 
involved in forebrain development. 
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Table 2.1: Dysregulated genes between Ctip2-/- homozygous, Ctip2-/+ heterozygous and 
wild-type. 
Probe Set ID p-value Regulation Fold change Gene symbol 
1449470_at 4.44E-06 up 4.25 Dlx1 
1416302_at 2.07E-05 up 2.33 Ebf1 
1448789_at 4.98E-05 up 6.02 Aldh1a3 
1416561_at 1.32E-04 up 2.26 Gad1 
1457072_at 2.62E-04 up 2.53 Ctip1 
1426637_a_at 3.73E-04 up 10.24 Six3 
1438194_at 5.57E-04 up 1.48 Slc1a2 
1434023_at 8.78E-04 up 3.07 Cep120 
1428939_s_at 0.002 up 2.04 Gnaq 
1427523_at 0.003 up 2.65 Six3 
1419271_at 0.004 up 4.18 Pax6 
1448877_at 0.004 up 3.49 Dlx2 
1416855_at 0.007 up 2.80 Gas1 
1422165_at 0.007 up 2.05 Pou3f4 
1427703_at 0.007 up 2.07 Pafah1b1 
1425094_a_at 0.008 up 2.23 Lhx6 
1438232_at 0.010 up 1.5 Foxp2 
1421978_at 0.012 up 2.17 Gad2 
1449863_a_at 0.020 up 1.36 Dlx5 
1448893_at 0.026 up 1.43 Ncor2 
1422206_at 1.58E-07 down 1.73 B3galt1 
1438784_at 8.27E-06 down -3.59 Ctip2 
1436868_at 3.17E-05 down 2.07 Rtn4rl1 
1431091_at 7.23E-05 down 1.62 Pygo1 
1417399_at 9.26E-05 down 2.41 Gas6 
1435227_at 1.51E-04 down 2.68 Ctip2 
1416221_at 1.58E-04 down 2.15 Fstl1 
1435649_at 1.99E-04 down 7.04 Nexn 
1450339_a_at 2.17E-04 down -3.58 Ctip2 
1448978_at 4.02E-04 down 3.50 Ngef 
1429485_a_at 4.30E-04 down 1.77 Utp11l 
1449465_at 0.002 down -3.9 Reln 
1446633_at 0.003 down -4.83 Atg7 
1456051_at 0.007 down -2.74 Drd1a 
1421140_a_at 0.010 down 1.42 Foxp1 
1437086_at 0.011 down -2.44 Mash1 
1433602_at 0.021 down 1.62 Gabra5 
1427044_a_at 0.021 down 1.40 Amph 
1424601_at 0.026 down -1.36 Xrcc4 
1422285_at 0.031 down -4.19 Otp 
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2.3.2 Identification of dysregulated genes related to brain 
development and neurogenesis using GO tree 
 
To focus on differentially expressed genes relevant to brain development and 
neurogenesis in Ctip2-/- homozygous, Ctip2-/+ heterozygous compared to control mice, 
GO tree analyses were performed. As the initial results revealed in Figure 2.3, over 
100 transcription factors, transcription repressors, target genes or effector genes 
associated with neuronal differentiation and development were dysregulated. Further, 
GO analysis to determine the individual genes involved was demonstrated and listed in 
Tables 2.2 to 2.4. Among the significant genes, both Dlx2 and Mash1 (also known as 
Ascl1) transcription factors are significantly dysregulated in Ctip2-/- homozygous and 
Ctip2-/+ heterozygous mice in comparison to controls, and they have an important role 
in ventral forebrain fate commitment and development (Tables 2.2 and 2.3). The GO 
analysis shows significant upregulation of Dlx2 (fold change of 3.49), but 
downregulation of Mash1 (fold change of -2.44). The key roles of these genes are 
consistent with previous findings (Yun et al. 2002; Petryniak et al. 2007; Long et al. 
2009b; Wang et al. 2013). Therefore, these two transcription factors are considered a 
complementary combination to differentiate stem cells into MSNs in this study. 
Interestingly, Gsx2, which also promotes early ventral telencephalon development 
through induction of Mash1, Olig2, and Dlx2 expression (Szucsik et al. 1997; Corbin et 
al. 2000; Toresson et al. 2000; Wang et al. 2013), is not expressed any different within 
this dataset (data not shown). Therefore, these two transcription factors, along with 
Gsx2, are considered a suitable combination to differentiate stem cells into MSNs.  
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Figure 2.3: Initial GO analysis of differentially expressed genes with a significant role 
in forebrain development.  
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Table 2.2: Gene Ontology (GO) analysis for the genes identified in the development of 
telencephalon. 
 
 
Table 2.3: Gene Ontology (GO) analysis for genes identified in the forebrain generation of 
neurons.
Fold Gene 
change symbol
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Probe Set ID p-value Regulation GO terms
1419271_at 0.01 up
1420995_at 0.04 up 2.34 Plxna3
1422165_at 0.01 up 2.05 Pou3f4
1425094_a_at 0.01 up 2.23 Lhx6
1422262_a_at 0.04 up 1.84 Lhx6
1422285_at 0.03 down -4.19 Otp
1448877_at 0.01 up 3.49 Dlx2
1449470_at 4.44E-06 up 4.25 Dlx1
1428938_at 0.02 up 1.79 Gnaq
1428939_s_at 0.002 up 2.04 Gnaq
1428940_at 0.01 up 1.91 Gnaq
1429559_at 0.02 up 1.72 Gnaq
1455729_at 2.00E-03 up 1.83 Gnaq
1446633_at 0.002 down -4.83 Atg7
Commitment of neuronal cell to 
specific neuron type in forebrain
1448877_at 0.01 up 3.49 Dlx2 Commitment of multipotent stem Forebrain neuron 
1449470_at 4.44E-06 up 4.25 Dlx1 cells to neuronal lineage in forebrain fate commitment
1425094_a_at 0.01 up 2.23 Lhx6
1422262_a_at 0.04 up 1.84 Lhx6
1420995_at 0.04 up 2.34 Plxna3
1446633_at 0.002 down -4.83 Atg7
1420995_at 0.04 up 2.34 Plxna3
1425094_a_at 0.01 up 2.23 Lhx6
1422262_a_at 0.04 up 1.84 Lhx6
1428938_at 0.02 up 1.79 Gnaq
1428939_s_at 0.002 up 2.04 Gnaq
1428940_at 0.01 up 1.91 Gnaq
1429559_at 0.02 up 1.72 Gnaq
1455729_at 2.00E-03 up 1.83 Gnaq
1446633_at 0.002 down -4.83 Atg7
1458560_at 0.04 down -2.23 Aspm
Pyramidal neuron development
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1419271_at 0.01 up 4.18 Pax6
Fold Gene 
 change symbol
1438231_at 0.014 up 1.56 Foxp2
1421140_a_at 0.01 down 1.42 Foxp1
1438232_at 0.01 up 1.5 Foxp2 Striatum Subpallium
1421140_a_at 0.01 down 1.42 Foxp1 development development
1448789_at 4.98E-05 up 6.02 Aldh1a3 Nucleus accumbens development
1456051_at 0.01 down -2.74 Drd1a
1437086_at 0.01 down -2.44 Mash1
1417086_at 0.02 up 1.61 Pafah1b1
1427703_at 0.01 up 2.07 Pafah1b1
1425094_a_at 0.01 up 2.23 Lhx6
1422262_a_at 0.04 up 1.84 Lhx6
1435577_at 0.04 up 1.71 Dab1
1449465_at 0.001 down -3.9 Reln
1451086_s_at 0.04 up 1.31 Rac1
1456051_at 0.01 down -2.74 Drd1a
1416561_at 1.32E-04 up 2.255 Gad1
1421978_at 0.01245 up 2.172 Gad2
1448789_at 4.98E-05 up 6.02 Aldh1a3
1438231_at 0.014 up 1.56 Foxp2
1438232_at 0.01 up 1.5 Foxp2
1456051_at 0.01 down -2.74 Drd1a
Probe Set ID p-value Regulation
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GO terms
Subpallium neuron fate commitment
Pallium development / Olfactory Lobe (OL) development /
Corpus callosum development
Putamen development
Caudate nucleus development
Telencephalon cell migration
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Table 2.4: Gene Ontology (GO) analysis for genes identified in the development of the 
 forebrain. 
 
2.3.3 Identification of DLX2 and MASH1 target gene interactions 
involved in forebrain neuron generation using pathway analysis 
 
We subjected differentially expressed genes with potential roles in forebrain 
development to cellular and molecular pathway analyses in order to identify target 
genes associated with DXL2 and MASH1 TFs and other potential effector genes.  
Fifty-three target genes were found to play critical roles in neurogenesis and 
anatomical structure morphologies (Figure 2.4). As shown in Figure 2.4, Mash1 
regulates Dlx1 and Dlx2 expression while Dlx1/2 regulates Arx, Dlx5, Uba2, and Spg7 
expression. Furthermore, the results allude to important candidate effector genes, such 
as Ctip2, Ebf1, Foxp1/2, DRD1/2, and GAD1/2, normally promoting striatal 
development and differentiation. Moreover, these genes including Foxp1, Ebf1, Drd1/2, 
Gad1/2 are also dysregulated as indicated by GO tree in previous Tables 2.2 and 2.3. 
Clearly, what is shown is that these target and effector genes are potential candidates 
for assessing the success of the differentiation program for stem cells into MSNs after 
transfecting stem cells with major TFs, i.e. Mash1, Dlx2 and Gsx2.  
Fold Gene 
 change symbol
1448893_at 0.03 up 1.43 Ncor2 Cell proliferation
1434023_at 8.78E-04 up 3.07 Cep120 Interkinetic nuclear migration in forebrain
1419271_at 1.00E-02 up 4.18 Pax6
1426637_a_at 3.73E-04 up 10.24 Six3 Anterior/posterior pattern Forebrain
1427523_at 0.003 up 2.65 Six3 formation regionalisation
1419271_at 0.004 up 4.18 Pax6 Dorsal/ventral pattern formation
1416967_at 0.04 up 1.29 Sox2
GO terms
Forebrain morphogenesis
Probe Set ID p-value Regulation
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Figure 2.4: The expanded interaction for the target genes involved in the forebrain neuron generation.  
The advanced interaction betw
een the target genes identified as significantly dysregulated in the forebrain neurons generation. 
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2.4 Discussion 
 
While the aetiology of HD is the “mHTT toxic gain of function” and “HTT loss of 
function”, the comprehensive understanding of pathogenic mechanisms with respect to 
altered gene expression is still developing. It is of importance to have a human HD 
model using a patient’s own stem cells that will differentiate into MSNs to understand 
the molecular and biological aspects of HD pathogenesis and to develop a future for 
gene therapy. To this end, we identified statistically dysregulated TFs and their target 
genes in the only NCBI available dataset (Ctip2-/- mutant mouse microarray) using 
bioinformatics tools such as “GeneSpring”. These dysregulated TFs and their target 
genes play a major part in ventral telencephalon (forebrain) development, 
differentiation and fate commitment. Here, we have demonstrated that significantly 
dysregulated TFs, Dlx2 and Mash1, are appropriate and complementary to use in 
combination to differentiate stem cells into GABAergic neurons. In addition, their 
dysregulated target genes Dlx1/2 by TF Mash1 and target genes Dlx5 and Arx by TF 
Dlx1/2 as well as other effector genes, like Foxp1/2, Drd1/2, Ebf1, and Gad1/2, can be 
used as striatal or GABAergic neuron markers to validate the success of stem cell 
differentiation into GABAergic neurons and maturation. 
From the gene expression profile using GeneSpring, Mash1 and Dlx2 were 
among the significantly dysregulated genes (Table 2.1). Mash1 and Dlx1/2 have a 
fundamental role in ventral telencephalon (forebrain) development, activation of 
transcription factors, regulation of neurogenesis, LGE differentiation, and neuronal fate 
commitment in the forebrain. Furthermore, Mash1 induces neuroblast proliferation, 
particularly in the ventricular zone (VZ). These functions are in line with the previously 
reported studies conducted in Mash1-/- and Dlx1/2-/- mutant mice and Mash1-/-;Dlx1/2-/- 
triple mutant mice models (Long, Swan, et al. 2009; Pauly et al. 2013; Yun et al. 2001; 
Yun et al. 2002; Yun et al. 2003; Toresson and Campbell 2001). 
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 Many studies have revealed that alternative GABAergic cell fate is controlled by 
the coordinated functions of Mash1 and Dlx1/2. During early neurogenesis, the 
increased expression of Mash1 in the ventral telencephalon (Lo et al. 1991, Guillemot 
et al. 1993, Horton et al. 1999) activates Notch signaling and enhances the expression 
of Dll1, Dll3, and Notch signalling’s target gene i.e. Hes5. Consequently, this gene 
profile triggers adjacent progenitor proliferation and inhibits differentiation (Horton et al. 
1999, Yun et al. 2002, Poitras 2007). Expression failure of these candidate effectors 
was observed in Mash1-/- mutant mice, causing loss of proliferative progenitor in the 
subventricular zone (SVZ) of the medial ganglionic eminence (MGE). In addition, the 
ventricular zone (VZ) progentiors precociously acquired prematurely the SVZ 
progenitors’ property of lateral ganglionic eminence (LGE), exhibited by an increased 
ectopic expression of GAD1 and Dlx5 in VZ (Casarosa et al. 1999). However, during 
late neurogenesis, domination by Dlx1/2 expression represses the expression of 
Mash1 and the Notch signaling pathway, subsequently promoting differentiation, 
specification and maturation of striatal neurons (GABAergic neurons), evidenced by 
increased expression of Drd2, Gad1/2 in SVZ and mantle zone (MZ) (Anderson et al. 
1997a, Yun et al. 2002, Cobos et al. 2007). Therefore, corroborating with the above 
results, the inhibitory negative feedback of Dlx1/2 on Mash1 expression explains the 
current observation of Dlx1/2 over-expression and Mash1 diminished expression in 
Ctip2-/- mutant mice, when compared to wild-type mice in this chapter. Migration of 
GABAergic neurons to the cerebral cortex is also mediated by Dlx1/2 through the 
induction of Arx expression and inhibition of p21-activated serine/theronine kinase 
(PAK3), as demonstrated by Arx-/- and/or Dlx1/2-/- mutant mice (Anderson et al. 1997a, 
Stühmer et al. 2002b, Cobos et al. 2005a, Yoshihara et al. 2005, Cobos et al. 2007, 
Colombo et al. 2007). Thus, it has been proposed that Mash1 is necessary for the early 
development of the subpallium (ventral) telencephalon, while Dlx1/2 is critical for late 
neurogenesis (Yun et al. 2002; Long et al. 2009a; Long et al. 2009b). 
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On the other hand, Mash1 and Dlx1/2 also have a parallel yet redundant manner 
of directing the neurogenesis program. This is supported by the partial blockage of 
striatal development in Dlx1/2-/- mutant mice, represented by preserved expression of 
DRD1/2 and GAD1/2 (Long et al. 2009a). These mutant mice presented with a clear 
defect of striatal neuron differentiation in dLGE, but vLGE neuronal identity is partially 
maintained, suggesting the presence of a parallel pathway to Dlx1/2 function. Such a 
preservation of vLGE development could be maintained by the expression of Mash1, 
Gsh1/2 (also named Gsx1/2), and Tlx (Long et al. 2009a). Another line of evidence 
giving credence to the parallel function of Mash1 is the sustained expression of the 
Dlx1/2 target gene, i.e. Gad1/2 in Dlx1/2-/- mutant mice (Stühmer et al. 2002a; Poitras 
et al. 2007). This sustained expression is accomplished by MASH1-induced Dlx1/2 
expression through binding to the enhancer, I12b (Fode et al. 2000). Such 
substantiation highlights the critical role of Mash1 and Dlx1/2 in early and late 
neurogenesis in the dLGE, and Mash1 alone in the septum and vLGE as well as MGE 
neurogenesis (Casarosa et al. 1999, Long et al. 2009a). These characteristic 
anatomical functions correspond with the expression pattern of Dlx1/2 and Mash1, both 
highly co-expressed in most dLGE VZ and SVZ progenitors, whereas there is much 
less expression of Dlx1/2 in vLGE and MGE (Porteus et al. 1994, Casarosa et al. 1999, 
Yun et al. 2002, Long et al. 2009a). These studies reveal the profound role of Dlx2 and 
Mash1 to induce efficient and successive progress of neurogenesis in striatum. Based 
on the parallel and overlapping function of Dlx1/2 and Mash1 in regulating 
neurogenesis of GABAergic neurons (MSNs), this combination of TFs will be used in 
the subsequent chapters for cloning and differentiating human pluripotent stem cell 
(hPSC)-derived naïve rosette neural progenitor cells (nrNPCs) into MSNs.   
Gsx2 is a further important TF in promoting the early identity of the ventral 
domain of the forebrain, with great emphasis on VZ in dLGE and dCGE (Hsieh et al. 
1995, Corbin et al. 2000, Toresson et al. 2000, Wang et al. 2013). The loss-of-function 
mouse model (Gsx2-/- mutant mice) has presented with a profound defect of LGE, 
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particularly dLGE, and reduction of Mash1, Dlx1/2, Ebf1, and GAD1 expression, while 
the ectopic expression of Gsx2 retained expression of all these genes (Szucsik et al. 
1997, Corbin et al. 2000, Toresson et al. 2000, Wang et al. 2013). Despite Gsx2 
expression not being dysregulated in the current bioinformatics analysis, the parallel 
function of Gsx2 with Mash1 and Dlx1/2 TFs in programming striatal progenitor 
development cannot be denied (Long et al. 2009a). Hence, in this project, Gsx2 was 
combined with Mash1 and Dlx1/2 TFs to differentiate hPSC-derived nrNPCs into 
GABAergic neurons.  
The other aim of this study was to validate previously described neuronal 
differentiation and maturation markers (Drd1/2, Gad2, Ebf1 and Foxp1) as well as to 
detect neuronal phenotypes in the SVZ and MZ, some of which are target genes for 
Dlx1/2. In this chapter, target genes of Dlx1/2 such as Drd1/2 and Gad2 were 
dysregulated in Ctip2-/- striatum (Stühmer et al. 2002a; Cobos 2005a; Yoshihara et al. 
2005; Cobos et al. 2007; Colombo et al. 2007; Long et al. 2009a). The striatum is a 
major part of the brain that controls inputs and outputs for motor and cognitive 
functions (Albin et al. 1989; Moyer et al. 2007). This is largely accomplished by the 
dopaminergic actions of Drd1 and Drd2. It has been shown that Drd1 provides 
projections to control direct pathways, whereas Drd2 provides projections to control 
indirect pathways. The expression of Drd1/2 is higher in the striatum than the frontal 
cortex in mice (Araki et al. 2007). In fact, expression of Drd1/2 is localized to the SVZ 
and MZ in the striatum, along with Gad1/2 expression (Long et al. 2009b). The 
dominant expression of Drd1/2 in the SVZ and MZ of the striatum is indicative of the 
correspondence between its expression pattern and striatal MSNs’ maturation and 
phenotype. In addition, Gad1/2 genes encode the glutamic acid decarboxylase 1/2 
enzyme, which converts glutamate into GABA (Pinal and Tobin 1998). This allows 
neurons to gain the GABAergic phenotype, which is the dominant neuron type in the 
striatum (Feyder et al. 2011). Gad1 and Gad2 are localized in the neuronal cytoplasm 
and the nerve terminal, respectively (Pinal and Tobin 1998). A growing number of 
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studies have been used Drd1/2 and Gad2 to closely examine LGE striatal 
differentiation and maturation status in SVZ and MZ in loss-of-function mouse models, 
such as Mash1-/- and Dlx1/2-/- (Anderson et al. 1997b; Casarosa et al. 1999; Garel et al. 
1999; Horton et al. 1999; Zerucha et al. 2000; Stühmer et al. 2002a; Yun et al. 2002; 
Long et al. 2007; Poitras et al. 2007;Colasante et al. 2008). Taken together, Drd1/2 
and Gad1/2 are major biomarkers for the differentiation and maturation stages that 
take place in the SVZ and MZ as described in previous mice models. The 
dysregulation of Drd1/2 and Gad1/2 observed in the current bioinformatics analysis 
and hence these biomarkers were utilized for further in in vitro analysis in the LGE 
striatal differentiation and maturation. 
The current microarray analysis of the Ctip2-/- striatum has also predicted 
dysregulation of effector TFs with a role in MSN differentiation. Some examples of 
dysregulated effectors are Ebf1, Foxp1/2, Drd1/2, Gad2 and Ctip2, which are normally 
expressed in the SVZ and MZ of the LGE (Long, Swan, et al. 2009; Pauly et al. 2013). 
Ctip2 TF is uniquely expressed in striatal MSNs during early post-mitotic maturation, 
and controls patch-matrix compartmentalisation of MSNs (Arlotta et al. 2008). Lack of 
Ctip2 in a mutant mouse exhibited defective organization of MSNs into striatal patches 
(Arlotta et al. 20008). In addition, Ctip2 is likely to be a downstream gene of Dlx1/2, 
Mash1, Gsx2, and Islet1 (Anderson et al. 1997a; Casarosa et al. 1999; Yun et al. 2002; 
Stenman et al. 2003). Foxp1 is a preferential marker for striatal projection neurons in 
the matrix compartment of the striatum, cortex, and hippocampus, while Foxp2 is a 
marker for striosomal compartment (Tamura et al. 2004; Ibanez et al. 2012). Ebf1, 
which is a target gene for GSX2 (Wang et al. 2013), is preferentially expressed in 
striatonigral neurons, and also involved in regulating striatal projection neuronal 
development and differentiation (Garel et al. 1999; Garcia-Dominguez et al. 2003; Lobo 
et al. 2006; Ibanez et al. 2012). The importance of Ebf1 is documented in mutant mice 
presented with defective projections of neurons to the substantia nigra (Lobo et al. 
2006). These various forms of evidence support the use of the target markers (Ebf1, 
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Foxp1/2, and Ctip2) in this study not only to assess phenotype of neurons, but also to 
examine the progress of the direct differentiation of hPSC-nrNPCs through the 
expression of critical TFs and effector genes. 
Overall, the TFs Dlx2, Mash1, and Gsx2 have a dramatic role in neurogenesis in 
striatum as evident by growing number of literature. Hence, Dlx2, Mash1, and Gsx2 
were selected for ectopic expression in the hPSC-nrNPCs to test the hypothesis that 
ectopic expression of TFs involved in MSN specification and differentiation could 
trigger differentiation of hPSC-nrNPCs into mature striatal GABAergic MSNs. In 
addition, candidate target and effector genes identified here as interacting genes 
involved in forebrain neuron generation were used to validate the success of combining 
TFs to re-program stem cell differentiation and maturation into GABAergic MSNs and 
to assess the phenotype of generated neurons. In addition, these target and effector 
biomarkers (Foxp1/2, Ebf1, Gad1/2, Drd1/2 and Ctip2) were used to determine the 
phenotype of neuronal differentiation. 
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3.1 PCR gene amplification and cloning 
 
3.1.1 GoTaq Flexi DNA Polymerase PCR Amplification 
 
DNA was amplified using different commercial polymerase chain reaction kits, 
including GoTaq Flexi DNA Polymerase (PCR) (Cat No. M8295, Promega, Southampton, 
UK) and Platinum Taq DNA high-fidelity polymerase (Cat No. 11304-029, Invitrogen, 
Paisley, Scotland, UK).  
PCR amplification conditions were optimized by varying the MgCl2 concentration 
and the annealing temperature. The set-up used in this project was as follows: 
 
Reagent 
MgCl2 concentration Negative (-ve) 
control 1.5 mM 2 mM 2.5 mM 3 mM 
5× GoTaq green buffer 5 µl 5 µl 5 µl 5 µl 5 µl 
25 mM MgCl2  --------- 0.5 µl 1 µl 1.5 µl 0.5-1.5 µl 
10 mM Nucleotide mix 
(dNTP)  0.5 µl 0.5 µl 0.5 µl 0.5 µl 0.5 µl 
Primers* 1 µl 1 µl 1 µl 1 µl 1 µl 
GoTaq DNA polymerase 0.13 µl 0.13 µl 0.13 µl 0.13 µl 0.13 µl 
Template DNA < 250 ng/25 µl -------------- 
dH2O (distilled water) Up to 25 µl 
Total 25 µl 25 µl 25 µl 25 µl 25 µl 
* The primers (forward and reverse) were diluted with dH2O from 100 pmol/µl to 10 pmol/µl (20 
µl of the forward primer + 20 µl of the reverse primer in 160 µl of dH2O = a total of 200 µl). 
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The thermal cycling conditions for GoTaq DNA polymerase are as follows: 
 
Steps Temperature Time Number of cycles 
Initial Denaturation 95°C 5 min 1 cycle 
Denaturation 95°C 1 min 
35 cycles Annealing 62–65°C* 1 min 
Extension 72°C 1 min/kb 
Final Extension 72°C 5 min 1 cycle 
* Each gene required for cloning has a different annealing temperature. DLX2, 
MASH1 and GSX2 have annealing temperatures of 63°C, 65°C and 62°C, 
respectively. 
 
The primers of each specific gene were designed to amplify and clone the four 
selected transcription factors. These are shown below: 
 
Primer name Sequence (5’-3’) 
Melting 
temperature 
(Tm) (°C) 
BglII-GSX2-F AACAGATCTATGTCGCGCTCCTTCTATGTCGA (32 bp) 68.2 
BglII-GSX2-R AACAGATCTTAAGGGGGAAAT
CTCCTTGTCATCG (34 bp) 
68.3 
NheI-DLX2-F AACGCTAGCATGACTGGAGTC
TTTGACAGTC (31 bp) 
68.2 
NheI-DLX2-R AACGCTAGCGAAAATCGTCCCCGCGCTCAC (30 bp) 72.2 
XbaI-FOXGI-F AACTCTAGAATGCTGGACATG
GGAGATAGGAAAG (34 bp) 
68.3 
XbaI-FOXGI-R AACTCTAGAATGTATTAAAGG
GTTGGAAGAAGACCC (36 bp) 
67.2 
BamHI-MASH1-F AACGGATCCATGGAAAGCTCTGCCAAGATGG (31 bp) 69.5 
BamHI-MASH1-R CTGGATCCGAACCAGTTGGTG
AAGGCGA (28 bp) 
68.0 
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3.1.2 Platinum Taq DNA Polymerase High Fidelity PCR (HF PCR) 
 
The Platinum Taq DNA high-fidelity polymerase used in this project was supplied by 
Invitrogen. This enzyme is a mixture of a recombinant enzyme (Taq DNA polymerase), an 
anti-Taq polymerase antibody and Pyrococcus species GB-D polymerase, which has DNA 
proofreading activity. This mixture helps to increase fidelity by about a factor of six, 
compared with Taq DNA polymerase alone. Platinum Taq DNA high-fidelity polymerase 
contains a 10× high-fidelity PCR buffer, magnesium sulphate (MgSO4), as well as high-
fidelity Platinum Taq DNA polymerase.  
 
The following reagents were added to DNase/RNase-free microcentrifuge PCR 
tubes: 
 
Reagent Volumes Negative (-ve) control Final concentration 
10× high-fidelity PCR 
buffer  2.5 µl 2.5 µl 1×  
50 mM MgSO4  1 µl 1 µl 2 mM 
10 mM nucleotide mix 
(dNTP)  0.5 µl 0.5 µl 0.2 mM 
Primer  1 µl 1 µl 0.4 mM 
Platinum Taq DNA high-
fidelity polymerase  0.1 µl 0.1 µl 1 unit 
Template DNA 1 µl ------------------- < 250 ng 
dH2O (distilled water) Up to 25 µl ------------------- 
Total 25 µl 25 µl ------------------- 
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The thermal cycle condition for Platinum Tag DNA polymerase is as follows: 
 
Step Temperature Time Number of cycles 
Initial 
Denaturation 95°C 5 min 1 cycle 
Denaturation 95°C 30 s 
30 – 32 cycles* Annealing 62–65°C* 30 s 
Extension 68°C 1 min/kb 
*The three genes, MASH1, DLX2 and GSX2, required different annealing 
temperatures as well as different numbers of cycles, these being 65°C – 32 cycles, 
63°C – 32 cycles and 62°C – 30 cycles, respectively. 
 
3.1.3 Agarose Gel Electrophoresis 
 
Using electrophoresis, DNA fragments can easily be separated on the basis of size. 
In an electric field, DNA migration is relative to its mass. Here, an agarose medium was 
used to retain the DNA sample and a loading dye (10×) was added to the DNA sample 
prior to loading. The reagents for DNA gel electrophoresis were as follows: 
 
0.8–2% agarose (in Tris-acetate-EDTA (TAE) buffer) 
10 mg/ml ethidium bromide 
0.1 M of guanosine (only for digestion and ligation steps) 
 
Ethidium bromide-stained DNA bands were visualized via UV tranilluminator at a 
wavelength of 254 nm. The required amount of guanosine solution (Cat No. G6752, 
Sigma-Aldrich, Gillingham, Dorset, UK) was added to the TAE buffer to protect the 
digested DNA from UV damage prior to gel extraction purification (Grundemann and 
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Schomig 1996). Gels were electrophoresed in 1 × TAE buffer at 80–100 V for 1 h and 30 
min. DNA fragments were sized using a 1-kb or 100-bp ladder. 
 
3.1.4 DNA Gel Extraction  
 
Following gel electrophoresis, DNA fragments were extracted either using the 
GeneClean II Kit (Cat No. 1001-400, MP Biomedicals, Cambridge, UK), or the Qiaquick 
Gel Extraction Kit (Cat. No. 28704, Qiagen, West Sussex, UK) following the 
manufacturer’s instructions. DNA fragments separated in agarose gels were excised with a 
razor blade and visualized under UV light (365 nm).  
For the GeneClean kit, gel slices were dissolved in three times the volume of sliced 
gel of 6 M sodium Iodide (NaI) by incubation for 5 min at 55°C with periodic agitation. DNA 
was then bound to GlassMilk, an aqueous suspension of silica, using 1 µl of GlassMilk per 
1–2 µg of DNA. The DNA/GlassMilk suspension was incubated at room temperature (RT) 
for 5 min. DNA bound silica was pelleted by centrifugation at 14,000×g for 5 s and the 
supernatant was removed. The pellet was washed three times with 500 µl of prepared 
New Wash solution (solution of NaCl, Tris, EDTA, ethanol and H2O), and after the final 
centrifugation, the pellet was air dried to remove any residual ethanol. DNA was eluted 
from the silica by re-suspension in 10 mM Tris (pH 7.6) and 1 mM EDTA (pH 8.0) (TE) 
buffer. Eluted DNA was separated from the silica matrix by centrifugation at 14,000×g for 
30 s.  
For Qiaquick gel extractions, gel slices were dissolved in three times the gel volumes 
of QG buffer and 10 µl of 3M sodium acetate by incubation for approximately 10 min at 
50°C. DNA was then bound to a Qiaquick column by adding QG buffer, followed by 
centrifugation at 13,000×g for 1 min. The flow-through was removed, and 500 µl of QG 
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buffer was added to the Qiaquick column and centrifuged for 1 min to eliminate any 
residual gel. The Qiaquick column was washed twice with 750 µl of PE buffer and allowed 
to stand for 2–5 minutes at RT to eliminate residual ethanol, followed by centrifugation at 
13,000×g for 1 min. The Qiaquick column was then placed into a new 1.5 ml tube. DNA 
was eluted from the membrane of the Qiaquick column by incubating for 1 min with 30 µl 
of EB buffer at RT. Eluted DNA was separated from the membrane of the Qiaquick column 
by centrifugation at 13,000×g for 1 min.  
 
3.1.5 DNA Cloning 
 
3.1.5.1 Gene amplification by PCR and insertion into the TOPO vector pENTR5’ 
TOPO 
 
PCR products for each gene were cloned into the TOPO vector pENTR5’ TOPO 
(Cat No. K591-10, K591-20 and K5910-00, Invitrogen) using the pENTR5’ TOPO TA 
cloning kit. This kit contained the linearized pENTR5’ TOPO vector, which had 3’ thymidine 
(T) overhangs, and topoisomerase I. Because the PCR products contained polyA 
overhangs and the linearized vector had 3’ T residues, this enabled the efficient ligation of 
the PCR products with the linearized vector. At the same time, the topoisomerase I bound 
at specific sites to the TOPO vector (CCCTT) and cleaved the phosphodiester bond 
between two nucleotides in one strand where the vector was subsequently linearized. 
Here, the covalent bond between the 3’ phosphate and the tyrosyl residue of the enzyme 
was formed because of the energy released when the phosphodiester bond was broken. 
The bond between DNA and enzyme (phospho-tyrosyl) was identified by the presence of a 
5’ hydroxyl from the original, cleaved strand. At this point, the covalent bond between 
phospho-tyrosyl was broken and the topoisomerase 1 enzyme was released (Invitrogen, 
2007).  
                                                                                                        Chapter 3: Materials and methods 
 92 
 
3.1.5.2 One-Shot TOP10 Chemically Competent Escherichia coli 
 
A PCR product (DNA of interest) was inserted into an entry vector called pENTR5’-
TOPO, which was supplied in the pENTR5’-TOPO TA cloning kit. Here, the recombinant 
vector can be transformed into chemically competent cells of E. coli. The following 
paragraphs describe the procedure for the TOPO cloning reaction and the transformation 
used in this project. 
 
TOPO cloning reaction 
Reagent Volume 
DNA (PCR product) 2 µl 
Salt solution 0.5 µl 
pENTR5’ - TOPO 0.5 µl 
Total 3 µl 
 
The reaction was mixed gently and incubated at RT for 5 min. Afterwards, it was 
placed on ice while preparing for the next step, namely, the transformation of One-shot 
competent E. coli. 
 
Transformation of One-shot TOP10 chemically competent E. coli 
One vial (50 µl) of competent cells for each transformation was placed on thawing 
ice. Then, 1–5 µl of the TOPO cloning reaction was gently added to the vial of competent 
cells and mixed. Then, the vial was incubated on ice for 30 min. A heat shock was then 
applied for 30 s in a 42°C water bath, after which the cells were returned to the ice for 2 
min. Next, 250 µl of pre-warmed S.O.C. medium (20 mM glucose, 10 mM NaCl, MgCl2 and 
MgSO4, 2.5 mM KCl, 2% tryptone and 0.5% yeast extract) (Cat. No. 15544-034, 
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Invitrogen) was added to the vial, which was incubated in a shaking (225 rpm) incubator at 
37°C for 1 h. Each of the transformation mixtures (20µl) was spread on a pre-warmed LB 
agar plate containing an appropriate antibiotic. Finally, the plate was incubated overnight 
at 37°C in an inverted position.  
Subsequently, colonies from the selective plate were selected and analysed to 
determine whether they were positive transformants. This was done by isolating the 
plasmid DNA and analysing it via restriction digest analysis; this was then followed by DNA 
sequencing. The correct sequences of the DNAs of interest were confirmed prior to 
subcloning.  
 
3.1.5.3 Transformation of DH5α Competent Cells 
 
DH5α competent cells (Cat. No. 18265-017, Invitrogen) were put on thawing ice, 
gently mixed with the tip of a pipette, and a 50 µl aliquot was used for each transformation 
(unused competent cells were placed in an ethanol-dry ice bath for 5 min and stored at -
80°C). Next, 1–5 µl of DNA was added. The cells were incubated on ice for 30 min and 
then heat shocked at 42°C for 20 s. Cells were returned to the ice for 2 min and 950 µl of 
pre-warmed S.O.C medium was added. Cells were then incubated in a shaking (225 rpm) 
incubator at 37°C for 1 h. Following the incubation, 20 µl of cells were spread on a pre-
warmed LB agar plate containing an appropriate antibiotic. Lastly, the plates were placed 
in an inverted position in an incubator at 37°C and left overnight. 
 
3.1.6 DNA sequencing 
 
After cloning the PCR-amplified genes into the pENTR5’ TOPO vector, plasmid DNA 
was purified, eluted with RNase free water, and sent to Eurofins MWG operon for DNA 
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sequencing. Sanger sequencing was performed using M13 forward and reverse primers. 
DNA sequences were analysed using BLAST on the NCBI website 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi). 
 
3.1.7 Plasmid Extraction & Purification 
 
3.1.7.1 Plasmid Miniprep  
 
Plasmid DNA was prepared by the alkaline lysis method (Sambrook et al. 1989). 
Bacterial colonies were picked and grown in 2 ml of LB medium containing the appropriate 
antibiotic (50 mg/ml kanamycin or 100 mg/ml ampicillin) by incubation in a shaker at 37°C 
overnight. Each bacterial culture 500 µl was transferred into an Eppendorf tube with 100% 
sterile glycerol and stored at -80°C to preserve the culture for future experiments.  
Bacterial cultures were transferred to sterile 1.5 ml Eppendorf tubes and cells were 
pelleted by centrifugation at 12,500×g for 5 min. Bacterial pellets were re-suspended in 
100 µl of ice-cold Solution I, which contained 50 mM glucose (Cat No. 1011747-500 G, 
BDH Laboratory Suppliers, Poole, UK), 10 mM EDTA (Cat. No. E5139-500 G, Sigma-
Aldrich) and 25 mM Tris (pH 8.0) (Cat. No. 10708968001-500 G, Roche, Applied Science, 
West Sussex, UK), and then lysed by the addition of 200 µl of freshly made Solution II, 
which contained 0.2 M NaOH (sodium hydroxide) (Cat. No. S5881-1Kg, Sigma-Aldrich) 
and 1% SDS (Cat. No. L3771-500 G, Sigma-Aldrich), followed by incubation for 5 min at 
RT. Ice-cold neutralization Solution III (150 µl), which contained potassium acetate (Cat. 
No. P1190-500 G, Sigma-Aldrich) and glacial acetic acid (Cat. No. 64-19-7, Thermo Fisher 
Scientific, Loughborough, Leicestershine, UK), was added and mixed by inversion and 
incubated on ice for 3 to 5 min until a white, downy precipitate was seen.  
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Plasmids were isolated by centrifuging the lysates at 12,500×g for 5 min. At this 
point, a clear solution was observed (supernatant), which was then transferred into a clean 
1.5-ml microcentrifuge tube. An equal volume of phenol-chloroform was added, mixed well 
and centrifuged at 12,000×g for 2 min. The top aqueous layer containing the DNA plasmid 
was transferred into a new microcentrifuge tube. Then, two volumes of 100% ethanol were 
added, mixed thoroughly and incubated at RT for 2 min, followed by centrifugation at 
12,000×g for 5 min. The pellet was washed with 70% ethanol (200 µl) and centrifuged at 
12,000×g for 5 min. The pellet was incubated at RT for 10 min to dry the ethanol. Then, 
the DNA pellet was re-suspended in 49 µl of TE buffer containing RNase (20 mg/µl) to 
eliminate any RNA molecules.  
 
3.1.7.2 Endotoxin Free Maxiprep 
 
The Endofree plasmid maxi kit (Cat. No. 12362, Qiagen) was used for large scale 
isolation of endotoxin-free plasmid DNA according to the manufacturer’s instructions. A 
colony was either picked from a master plate or a stab from a glycerol stock and grown in 
a 3 ml starter culture of LB containing an appropriate antibiotic, and incubated overnight on 
a shaker (220 rpm) at 37°C. The starter culture was diluted with 100 or 250 ml of LB for 
high- or low-copy plasmid, respectively, containing an appropriate selective antibiotic. It 
was then incubated overnight under the same conditions for 12–16 h. Next, the resulting 
bacterial suspension was harvested via centrifugation at 4°C, 6,000×g for 15 min. Then, 
plasmids were isolated using the Endofree plasmid maxi kit according to the 
manufacturer’s instructions.  
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3.1.8 Glycerol Stocks 
 
Stocks of competent cells containing the plasmid of interest were made by adding 
glycerol to 500 µl of a bacterial suspension from an overnight culture at a ratio of 1:1, 
mixed well and stored at -80°C. 
 
3.1.9 Analysis by Restriction Digestion  
 
For the plasmid miniprep or maxiprep purifications, restriction digestion analysis was 
carried out as follows: 
 
Solution Volumes 
DNA 5 µl 
Enzyme 0.5 µl 
Buffer (×10) 2.5 µl 
BSA (×100)* 0.25 µl 
dH2O up to 25 µl 
*Some enzymes require bovine 
serum albumin (BSA). 
 
The normal protocol for restriction digestion is as follows: 
 
Solution Concentration // Volume 
DNA  0.5–1 µg 
Enzyme  5 units 
Buffer (×10) 1× 
BSA (×100) 1× 
dH2O up to 25 µl 
 
Restriction digestion analysis was used to check the ligations and for subcloning 
purposes.  
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Enzymes were purchased from New England Biolabs (NEB, Hitchin, UK). The 
incubation temperature and the time depended on the DNA concentration, as well as the 
enzyme. The completion of the digestion was then checked by gel electrophoresis.  
If a ligation reaction was being conducted, the vector was treated with 0.5 units of 
calf intestinal alkaline phosphatase (CIP) (Cat. No. M0290S, NEB) and then incubated at 
37°C for 20 min, followed by purification and ligation. 
 
The enzymes used in this project are listed below: 
 
AhdI AseI BamHI-HF 
BgIII BspMI BstXI 
EcoRI-HF KpnI-HF NdeI 
NheI-HF NotI-HF PstI 
SacII SalI-HF XbaI 
XmnI   
 
 
3.1.10 Ligation 
 
A T4 DNA ligation kit was used (Cat. No. M0202, NEB). T4 DNA ligase forms a 
phosphodiester bond between two nucleotides: between the 5’ phosphate and the 3’ 
hydroxyl group. This ligase can be used to ligate both blunt and cohesive ends. The 
incubation time and depends on the type of DNA ends. For cohesive ends, the incubation 
is typically at RT for 10 min (2 h for blunt ends). However, in this project, the ligation 
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mixture was incubated in a thermocycler for different lengths of time and at different 
temperatures. 
T4 DNA ligase buffer (pH 7.5) contains 50 mM Tris - HCl, 10 mM MgCl2, 1 mM ATP 
and 10 mM dithiothreitol (DTT). The ratio of vector-insert (v:i) used in this project varied in 
each experiment, starting from a 1:3 ratio. Here, the amount of vector was 100 ng, and the 
amount of insert was calculated from the following equation: 
 
 
 
The following table shows the setup for the ligation experiment: 
 
Reagent Volume Vector only 
10x T4 DNA ligase 
buffer 2 µl 2 µl 
T4 DNA ligase 1 µl 1 µl 
Insert * ------------ 
Vector * * 
dH2O Up to 20 µl 
Total  20 µl 20 µl 
* The calculated amount of insert and vector depends on a ratio 
of v:i 
 
In each ligation experiment, a vector-only control was used. After incubation, 1–5 µl 
of the ligation sample was used for bacterial transformations.  
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3.1.11 Construct the expression vectors 
 
The open-reading frame (ORF) of each TF was cloned by PCR using specific primers 
that were designed with appropriate sequence and a specific restriction enzyme 
recognition sequence that is required for cloning into the expression vector (Table 3.1). In 
addition, the generation of the TF expression vectors required the subcloning of the ORF 
for each TF into the interim vector p3X-2A, without initiation and stop codons, as both of 
these sequences were already present in the p3X-2A vector between the restriction site 
SalI, where the cloned TFs would be inserted (Figure 3.1). The initiation codon (ATG) was 
located before the BamHI restriction site that was used for the first fragment insertion, and 
the stop codon was located after the fourth fragment insertion in the NheI restriction site 
(Figure 3.1). 
 
Table 3.1: The PCR primers used for PCR cloning to subclone the three desired TFs 
Restriction enzyme 
name-Primer name Forward Sequence (5’-3’) Reverse Sequence (5’-3’) 
Product 
size 
(bp) 
BamHI-MASH1 AAC GGA TCC ATG GAA 
AGC TCT GCC AAG ATG G 
CTG GAT CCG AAC CAG TTG 
GTG AAG GCG A 
725 
BglII-GSX2 AAC AGA TCT ATG TCG 
CGC TCC TTC TAT GTC GA 
AAC AGA TCT TAA GGG GGA 
AAT CTC CTT GTC ATC G 
930 
NheI-DLX2 AAC GCT AGC ATG ACT 
GGA GTC TTT GAC AGT C 
AAC GCT AGC GAA AAT CGT 
CCC CGC GCT CAC 
1,002 
Abbreviations: BamHI-MASH1: primer for Achaete-scute complex homologue 1 with restriction 
enzyme site BamHI, BglII–GSX2: primer for GS homeobox 2 with restriction enzyme site BglII, 
NheI–DLX2: primer for Distal-less homeobox with restriction enzyme site NheI; bp: base pair. 
 
The p3X-2A vector was designed to insert cloned genes using restriction enzyme 
sites located between three 2A peptide linked sequences (Figure 3.1). In addition, a 
Kozak sequence (GCC GCC) is present upstream of the start codon (ATG) to enable 
efficient translation initiation (Kozak 1987) (Figure 3.1). Genes inserted into the p3X-2A 
vector could then be released as a SalI restriction fragment and inserted into the unique 
SalI site in pCAGG-IRES-EGFP (Figure 3.2). 
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The pCAGG-IRES-EGFP (pCAGG) vector was constructed from the vector 
“pIRES2EGFP” (from Clontech) that contains the cytomegalovirus (CMV) promoter, a 
multiple cloning site (MCS), internal ribosome entry site (IRES), coding sequences for 
enhanced green fluorescent protein (EGFP) and a gene conferring kanamycin 
resistance (Figure 3.2). Because the CMV promoter is known to be silenced in hESCs, 
this promoter was replaced by the artificial CAGG promoter, which has been shown to 
drive high levels of transgene expression in hESCs (Alexopoulou et al. 2008) (Figure 
3.2).  
 
 
Figure 3.2: Circular and linear map of optimized pIRES2EGFP to pCAGG–
IRES–EGFP. 
The linear map of the vector pCAGG in which the CMV promoter was replaced 
with CAG promoter (A). The backbone of the expression vector was CAGG-MCS-
IRES–EGFP with kanamycin resistance gene. The circular map of pCAGG (6.4 
kb) (B).  
Abbreviations: CMV: Cytomegalovirus (CMV) promoter, CAGG: CMV early 
enhancer/chicken beta actin (CAG) promoter, MCS: Multiple cloning site, IRES: 
Internal ribosome entry site, EGFP: Enhanced green fluorescent protein; 
NeoR/KanR: Neomycin resistance/Kanamycin resistance. 
CMV MCS IRES EGFP NeoR/KanR pIRES2EGFP 
pCAGG-IRES-EGFP CAGG MCS IRES EGFP NeoR/KanR 
Replaced CMV 
promoter with 
CAGG promoter 
A) 
B) 
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The specific order of cloning was essential in this study, as all the cloned TFs 
have overlapping restriction enzyme sites. Therefore, the MASH1 gene was first 
subcloned into the p3X-2A vector, and then the DLX2 gene was inserted, yielding p3X-
2A-MASH1/DLX2 (Figure 3.3 A). In addition, each gene was cloned separately into the 
vector p3X-2A to construct p3X-2A-MASH1 and p3X-2A-DLX2 (Figure 3.4 A and 
Figure 3.5 A). The GSX2 gene was not added directly to the p3X-2A vector, as this 
cloned gene has the restriction enzyme site for SalI, which was used to subclone the 
polyprotein from the p3X-2A vector into the pCAGG expression vector. Therefore, 
GSX2 was inserted into the BglII restriction site into the pCAGG vector after the 
insertion of the polyprotein coding sequence into pCAGG using the SalI restriction site.  
The sequence encoding the polyprotein, comprising the cloned genes of MASH1 
and DLX2, separately or together, from the p3X-2A vector that was flanked by Sall 
restriction sites, was digested and inserted into the expression vector pCAGG to 
construct the expression vectors pCAGG-MASH1/DLX2, pCAGG-MASH1 and pCAGG-
DLX2 (Figure 3.3 B, Figure 3.4 B and Figure 3.5 B). Then, the cloned gene GSX2 
was inserted into the expression vector pCAGG using BglII sites. There is only one 
BglII restriction site in this vector, located upstream of the T2A peptide, for the insertion 
of GSX2. GSX2 was inserted into pCAGG-MASH1/DLX2 and pCAGG-DLX2. The 
insertion of GSX2 yielded the expression vectors pCAGG-MASH1/DLX2/GSX2 and 
pCAGG-DLX2/GSX2 (Figure 3.3 B and Figure 3.5 B). The sequences are shown in 
Appendix 3.2. 
TF expression vectors were validated through the transient nucleofection of 
human embryonic kidney 293 (HEK293) cells. The cloned TF expression vectors, with 
different combinations of TFs and the empty vector (pCAGG), were validated before 
nucleofecting them into hPSCs. To do so, the TF expression vectors were nucleofected 
(transient nucleofection) into HEK293 cells for western blotting analysis to confirm that 
the appropriate combinations of TFs were co-expressed via the self-cleavage of 2A 
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peptides from the polycistronic vector. Gene expression from the HEK293 nucleofected 
cells was analysed by western blotting 48 h after nucleofection. As the percentage of 
the GFP expressing cells was high, protein lysates were harvested and western 
blotting was performed. 
HEK293 cells were used for the TF vector validation, since they are commonly 
used, and the AMAXA nucleofection efficiency is very high (93%) and the toxicity is low 
(Maurisse et al. 2010). 
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Figure 3.3: The cloning of TFs MASH1, DLX2 and GSX2 into the p3X-2A vector, and 
subsequent subcloning into the expression vector pCAGG via the SalI restriction site. 
The TF MASH1 was first inserted into the p3X-2A vector using the BamHI restriction site (A-1). 
Afterwards, the TF DLX2 was inserted using NheI to yield the construct p3X-2A-MASHI/DLX2 
(A-2 and A-3). Next, the polycistronic construct containing both DLX2 and MASH1 was 
subcloned into the pCAGG expression vector using the SalI restriction site to yield the construct 
pCAGG-MASH1/DLX2 (B-1). At this point, the TF GSX2 was inserted to yield pCAGG-
MASHI/DLX2/GSX2 (B-2 and B-3).  
DLX2 
NheI                           NheI 
(A) 
(B) 
SalI KOZAK E2A T2A P2A 
✖ 
SalI 
ATG 
    BamHI                            BglII                               XbaI                                NheI 
AmpR 
(1) p3X-2A pMA-T 
     2605 bp 
MASH1 
BamHI                       BamHI 
(1) pCAGG-IRES-
EGFP 
6407 bp 
CAGG Promoter MCS IRES EGFP NeoR/KanR 
SalI restriction site 
SalI KOZAK E2A T2A P2A 
✖ 
SalI 
ATG 
                                           BglII                               XbaI                                NheI 
AmpR (2) p3X-2A-MASH1      3319 bp 
MASH1 
BamHI                       BamHI 
BamHI                       BamHI 
CAGG Promoter IRES EGFP NeoR/KanR SalI KOZAK E2A T2A P2A 
✖ 
SalI 
ATG 
BglII            XbaI                
MASH1 DLX2 (2) pCAGG-MASH1/DLX2 
8336 bp 
SalI KOZAK E2A T2A P2A 
✖ 
SalI 
ATG 
                                          BglII                               XbaI                      
AmpR 
(3) p3X-2A-MASH1/
DLX2 
     4309 bp 
MASH1 
NheI                           NheI 
DLX2 
GSX2 
BglII                           BglII 
CAGG Promoter IRES EGFP NeoR/KanR SalI KOZAK E2A T2A P2A SalI 
ATG 
XbaI                
MASH1 DLX2 GSX2 
BglII                BglII 
(3) pCAGG-MASH1/
DLX2/GSX2 
9254 bp 
✖ 
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Figure 3.4: The cloning of TF MASH1 into the p3X-2A vector, and subsequent subcloning 
into the expression vector pCAGG using the SalI restriction site. 
The TF MASH1 was inserted into the p3X-2A vector using the BamHI restriction site (A-1 and 
A-2). Next, the polycistronic construct containing the TF MASH1 was subcloned into the 
pCAGG expression vector using the SalI restriction site to yield the construct pCAGG-MASH1 
(B-1 and B-2). 
 
  
(A) 
(B) 
SalI KOZAK E2A T2A P2A 
✖ 
SalI 
ATG 
    BamHI                             BglII                                XbaI                                 NheI 
AmpR 
(1) p3X-2A pMA-T 
     2605 bp 
MASH1 
BamHI                       BamHI 
SalI KOZAK E2A T2A P2A 
✖ 
SalI 
ATG 
BglII                                  XbaI                                NheI 
AmpR 
(2) p3X-2A-MASH1 
3319 bp MASH1 
BamHI                       BamHI 
(1) pCAGG-IRES-EGFP 
6407 bp 
CAGG Promoter MCS IRES EGFP NeoR/KanR 
SalI restriction site 
CAGG Promoter IRES EGFP NeoR/KanR SalI KOZAK E2A T2A P2A 
✖ 
SalI 
ATG 
BglII             XbaI                
MASH1 (2) pCAGG-MASH1 
7346 bp 
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Figure 3.5: The cloning of TFs DLX2 and GSX2 into the p3X-2A vector, and subsequent 
subcloning into the expression vector pCAGG using the SalI restriction site. 
The TF DLX2 was inserted via the NheI restriction site into p3X-2A to yield the construct p3X-
2A-DLX2 (A-1 and A-2), and then subcloned into the pCAGG expression vector via the SalI 
restriction site (B-1); at this point, GSX2 was inserted using the BglII restriction site into 
pCAGG-DLX2 to construct the expression vector pCAGG-DLX2/GSX2 (B-2 and B-3). 
 
  
DLX2 
NheI                            NheI 
(A) 
(B) 
(1) p3X-2A pMA-T 
     2605 bp SalI KOZAK E2A T2A P2A 
✖ 
SalI 
ATG 
    BamHI                             BglII                                XbaI                                 NheI 
AmpR 
SalI KOZAK E2A T2A P2A 
✖ 
SalI 
ATG 
    BamHI                             BglII                                XbaI     
AmpR 
(2) p3X-2A-DLX2 
     3595 bp 
NheI                            NheI 
DLX2 
(1) pCAGG-IRES-
EGFP 
6407 bp 
CAGG Promoter MCS IRES EGFP NeoR/KanR 
SalI restriction site 
CAGG Promoter IRES EGFP NeoR/KanR SalI KOZAK E2A T2A P2A 
✖ 
SalI 
ATG 
 BamHI               BglII            XbaI                
DLX2 (2) pCAGG-DLX2 7622 bp 
GSX2 
BglII                           BglII 
CAGG Promoter IRES EGFP NeoR/KanR SalI KOZAK E2A T2A P2A SalI 
ATG 
BamHI                                                  XbaI                
DLX2 GSX2 
BglII                 BglII 
(3) pCAGG-DLX2/
GSX2 
8540 bp 
✖ 
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3.2 Cell culture techniques 
 
3.2.1 Maintenance of cell lines in culture 
 
3.2.1.1 H9 human embryonic stem cells (hESCs)  
 
H9 cells were grown in the H9 medium. KnockOut Dulbecco's modified Eagle's 
medium (DMEM) (Cat. No. 10829018, Invitrogen), was supplemented with 15% 
knockout serum replacement (KSR) (Cat. No. 10828028, Invitrogen), 1% non-essential 
amino acids (NEAA) (100×) (Cat. No. 11140035, Invitrogen), 1% L-Glutamine (L–G) 
(200 mM) (Cat. No. 25030024, Invitrogen), 1% penicillin (100 U/ml) streptomycin (100 
µg/ml) (Pen/Strep) (Cat. No. 15070063, Invitrogen), and 0.68% beta-mercaptoethanol 
(55 mM) (Cat. No. 21985-023, Invitrogen). H9 cells were grown in 6- or 10-cm Nunc 
tissue culture plates (Cat. No. TKT–110-010S, TKT–110-170T, respectively, Thermo 
Fisher Scientific) in a humidified incubator at 37°C, 5% carbon dioxide (CO2).  
H9 cells were passaged 1:4. Prior to passaging, areas of differentiated cells 
were pruned from culture plates by scraping with a P20 Gilson pipette tip. Plates were 
then washed once with phosphate-buffered-saline (PBS) without calcium and 
magnesium (Cat. No. 100-10-056, Invitrogen). hESC colonies were then lifted from 
their matrix by digestion with pre–warmed, filter sterilised, collagenase type IV 
(1mg/ml) (Cat. No. 17104019, 1 g/U, Invitrogen) in DMEM containing 10 µM Y-27632 
Rho-associated protein kinase (ROCK) inhibitor (Cat. No. ab120129, Abcam 
Biochemicals, Cambridge, UK) and incubated for a maximum of 20 min in a humidified 
incubator at 37°C, 5% CO2. Lifted colonies were gently collected using P1000 Gilson 
tips with pre-warmed H9 medium (without fibroblast growth factor 2 (FGF2), Cat. No. 
10018B, 1 mg/U, PeproTech, Rocky Hill, NJ, USA) in a 15-ml polypropylene tube 
(Falcon tubes) and pelleted by centrifugation at 1,000×g for 3 min. The pellet was re-
suspended in pre-warmed H9 medium containing 5 ng/ml FGF2 and 10 µM Y-27632 
ROCK inhibitor. Cells were plated into freshly prepared, irradiated mouse embryonic 
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fibroblasts (mefi) plates. Cultures were incubated in a humidified incubator at 37°C, 5% 
CO2 and were fed with fresh medium daily. 
 
3.2.1.1.1 Preparing irradiated mouse embryonic fibroblasts (mefi) for plating  
 
E13 mouse embryos were dissected to remove extra-embryonic tissues, heads 
and viscera. The carcasses were minced in Hank’s balanced salt solution (HBSS) with 
a sterile blade and incubated with trypsin – EDTA (Cat. No. 253-00-054, 100ml/U, 
Invitrogen) for 5 min in a humidified incubator at 37°C, 5% CO2. Digested tissue was 
collected with MEF medium (DMEM, 10% foetal bovine serum (FBS), 1% Pen/Strep 
and 1% Antibiotic/Antimycotic (Anti/Anti) (Cat. No. 15240062, 100ml/U, Invitrogen). 
The cell suspension was centrifuged at 1,000×g for 3 min and the cell pellet was 
washed three times by re-suspension in MEF medium. Cells from one embryo were 
plated on a 14-cm Nunc plate (Cat. No. TKT-110-130Y, Thermo Fisher Scientific). 
Cells were fed every other day with fresh medium.  
When MEFs reached confluence, they were passaged using trypsin (P1), 80% 
of the cells were irradiated by γ-radiation (see below) and stored at –80°C, while the 
other 20% was sub-cultured at a 1:5 ratio. For the second passage (P2), all the cells 
were irradiated and stored at -80°C. Here, the mefi (irradiated mef) cells were frozen 
with the freezing medium, 10% dimethyl sulfoxide (DMSO) (Cat. No. D2650, Sigma-
Aldrich) and mef medium; this was done at a density of 1 x 106 cells/vial. 
At this point, when the mef cells were ready to be irradiated, the cells were 
dissociated by adding trypsin, and then the cells were collected in a 50-ml Falcon tube, 
after which they were centrifuged at 1,000×g for 3 min. Then, the pellet was re-
suspended in 20 ml of mef medium, and irradiated by γ-radiation for 30 min. 
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Plating mefi cells on gelatin-coated Nunc plate dishes for H9–hESCs 
maintenance 
 
Eight 6-cm Nunc plates were coated with gelatin (ultrapure water with 0.1% 
gelatin, Cat. No. ES006B, Millipore, Hertfordshire, UK) and incubated in a humidified 
incubator for 30 min. One vial of mefi cells was then thawed with 1 ml of pre-warmed 
mef media and mixed. All the cells were transferred into a 15-ml Falcon tube containing 
4 ml of mef medium and centrifuged at 1,000×g for 3 min. The pellet was re-suspended 
in pre-warmed mef medium and plated into a gelatin-coated 6-cm Nunc plate. Cultures 
were incubated in a humidified incubator. The mefi cells were prepared one day prior to 
use and used within 7 days of plating. 
 
3.2.1.2 Human-induced pluripotent stem cells (h-iPSCs)  
 
The iPSCs were the 34D6 cell line (Bilican et al. 2012); these cells were 
cultured with mTeSR1 media (Cat. No. 05850, StemCell Technologies, Manchester, 
UK). The medium was complete and serum-free. It was supplemented with 1% 
Pen/Strep and 5× supplement (Cat. No. 05852, StemCell Technologies), which 
contains recombinant human basic fibroblast growth factors (rhbFGF), as well as 
recombinant human transforming growth factor β (rhTGFβ). 34D6 cells were grown in a 
6–10 cm Nunc tissue culture plate in a humidified incubator at 37°C, 5% CO2. 
The 34D6 cells were sub-cultured when they reached a dense state; when the 
colonies were large and starting to merge, the centers of the colonies were dense with 
a bright phase in comparison to the edges. Prior to passaging, 10-cm petri dishes were 
coated with BD Matrigel (Cat. No. 7341440, VWR, Leicestershire, UK) and incubated 
at 37°C. h-iPSCs colonies were then lifted from their matrix by digestion with pre–
warmed dispase solution, which is a protease that is inhibited by EDTA, at a 
concentration of 1 mg/ml (Cat. No. 07923, StemCell Technologies) with 10 µM Y-
27632 ROCK inhibitor and incubated at 37°C for 8 to 20 min depending on when the 
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edges of the colonies started to fold back slightly. After incubation, the dispase was 
aspirated, and each plate was gently rinsed 2–3 times with pre–warmed DMEM/F12 (5 
ml/plate) to eradicate any remaining dispase. Lifted colonies were gently dislodged with 
P1000 Gilson tips or a cell scraper in pre-warmed DMEM/F12 or mTeSR1 and 
collected in 15-ml Falcon tubes. If the cells were detached with mTeSR1, then the 
volume of the mTeSR1 medium was adjusted and the cells were plated onto Matrigel-
coated plates. However, if the cells were removed using DMEM/F12 medium, they 
were pelleted by centrifugation for 3 min at 1,000×g. Next, the pellet was re-suspended 
with an accurate amount of pre-warmed mTeSR1 and plated on Matrigel-coated plates. 
Cultures were incubated in a humidified incubator at 37°C, 5% CO2 and were fed with 
fresh medium daily. 
 
3.2.1.3 Human embryonic kidney 293 (HEK293) cells  
 
HEK293 cells were grown in DMEM/F12 (1:1) medium (Cat. No. 21331020, 
Invitrogen) supplemented with 10% FBS (Cat. No. 10106-169, Invitrogen), 1% L-G and 
1% Pen/Strep. Medium was sterilized by filtration through a 0.2-µm sterile filter before 
use. HEK293 cells were cultured in T25 tissue culture flasks (TKT-130-150-L, Thermo 
Fisher Scientific) in a humidified incubator at 37°C, 5% CO2.  
When the cells became dense, they were passaged with 3 ml trypsin for 5 min 
at 37°C. The cells were lifted off by flicking the flask with HEK293 medium and 
collected in a 15-ml Falcon tube. Then, the cells were pelleted by centrifugation for 3 
minutes at 1,000×g. The pellet was re-suspended with an appropriate amount of 
HEK293 medium and re-plated into T25 flasks at a ratio of 1:8 or 1:10. Cultures were 
incubated in a humidified incubator at 37°C, 5% CO2 and fed with fresh medium every 
other day. 
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3.2.2 Preparation of frozen cells 
 
The cells were preserved at -80°C or in liquid nitrogen for long-term storage. 
Prior to freezing, H9 and 34D6 cells were detached from plates by collagenase 
(Section 3.2.1.1) or dispase (Section 3.2.1.2), respectively. Then, the cells were 
centrifuged at 1,000×g for 3 min and re-suspended in freezing media containing 10% 
DMSO in FBS for H9 cells and Cryostor CS10 (Cat. No. 7930, StemCell Technologies) 
for 34D6 cells. Then, the cells were divided into aliquots using1-ml cryopreservation 
vials (Cat. No. 4000198, 100ml/U, Thermo Fisher Scientific) and stored at 80°C in a Mr. 
Frosty freezing container (Cat. No. 5100-0036, Thermo Fisher Scientific) overnight, 
and then transferred to a liquid nitrogen tank.  
 
3.2.3 Thawing frozen cells 
 
3.2.3.1 H9 and 34D6 cells  
 
Using a P1000 pipette, a vial of H9 or 34D6 cells was quickly thawed to a semi-
solid state and returned to a pre-warmed medium, such as H9 medium, in a 15-ml 
Falcon tube. Tubes were centrifuged at 1,000×g for 3 min to remove the DMSO. After 
centrifugation, the pellets were re-suspended in 5 ml of H9 medium for H9 cells and 
DMEM/F12 medium for 34D6 cells and centrifuged again. Subsequently, the cells were 
re-plated.  
For H9 cells, the mefi cells plates were prepared by removing the mef medium 
and washed once with PBS. Then 5 ml of H9 media containing FGF2 and Y-27632 
ROCK inhibitor was added to the mefi plate. After a second centrifugation step, the cell 
pellet was re-suspended in 1 ml of H9 medium, and the cells were transferred to the 
mefi plate.  
For 34D6 cells, after the second centrifugation step, the pellet was re-
suspended in mTeSR1 medium and re-plated on Matrigel-coated plates. 
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Feeding was initiated 24 h after thawing, and the cells were fed every day. 
 
3.2.3.2 HEK293 cells 
 
One vial of HEK293 cells was quickly thawed using a 37°C water bath. Then, 1 
ml of DMEM/F12 medium was gently added to the cells (in drops) and transferred to a 
15-ml Falcon tube, which was centrifuged at 1,200×g for 4 min. The pellet was washed 
again with DMEM/F12 and re-suspended in HEK293 medium (Section 3.2.1.3), then 
re-plated in a T25 flask. 
 
3.2.4 Neural induction (Neurogenic Embryiod Bodies – NEBs) 
 
Neural differentiation was performed in either embryoid body (EB) culture or 
monolayer culture. For EB culture, hPSC colonies were washed 3× with PBS and 
whole colonies lifted by collagenase (for H9 hESCs) or dispase (for 34D6 h-iPSCs) 
treatment, as described for cell passaging above (Sections 3.2.1.1 and 3.2.1.2, 
respectively). After collection, colonies were re-suspended in Advanced DMEM/F12 
(ADF) medium supplemented with 700 µl of 10 mg/ml insulin (Cat. No. 407709, 
Millipore), 300 µl of 12.5 mg/ml transferrin (Cat. No. T8158, Sigma–Aldrich), 1% lipid 
concentrate (Cat. No. 11905031, Invitrogen), 1% L-G, 1% Pen/Strep and 0.68% beta–
mercaptoethanol, Y-27632 ROCK inhibitor (for the first day), 0.5 µM LDN193189 (Cat. 
No. 04-0074-10, StemGent, Cambridge, UK) and 10 µM SB431542 (for the first four 
days) (Cat. No. ab120163, Abcam Biochemicals) and plated in a sterile dish plate (Cat. 
No. PDS140050F, Thermo Fisher Scientific) to obtain suspension cells in ADF media. 
The SB431542 was then removed on the fourth day. The NEBs were fed every other 
day with half a quantity of fresh media (Figure 3.6). 
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Figure 3.6: The differentiation protocol, from the undifferentiated state to NEBs to 
Nr-NPCs 
The NEBs were cultured with SB431542 and LDN193189 and then they were removed 
on days 4 and 8, respectively. Subsequently, the rosettes state was performed and 
cultured with ADF medium until day 18 (D18). 
 
NEB differentiation 
Differentiation of hESCs generates naïve rosette-stage neural progenitors (Nr-
NPCs). The day before plating, a 24-well plate was prepared, coated with 2 µg/ml poly-
L-Lysine (PLL) (diluted with dH2O) (Cat. No. P5899-5 MG, Sigma-Aldrich) and 
incubated at 37°C for 30 min, washed with dH2O (Cat. No. 15230188, Invitrogen), and 
incubated overnight inside a hood. The next day, the plate was coated with 10 µg/ml 
laminin (Cat. No. 130095602, Miltenyi Biotec, Surrey, UK) and incubated at 37°C for 30 
min. The NEBs were centrifuged at low speed (500×g for 2 min) and mixed with 
Accutase for 5 min to obtain a single cell suspension (Accutase, Cat. No. L11007, PAA 
Laboratory, Farnborough, Hamsphire, UK). Subsequently, they were centrifuged at 
1,000×g for 3 min and 1 ml of ADF media was added to conduct cell counts. An 
appropriate amount of ADF was added to the cells, which were re-plated onto coated 
PLL/Laminin plates at a concentration of 50 x 103 cells/well; cells were fed every other 
day. 
 
D0                         D4                         D8                        D12                         D18 
NEBs Rosette Stage (nrNPCs) 
ADF MEDIUM 
10µM SB431542 
0.5µM LDN193189 
Where 
nucleofection 
started 
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3.2.5 Cell counts  
 
From a 1 ml cell suspension, 10 µl of the cells were added to 10 µl of trypan blue 
(Cat. No. T8154, Sigma-Aldrich), after which they were added to a haemocytometer 
with a glass cover slip. The cells in the central square (5 × 5 grid) and the four corner 
squares were then counted, and the number of cells per ml was calculated using the 
following equation: 
Total number of cells × (dilution factor / number of squares) ×104 cell/ml = 
cells/ml 
 
3.2.6 AMAXA Nucleofection  
 
The cells were treated with ROCK inhibitor prior to nucleofection. Lonza AMAXA 
kits (AMAXA Mouse NSC (MNSC) with the Nucleofector kit, Cat. No. VPG-1004 with 
the optimized programme A-023, Lonza Biologics plc, Cambridge, UK) were used for 
hESCs, and the AMAXA cell line kit V, Cat. No. VCA-1003, with the programme 
HEK293, was used for HEK293 cells. 
The medium was aspirated and cells were washed once with PBS. Then, 
Accutase with ROCK inhibitor was added for 2–5 min. Then, the cells were collected 
into a 15-ml Falcon tube and centrifuged at 1,000×g for 3 min, and washed again with 
PBS. At this point, the pellet was re-suspended with nucleofection solution, which was 
composed of 78 µl of MNSC solution plus 22 µl of nucleofector supplement, and 
plasmid DNA (up to 20 µg/ml) was added to the nucleofection solution. The whole 
mixture of cells, plasmid DNA solution and the supplement was transferred into a new 
cuvette, and subjected to nucleofection with the appropriate programme. Immediately 
after this, 1 ml of pre–warmed media (ADF or HEK293 medium with ROCK inhibitor) 
was added to the nucleofected cells, and this process was followed by a cell count 
(see section 3.2.5) and re-plating into Matrigel-coated, 6-well Nunc plates at a 
concentration of 1 x 106 cells/well. Green fluorescent protein (GFP) expression was 
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checked after 24 and 48 h, and cells were fed every other day. The selection was 
started after 48 h. 
 
3.2.7 Neomycin selection  
 
Because they were neomycin-resistant, 48 h after nucleofection, the cells were 
selected using G418 sulphate, (Cat. No. 10131-027, 50 mg/ml, Invitrogen). Different 
concentrations of G418 with different incubation times were tested to find the most 
suitable concentration of G418 and duration time to select GFP+ve cells.  
Hence, the surviving cells were the ones that expressed the cloned transcription 
factors (TFs), and they were, therefore, selected. After selection, the surviving cells 
were washed and fed with ADF media for one day. Then, the selected cells were re-
plated into 24-well plates (Section 3.2.7.1 below) at a density of 30 × 103 cells/well for 
the differentiation experiments. Before re-plating, cover slips placed onto the 24-well 
plates were subjected to a specific treatment as described below, to ensure strong 
adherence and subsequent growth on the cover slips for further downstream 
applications.  
For the H9 differentiation experiments, cover slips were placed onto 24-well 
plates and coated with 10 mg/ml poly-L-lysine (PLL) (diluted with dH2O) and incubated 
at 37°C for 30 min. Next, the cover slips were washed three times with dH2O and 
incubated overnight inside a sterile hood to dry. The next day, the cover slips were 
coated with 10 µg/ml laminin and incubated at 37°C for 30 min. Approximately 5 ml of 
dH2O was added between the wells (inter-well space) to avoid drying of the re-plated 
cells (H9 neural progenitors).  
For the 34D6 differentiation experiments, poly-D-lysine (Cat. No. 27964-99-4, 5 
mg/ml, Sigma-Aldrich) (PDL)/Matrigel-coated cover slips were used. In addition, the 
cover slips were treated with nitric acid. One hundred cover slips were placed into a 
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50-ml Falcon tube containing 25 ml of nitric acid and rocked overnight. Then, the cover 
slips were washed 3-5 times with ddH2O. Then, they were washed once with absolute 
ethanol. Finally, the cover slips were placed on a glass petri dish and baked at 150°C 
overnight.  
Subsequently, the cover slips were placed onto 24-well plates and coated with 
100 µl of 100 µg/ml PDL in borate buffer, at pH 8.4 for 1 h at RT. The borate buffer was 
prepared with 1.24 g of boric acid, 1.90 g sodium tetraborate and 400 ml H2O at pH 
8.4. Each well was washed three times with dH2O to remove the borate buffer. The 
plates were placed inside a hood to dry off the cover slips. Then, the cover slips were 
coated with 50 µl of Matrigel, and incubated for 1 h. The Matrigel was diluted (1:25) in 
cold medium using Knockout DMEM. Approximately 5 ml of H2O was added between 
the wells (inter-well space) to avoid drying the Matrigel and the re-plated cells (34D6 
neural progenitors).  
 
3.2.7.1 Re-plating the selected nucleofected cells into 24-well plates 
containing treated cover slips 
 
The media was aspirated off the 24-well plate, which was washed once with 
PBS without calcium and magnesium. The cells were dissociated with Accutase with Y-
27632 ROCK inhibitor for 2 to 5 min, and the pellet was collected by centrifugation at 
1000×g for 3 min. The pellet was re-suspended in 1 ml of ADF to conduct cell counts 
(Section 3.2.5). After cell counting, 30 × 103 cells were re-plated as a droplet onto the 
treated cover slips and incubated at 37°C for 30 min to allow the selected nucleofected 
cells to attach to the cover slips. Then, each well of the 24-well plates was flooded with 
ADF media for 3 to 5 h. Subsequently, the ADF media was aspirated off and replaced 
with differentiation media. The cells were fed every 2 days. 
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3.3 Immunocytochemistry (ICC) 
 
The cells were washed once with PBS and fixed with fresh 4% paraformaldehyde 
(PFA) (Cat. No. P6148, Sigma-Aldrich) at pH 7.8 for 10 min at 4°C. Next, they were 
washed three times for 5 min with PBS. In the next stage, cells were permeabilized 
using PBS with 0.1% Triton X-100 (for internal antibody (Ab) only) (Cat. No. T8787, 
Sigma-Aldrich) for 20 min at RT or 100% ethanol for 20 minutes at RT. The solution 
was aspirated, and the cells were washed three times with PBS for 5 min. Next, 1 M 
glycine (Cat. No. 67419, Sigma-Aldrich) was added for 20 min at RT. Next, blocking 
was initiated using 2% normal goat serum (NGS) (Cat. No. S-1000, Vector Laboratory, 
Peterborough, UK), according to the secondary Ab, 3% BSA (Cat. No. A8531, Sigma-
Aldrich) and 0.1% Triton X-100 (for internal Ab only). Blocking was carried out at RT for 
1 h, followed by incubation with the primary Ab (1° Ab) overnight at 4°C; cells were 
then washed three times with PBS, followed by secondary Ab (2° Ab) incubation for 1 h 
in the dark at RT. At this point, cells were washed again. For nuclear staining and 
mounting, VECTASHIELD Mounting Medium with DAPI (Cat. No. H1200, Vector 
Laboratories) was used. 
 
The Abs used in this study and their dilutions are shown in the table below  
 
Table 3.2: Antibodies and dilutions used for ICC 
ABs Primary Antibody (1°Ab) Species 1°Ab Dilution 
β – TUBULIN 
III 
Anti-mouse (Cat. No. 
T8660, Sigma-Aldrich) 
and Anti-rabbit (Cat. 
No. T2200, Sigma-
Aldrich) 
1:800 (for anti-mouse) 
1:400 (for anti-rabbit) 
CTIP2 Anti-rat (Cat. No. ab18465, Abcam) 1:500 
DARPP-32 Anti-rabbit (Cat. No. sc-
11365, Santa Cruz 
1:100 
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Biotechnology, 
Heidelberg, Germany)  
DLX2 Anti-rabbit (Cat. No. ab18188, Abcam) 1:800 
FOXG1 
Anti-rabbit (Cat. No. 
518-694-8188, 
NeuraCell, Rensselaer, 
NY, USA) 
1:1000 
GFP Anti-rabbit (Cat. No. ab290, Abcam) 1:4,000 
GSX2 Anti-rabbit (Cat. No. ABN162, Millipore). 1:500 
2A Anti-rabbit (Cat. No. ABS31, Millipore). 1:500 
Ki67 
Anti-mouse (Cat. No. 
VP-K451, Vector 
Laboratory). 
1:100 
MASH1 
Anti-mouse (Cat. No. 
556604, BD 
Biosciences, Oxford, 
UK) 
1:500 
MAP2 
Anti-rabbit (Cat. No. 
ab24640, Abcam). 
Anti-mouse (Cat. No. 
MAB3418, Millipore). 
1:1000 (for anti-rabbit) 
1:500 (for anti-mouse) 
Human ZO-1 
Anti-mouse (Cat. No. 
610966, BD 
Biosciences) 
1:250 
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3.4 RNA/DNA-related techniques  
 
3.4.1 RNA extraction 
 
RNA extraction was performed using the RNeasy mini kit (Cat No. 74104, 
Qiagen) according to the manufacturer’s guidelines. 
The media was removed from the cell-culture dish, which was washed once 
with PBS, and then 350 µl of RLT buffer was added to disrupt the cells. The lysate was 
collected into an Eppendorf tube and mixed by vortexing or pipetting to ensure that 
there were no clumps. The lysate was homogenized using a QIAshredder spin column 
and centrifuged for 2 min at 13,000×g. One volume of 70% ethanol was added to the 
homogenized lysate, and cells were mixed by pipetting. Then, the samples were 
transferred into an RNeasy mini column and centrifuged for 15 s at 10,000×g. 
Afterwards, the supernatant was removed and 350 µl of RW1 buffer (contains 
guanidine thiocyanate) was added to the RNeasy mini column, followed by 
centrifugation for 15 s. A mixture of RNase-Free DNase I stock and RNase-Free 
DNase buffer (RDD) was made by adding 10 µl and 70 µl of each component, 
respectively (Cat. No. 79254, Qiagen). The mixture (80 µl) was added to the RNeasy 
mini column and incubated at RT for 15 min. Then, 350 µl of RW1 was added, followed 
by centrifugation for 15 s. Then 500 µl of RPE buffer, which contained 80% of ethanol, 
was added to the RNeasy mini column, followed by centrifugation for 15 s. The last 
step was repeated by adding the RPE buffer and centrifuging for 2 min to dry the 
RNeasy silica-gel membrane. Subsequently, the collection tube was changed, followed 
by centrifugation at 13,000×g for 1 min. Afterwards, the RNeasy mini column was 
transferred to a new 1.5 ml collection tube and 30 µl of Rnase-free water was added. 
Finally, the column was centrifuged for 1 min and the eluted RNA was stored at -80°C. 
The RNA concentration was determined using a NanoDrop spectrophotometer. 
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3.4.2 Complementary DNA (cDNA) synthesis by reverse transcriptase 
polymerase chain reaction (RT-PCR) 
 
After RNA extraction, 1 µg mRNA was reverse transcribed into cDNA using 
SuperScriptTM II Reverse Transcriptase (Cat. No. 18064-022, Invitrogen). The protocol 
was conducted according to the manufacturer’s guidelines. 
RNA (1 µg in a total volume of 10 µl) was added to 1.5 ml, nuclease-free 
Eppendorf tubes and kept on ice. Firstly, a master mix (mm) was prepared (1 µl of 10 
mM dNTPs (10 mM each of dCTP, dATP, dTTP and dGTP at neutral pH) and 1 µl of 
random primers (Cat. No. 48190-011, Invitrogen). Two mRNA samples were prepared 
and labelled as RT+ and RT-. In the RT- sample, H2O was added instead of 
SuperScript reverse transcriptase, followed by the addition of 2 µl of mm to the RT+ 
and RT- samples. The samples were then incubated at 65°C for 5 min and quickly 
chilled on ice. Then, a mixture of 0.1 M DTT (2 µl), 5× first standard buffer (250 mM 
Tris-HCl, pH 8.3 at RT; 375 mM KCL; 15 mM MgCL2) (4 µl) and RNaseOUTTM 
Recombinant Ribonuclease Inhibitor (1 µl) was added. Then, the samples were gently 
mixed by flicking the tubes, and centrifuged for 2 min at 25°C. Finally, 1 µl of 
Superscript II reverse transcriptase was added, but only to the RT+ tube, and samples 
were incubated at 25°C, 42°C and 70°C for 10, 50 and 15 min, respectively. The 
samples were incubated at 70°C for 15 min to inactivate the reverse transcriptase. The 
samples were stored at -20°C.  
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3.4.3 Quantitative polymerase chain reaction (Q-PCR) 
 
Real-time quantitative reverse transcription polymerase chain reactions (qRT-
PCR) were conducted using a standard protocol. The cDNA was diluted in TE or 
Rnase-free water for use in the Q-PCR reactions. mm was prepared as follows: 
 
Components Volume 
Primer (10 pmol/µl) 1 µl 
dH2O 8 µl 
mm (DyNAmo HS SYBR 
Green 5×; F410L) 10 µl 
 
 
mm (19 µl) was pipetted into each well of a 96-well plate. Then, 1 µl of template 
DNA was added to each well. All reactions were conducted in triplicate. The Q-PCR 
reaction was performed in a CFX Connect real-time PCR system machine (Cat. No. 
185-5200, Bio-Rad Laboratory, Hertfordshire, UK) using the following conditions: 
 
Cycle repeat Purpose Temperature Time 
1x Initial denaturation 95°C 15 min 
40x Denaturation 95°C 30 s 
 Annealing 60°C 30 s 
 Extension 72°C 30 s 
Plate read 
1x Melting curve 53°C–95°C 
Read every 
0.5°C, and hold 
00:00:02 
End 
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The primers used in this project are shown in Table 3.3. New primers were also 
tested (Appendix 3.1).  
 
Table 3.3: Lists of primers used in this project 
Gene/Primer Sequences 5’-3’ Annealing temp. 
Amplicon
size (bp) 
ARX-F 
ARX-R 
GCTGAAACGCAAACAGAGGC (20 bp) 
AGTTCCTCCCTGGTGAAGACGT (22 bp) 
59.4°C 
62.1°C 
114 
B-ACTIN-F 
B-ACTIN-R 
CCCAGCACAATGAAGATCAA (20 bp) 
ACATCTGCTGGAAGGTGGAC (20 bp) 
55.3°C 
59.4°C 
103 
CALBIN-1-F 
CALBIN-1-R 
TGT GGA TCA GTA TGG GCA AAG (21 bp) 
CGG AAG AGC AGC AGG AAA T (19 bp) 
57.9°C 
56.7°C 
96 
CTIP2-F 
CTIP2-R 
CCATCCTCGAAGAAGACGAG (20 bp) 
ATTTGACACTGGCCACAGGT (20 bp) 
57.5°C 
59.8°C 
106 
DARPP-32-F 
DARPP-32-R 
CTCCAGAGAACGGCATTGTT (20 bp) 
TCCTGCTCCTGACTTGGATT (20 bp) 
58.2°C 
58.3°C 
116 
DRD1-F 
DRD1-R 
TGC CAT AGA GAC GGT GAG TA (20 bp) 
CAG CAT GTG GGA TCA GGT AAA (21 bp) 
57.3°C 
57.9°C 
116 
DRD2-F 
DRD2-R 
CAC TCC TCT TCG GAC TCA ATA AC (23 bp) 
GAC AAT GAA GGG CAC GTA GAA (21 bp)  
60.6°C 
57.9°C 
107 
EBF1-F 
EBF1-R 
GTGGAGATCGAGAGGACAGC (20 bp) 
AAGCTGAAGCCGGTAGTGAA (20 bp) 
59.6°C 
59.3°C 
99 
EMX2-F 
EMX2-R 
ACCTTCTACCCCTGGCTCAT (20 bp) 
AAAGGAAACTCTCGGGGCTA (20 bp) 
57.8°C 
55.8°C 
85 
Endo-DLX2-F 
Endo-DLX2-R 
TCACCACCACCACCATCAC (19 bp) 
CTCTGCTCTCAGTCTCTGGC (20 bp) 
58.8°C 
61.4°C 
96 
Endo-MASH1-
F 
Endo-MASH1-
R 
CCCCCAACTACTCCAACGAC (20 bp) 
TCCAAAGTCCATTCGCACCA (20 bp) 
61.4°C 
57.3°C 
173 
Endo-GSX2-F 
Endo-GSX2-R 
CTCCGAGGATGAGGACTC (18 bp) 
AGGAGCGGGGGATGTGAG (18 bp) 
60.5°C 
58.2°C 
100 
Exo-DLX2-F ATGTTGAAGAAAACCCCGGTCCT (23 bp) 60.6°C 74 
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Exo-DLX2-R GGTCGAGTGCATATCAGCCACTA (23 bp) 62.4°C 
Exo-MASH1-F 
Exo-MASH1-R 
AACTACTCCAACGACTTGAACTCCAT (26 bp) 
AGAGCATAATTAGTACACTGGGATCC (26 bp) 
61.6°C 
61.6°C 
97 
Exo-GSX2-F 
Exo-GSX2-R 
AGTGAAGCACAAGAAGGAGGGG (22 bp) 
GACTTCCTCTGCCCTCAGATCT (22 bp) 
62.1°C 
62.1°C 
129 
FOXP1-F 
FOXP1-R 
CGATCCCTTCTCTGATTTGC (20 bp) 
CATGCATAATGCCACAGGAC (20 bp) 
56.3°C 
57.2°C 
103 
GAD2-F 
GAD2-R 
GCT CTG GCG ATG GGA TAT TT (20 bp) 
CCA TTC CTT TCT CCT TGA CTT CT (23 bp) 
57.3°C 
58.9°C 
105 
GAPDH-F 
GAPDH-R 
TGCACCACCAACTGCTTAGC (20 bp) 
GGCATGGACTGTGGTCATGAG (21 bp) 
58.3°C 
58.1°C 
87 
NKX2.1-F 
NKX2.1-R 
AGGACACCATGAGGAACAGC (20 bp) 
CCCATGAAGCGGGAGATG (18 bp) 
57.1°C 
55.8°C 
88 
PAX6-F 
PAX6-R 
AGGCCAGCAACACACCTAGT (20 bp) 
AGCCAGATGTGAAGGAGGAA (20 bp) 
61.4°C 
58.3°C 
108 
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3.5 Western blotting analysis  
 
The compositions of the stock solutions and buffers for protein analysis by SDS-
PAGE and western blotting are shown in Table 3.4 below. 
 
Table 3.4: Composition of solutions used for western blotting 
Solutions Composition 
Lysis Buffer 
10 ml RIPA Buffer (Cat. No. R0278, Sigma-Aldrich), 1 tablet of 
PhosStop (Cat. No. 04906845001, Roche) and 1 tablet of 
Complete Mini 1× solution (Cat. No. 11836153001, Roche). 
10x Running Buffer 
0.25 M Tris base (Cat. No. T1503, Sigma-Aldrich), 1.92 M 
glycine (Cat. No. G8898, Sigma-Aldrich), 0.1% sodium 
dodecyl sulphate (SDS) (Cat. No. L3771, Sigma-Aldrich), and 
pH 8.3 (diluted 10× before use). 
10% SDS 10 g SDS in 100 ml. 
1% SDS 1 g SDS in 100ml. 
Transfer Buffer 0.25 M Tris base, 1.92 M glycine, and 20% methanol (Cat. No. 34860, Sigma-Aldrich). 
Sample Loading Buffer 
2% SDS, 10% glycerol (Cat. No. G5516, Sigma-Aldrich), 60 
mM Tris base, pH 6.8, 0.005% bromophenol blue (Cat. No. 
B0126, Sigma-Aldrich) and 500 mM DL-dithiothreitol (DTT) 
(Cat. No. D0632, Sigma-Aldrich). 
Resolving Gel 
10% acrylamide (Cat. No. A8887, Sigma-Aldrich), 0.37 M Tris, 
0.1% SDS, 0.1% ammonium persulphate (APS) (Cat. No. 
A3678, Sigma-Aldrich) and 0.06% tetramethylethylenediamine 
(TEMED) (Cat. No. T9281, Sigma-Aldrich). 
Stacking Solution 5% acrylamide, 0.125 M Tris, 0.1% SDS, 0.05% APS and 0.5% TEMED. 
Ponceau S 0.1% in 5% acetic acid (Cat. No. P3504, Sigma-Aldrich). 
Wash Buffer 1×PBS (Cat. No. 70011-044, Invitrogen), 0.1% Tween 20 (Cat. No. P1379, Sigma-Aldrich) 
Blocking Solution 5% skimmed milk powder (Marvel, Lincolnshire, UK) in 1×PBS and 0.1% Tween 20. 
Antibody blocking solution 5% milk powder in PBS/Tween + 100 µl sodium azide (Cat. No. S2002, Sigma-Aldrich) (1 M) / 20 ml. 
SuperSignal West Dura 
chemiluminescent 
substrate 
1:1 ratio of SuperSignal West Dura Liminol:Enhancer solution 
(Thermo scientific, Massachusetts, USA, Cat. No. 34075) 
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3.5.1 Protein extraction from monolayer cells using RIPA buffer 
 
A confluent, 10-cm dish was washed once with cold PBS then placed on ice. 
Ice-cold lysis buffer (see Table 3.4) and 1× PhosStop solution were added, and the 
cells were scraped using a rubber policeman. Next, the solution was incubated for 30 
min at 4°C with intermittent agitation and centrifuged at 13,000×g for 20 min at 4°C. 
The supernatant was then transferred to a new tube and the pellet was discarded. 
Samples were stored as aliquots at -80°C. 
 
3.5.2 Protein assay  
 
After the protein extraction from the cells, the concentration of total protein was 
measured by the Pierce Bicinchoninic Acid (BCA) Protein Assay Kit (Cat. No. 23227, 
Thermo Fisher Scientific). 
Nine standards were prepared using a dilution series of BSA (Cat. No. A9418-
100-G, Sigma-Aldrich) ranging from 20 to 2,000 µg/ml. The standards and unknown 
samples (25 µl each) were plated in triplicate in a 96-well plate. Then, the BCA working 
reagent (WR) was prepared, as recommended by the manufacturer:  
 
(Number of standards + number of unknown samples) × (number of 
triplicates) x (volume of WR per samples) = total volume of WR 
required.  
 
The BCA WR consisted of BCA reagent A and BCA reagent B. The mixing ratio 
was 1:50 (B:A). WR (200 µl) was added to each well of the standards - in addition to 
the unknown samples in the 96-well plate - and mixed thoroughly on a plate shaker for 
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30 s. Then, the plate was incubated at 37°C for 30 min, and allowed to cool to RT. The 
absorbance was measured at 590 nm using a Bio-Tek plate reader (Epson, California, 
UK).  
 
3.5.3 SDS polyacrylamide gel electrophoresis 
 
A resolving gel (Table 3.4) was prepared and left to set with a layer of 1% SDS 
on the surface. The SDS was removed; the stacking gel (Table 3.4) was added and 
then left to set with an appropriate comb size. While waiting for the gel to set, the 
protein samples were prepared by adding a 1:1 ratio of sample loading buffer and 
protein samples. These were then incubated at 95°C for 5 min to denature the protein 
samples. Once the gel was set, the samples (20-40 µg/lane) were loaded into the gel 
wells alongside a rainbow protein ladder (10 µl/lane) (The Novex® Sharp Pre-Stained 
Protein Standard, Cat. No. LC5800, Invitrogen). Running buffer (Table 3.4) was added 
to the running tank and the stacking gel was run at 80 V, and the resolving gel was run 
at 120 V for 2 h.  
 
3.5.4 Western blotting 
 
After SDS-PAGE, the gel was removed from its casing. A Hybond ECL 
membrane (0.2 µm pore size nitrocellulose) (Cat. No. RPN3032D, GE Healthcare Life 
Science, Belfast, UK) was soaked briefly in dH2O, and then placed in transfer buffer for 
10 min. The gel, sponges and filter paper were soaked in transfer buffer before being 
layered with filter paper, thus sandwiching the gel and the membrane. They were 
arranged in the sandwich cassette as follows: 
Cathode (-): sponge : filter paper : Gel : Nitrocellulose : filter paper : sponge : Anode 
(+)  
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Next, transfer buffer (Table 3.3) was added to a tank containing a magnetic 
spinner and left in a cold room overnight at 25 V or at 100 V for 1 h. The following day, 
the membrane was carefully removed and washed once with dH2O and then with wash 
buffer (Table 3.3). Finally, it was washed with a wash buffer on a shaker to remove the 
stain. 
 
3.5.5 Immuno-detection of proteins 
 
Following the blotting, the membrane was removed from the sandwich and 
washed, as previously described (section 3.5.4). The wash was then removed and 
replaced with a blocking solution (Table 3.4) for 1 h with shaking. At this point, the 
blocking solution was replaced with a specific primary antibody (a dilution of primary 
antibody in blocking solution, Table 3.5) and left for 2 h at RT, and then left overnight 
at 4°C. At this stage, the membrane was washed three times for 5 min in wash buffer. 
Afterwards, the secondary antibody in blocking solution (diluted in blocking solution, 
Table 3.5) was added for 1 h at RT. Then, the membrane was washed again under the 
same conditions.  
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Table 3.5: Antibodies and dilutions used for western blotting 
Protein Primary Antibody (1°Ab) Species 
1°Ab 
Dilution 
Secondary 
Antibody 
(2°Ab) 
Species 
2°Ab 
Dilution 
Protein 
Size 
β-ACTIN Mouse (Cat. No. 
A2228, Sigma) 
1:10,000 Mouse 1:10,000 42 kDa 
GSX2 
Rabbit (Cat. No. 
ARP32208-P050, 
Aviva System 
Biology, San Diego, 
USA) 
1:1000 Rabbit 1:10,000 ≈ 32 kDa 
MASH1 Mouse (BD Biosciences) 1:100 Mouse 1:10,000 ≈ 34 kDa 
DLX2 Rabbit (Abcam) 1:400 Rabbit 1:10,000 ≈ 34 kDa 
DARPP-32 Rabbit (Santa Cruz) 1:100 Rabbit 1:10,000 ≈ 32 kDa 
 
3.5.6 Detection of chemiluminescence  
 
After the nitrocellulose had been probed with the appropriate antibodies, the 
membrane was placed in the developing cassette and incubated with SuperSignal 
West Dura buffer (0.5 ml) (Table 3.4) for 5 min in dark. Then, the solution was poured 
off, and film (Cat. No. 11666657001, Roche) was placed over the membrane and 
exposed for various time intervals.  
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3.6 Electrophysiology studies 
 
3.6.1 Whole-cell patch 
 
Standard whole cell patch clamp and analysis was carried out by Dr Vsevolod 
Telezhkin (Cardiff University), following methods previously reported (Telezhkin et al. 
2010). Briefly, nucleofected hPSC-derived nrNPCs were mounted on an inverted 
microscope (Olumpus CK40) and the whole cell patch clamp configuration obtained. 
Internal solution consisted of 117 mM KCl, 10 mM NaCl, 11 mM HEPES, 11 mM 
EGTA, 2 mM MgCl2, 1 mM CaCl2 and 2 mM Na2-ATP and external consisted of 135 
mM NaCl, 5 mM KCl, 5 mM HEPES, 10 mM Glucose, 1.2 mM MgCl2 and 1.25 mM 
CaCl2.  
Upon successful cell access, zero current injection continuous recordings were 
made in current clamp mode for measurement of resting membrane potential and 
spontaneous synaptic activity. Offline data was reviewed and analysed by Axon 
Laboratory’s Clampfit and Microsoft Office Excel.   
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3.7 Statistical analysis of data 
 
GraphPad PRISM version 6.0d software was used to analyse the data. All 
datasets were tested for normality using the D'Agostino-Pearson test.  
For single comparisons of the data, a Student’s t-test (two-tailed, paired or 
unpaired) was used. For multiple comparisons, however, two-way analysis of variance 
(ANOVA) was used with Bonferroni correction, which is one of the multiple-comparison 
corrections. The results were regarded as significant if the p-value was equal or less 
than 0.05 (p-value ≤ 0.05). 
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4.1 Introduction 
 
The transcription factors (TFs) DLX2, MASH1 and GSX2 have proven roles in the 
specification of the Lateral Ganglionic Eminence (LGE) and medium spiny neuron (MSN) 
fate determination. This chapter describes the construction of plasmid expression vectors 
for the three TFs. The open reading frames of the genes were cloned, from cDNA, into 
polycistronic vectors to enable the co-expression of linked TFs from a single pro-protein 
(O’Malley et al. 2009).  
The ability to express more than one protein from a single vector that contains 2A self-
cleaving peptides could be used for gene therapy of diseases, such as HD, in which it is 
unknown whether one or more genes are essential for the efficient production of MSNs. 
Therefore, in this thesis, the co-expression of different combinations of the three desired 
TFs was examined to investigate which combination of TFs had a significant role in the 
production of MSNs. For example, in Parkinson’s disease, using a polycistronic vector 
three genes encoding catecholarminergic synthetic enzymes (tyrosine hydroxylase (TH), 
aromatic amino acid L-3,4-dihydroxyphenylalanine (DOPA) decarboxylase (AADC) and 
GTP cyclohydrolase (CH1)) were found to be essential for the efficient generation of 
dopamine (Azzouz et al. 2002; Radcliffe and Mitrophanous 2004).  
 
4.1.1 Self-cleavage 2A peptide  
 
The polycistronic vector used in this study contains three self-cleaving 2A peptide 
sequences, E2A, T2A and P2A. The 2A peptide sequences was initially reported by Ryan 
and collaborators (1991) in one genus of the picornavirus family, the foot-and-mouth 
disease virus (FMDV) (Ryan et al. 1991; J. H. Kim et al. 2011). The self-cleavage of 2A 
peptides takes place during translation, thereby releasing each protein (Donnelly et al. 
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2001). Self-cleavage occurs by a process known as ribosome skipping at the C-terminus 
of the 2A peptide, where the ribosome skips the synthesis of the glycyl-prolyl (G-P) peptide 
bond. As a result of the cleavage, two proteins will be formed: the upstream peptide (that 
contains glycine (G) at its C-terminus) and the downstream peptide (that contains proline 
(P) at its N-terminus) (Figure 4.1) (Donnelly et al. 2001; J. H. Kim et al. 2011). 
 
Figure 4.1: Construction of self-cleaving 2A peptide by ribosome skipping. 
Diagrammatic representation of self-cleavage of the 2A peptide in the FMDV during translation. The 
red area indicates where the cleavage site starts, which releases the 2A peptide that contains a G 
residue at the N-terminus and the downstream peptide that contains a P residue at its C-terminus. 
Abbreviations: G: Glycine, P: Proline; NPGP: amino acid sequence of asparagyl-prolyl-glycyl-
prolyl.  
 
4.1.2 DLX2 
 
Dlx genes expressed in the telencephalon are confined to the differentiating, γ-
aminobutyric acid (GABA)-expressing neurons (Stühmer et al. 2002b). The expression of 
Dlx1 is localised in the telencephalon of the ventricular zone (VZ) and sub-ventricular zone 
(SVZ) of the LGE and MGE; Dlx1 is also expressed in the mantle zone (MZ) (Poitras et al. 
2007). The expression of Dlx2 is found in the ventricular and sub-ventricular telencephalon 
zones of mouse embryos at E12.5, where early differentiation occurs (Panganiban and 
Upstream Downstream ……NPGP 
2A 
N-terminus C-terminus 
Upstream Downstream ……NPG                 P  
                                                                                                                          Chapter 4: Introduction 
 135 
Rubenstein 2002). Recently, it was found that the DLX2 gene was expressed in the 
developing human foetal forebrain at late embryonic stages, and was localised to the SVZ 
of the entire ventral telencephalon domain (Pauly et al. 2013). Dlx expression in the MGE 
is associated with GABA interneuron development, whereas Dlx expression in LGE 
progenitors is associated with striatal and olfactory bulb GABA neurogenesis (Poitras et al. 
2007).  
Dlx2 has a role in ventral forebrain patterning and neuronal subtype specification, and 
it also plays a significant role in striatal and olfactory bulb GABA neurogenesis (Poitras et 
al. 2007). Mice lacking Dlx1 and Dlx2 lack migrating GABAergic interneurons from the 
telencephalon of the SVZ and VZ of the LGE and MGE to the cerebral cortex, which then 
results in a four-fold reduction in the number of GABAergic expressing cells in the cerebral 
cortex, striatum and olfactory bulb, which are the final destinations of the GABAergic 
interneurons (Anderson 1997). In addition, a mutation in Dlx2 causes abnormalities in the 
differentiation of late-born striatal neurons (Anderson et al. 1997; Anderson 1997; Marin et 
al. 2000).  
 
4.1.3 MASH1 
 
The MASH1 is highly expressed in the region of the SVZ, VZ and MZ of the ventral 
telencephalon of the LGE and MGE at E12.5 (Parras et al. 2004; Castro et al. 2011). 
MASH1 has a major function in regulating neurogenesis in the brain during embryogenesis 
(Castro et al. 2011). The loss of MASH1 results in the acute failure of the basal ganglia 
neurons in the telencephalon, as well as the loss of cortical projection neurons (Casarosa 
et al. 1999; Horton et al. 1999; Marin et al. 2000; Yun et al. 2002; Castro et al. 2011). 
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MASH1 also regulates a large number of other target genes that promote 
neurogenesis and have roles in distinct biological processes, molecular functions and 
cellular processes, as determined by microarray data (Castro et al. 2011). In the biological 
processes, the target genes activated by MASH1 are involved in the early steps of 
inhibition processes (Notch signaling), cell fate specification, the regulation of cell 
proliferation and neuronal differentiation in the later steps of neurogenesis (Castro et al. 
2011). Moreover, in the molecular processes, 48% of the target genes are involved in the 
regulation of transcription, 36% in signal transduction, 64% in nucleic acid binding, and 
small percentages in kinase activity (19%), enzyme activity (13%), transporter activity 
(14%) and cytoskeletal activity (11%) (Castro et al. 2011). In addition, MASH1 directly 
regulates a number of positive cell cycle regulators that promote cell cycle exit (Castro et 
al. 2011).  
MASH1 plays a role as a direct regulator of DLX1/2 expression. The human DLX1&2 
are orientated in an inverted convergent pattern and named as bigene cluster DLX1/2 
(Figure 4.2) (Simeone et al. 1994; McGuinness et al. 1996). It has been reported that 
MASH1 is an upstream regulator of DLX2 (Porteus et al. 1994; Casarosa et al. 1999; Fode 
et al. 2000; Letinic et al. 2002; Yun et al. 2002). Chromatin immunoprecipitation (ChIP) 
and electromobility shift assay (EMSA) analyses have shown that Mash1 binds to the E-
box sequence at FP5, which is a functional basic helix–loop–helix (bHLH) binding site 
present in the I12b enhancer. This enhancer is located upstream of the bigene cluster 
Dlx1/2, in which Mash1 binds to the E-box site of the I12b enhancer and activates 
transcription, and, hence, regulates the Dlx1/2 bigene directly (Figure 4.2) (Poitras et al. 
2007). 
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Figure 4.2: Schematic representation of the orientation of the human DLX1&2 loci 
The DLX1&2 are closely linked and located in an inverted transcribed manner. The enhancer l2b 
and l12a are located upstream of the bigene cluster DLX1/2.  
 
Both DLX1/2 and MASH1 have similar expression patterns in the ventral 
telencephalon region of the proliferation zone of the LGE and MGE (Porteus et al. 1994). 
Further evidence from Mash1 knockout mice shows a reduction in Dlx gene expression in 
the SVZ of the MGE and the LGE at E12.5 (Horton et al. 1999). Moreover, when Mash1 is 
ectopically expressed in neocortical neurons, Dlx1/2 expression is up-regulated (Fode et 
al. 2000). 
The timing of cell fate specification and differentiation in the nervous system of 
vertebrates is regulated by a lateral inhibition process mediated by Notch signaling (Chitnis 
and Kintner 1996; Henrique et al. 1997; Lewis 1996). MASH1 indirectly influences the 
activation of this signaling pathway by controlling the expression of Notch ligands, such as 
Delta and Jagged (Lindsell et al. 1996; Castro et al. 2006; Henke et al. 2009). Notch 
signaling represses the differentiation of neurons and inhibits proneural bHLH expression, 
including that of MASH1 (Artavanis-Tsakonas et al. 1995; de la Pompa et al. 1997; Robey 
1997).  
It has been suggested that the MASH1 gene is required in the early stages of 
neurogenesis, and that DLX2 is needed in the late stages of neurogenesis, during the 
specification and differentiation steps, to down-regulate Notch signaling. Hence, cell fate 
commitment is regulated by the coordinated functioning of MASH1 and DLX1/2 via the 
distinct influence on the Notch signaling pathway (Yun et al. 2002).  
DLX2 DLX1 
l12b                   l12a TAA              ATG ATG             TAA 
5’                              3’   3’                             5’   
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4.1.4 GSX2 
 
GSX1 and GSX2 are the earliest TFs expressed in the LGE progenitor cells. Here, the 
homeobox GSX genes are involved in the initial specification of the neural progenitors of 
the LGE (Pei et al. 2011). They also play a role in the development of striatal pyramidal 
neurons and interneurons of the olfactory bulb (Toresson and Campbell 2001; Yun et al. 
2003). In the early stages of neurogenesis, GSX2 is highly expressed in the progenitors of 
the ventral LGE, whereas in the later stages, GSX2 is expressed in the progenitor cells of 
the dorsal LGE (Waclaw et al. 2009). During LGE neurogenesis, GSX2 plays a 
fundamental role in the cell fate commitment of striatal projection neurons, as well as 
olfactory bulb interneurons, at distinct time points. In the early stages of telencephalic 
development, GSX2 is highly expressed in the ventral LGE and its main derivatives, such 
as the striatum. Meanwhile, during the later stages, it is mainly expressed in the dorsal 
LGE and its derivatives, such as the olfactory bulb (Waclaw et al. 2009).  
With the loss of Gsx2 in mice, both the ventral and dorsal LGE, coupled with their 
derivatives, are acutely reduced (Yun et al. 2001; Yun et al. 2003; Waclaw et al. 2004; 
Waclaw et al. 2006). However, when Gsx2 is mutated in the early stages of telencephalon 
development, the number of striatal projection neurons is reduced. This notwithstanding, 
when the mutation of Gsx2 is delayed, the olfactory interneurons are defective (Waclaw et 
al. 2009). Hence, the development of the striatum depends on the early expression of 
Gsx2, and this is also true for the olfactory bulb. 
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4.2 Aims 
 
The aim of this section was to clone different combinations of the TFs of interest into 
expression vectors of and to validate vector function before utilizing these vectors in cell 
differentiation studies with the hPSCs reported in Chapter 5.  
 
4.3 Experimental design  
 
In this chapter, to address the above aim, several experimental strategies were 
undertaken. The detailed methodology has been described in the Materials and Methods 
section (Section 3.1.11) in Chapter 3.  
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4.4 Results 
 
4.4.1 DLX2, MASH1 and GSX2 expression vectors 
 
The generation of the TF expression vectors required the subcloning of the ORF for 
each TF into the interim vector p3X-2A. To achieve this, the ORFs were cloned by PCR 
using specific primers. The primers used for PCR cloning are shown in Materials and 
Methods section (Section 3.1.11, Table 3.1) in Chapter 3. 
PCR cloning was performed from cDNA, which cloned into a plasmid, stocks 
obtained from the Harvard PlasmID Repository (Table 4.1).  
 
Table 4.1: The plasmidID list from Harvard. 
Clone ID Clone Type 
Gene 
Symbol Gene Name 
Reference 
Sequence Vector Selection Markers 
HsCD00345838 cDNA GSX2 GS homeobox 2 BC075089 pCR4-TOPO Bacterial: ampicillin; 
bacterial: kanamycin; 
HsCD00338128 cDNA DLX2 Distal-less 
homeobox 2 
BC032558 pCMV-
SPORT6 
Bacterial: ampicillin 
HsCD00076006 cDNA MASH1 Achaete-scute 
complex-like 1 
BC002341 pDONR221 Bacterial: kanamycin; 
The table above illustrates the three plasmid cDNAs from Harvard used for PCR cloning. Each 
plasmid contains the gene of interest, (GSX2, DLX2 and MASH1), and a selection marker for 
growth in E. coli. The reference sequence is the GenBank number (NCBI website) that has the 
information about the insertion of the genes of interest. 
 
4.4.1.1 PCR and pENTR5’ TOPO TA cloning 
 
DNA was amplified using a proofreading polymerase (Platinum Taq DNA high-fidelity 
polymerase). The three genes, DLX2, MASH1 and GSX2, were amplified under different 
conditions. The PCR primers used amplified 930-bp, 725-bp and 1,002-bp products which 
corresponded to the GSX2, MASH1 and DLX2 gene products, respectively (Figure 4.3), 
and the products were inserted into the TOPO vector pENTR5’ TOPO (Invitrogen, UK: 
Paisley, 2007) using the pENTR5’ TOPO TA cloning kit.  
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Figure 4.3: Full-length amplification of MASH1, DLX2, GSX2 ORFs 
PCR products of the amplified genes (A). Linear map of the PCR products for the three genes: 
MASH1, DLX2 and GSX2, with restriction sites. (B) In the diagram, it can be seen that there is 
an overlap of restriction sites between the cloned genes, which is important to take into a count 
for subcloning into the interim vector p3X-2A and the expression vector pCAGG. 
 
4.4.1.2 Subcloning into the p3X-2A vector designed to insert the cloned genes 
with three 2A peptide linkers, followed by the transfer of these genes 
into the expression vector pCAGG-IRES-EGFP  
 
After confirming the proper cloning of TFs by DNA sequencing, the genes, MASH1 and 
DLX2, were subcloned sequentially into the p3X-2A vector.  
Initially, the MASH1 gene was digested with BamHI and ligated with the p3X-2A vector 
before the DLX2 gene was introduced; this is because this particular gene has the 
restriction site for BamHI (Figure 4.3 B). Subsequently, p3X-2A-MASH1/DLX2 was 
digested with SalI and the two cloned genes, MASH1 and DLX2, were inserted into 
pCAGG-IRES–EGFP to generate the construct pCAGG–DLX2/MASH1. The GSX2 ORF 
DLX2 
100 bp 
Ladder MASH1 
1 Kb 
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100 bp 
Ladder GSX2 
1 Kb 
1 Kb 
0.5 Kb 
1 Kb 
0.5 Kb 
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B) 
725 bp 1002 bp 
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MASH1 
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was then inserted into the pCAGG-DLX2/MASH1 vector at the BglII restriction site. Then, 
the MASH1 and DLX2 genes were inserted separately into the p3X-2A vector. In the next 
phase, the gene GSX2 ORF was inserted into the pCAGG-DLX2 vector, thus yielding the 
pCAGG-DLX2/GSX2 vector. Together, five combinations of the three cloned genes were 
made for this project. Restriction digestion analyses of these constructs, as well as the 
gene orientations, is shown in Figure 4.4. 
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4.5 TF expression vectors validation through transient 
nucleofection of HEK293 cells 
 
To monitor the transfection efficiency, GFP reporter expression in transfected 
HEK293 cells was observed and measured. Western blotting was then used to assess 
the appropriate expression, as well as self-cleavage, for each TF. 
Forty eight hours after nucleofection, GFP expression was observed, and the 
efficiency of the transfection calculated using ImageJ software, which ranged from 80–
90% (using number of GFP+ve cells as a percentage of total number of cells in bright 
field) (Figure 4.5). In addition, lysates were prepared from harvested cells and the 
cellular proteins were analysed by western blotting. The nitrocellulose membranes 
were probed with antibodies specific for each TF. The correct size of each protein, 
DLX2, MASH1 and GSX2, was observed, 36, 35 and 34 kDa, respectively (Figure 
4.6). β-actin was used to confirm the level of protein in each sample and to normalize 
the expression levels of the desired TFs. 
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Figure 4.5: Transiently transfected HEK293 cells with the four cloned -polycistronic 
expression vectors, pCAGG-DLX2, pCAGG-DLX2/MASH1, pCAGG-DLX2/GSX2, and 
pCAGG-DLX2/MASH1/GSX2, plus the control, which is the empty vector pCAGG. 
The five cloning expression vectors were nucleofected into HEK293 cells. After 48 h, GFP 
expression for each vector, as shown in the above graph, was calculated using ImageJ 
software. The efficiency of the nucleofection was approximately 80–90%. 
 
 
Figure 4.6: Western blotting of the cloned TFs (DLX2, MASH1 and GSX2) expressed by 
the pCAGG vector  
The transfected HEK293 cells with the five expression vectors were lysed for western blotting 
analysis. HEK293 cells transiently transfected with the expression vector pCAGG-
DLX2/MASHI/GSX2 were harvested and analysed with anti-DLX2, anti-MASHI, anti-GSX2 and 
anti-β-actin antibodies (D); HEK293 cells transfected with the expression vectors pCAGG-DLX2, 
pCAGG-DLX2/MASHI and pCAGG-DLX2/GSX2 were lysed and analysed with anti-DLX2 and β-
actin antibodies (A). GSX2 expression for the pCAGG-DLX2/GSX2 and pCAGG-
DLX2/MASH1/GSX2 vectors was obtained (B). In addition, MASH1 expression by the 
constructs pCAGG-DLX2/MASH1 and pCAGG-MASH1 was analysed (C). 
Abbreviations: MSTM: Mouse striatum; HEK293: Human embryonic kidney 293 cells. 
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4.6 Conclusion 
 
The role of the DLX2, MASH1 and GSX2 TFs in LGE specification 
 
The TFs DLX2, MASH1 and GSX2 are required for the specification of LGE 
progenitor cells. DLX2 and MASH1 are expressed in the ganglia regions of the VZ and 
SVZ of LGE and MGE, while GSX2 is strongly expressed in the dorsal LGE and is 
weakly expressed in the ventral LGE and MGE. MASH1 regulates DLX2, and together 
they regulate the differentiation of GABAergic neurons, as well as neurogenesis, by 
activating the Notch signaling pathway. MASH1 regulates neurogenesis in 
telencephalic development, as well as the patterning and specification of LGE, while 
MASH1 and GSX2 play a role in striatum development. When LGE progenitor cells are 
produced, MASH1, DLX2 and GSX2 are required for these precursors to develop to 
striatal complex (Anderson et al. 1997; Casarosa et al. 1999; Toresson and Campbell 
2001). Because of the interaction of these genes and their essential functions in LGE 
development, they were selected as candidates to drive the differentiation of hESC–
naïve rosette-stage neural progenitors (nrNPCs) towards an LGE fate via their ectopic 
expression (Chapter 5). This chapter described the successful cloning of these genes 
into a novel vector designed for high-level, transient, TF co-expression (Table 4.2). 
Table 4.2: Summary of completed constructs 
TFs combination Completed constructs in p3X-2A 
vector 
Completed constructs in pCAGG 
vector 
DLX2 p3X-2A-DLX2 pCAGG-DLX2 
MASH1 p3X-2A–MASH1 pCAGG–MASH1 
DLX2/MASH1 p3X-2A-DLX2/MASH1 pCAGG-DLX2/MASH1 
DLX2/GSX2 -------------------- pCAGG-DLX2/GSX2 
DLX2/MASH1/GSX2 -------------------- pCAGG-DLX2/MASH1/GSX2 
Both the MASH1 and DLX2 TF genes were first inserted into the polyprotein vector p3X-2A and 
then subcloned into the expression vector pCAGG. However, the TF GSX2 gene was not inserted 
into p3X-2A. Instead, it was inserted into the expression vector pCAGG, after subcloning the other 
TFs into the pCAGG vector. 
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Using alternatives to the 2A peptide strategy 
 
There are alternatives to express more than one gene in one vector, such as 
using an internal ribosome entry site (IRES) between TFs or different promoters 
located upstream of a gene ORF (Radcliffe and Mitrophanous 2004; J. H. Kim et al. 
2011). However, there are some disadvantages of using these approaches, such as 
their sizes and their expression efficiency (Radcliffe and Mitrophanous 2004; J. H. Kim 
et al. 2011). When using an IRES between genes, the expression of a gene located 
after the IRES is lower than that of a gene located before the IRES, and IRES sizes are 
more than 500 nucleotides in length (J. H. Kim et al. 2011). Additional promoters can 
result in different amounts of encoded proteins (Radcliffe and Mitrophanous 2004). 
Therefore, in this study, self-cleaving 2A peptide sequences between the TFs were 
used, as it has a high cleavage efficiency among TFs, and their sizes are small (J. H. 
Kim et al. 2011). However, it was stated that the use of the 2A peptide is not common 
in biomedical studies, as it is not yet established; 2A peptide of the four, E2A, P2A, 
T2A and F2A, has the highest cleavage productivity, and there is not any commercially 
available 2A technology for the expression of more than one gene in a single vector (J. 
H. Kim et al. 2011).  
 
TFs validation by transient transfection of HEK293  
 
The high efficiency of the HEK293 nucleofection with the expression vectors 
containing the four TFs and the control vectors was useful for validating the vector 
function prior to using the vectors in neural stem cells.  
Significantly, all of the cloned genes, together with the GFP reporter, were 
expressed. Secondly, the western blotting analysis indicated that a polyprotein of the 
predicted size, ~132 kDa (GSX2 (34 kDa), DLX2 (36 kDa) and MASH1 (36 kDa)) was 
generated. This indicates that the 2A peptides within the construct were successfully 
cleaved during translation. Therefore, the expression vectors with the TFs and the 
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control vectors were nucleofected into hPSCs at day 18, followed by the 
characterisation of TF expression and differentiation into MSNs. These experiments 
will be described in the next chapter. 
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5.1 Introduction 
 
The TFs, DLX2, MASH1 and GSX2, showed appropriate transgene expression in 
HEK293 cells (Chapter 4). In this study, ectopic expression of TFs, i.e. DLX2, MASH1 and 
GSX2 in hESC or iPSC-derived naïve rosette stage neural progenitors cells (nrNPCs), was 
conducted to investigate whether the hESC or iPSC derived nrNPCs could differentiate 
into LGE-specific cell type, and subsequently into MSNs. To further validate their potential 
use for differentiation in hESC- or iPSC-derived nrNPCs, expression of the TFs in the 
nrNPCs of interest was examined in this chapter. Transgene expression of DLX2, MASH1, 
and GSX2, as well as 2A self-cleavage peptide were confirmed by immunocytochemistry 
(ICC). In addition, the expression of exogenous and endogenous TFs was also confirmed 
by qRT-PCR. 
34D6 and H9 nrNPCs (at platting down day (PdD) 18) used for nucleofection were 
FOXG1 positive. FOXG1 plays a role in the development of the telencephalon, as well as 
in the expansion of the forebrain, as it promotes the proliferation of progenitor cells and 
suppresses the differentiation of those cells during neurogenesis (Regad et al. 2007; 
Hanashima et al. 2002). It also plays a major role in regulating the timing of neurogenesis 
in the telencephalon (Hanashima et al. 2002). Interestingly, its function is important 
because of its restricted expression pattern. Its expression is nuclear in progenitor cells, 
but cytoplasmic in differentiating cells (Regad et al. 2007). Hence, investigating FOXG1 
expression in nrNPCs is important for this study.  
Neurons are generated from two proliferative populations, which are in the VZ and 
SVZ. In these regions, cell proliferation continues throughout life. In these two populations, 
the neuron progenitors are in the cell cycle; once they exit the cell cycle, they differentiate 
and migrate from to the periphery of the telencephalic vesicles and complete their 
differentiation (Casarosa et al. 1999). For example, striatal progenitors or GABAergic 
                                                                                      Chapter 5: Introduction and aim of the project 
 154 
interneurons that are generated in the LGE proliferative VZ and SVZ migrate tangentially 
to the cortical intermediate zone (IZ) and marginal zone (MZ) (Anderson 1997b; Tamamaki 
et al. 1997; Casarosa et al. 1999; Dehay and Kennedy 2007). A similar concept also 
applies to stem cells. For example, in early development, embryonic stem cells are 
characterised by rapid proliferation and the production of daughter cells, which either 
remain stem cells or differentiate into a specific cell-type (Takahashi and Yamanaka 2006). 
As the cells undergo differentiation, the rate of cell proliferation decreases, and when fully 
differentiated, cell proliferation ceases. Therefore, proliferation and differentiation are 
regulated by a balance of intrinsic and extrinsic cues that direct progenitors to enter the 
cell cycle and proliferate, or exit the cell cycle and begin differentiation (Dehay and 
Kennedy 2007). It is believed that such a balance is maintained by the parallel, 
overlapping and/or sequential function of TFs such as Dlx2 and Mash1 (Anderson 1997; 
Horton et al. 1999; Yun et al. 2002; Cobos et al. 2007; Colombo et al. 2007; Poitras et al. 
2007; Long et al. 2009b).  
At the proteomic level, there are many proteins that program the cell cycle upon 
expression. There are two categories of cell cycle proteins: one group drives the cell cycle, 
while the other inhibits cell cycle (Figure 5.1). In the developing cortex during 
neurogenesis, neuroepithelial cells divide in proliferative VZ and express phospho-histone 
H3, which is an M-phase marker, and cyclin E and Ki67, which are the markers for G1-, S-, 
G2- and M- phases (Herrup and Yang 2007). Brdu/3H-T is the S-phase marker. The mitotic 
activity takes place in the SVZ (Herrup and Yang 2007). When cyclin-dependent kinase 
inhibitors (CDKI), such as CDK5, P27, P21 and p57, are expressed, cells exit the cell 
cycle, start the process of early differentiation and migrate from the proliferative VZ and 
SVZ to the IZ, cortical plate and MZ. In the cortical plate, the cells are fully differentiated to 
mature neurons driven by the presence of CDKI (Herrup and Yang 2007) (Figure 5.2). 
Therefore, in this chapter, the functional consequences of transient expression of the TFs, 
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DLX2, MASH1, GSX2 and downstream effector genes, on cell proliferation was assessed 
by looking at the cell cycle protein Ki67.  
 
Figure 5.1: The phases of cell cycle and the proteins involved in cell cycle regulation. 
The cell cycle phases include: G1 phase, where the cells commit to divide or exit from the cell cycle 
due to responses to extracellular signals, S phase, where DNA synthesis and process of replication 
take place, G2 phase, where the completion of DNA replication is checked and M phase, where 
two daughter cells are generated. Following the M phase, the new daughter cells can re-enter the 
cell cycle and proliferate or exit the cell cycle and start to differentiate. The cell cycle proteins in 
orange boxes drive progression through the different stages of the cell cycle while the ones in red 
inhibit progression of the cell cycle. 
Abbreviations: G1: Gap 1 or growth 1, S: DNA synthesis, G2: Gap 2 or growth 2, M: Mitosis, 
CDK: Cyclin-dependent kinases; CDKI: Cyclin-dependent kinases inhibitor. 
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Figure 5.2: Cell cycle proteins involved in neuronal development.  
This schematic represents the developing cortex and the cell cycle proteins that are involved in the 
development of each layer (A). The neuroepithelial cells (shown in blue) divide in the VZ and their 
mitotic activity continues in the SVZ. The protein phospho-histone H3 is associated with the M 
phase, BrdU/3H-T uptake is associated with the S phase and Cyclin E and Ki67 are associated with 
cell cycle phases (G1, S, G2 and M). CDKI expression drives neuronal cell exit from the cell cycle 
and migration along the radial glia (shown in green) from VZ and SVZ to IZ and cortical plate, where 
they are fully differentiated (shown in yellow). Cell cycle proteins are associated in the three stages 
of neuronal development: neurogenesis, migration and maturation stages (B). Figure taken from 
Herrup and Yang 2007.  
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Previously, it has been shown that the three TFs - DLX2, MASH1 and GSX2 - play a 
role in neuronal fate in the subpallium (Table 2.3) (Pauly et al. 2013; Wang et al. 2013). 
Furthermore, the TFs together play a role in the transcriptional network that drives striatal 
and MSN development (Figure 5.3) (Stühmer et al. 2002b; Poitras et al. 2007; Colasante 
et al. 2008; Wang et al. 2013). GSX2 regulates the expression of MASH1, DLX2 and EBF1 
(Wang et al. 2013). MASH1 regulates the expression of DLX2 by binding to the I12b 
enhancer that is located downstream of DLX2 (Poitras et al. 2007). DLX2 regulates the 
expression of ARX, which triggers migration, through binding to the UAS3 enhancer 
downstream of ARX (Colasante et al. 2008). DLX2 also induces the expression of DLX5, 
and together they regulate the expression of GAD1/2 (Stühmer et al. 2002b). These 
interactions aid in proliferation, differentiation and migration in neurogenesis (Yun et al. 
2002; Long et al. 2009b; Wang et al. 2013). In this chapter, the target genes of DLX2, 
MASH1 and GSX2 are examined at transcriptional level (qRT-PCR) to validate the 
progress of the stem cell differentiation program. We address the following question: does 
ectopic expression of the TFs DLX2, MASH1 and GSX2 in 34D6 nrNPCs cause them to 
differentiate into ventral telencephalic neuronal progenitors and LGE-specific progenitor 
cells?  
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Figure 5.3: Transcriptional network of the TFs that play a role in striatal and 
MSN differentiation. 
The GSX2 regulates the expression of EBF1, MASH1 and DLX2. MASH1 regulates 
the expression of DLX2 by binding to the I12b enhancer. In addition, DLX2 
regulates the expression of ARX by binding to the UAS3 enhancer, and DLX5 by 
binding to I56i enhancer. Together, DLX2 and DLX5 regulate the expression of 
GAD1/2. 
 
5.2 Aims 
 
The main aim of this study was to determine whether the protocol of ectopic 
expression for the different combinations of TFs (DLX2, GSX2 and MASH1) drives 
differentiation of hPSC-derived nrNPCs into LGE-like specific progenitors cells. For this 
purpose, the strategy was initially optimized for the expression of TFs using GFP as a 
marker that was fused with the TFs using a small molecule inhibitor (G418) to eliminate 
those cells not expressing GFP in the 34D6 cell line model. Then, the nucleofected TFs of 
various combinations in H9 and 34D6 cell line models were assessed for their expression 
profiles at the molecular level. Finally, to test the functionality of the ectopically expressed 
TFs, nucleofected nrNPC FOXG1+ve progenitor cells were assessed for their ability to re-
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programme into LGE-like neuronal progenitors using PAX6, EMX2 (dorsal marker) and 
NKX2.1 (ventral-specific marker for MGE).  
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5.3 Experimental design 
 
The experimental design used, in this chapter, for cell maintenance is illustrated 
in Figure 5.4. The detailed methodology has also been described in the Materials and 
Methods section (section 3.2) in Chapter 3.  
 
Figure 5.4: Experimental design.  
The experimental protocol used in this chapter for cell maintenance from the human pluripotent 
stem cells (hPSCs) stage (D0) to naïve rosette stage neural progenitors (nrNPCs) at PD 20.  
Abbreviations: D: Day, nrNPC: Naïve rosette stage neural progenitors, EB: Embryonic body, 
PdD8: Platting down Day 8, Pen/Strep: Penicillin (100 U/ml)/Streptomycin (100 µg/ml); PLL: 
poly-L-Lysine. 
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5.4 Results 
 
5.4.1 Characterisation of TF vector expression in transiently 
nucleofected H9 and 34D6 cells  
 
5.4.1.1 Quality control prior to nucleofection: nrNPCs at day 18 were positive 
for FOXG1, human ZO.1 and NESTIN [multipotent neural stem cells 
(NSCs)], and were negative for OCT4 (pluripotency marker).  
 
Quality control prior to nucleofection of hPSC-derived nrNPCs at platting down day 
18 (PdD18) was performed for the protein and transcriptome levels using ICC and qRT-
PCR. Prior to nucleofection of hPSCs-derived nrNPCs at PdD18, nrNPC quality was 
determined by assessing the FOXG1 and human ZO.1 expression by ICC. These cells 
stained positively for forebrain marker (FOXG1+ve) and tight junctions (ZO.1+ve) (Figure 5.5 
A and B). The neural precursors of H9 and 34D6 were examined by qRT-PCR for 
expression of NESTIN, a multipotent neural stem cell (NSC) marker, and OCT4, 
pluripotency marker. The nrNPCs were NESTIN+ve and OCT4-ve at PdD12; however at D0, 
the undifferentiated 34D6 and H9 cells were NESTIN-ve and OCT4+ve (Figure 5.5 C). The 
negative control for FOXG1 staining is shown in Appendix 5.1. FOXG1 expression was 
clearly evident, suggesting that these cells were forebrain neuron precursors and hence 
could be used to differentiate into LGE-like progenitor cells through ectopic expression of 
the TFs MASH1, DLX2 and GSX2.  
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Figure 5.5: Quality control prior to the nucleofection of nrNPCS using ICC with FOXG1 and 
human ZO.1 antibodies, and qRT-PCR expression analysis of the pluripotency marker, 
OCT4, and neural marker, NESTIN.  
Before nucleofection, some of the H9 and 34D6-derived nrNPCs at PdD16 were fixed and stained 
for forebrain marker, i.e. FOXG1 (Primary dilution: 1:1000, NeuraCell) with an Alexa Fluor® 594 
labelled anti-rabbit IgG secondary antibody (red), Abcam (A). The cells were also stained for tight 
junction marker, i.e. human ZO-1 (Primary dilution: 1:250, BD Biosciences) with an Alexa Fluor® 
488 labelled anti-mouse IgG1 secondary antibody (green), Abcam (A). The confocal microscope 
images of human ZO-1 (green) and Dapi/nuclear (blue) staining (Hoechst) were obtained (B). qRT-
PCR of OCT4 and NESTIN at D0 and PDd12 for H9 and 34D6 cell culture (C).  
The blue scale bar indicates 100 µm, the red scale bar indicates 50 µm, and the green scale bar 
indicates 36 µm. 
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5.4.1.2 The efficiency of TF expression was approximately 45% higher following 
acute G418 selection at 48h post-nucleofection, as compared to non-
selected cells.  
 
The PdD18 nrNSCs were nucleofected with either the empty vector (pCAGG), or 
one of the pCAGG-DLX2, pCAGG-DLX2/MASH1, pCAGG-DLX2/GSX2 and pCAGG-
DLX2/MASH1/GSX2 vectors. The efficacy of nucleofection was determined by GFP 
expression, using ImageJ software, after 24, 48, 72 and 96 hours (h) post-nucleofection 
(Figure 5.6 A and B). GFP was highly expressed from all the vectors at 48 h post-
nucleofection; however, the percentage of GFP expressing cells had declined at 72 and 96 
h time points (Figure 5.6 B). This decline could be due to transient expression from a non-
integrated plasmid. Since DLX2, MASH1 and GSX2 were only required in a restricted 
window of time during the differentiation of cells from progenitor through to mature neuron, 
a transient G418 selection strategy was used to select against non-transfected cells from 
the mixed population. To achieve this, different concentrations of G418 (200, 400, 600 and 
800 µg/ml) with different incubation times (1 day to 1 week) were tested to find the most 
suitable concentration of G418 and duration time to select GFP+ve cells (Figure 5.7).  
At a low concentration of G418 (200 µg/ml), GFP expression was low (15%); this 
was increased (40%) at a higher concentration of G418 (400 µg/ml) at week 1. At the 800 
µg/ml concentration of G418, an increase in GFP+ve cells (45%) was only seen at day one; 
surprisingly the cells did not show similarly high GFP expression at week 1, suggesting 
that G418 causes toxicity at higher doses with prolonged incubation. 
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Figure 5.6: GFP expression in nucleofected PdD18 nrNSCs. 
GFP expression in nrNSCs 24, 48 and 72 h after nucleofection with the vectors shown (left 
column) (A). The percentage of GFP expressing cells after each nucleofection was determined by 
ImageJ (B). 
 
Figure 5.7: Percentage of GFP+ve cells and cell survival post G418 selection of 
nucleofected cells, with different concentrations and incubation times 
Twenty four hours post-nucleofection of nrNPCs, the cells were incubated for 1 day to 1 week in 
different concentration of G418 (200, 400, 600 or 800 µg/ml). At low concentrations of G418, the 
percentage of GFP+ve cells was low. This percentage increased at 400 µg/ml G418 
concentration with an incubation time of 1 week. In comparison with 400 µg/ml of G418, GFP+ve 
cells were increased at 800 µg/ml of G418 on day one, exhibiting a cell survival of around 35% 
and a nucleofection efficiency of 45% (N = 2).  
 
 
  
24 48 72 96
0
10
20
30
40
Hours (h)
Pe
rc
en
ta
ge
 (%
)
GFP expression after 24, 48, 72 and 96 hours
pCAGG
pCAGG-DLX2
pCAGG-MASH1
pCAGG-DLX2/GSX2
pCAGG-DLX2/MASH1
pCAGG-DLX2/MASH1/GSX2
B) 
1 day 1 week
0
20
40
60
G418 (200 µg/ml)
P
e
rc
e
n
ta
g
e
 (
%
)
1 day 1 week
G418 (600 µg/ml)
1 day 1 week
G418 (400 µg/ml)
1 day 1 week
G418 (800 µg/ml)
Cell survival
GFP+ve cells
GFP+ve cells and cell survival post G418 selection 
                                                                                                                                 Chapter 5: Results 
 166 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.8: GFP expression in nucleofected nrNSCs after G418 selection. 
G418 sulfate selection was started 48 h after nucleofection with the vectors. 
GFP expression and bright field of each group of nucleofected cells after G418 
selection. 
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5.4.1.3 Successful expression of DLX2, MASH1, GSX2 and self-cleavage 
peptides 2A into H9 and 34D6 cells from all six expression vectors at 
nucleofection day 4 (ND4). 
 
At PdD18 of nrNPCs, nucleofection with the six expression vectors (pCAGG-DLX2, 
pCAGG-MASH1, pCAGG-DLX2/GSX2, pCAGG-DLX2/MASH1 and pCAGG-
DLX2/MASH1/GSX2) and the control (pCAGG) was performed. Following acute selection 
with G418, TF transgene expression in selected cells was assessed by ICC. At ND4, the 
nucleofected H9 cells (not shown) and 34D cells were fixed for ICC to determine the 
expression of DLX2, MASH1, GSX2 genes and the 2A self-cleavage peptide tag. Self-
cleavage of the 2A peptide allows the release of cloned TFs in nucleofected cells 
(Donnelly et al. 2001). The negative control for MASH1, DLX2, GSX2 and GFP staining is 
shown in Appendix 5.1.  
All nrNPCs nucleofected with the TFs expressing pCAGG-DLX2, pCAGG-
DLX2/GSX2, pCAGG-DLX2/MASH1 and pCAGG-DLX2/MASH1/GSX2 were 
immunopositive for the 2A peptide and for DLX2, whilst cells transfected with the empty 
vector showed no expression for 2A peptide and DLX2 (Figures 5.9 and 5.10). Similarly, 
MASH1 and GSX2 expression was only evident in cells transfected with the MASH1 
and/or GSX2 containing vectors (pCAGG-DLX2/GSX2, pCAGG-DLX2/MASH1, and 
pCAGG-DLX2/MASH1/GSX2) (Figures 5.11 and 5.12).  
H9 and 34D6 transient nucleofected nrNPCs at PdD18 had the same 
characteristics, such as, the morphology and the viability of the cells. In addition, TF 
characterisation yielded equivalent results in both H9 and 34D6 nrNPCS PdD18 cell lines, 
therefore, any one of the cell lines could be carried forward for further analysis. The 34D6 
was chosen for further experiments as the differentiation protocol can be used with HD-iPS 
cell lines for disease modeling studies. These results clearly demonstrate successful 
expression of all cloned TFs in 34D6-derived nrNPC cells at the protein level using ICC. 
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Figure 5.9: 2A
 peptide expression in 34D
6 nrN
PC
s four days after nucleofection w
ith the TF expressing vectors.  
The six expression vectors (left colum
n) w
ere nucleofected into 34D
6-derived neural progenitors. Four days later, the cells w
ere fixed and analysed by IC
C
 
w
ith anti-E
2A
, w
hich is an antibody against 2A
 peptide (prim
ary dilution: 1:500, M
illipore), the cells w
ere stained w
ith H
oechst (nuclear staining) and G
FP
 
expression w
as also analysed (prim
ary dilution: 1:4,000, A
bcam
). 
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Figure 5.10: D
LX2 transgene expression in 34D
6 nrN
PC
s four days after nucleofection w
ith the TF expressing vectors.  
The six expression vectors (left colum
n) w
ere nucleofected into 34D
6-derived neural progenitors. Four days later, the cells w
ere fixed and analysed by IC
C
 
w
ith anti-D
LX
2 (prim
ary dilution: 1:800, A
bcam
), the cells w
ere stained w
ith H
oechst (nuclear staining) and G
FP
 expression w
as also analysed (prim
ary 
dilution: 1:4,000, A
bcam
). 
  
 
                                                                                                                                                                                                                            C
hapter 5: R
esults 
 
172 
 
                      D
A
P
I                                            α
"G
F
P
                                             α
"M
A
S
H
1
                                        M
E
R
G
E
             #
    
p
C
A
G
G
 
       
p
C
A
G
G
-
D
L
X
2
 
       
p
C
A
G
G
-
M
A
S
H
1
 
      
p
C
A
G
G
-
D
L
X
2
/
G
S
X
2
 
     
p
C
A
G
G
-
D
L
X
2
/
M
A
S
H
I 
    
p
C
A
G
G
-
D
L
X
2
/
M
A
S
H
I/
G
S
X
2
 
     
                                                                                                                                                                                                                            C
hapter 5: R
esults 
 
173 
Figure 5.11: M
A
SH
1 transgene expression in 34D
6 nrN
PC
s four days after nucleofection w
ith the TF expressing vectors.  
The six expression vectors (left colum
n) w
ere nucleofected into 34D
6-derived neural progenitors. Four days later, the cells w
ere fixed and analysed by IC
C
 
w
ith anti-M
A
S
H
1 (prim
ary dilution: 1:500, B
D
 P
harm
ingen), the cells w
ere stained w
ith H
oechst (nuclear staining) and G
FP
 expression w
as also analysed 
(prim
ary dilution: 1:4,000, A
bcam
). 
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Figure 5.12: G
SX2 transgene expression in 34D
6 nrN
PC
s four days after nucleofection w
ith the TF expressing vectors.  
The six expression vectors (left colum
n) w
ere nucleofected into 34D
6-derived neural progenitors. Four days later, the cells w
ere fixed and analysed by IC
C
 
w
ith anti-G
S
X
2 (prim
ary dilution: 1:500 M
illipore), the cells w
ere stained w
ith H
oechst (nuclear staining) and G
FP
 expression w
as also analysed (prim
ary 
dilution: 1:4,000, A
bcam
). 
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5.4.2 Both endogenous and exogenous expression of MASH1, GSX2 
and DLX2 were examined by qRT-PCR in 34D6 nrNPCs using TF 
expression vectors.  
 
To corroborate the expression of cloned TFs and to further confirm whether the 
expression of TFs is endogenous or exogenous, qRT-PCR was performed. nrNPCs 
were nucleofected with the different TF expression vectors and cultured in ADF media. 
The cells were then harvested at nucleofection day (ND) 0, ND2, ND3, ND5 and ND7. 
Their RNA was extracted and qRT-PCR was performed to measure the expression of 
the DLX2, MASH1 and GSX2 transgenes and their endogenous gene counterparts. 
The primers used to distinguish exogenous and endogenous genes for the expression 
studies are shown in the Materials and Methods section (section 3.4.3) in Chapter 3 
and the characterisation of the primers is shown in Figure 5.13. 
 
Figure 5.13: Schematic showing primers used for qRT-PCR to distinguish between 
exogenous and endogenous TF expression. 
The position of the exogenous and endogenous primers (F or R) for the TFs DLX2, MASH1 and 
GSX2 are shown. The exogenous primers contain a few base pairs of the 2A peptides and 
therefore will only detect a transcript derived from the expression vectors. The endogenous 
primers contain a few base pairs of the 3’UTR in the R primers and therefore will only detect 
endogenously derived transcripts. 
Abbreviations: CAP: RNA 7-methyl-guanosine cap, 5’UTR: 5 prime untranslated region, CDS: 
Coding sequence, 3’UTR: 3 prime untranslated region, F: forward primer and R: Reverse 
primer, ATG: Methionine - start codon; TAA: Stop codon.   
ATG                                                                          TAA 
CAP 
5’UTR 
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5.4.2.1 The expression pattern of endogenous MASH1 was altered in a time-
dependent manner. 
 
Forty-eight hours after nucleofection, the mean relative expression of 
exogenous MASH1 peaked in all cells that contained the MASH1 transgene (Figure 
5.14 A, B and C). Its expression was considerably higher in the pCAGG-MASH1 
nucleofected cells compared to pCAGG-DLX2/MASH1 and pCAGG-
DLX2/MASH1/GSX2 nucleofected cells (Figure 5.14 A, B and C). The expression of 
endogenous MASH1 was increased even after expression of MASH1 transgene 
declined after ND2 in both pCAGG-MASH1 and pCAGG-DLX2/MASH1/GSX2 
nucleofected cells; between ND2 to ND5, it remained constant and, at ND5, it started 
to increase gradually (Figure 5.14 A and C). Meanwhile, in the pCAGG-DLX2/MASH1 
nucleofected cells, the mean relative expression of endogenous MASH1 was low in 
comparison to endogenous expression of DLX2, beginning to increase slightly after 
ND5 (Figure 5.14 B). However, in the same nucleofected cells, the expression of 
endogenous DLX2 reached its maximum level at ND7 relative to the expression of 
endogenous MASH1 (Figure 5.14 B and E). Therefore, from these results, it was 
demonstrated that the expression of endogenous MASH1 increases slightly in a time-
dependent manner, while DLX2 increases rapidly, indicating the presence of an 
alternative mode of action between these two TFs in the neuronal differentiation 
program.  
5.4.2.2 The expression of endogenous DLX2 was altered by the co-
expression of the TFs MASH1 and GSX2  
 
In the 34D6 nrNPCs nucleofected with four constructs (pCAGG-DLX2, pCAGG-
DLX2/MASH1, pCAGG-DLX2/GSX2, and pCAGG-DLX2/MASH1/GSX2), the mean 
relative expression of exogenous DLX2 transgene peaked after 48 h as compared to 
control group (pCAGG). The expression of exogenous DLX2 was maximal at 48 h in 
the pCAGG-DLX2 nucleofected cells (Figure 5.14 D). On the other hand, the mean 
relative expression of endogenous DLX2 gradually increased in pCAGG-DLX2/MASH1 
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nucleofected cells from ND3 to ND7 (Figure 5.14 E), but decreased in pCAGG-
DLX2/GSX2 (Figure 5.14 F), and pCAGG-DLX2/MASH1/GSX2 nucleofected cells 
(Figure 5.14 G). In the pCAGG-DLX2/MASH1/GSX2 nucleofected cells, the 
endogenous expression started to rise slightly at ND7 (Figure 5.14 G). In the pCAGG-
DLX2 nucleofected cells, endogenous DLX2 expression was constant from ND5 to 
ND7.  
Interestingly, when the gene DLX2 was co-expressed with MASH1, the 
expression of endogenous DLX2 increased dramatically (ND3 - ND7) (Figure 5.14 D 
and E), whereas, the endogenous expression of MASH1 was very low (Figure 5.14 B 
and E). Furthermore, when DLX2 was co-expressed with MASH1 and Gsx2, the 
endogenous DLX2 expression was initially low at ND5 and then started to increase 
slightly at ND7, whereas the expression of endogenous GSX2 was dramatically 
elevated at ND7. The expression of endogenous MASH1 was also visibly increased at 
ND7 (Figure 5.14 C, G and I). Together, these results show that expression of 
endogenous DLX2 gene was transiently affected by ectopic expression of MASH1 and 
GSX2. The expression of DLX2 was reduced when co-expressed with GSX2, but 
increased when co-expressed with MASH1. However, co-expression of GSX2 and 
MASH1 caused a decrease in DLX2 expression followed by an increase (Figure 5.14 
D, E, F and G). These results clearly show that TFs interact to drive the level of 
endogenous gene expression. 
5.4.2.3 MASH1 co-expression increases GSX2 starting at ND5 
 
The mean relative expression of exogenous GSX2 peaked two days after 
nucleofection with pCAGG-DLX2/GSX2 or pCAGG-DLX2/MASH1/GSX2 (Figure 5.14 
H and I). The mean relative expression of endogenous GSX2 differed depending on 
the constructs expressed in the 34D6 cells. In the pCAGG-DLX2/GSX2 cells, the 
expression of endogenous GSX2 reached its maximum level at ND5 then declined at 
ND7 (Figure 5.14 H). However, when the GSX2 was co-expressed with DLX2 and 
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MASH1, the endogenous expression of GSX2 started to increase at ND5 reaching its 
peak at ND7 (Figure 5.14 I), whereas the expression of endogenous DLX2 and 
MASH1 was only increased slightly at ND7 in the pCAGG-DLX2/MASH1/GSX2 
nucleofected cells (Figure 5.14 C, G and I). Section 5.4.2 demonstrates the complexity 
of TF interaction and expression, which likely influence the proliferation-differentiation 
drive in neurogenesis in this model.  
This experiment was done in order to examine whether or not the exogenous 
expression of TFs become integrated (endogenous expression of TFs) in nucleofected 
cells. The results show that the post-nucleofection expression of endogenous TFs is 
increased when the expression of exogenous TFs is decreased.  
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Figure 5.14: Endogenous and exogenous expression of the TFs, DLX2, MASH1 and 
GSX2, in the nucleofected 34D6 cells compared to the control (pCAGG empty vector) 
nucleofected cells.  
The endogenous and exogenous expression of MASH1 in pCAGG-MASH1, pCAGG-
DLX2/MASH1 and pCAGG-DLX2/MASH1/GSX2 nucleofected 34D6 cells (A, B, C). The 
endogenous and exogenous expression of DLX2, in all nucleofected cells (D, E, F, G). The 
endogenous and exogenous expression of GSX2 in pCAGG-DLX2/GSX2 and pCAGG-
DLX2/MASH1/GSX2 nucleofected cells (H, I). 
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5.4.3 Transient ectopic expression of DLX2, MASH1 and GSX2 
resulted in cell cycle exit leading to neuronal differentiation, as 
observed by downregulation of the proliferation marker Ki67 
 
The previous section described the nucleofection and validation of expression 
of DLX2, MASH1 and GSX2 TFs in nrNPCs. In this section, in order to determine when 
the cells exit the cell cycle and start to differentiate, the nucleofected cells were 
analysed for expression of GFP and Ki67, a proliferation marker. Two different 
populations of nucleofected cells were involved in this analysis: GFP+ve cells 
populations indicated the transient ectopic expression of TFs, meanwhile, GFP-ve cells 
populations indicated the non-ectopic expression of TFs. Therefore, for this analysis, 
nucleofected cells were not placed under G418 selection in order to examine the Ki67 
expression in the GFP-ve cell population.  
Between ND3 and ND4, the nucleofected cells were fixed and stained with the 
proliferation marker Ki67 and GFP (Figure 5.15 A). The percentage of GFP+ve and 
GFP-ve cells that were Ki67+ve was calculated using ImageJ software from 4 replicates. 
Statistically, there was a significant (p-value < 0.0001) decrease in the percentage of 
Ki67+ve cells in the GFP+ve populations as compared to the GFP-ve populations in all the 
TF vector nucleofected groups (Figure 5.15 B). The p–value of Ki67+ve cells between 
GFP+ve and GFP-ve cells for pCAGG-DLX2, pCAGG-MASH1, pCAGG-DLX2/MASH1, 
pCAGG-DLX2/GSX2 and pCAGG-DLX2/MASH1/GSX2 nucleofected cells, was 
<0.0001, 0.01, 0.0001, 0.001 and 0.01, respectively (N= 4 for each nucleofection). 
However, the empty vector (pCAGG) nucleofected cells did not show any significant 
difference in the percentage of Ki67 cells between GFP+ve and GFP-ve cells. 
In the GFP+ve population, the pCAGG-DLX2/MASH1 nucleofected cells showed 
the lowest Ki67 expression (p-value = 0.0001) compared with the control pCAGG, and 
pCAGG-DLX2, pCAGG-DLX2/GSX2 and pCAGG-DLX2/MASH1/GSX2 nucleofected 
cells with p-value = 0.001 (Figure 5.15 B).  
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These data suggest that the 34D6 nrNPCs ectopically expressing the different 
TFs constructs (with emphasis on pCAGG-DLX2/MASH1) experience decreased 
proliferation, as evidenced by the decline in cell cycle marker Ki67. This, therefore, 
indicates that these cells have exited the cell cycle and have committed to 
differentiation.  
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Figure 5.15: Analysis of cell proliferation, using Ki67, in 34D6 nrNPCs four days 
after nucleofection with TF vectors.  
The six expression vectors were nucleofected into 34D6 nrNPCs, and at ND4 the cells 
were fixed and immuno-stained against Ki67 (Cell cycle marker-Red), GFP (Green) and 
Dapi (Nuclear staining-Blue) (A). The scale bar shows 100µm. The percentage of Ki67+ve 
cells, in each nucleofection group, was calculated between GFP+ve and GFP-ve 
populations (N = 4 for each nucleofection) (B).  
* indicates p-value = 0.01, ** indicates p-value = 0.001, *** indicates p-value = 0.0001 and 
**** indicates p-value < 0.0001 (Two-way ANOVA with Bonferroni correction). 
 
5.4.4 Ectopic expression of TFs induces an LGE-like progenitor fate 
from 34D6-derived forebrain nrNPCs, as assessed by dorsal-
specific markers (PAX6 and EMX2) and a ventral-specific marker 
for MGE (NKX2.1). 
 
In order to understand and demonstrate the functional effect of the five TFs 
expression constructs along with empty vector (control group), on the 34D6 nrNPCs, 
RNA samples were analysed by qRT-PCR for expression of the dorsal markers, EMX2 
and PAX6, and the ventral MGE specific marker, NKX2.1 (Figures 5.16, 5.17 and 
5.18). This analysis was repeated at ND0, ND2, ND3, ND5 and ND7 for EMX2 and 
NKX2.1 expressions, plus ND21 and ND42 for PAX6 expression. For this analysis, 
nucleofected cells were placed under G418 selection. 
It was observed that there was a significant difference, in the expression of the 
dorsal marker, EMX2, between the nucleofected 34D6 nrNPCs (p = 0.0126) and 
between different time points (p < 0.0001). Moreover, the interaction of nucleofected 
34D6 nrNPCs and incubation time was significant (p < 0.0001). From ND0 to ND2, only 
four groups of nucleofected cells displayed significantly decreased EMX2 expression (p 
= 0.0126). Those were pCAGG-DLX2, pCAGG-DLX2/GSX2, pCAGG-MASH1 and also 
the control (Figure 5.16). From ND1 to ND3, there was a steady expression of EMX2 
in all nucleofected cells in the control; however, there was a significant increase (p = 
0.001) (Figure 5.16). From ND3 to ND5 and ND7, there was dramatic decrease in 
EMX2 expression in all nucleofected cells with a p-value of less than 0.0001 (Figure 
5.16). Between ND5 and ND7, EMX2 expression in the pCAGG-DLX2/MASH1 
nucleofected cells decreased significantly (p = 0.001) compared to the control group 
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(pCAGG nucleofected cells) (Figure 5.16). Furthermore, EMX2 expression in pCAGG-
DLX2 nucleofected cells declined significantly (p-value = 0.0126) at ND7 compared to 
the control group (Figure 5.16).  
There were significant differences between PAX6 expression among the 
nucleofected 34D6 nrNPCs (p-value 0.0102) and also at the different time points (p-
value 0.0001). In addition, the interaction of nucleofected 34D6 nrNPCs and incubation 
time was significant (p = 0.0168). Interestingly, the expression of PAX6 in the 34D6 
nrNPCs nucleofected with pCAGG and pCAGG-DLX2/MASH1 were the same from 
ND0 to ND5 (Figure 5.17). Expression of PAX6, after ND5, in the pCAGG-
DLX2/MASH1 nucleofected cells was reduced statistically significant compared with 
ND0; however, in control (pCAGG nucleofected) cells, expression increased from ND5 
to ND7 (Figure 5.17). Moreover, there was a further decrease in PAX6 expression in 
pCAGG-DLX2/MASH1 nucleofected cells from ND7 to ND21 (p = 0.0102); no 
statistically significant reduction in PAX6 expression was observed in the other 
nucleofected cells over the same period (Figure 5.17). From ND3 to ND21 and ND42, 
the most significant reduction in PAX6 expression was the pCAGG-DLX2/MASH1 
nucleofected 34D6 nrNPCs (p-value < 0.0001) (Figure 5.17). In contrast, expression of 
PAX6 in pCAGG-MASH1 nucleofected cells was noticeably increased at ND21 and 
ND42 compared with control (p = 0.0102 and 0.001, respectively) (Figure 5.17). In 
summary, pCAGG-DLX2/MASH1 nucleofected cells showed significant downregulation 
in the PAX6 expression from ND0 to ND42 (p-value < 0.0001) (Figure 5.17). 
There was a statistical difference in the expression of NKX2.1 between the 
nucleofected 34D6 nrNPCs (p-value < 0.0001) and at different time points (p-value < 
0.001) (Figure 5.18). At ND2, only the pCAGG-MASH1 nucleofected cells showed 
dramatic reduction of NKX2.1 levels (p = 0.001) compared with the control group 
(pCAGG) (Figure 5.18). At ND3, ND5 and ND7, there was a significant decrease in the 
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expression of NKX2.1 in all nucleofected cells compared to the control group (pCAGG) 
(p-value < 0.0001) (Figure 5.18).  
NKX2.1 expression decreased considerably in pCAGG-DLX2/MASH1 (p < 
0.0001) and pCAGG-DLX2/MASH1/GSX2 (p = 0.001) nucleofected cells from ND3 to 
ND5 (Figure 5.18). From ND3 to ND7, there was a dramatic reduction of NKX2.1 
expression in pCAGG-DLX2/MASH1, pCAGG-DLX2/GSX2 and pCAGG-
DLX2/MASH1/GSX2 nucleofected cells (p = 0.001, 0.01 and 0.001, respectively) 
(Figure 5.18). From these results, we noticed that in all the cells nucleofected with 
vectors containing different combinations of DLX2, MASH1 or GSX2, there was a 
significant decrease in NKX2.1 expression from ND3 to ND7 
The above experimental data suggest that, in combination, the TFs DLX2, 
MASH1 and GSX2 are capable of inducing an LGE-like progenitor fate from 34D6-
derived forebrain nrNPCs. 
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5.4.4.1 Overexpression of TFs DLX2, GSX2 and MASH1 in nrNPCs have an 
effect on endogenous target genes 
 
In this section, the target genes for the TFs DLX2, MASH1 and GSX2 were 
analysed at the transcriptional level by qRT-PCR at different time points (ND0, ND2, 
ND3, ND5 and ND7). The DLX2 target genes are ARX (Figure 5.19) (Colasante et al. 
2008) and GAD2 (Figure 5.20) (Stühmer et al. 2002b). The GSX2 target genes are 
EBF1 (Figure 5.21), DLX2 (See previous Figure 5.14 F and G) and MASH1 (See 
Figure 5.14 C for pCAGG-DLX2/MASH1/GSX2 nucleofected cells) (Wang et al. 2013). 
The MASH1 target genes are DLX2 (Poitras et al. 2007) (See Figure 5.14 E and G for 
pCAGG-DLX2/MASH1 and pCAGG-DLX2/MASH1/GSX2 nucleofected cells). 
The pallial-subpallial boundary (PSB) is determined by the related repression of 
PAX6 and GSX2, and both of these TFs play a role in the patterning of DV of 
telencephalon (Yun et al. 2001; Pauly et al. 2013). When GSX2 was ectopically 
expressed in pCAGG-DLX2/GSX2/MASH1 and pCAGG-DLX2/GSX2 nucleofected 
34D6 nrNPCs, the expression of PAX6 was affected (Table 5.1). In pCAGG-
DLX2/MASH1/GSX2 nucleofected cells, ectopic expression of endogenous GSX2 was 
increased and reached its peak at ND7, and the expression of PAX6 was reduced at 
ND7 compared to the control group (pCAGG) (Table 5.1). Moreover, in pCAGG-
DLX2/GSX2 nucleofected cells, the ectopic expression of endogenous GSX2 was 
increased from ND3 to ND5, while the expression of PAX6 was reduced (Table 5.1). 
These findings suggest that ectopic expression of GSX2 in the nucleofected 34D6 
nrNPCs repressed the expression of PAX6. 
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Table 5.1: Summary of the outcome of PAX6 and GSX2 expression, which determines the 
boundary of pallial-subpallial (PSB) of telencephalon. 
Expression 
Construct expression 
PAX6 GSX2 
pCAG-DLX2/MASH1/GSX2 
The expression was 
decreased at ND7 in the 
pCAGG-DLX2/MASH1/GSX2 
nucleofected 34D6 nrNPCs. 
The expression was 
increased and reached its 
peak at ND7 in the pCAGG-
DLX2/MASH1/GSX2 
nucleofected 34D6 nrNPCs. 
pCAG-DLX2/GSX2 
The expression was 
decreased from ND3-ND5 in 
the pCAGG-DLX2/GSX2 
nucleofected 34D6 nrNPCs. 
The expression was 
increased from ND3 to ND5 
in the pCAGG-DLX2/GSX2 
nucleofected 34D6 nrNPCs. 
 
 
There was a significant difference in the expression of ARX in all nucleofected 
nrNPCs, compared to control (pCAGG nucleofected) cells, across the time points (p < 
0.0001) (Figure 5.19). Furthermore, there were significant differences in the 
expression of ARX between the different groups of nucleofected cells (p < 0.0001). In 
the pCAGG-DLX2/MASH1 nucleofected cells, there was an 8 fold increase in the 
expression of ARX at ND7 as compared to ND0 (p < 0.0001) (Figure 5.19). 
Additionally, compared to the control at ND7, the increase in expression of ARX, in the 
pCAGG-DLX2/MASH1 nucleofected nrNPCs, was statistically significant (p < 0.0001) 
(Figure 5.19). The pCAGG-DLX2 nucleofected cells showed a significant increase in 
ARX expression from ND0 to ND7 (p-value < 0.0001) (Figure 5.19). Compared to 
pCAGG-DLX2 nucleofected cells, the expression of ARX at ND7 was significantly 
increased in pCAGG-DLX2/MASH1 nucleofected cells (p < 0.0001) (Figure 5.19). 
Consequently, it was strongly indicated that overexpression of DLX2 and MASH1 is 
associated with intracellular accumulation of ARX. 
GAD2 is one of DLX2’s target genes (Stühmer et al. 2002b) and is commonly 
used as a striatal neuron marker in SVZ and MZ (Anderson 1997b; Casarosa et al. 
1999; Horton et al. 1999; Yun et al. 2002; Long et al. 2009a). Results also reveal a 
significant difference in the expression of GAD2 in all nucleofected nrNPCs, compared 
to control (pCAGG nucleofected) cells, across the time points (p < 0.0001) (Figure 
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5.20). Moreover, there was a significant difference in the expression of GAD2 between 
the different groups of nucleofected cells (p < 0.0001). In the pCAGG-DLX2 
nucleofected cells, the expression of GAD2 at ND2 was significantly increased (p = 
0.001) compared to the control. Then, from ND2 to ND3, there was a sharp decline, 
and then start to increase from ND5 to ND7 (Figure 5.20). This can be explained by 
the outcome of exogenous and endogenous expression of DLX2. The exogenous 
expression of DLX2 was reached its peak at ND2 and then declined sharply from ND2 
to ND3. In this duration time (ND2 to ND3), the endogenous expression of DLX2 was 
initiated to increase and stayed constant from ND5 to ND7 (Figure 5.14 D). In the 
pCAGG-DLX2/MASH1 nucleofected cells, the expression of GAD2 from ND3 to ND5 
was increased significantly (p < 0.0001) compared to the control (Figure 5.20). Then, 
there was a slight decreased but was not significant from ND5 to ND7. However, 
compared to the control at ND7, the increase in expression of GAD2, in the pCAGG-
DLX2/MASH1 nucleofected cells, was statistically significant (p = 0.01) (Figure 5.20). 
In addition, in the pCAGG-DLX2/GSX2 nucleofected cells, the expression of GAD2 
was increased significantly at ND3, ND5 and ND7 compared to the control (p = 0.0001, 
p = 0.01 and p = 0.01, respectively) (Figure 5.20). Furthermore, in the pCAGG-
DLX2/GSX2/MASH1 nucleofected cells, the increase in expression of GAD2 was in 
accordance with the increase of endogenous expression of DLX2 (Figures 5.14 G and 
5.20). The expressions of DLX2 and GAD2 were increased from ND2 to ND3, then 
declined from ND3 to ND5 and started to increase from ND5 to ND7 (Figures 5.14 G 
and 5.20). 
EBF1 is a target gene for Gsx2 (Wang et al. 2013) that is also used as a marker 
for LGE-specific and striatal projection neurons (Garel et al. 1999; Lobo et al. 2006; 
Garcia-Dominguez et al. 2003). EBF1 expression in the cells nucleofected with 
different TF vectors (Figure 5.21) was subjected to ANOVA analysis. There was a 
significant difference between the various groups of nucleofected cells (p < 0.0001). 
Furthermore, both the ectopically expressed TFs and the time post-nucleofection 
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interacted together to significantly affect EBF1 expression (p = 0.0218) (Figure 5.21). 
Ectopic expression of DLX2 and GSX2 resulted in a significant increase in EBF1 
expression from ND0 to ND5 (p = 0.001.) At ND5 EBF1 expression in these cells was 
increased compared to pCAGG nucleofected nrNPCs (p < 0.0001) (Figure 5.21). 
However, when MASH1 was expressed with the other TFs in the same cells, it caused 
a sharp reduction of EBF1 expression at ND5 (p < 0.0001) (Figure 5.21). From ND5 to 
ND7, there was a reduction in the expression of EBF1 in pCAGG-DLX2/GSX2 
nucleofected nrNPCs (Figure 5.21), and this same time point at which endogenous 
GSX2 expression was decreased (Figure 5.14 H). However, expression of EBF1 in 
pCAGG-DLX2/GSX2 nucleofected cells was significantly increased compared to the 
control group (pCAGG nucleofected cells) at ND7 (p = 0.0218) (Figure 5.21). 
In conclusion, the ectopic expressions of the TFs MASH1, DLX2 and GSX2 
have an effect on their target genes, which in turn regulate striatal differentiation and 
define the striatal phenotype. Hence, the ectopic expression of TFs can trigger 
differentiation into LGE-like cells via the fundamental functions of their target genes.  
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5.5 Discussion 
 
In this chapter, H9 hESCs and 34D6 iPSCs were differentiated using the 
differentiation protocol outlined in section 3.2.4 for neural induction and neural rosette 
formation (nrNPCs). Subsequently NSC specification towards a LGE progenitor 
phenotype was promoted by ectopic expression of the TFs DLX2, MASH1 and GSX2. 
The experimental protocol was designed to elicit transient expression of nucleofected 
transcription factor vectors. This was for two reasons. First, in order to investigate if cell 
proliferation was decreased as a result of nucleofection with control and TF expression 
vectors, thus, two populations of cells (GFP-ve and GFP+ve) were analysed to determine 
the percentage of Ki67 positive cells. Second, to compare the exogenous mRNA 
expression of TFs DLX2, MASH1 and GSX2 in the TF vector nucleofected 34D6 
nrNPCs versus control (pCAGG) nucleofected cells. In this way, the time point of peak 
expression of exogenous mRNA (transient expression) could be observed. If the G418 
selection was initiated, the mRNA expression of the transgenes would be maintained; 
therefore, it would not be possible to determine the time point at which transgene 
expression reaches its peak. Determining the time point of peak expression, after 
nucleofection, was necessary in order to determine the ideal time to initiate G418 
selection.  
ICC analysis of the nucleofected nrNPCs showed that the specific TF 
expression was only apparent in cells transfected with the specific cloned TF 
containing vector. For example, DLX2 was only expressed in the nucleofected nrNPCs 
with the DLX2 containing vectors (pCAGG-DLX2, pCAGG-DLX2/MASH1, pCAGG-
DLX2/GSX2 and pCAGG-DLX2/MASH1/GSX2). Previous studies have established the 
use of polycistronic-vector-containing 2A self-cleaving peptides to express more than 
one gene from a single vector in vitro (Sommer et al. 2009) and in vivo (Szymczak et 
al. 2004). In this study, the expression of 2A peptides was evident in cells transfected 
with all five expression vectors (pCAGG-DLX2, pCAGG-MASH1, pCAGG-
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DLX2/MASH1, pCAGG-DLX2/GSX2 and pCAGG-DLX2/MASH1/GSX2) compared to 
the empty vector. These observations point out to successful self-cleavage of 2A 
peptides during translation and processing of the polycistronic vector, to release the 
cloned TFs DLX2, GSX2 and MASH1. Therefore, the cloned TFs were successfully 
expressed in the 34D6 and H9 derived nrNPCs. 
 
Cell proliferation on the nucleofected 34D6 nrNPCs at day 4 post-nucleofection 
(ND4)  
In neural tube, neurogenesis is characterised by the generation of different cell 
types at specific periods, locations and production numbers. The complexity of 
neurogenesis involves the regulation and organization of following processes, such as, 
cell proliferation, neuron differentiation, neuron specification and migration (Toresson 
et al. 2000; Yun et al. 2002; Suh et al. 2009; Jones and Connor 2012). However, TFs 
that play a role in these processes are not fully characterised.  
A growing number of studies have shown that TFs play a role in neurogenesis 
and also play a role in regulating cell proliferation (Casarosa et al. 1999; Toresson et 
al. 2000; Yun et al. 2002; Suh et al. 2009; Jones and Connor 2012). Interestingly, 
DLX2, MASH1 and GSX2, particularly DLX/Mash1 combination, seemed to have an 
effect on cell proliferation in this study. The amount of cell proliferation was significantly 
reduced in pCAGG-DLX2, pCAGG-DLX2/GSX2 and pCAGG-DLX2/MASH1/GSX2 
nucleofected 34D6 nrNPCs, and almost absent in pCAGG-DLX2/MASH1 nucleofected 
progenitors, as indicated by decreased Ki67. Indeed, this indicates that these cells are 
no longer proliferative progenitors, i.e. they are exiting the cell cycle and have the 
potential to differentiate. TFs, particularly DLX2 and MASH1, which have parallel and 
complementary roles in neurogenesis (Casarosa et al. 1999; Yun et al. 2002; Long et 
al. 2009a) regulate the interface between proliferation and cell cycle exit/differentiation 
through different mechanisms. One of these mechanisms is proneural Mash1-
stimulatory and DLX2-inhibitory effect on the Notch signalling pathway, which controls 
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proliferation (Casarosa et al. 1999; Horton et al. 1999; Yun et al. 2002; Poitras et al. 
2007; Castro et al. 2011; Jones and Connor 2012). The loss of proliferative progenitors 
is evident in the SVZ of MGE in the Mash1-/- mutant mice model (Casarosa et al. 1999). 
Epidermal growth factor receptor (EGFR)-mediated reduction of the Notch signalling 
pathway also contributes to reduced proliferation (Aguirre et al. 2010). Gil is another TF 
that controls the cell cycle through EGFR+ progenitors or MASH11+ve or DLX2+ve 
transient-amplifying precursors (TAPs) in the SVZ (Doetschman et al. 1985; Suh et al. 
2009). Furthermore, the interaction of basic helix-loop-helix factor (bHLH) with cyclin-
dependent kinase inhibitors (CDKIs), such as p27Kip1, induces cell cycle exit and 
simultaneously promotes differentiation of neurons by increasing the number of 
DLX2+ve TAPs (Doetschman et al. 1985). In this respect, MASH1 is also a bHLH gene, 
which could suggest an interaction between MASH1 and CDKI to halt neuronal 
proliferation and initiate differentiation, lineage fate commitment and neuron 
specification through DLX2 and GSX2 (Casarosa et al. 1999; Jones and Connor 2012).  
Dorsal-ventral marker expression in the nucleofected nrNPCs at PdD18 
As described earlier in this chapter, only pCAGG-DLX2/MASH1 nucleofected 
34D6 nrNPCs showed a significant and constant reduction of dorsal markers, i.e. PAX6 
and EMX2, compared to the control group (pCAGG), from ND3 to ND21. However, all 
ectopic expression of cloned TFs in pCAGG vector (DLX2, MASH1, DLX2/MASH1, 
DLX2/MASH1/GSX2, and DLX2/GSX2) showed significant reduction in the expression 
of the ventral MGE marker NKX2.1, as compared to control group, in 34D6 nrNPCs. 
This reduction of dorsal and ventral MGE markers points toward differentiation 
of progenitor cells into the LGE phenotype. The DLX2 and MASH1 play a critical role in 
maintaining subpallium telencephalon fate commitment, specification and eventually 
LGE development, i.e. GABAergic (Anderson et al. 1997; Casarosa et al. 1999; Horton 
et al. 1999; Fode et al. 2000; Yun et al. 2002; stuhmer et al. 2002b). These roles are 
demonstrated further in Dlx-/- mutant mice, which show a profound defect in LGE 
development and the differentiation of striatal matrix neurons (Anderson et al. 1997a). 
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In the same mutant mouse model, an increase in Pax6 has also been observed (Long 
et al. 2009a; Long et al. 2009b), suggesting that neuron differentiation is diverted into 
the dorsal part of the brain. Therefore, it has been concluded that the functional Dlx1&2 
are essential for supressing some LGE progenitor TFs, including Pax6, and ventral 
cortical TFs, such as Nkx2.1 (cortical interneurons), and cortical TFs, thus maintaining 
the identity of LGE (Long et al. 2009a; Long et al. 2009b).  
It was observed that, compared with the single ectopic expression of DLX2 or 
MASH1, co-expression of different combinations of DLX2, MASH1 or GSX2 in 34D6 
nrNPCs resulted in a dramatic reduction in the expression of NKX2.1. These findings 
could indicate that the combinations of TFs DLX2, MASH1 or GSX2 play a critical role 
in LGE specific neurons. Many studies have reported that MASH1, DLX2 and GSX2 
were required for LGE differentiation (Casarosa et al. 1999; Horton et al. 1999; Corbin 
et al. 2000; Toresson et al. 2000; Toresson and Campbell 2001; Yun et al. 2002; Yun 
et al. 2003). In the Dlx1&2-/- mutant LGE mouse, ectopic expression of cortical and 
MGE TFs was observed, indicating that Dlx1&2 regulate the identity of LGE by 
repression of some MGE TFs, such as Nkx2.1 and cortical TFs (Long et al. 2009a; 
Long et al. 2009b). Moreover, it was shown that the Dlx1/2-/-:Mash1-/- mutants showed 
similar results in the expression of Nkx2.1 and more severe deficiency in the 
phenotype of LGE progenitors than in the single mutants of Dlx1/2/- or Mash1-/- as 
shown previously by other group (Long et al. 2009a; Long et al. 2009b; Wang et al. 
2013). The same findings were observed in the Gsx2 and Mash1 double mutant (Wang 
et al. 2009). 
The data presented in this chapter are in line with the previous studies 
suggesting that the reduction of dorsal and ventral MGE markers confirms correct route 
of differentiation into an LGE-like progenitor fate through the combination of ectopic 
expression of TFs in 34D6-derived forebrain nrNPCs. 
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The expression of target genes is regulated by ectopic expression of DLX2  
DLX2 targets the ARX gene expression, which means that DLX2 has a role in 
regulating ARX expression (Colasante et al. 2008). In this study, it was found that the 
mRNA expression of ARX was increased in the pCAGG-DLX2 and pCAGG-
DLX2/MASH1 nucleofected cells. However, the expression of ARX in pCAGG-
DLX2/MASH1 nucleofected cells was higher than those in pCAGG-DLX2 nucleofected 
cells at ND7. The same observation has been made with endogenous DLX2 
expression in pCAGG-DLX2/MASH1 and pCAGG-DLX2 nucleofected cells at ND7. 
Therefore, the overexpression of DLX2 has an effect in the expression of ARX. These 
outcomes were in agreement with earlier findings regarding the influence of Dlx2 
activity on endogenous expression of ARX. It was previously observed that 
overexpression of Dlx2 in the forebrain of E13.5 mouse models regulated the 
endogenous expression of Arx by the activation of the cis-regulatory element UAS3 
enhancer, which is located downstream of Arx (Colasante et al. 2008). This evident in 
Dlx1/2-/- mutant knockout mice, where Arx expression was decreased (Colasante et al. 
2008). 
The TF Arx is known as aristaless related homeobox (Colasante et al. 2008). It 
is located in the developing subpallium telencephalon in the LGE and MGE in the 
proliferating cells in subventricular zone (SVZ) and mantle zone. In the cerebral cortex, 
it is expressed in the proliferating cells in the ventricular zone (VZ), as well as in other 
parts of brain (Colasante et al. 2008). It has a role in forebrain development and in late 
born striatal projection neuron migration to the pallium (Colasante et al. 2008; Colombo 
et al. 2007). Mutation of the TF ARX leads to neuropathological diseases, such as, 
motor deficiency, mental retardation and epilepsy (Colasante et al. 2008; Nawara et al. 
2006). According to Colasante et al. (2008), in a study of loss and gain of function 
models, Arx is essential for stimulation of Dlx-dependent interneuron migration but it is 
not required for GABAergic cell fate specification, which is regulated by the TF Dlx. 
Therefore, TF Arx is essential for migration of GABAergic neurons.  
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GAD2 is the enzyme synthesize the GABA neurotransmitter (Stühmer et al. 
2002b). In this study, it was found that GAD2 expression, which is a Dlx target gene, 
was in accordance with the expression of exogenous or endogenous Dlx2. The same 
outcome was found in the study of embryonic mouse forebrain, where the pattern of 
Dlx2 expression was closely identical to the pattern of GAD2 expression (Stühmer et 
al. 2002b). In addition, in the gain of function study, it was found that when Dlx2 was 
ectopic expressed into coronal slices of embryonic mouse forebrain, more than 85% of 
the Dlx2 transfected cells expressed GAD2 (Stühmer et al. 2002b). However, the 
knock out studies of Dlx2, showed a decrease in GAD2 expression (Stühmer et al. 
2002b; Petryniak et al. 2007; Long et al. 2009b). In addition, at early stages of 
embryogenesis, the ventral telencephalon expresses GAD1&2 and Dlx1/2/5&6, but not 
in the dorsal telencephalon (Stühmer et al. 2002b; Fode et al. 2000). When the 
tangential migration from subpallium to pallium take place, the expression of Dlx2 and 
Gad2 has similar expression in pallium (Stühmer et al. 2002b). Taken together, these 
data indicate that DLX2 has a fundamental role in regulating the expression of GAD2, 
hence stimulating the GABAergic neuronal phenotype. Its expression, along with ARX 
genes, indicates the successful differentiation of stem cells into striatal MSNs in this 
study.  
The expression of these target genes, as indicated through the above research, 
clearly suggests the active role of TFs in proliferation, differentiation and cell fate 
commitment. 
Endogenous DLX2 expression was affected by ectopic expression of other TFs 
cloned in the same expression vector.  
The pCAGG-DLX2 and pCAGG-DLX2/MASH1, two days post nucleofection in 
nrNPCs, showed decreased exogenous DLX2 transgenic expression at ND3 in both 
the constructs, while the endogenous DLX2 expression increased from ND0 to ND3 
and then remained constant from ND5 to ND7 in pCAGG-DLX2 construct only. 
Interestingly, when DLX2 and MASH1 were co-expressed, the endogenous DLX2 
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expression was increased sharply from ND3 to ND7. However in the same vector 
construct, exogenous MASH1 expressed until ND5, whereas endogenous expression 
of MASH1 increased slightly from ND5 to ND7, when co-expressed with DLX2. These 
findings strongly support the regulatory role of MASH1 in DLX2 expression. 
Corroborating these findings, the potential importance of Mash1 on Dlx2 expression 
has previously been reported in Dlx-/- mutant mice, where striatal histogenesis (but not 
that of the dLGE) was partially preserved due to expression of Mash1 (Long et al. 
2009a; Long et al. 2009b). It can be speculated that the expression of MASH1 might 
maintain low expression of DLX2, thus preserving vLGE. In fact, it has previously been 
shown that MASH1 regulates the expression of DLX2 by binding to the I12b enhancer 
in the E-box sequences located upstream of DLX2 (Poitras et al. 2007). 
The findings presented here also suggest that DLX2 represses MASH1, since 
the expression of endogenous MASH1 was lower in pCAGG-DLX2/MASH1 than 
pCAGG-MASH1 nucleofected cells. This is further supported by findings that DLX2-
mediated down-regulation of Mash1 suppresses Notch downstream target genes (Dll1 
and Hes5), leading to differentiation of nrNPCs (Anderson et al. 1997a, Yun et al. 
2002). It has been also shown that Dlx1/2 causes progenitors to exit the cell cycle in 
order to begin differentiating into GABAergic neurons, particularly in the late stage of 
neurogenesis, as evidenced through increased expression of DRD2, GAD1/2 in the 
SVZ and mantle zone (MZ) (Anderson et al. 1997a, Yun et al. 2002, Cobos et al. 
2007). This effect has been further supported in Dlx1/2-/- mutant mice, where 
upregulation of MASH1 and Mash1-mediated Notch signalling blocks differentiation 
(Yun et al. 2002). From this and previous studies, it has been concluded that 
coordination of Dlx2 and Mash1 plays a role in the balance between proliferation and 
differentiation, as well as in defining cell fate commitment to aid the development of the 
subpallial telencephalon (Yun et al. 2002; Castro et al. 2011). Moreover, it was shown 
that expression of Mash1 only promotes the subpallial progenitor state via Notch 
signaling, and co-expression of Mash1 with Dlx2 promotes subpallial differentiation 
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(Wang et al. 2013). It is believed that Mash1 is required in early neurogenesis, 
whereas Dlx2 is needed by late progenitors for differentiation and specification through 
repression of Notch signalling (Yun et al. 2002). Future studies of Notch ligand 
expression in cells ectopically expressing DLX2 and MASH1 together or on their own 
would facilitate a better understanding of the relationship between DLX2 and MASH1 in 
relation to the Notch signaling pathway.  
All of the above findings clearly show that DLX2 and MASH1 co-expression 
plays an important role in neurogenesis and differentiation into LGE-like progenitor fate 
from hPSC-derived forebrain nrNPCs, which were required in this study for further 
differentiation into MSN-like cells. 
The expression of EBF1 is regulated by ectopic expression of GSX2 and DLX2 
One of the GSX2 target genes is EBF1. Expression of EBF1 mRNA was 
increased in pCAGG-DLX2/GSX2 nucleofected cells and reached its maximum at ND5. 
The expression of endogenous DLX2 and GSX2 also reached its peak at ND5. When 
MASH1 was co-expressed with DLX2 and GSX2, endogenous GSX2 mRNA 
expression started to increase after ND5, and it was observed that the EBF1 
expression increased after ND5 in pCAGG-DLX2/MASH1/GSX2 nucleofected cells. 
From these findings, it was shown that GSX2 regulates the expression of EBF1, as 
previously reported by Wang and colleagues. They also reported that in the mouse 
homologous mutant Gsx2-/-, expression of EBF1 was reduced compared to the wild 
type (Wang et al. 2013).  
As described earlier in this chapter, it was found that at ND7, EBF1 expression 
was higher in pCAGG-DLX2/GSX2 nucleofected cells than in pCAGG-
DLX2/MASH1/GSX2 nucleofected cells. This could be due to the differences in the 
endogenous expression of DLX2 in both pCAGG-DLX2/GSX2 and pCAGG-
DLX2/MASH1/GSX2 nucleofected cells. The expression of endogenous DLX2 was 
higher in pCAGG-DLX2/GSX2 nucleofected cells than in pCAGG-DLX2/MASH1/GSX2 
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nucleofected cells. Therefore, it could be concluded that the expression of EBF1 was 
regulated by both DLX2 and GSX2. This finding is supported by Dlx2-/-;Gsx2-/- double 
mutant and single Dlx2-/- and Gsx2-/- homologous mutants mice models, which 
demonstrated that EBF1 expression was reduced in all mutants (Dlx2-/-;Gsx2-/-, Dlx2-/- 
and Gsx2-/-) compared to the wild type mouse (Wang et al. 2013). 
Overall, these findings suggest that the complex molecular regulation seen in in 
vitro models successfully stimulates proliferation and differentiation of nrNPCs into 
LGE-like progenitors. Furthermore, in in vitro models, DLX2/MASH1 nucleofected cells 
seem to closely regulate the neurogenesis process to promote LGE-like progenitor 
fate, which can lead to further differentiation into MSNs. 
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6.1 Introduction 
 
Many TFs are known to have a parallel or in-series role in ventral telencephalic 
development and differentiation (Porteus et al. 1994; Anderson 1997b; Horton et al. 
1999; Casarosa et al. 1999; Fode et al. 2000; Yun et al. 2002; Long et al. 2009b). One 
of these TFs is Dlx1/2, which acts in concert with Mash1 to specify GABAergic MSN 
differentiation and fate commitment in the LGE (Porteus et al. 1994; Yun et al. 2002; 
Long et al. 2009b). The distinct role of Dlx1/2 and Mash1 is further supported by the 
findings of reduced GABAergic interneurons in many mutant mice models, including 
Dlx1/2−/−, Mash1−/−, double Gsx2−/−;Mash1−/− mutant and triple Dlx1/2−/−;Mash1−/− 
mutant (Yun et al. 2002; Long, Swan, et al. 2009; Wang et al. 2009). For example, 
there is a partial preservation of vLGE identity, but a severe defect in the dLGE of 
Dlx1/2−/− mice, as evidenced by striatal markers such as Drd1/2 and Gad1/2 (Long et 
al. 2009b). This outcome indicates that Dlx1/2 has a profound role in dLGE 
development and the subsequent fate commitment of GABAergic neurons, whereas 
the development of the LGE’s remaining parts is maintained by the expression of 
Mash1 and other TFs such as Gsx1/2 and Tlx (Long et al. 2009b). The parallel action 
of Dlx2 and Mash1 is further supported by the induced expression of ventral 
biomarkers Dlx1/2/5 and Gad2 when Mash1 is ectopically expressed in the dorsal 
telencephalon of Ngn−/− mutant mice (Fode et al. 2000; Wilson and Rubenstein 2000). 
Furthermore, Dlx1/2 and Mash1 have been shown to regulate the complex 
proliferation, differentiation and maturation phases of neurogenesis (Anderson et al. 
1997a; Horton et al. 1999; Stühmer et al. 2002a; Yun et al. 2002; Yoshihara et al. 
2005; Colombo et al. 2007; Cobos et al. 2007; Poitras et al. 2007; Long et al. 2009b). 
More specifically, Mash1 drives the proliferative phase of neurogenesis, while Dlx1/2 
triggers the differentiation process (Casarosa et al. 1999; Yun et al. 2002; Castro et al. 
2011). Gsx2 is another important TF with a role in promoting the early identity of the 
telencephalic ventral domain (Hsieh-Li et al. 1995; Corbin et al. 2000; Toresson et al. 
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2000; Wang et al. 2013), as documented by a profound decrease in LGE size, 
reduction in Mash1, Dlx1/2, Ebf1 and Gad1/2 expression at E12.5, and subsequent 
reduction of DARPP-32+ve MSNs in GSX2−/− mutant mice (Corbin et al. 2000; Toresson 
et al. 2000; Wang et al. 2013). 
The critical role of TFs in neurogenesis has encouraged researchers to pursue 
the differentiation of mainly somatic cells into relatively high-yield induced neuronal 
cells (Berninger et al. 2007; Heinrich et al. 2010; Yoo et al. 2011; Son et al. 2011; 
Lujan et al. 2012; Yang et al. 2013; Lau et al. 2014). In fact, quite a few studies have 
succeeded in differentiating human or mouse stem cells into induced neurons 
(Vierbuchen et al. 2010; Pang et al. 2012; Zhang et al. 2013). Interestingly, forced 
expression of different TF constructs, including Dlx2 and Neurog2 in cortical astroglial 
cells (non-neuronal cells), has resulted in a relatively high percentage of mature 
glutamatergic neurons (excitatory neurons) with Neurog2 alone (58%) and a low 
percentage of mature GABAergic neurons (inhibitory neurons) with Dlx2 alone (6%) 
(Heinrich et al. 2010). To date, however, a protocol for differentiating hPSCs into MSNs 
via forced expression of key ventral TFs (such as Dlx2, Mash1 and Gsx2) has not been 
attempted. Instead, ectopic expression of morphogens, such as SHH and DKK1, in 
hPSCs has been used to induce the indirect expression of key ventral TFs (such as 
Gsx2), which has then triggered differentiation into a low number of pure MSNs (Carri 
et al. 2013). Hence, it is necessary to identify an effective combination of TFs that will 
trigger the cascade of intracellular pathways leading to cell proliferation and 
differentiation into mature GABAergic MSNs.  
To induce the differentiation of human stem cells into a specific neuron type, two 
stages of development are crucial. The first stage of development is the differentiation 
of human stem cells into naïve rosette-stage neural progenitors (nrNPCs), a process 
dependent on the addition of instructive factors, such as fibroblast growth factor (FGF), 
or inhibitors, such as bone morphogenetic protein-antagonists (BMPa) (Nat and 
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Hovatta 2004; Dhara and Stice 2008). The second stage is the differentiation of 
nrNPCs into a target neuron type (Martinez et al. 2012). This approach was recently 
used by Carri et al. (2013). Briefly, hPSCs were directly differentiated into ventral 
progenitors (FOXG1+ve and GSX2+ve) via dual inhibition of BMP/TGFβ, and then 
terminally differentiated upon treatment with sonic hedgehog/dickkopf WNT signaling 
pathway inhibitor 1 (SHH/DKK1) into functional MSNs. However, among these MSNs, 
few were DARPP-32+ve neurons (20%) (Carri et al. 2013).  
A similar approach is employed in this study. The major goal of this research is to 
successfully differentiate human pluripotent stem cells (hESCs- and iPSCs) into LGE-
specific progenitors, as discussed in Chapter 5. Subsequently, these progenitors (H9 
or 34D6 nrNPCs) will be differentiated further into MSNs through ectopic expression of 
DLX2, MASH1, GSX2, and DLX2/MASH1 with or without external GSX2 treatment, as 
these TFs are well known for playing a critical role in subpallial fate commitment and 
striatal development (Yun et al. 2002; Long et al. 2009a; Pauly et al. 2013) MSN fate 
commitment is examined using biomarkers that are widely utilized for detecting 
neurons, MSNs, and GABAergic neurons, as described in Table 6.1. Moreover, 
maturity is investigated using biomarkers (Table 6.1) and electrophysiological analysis. 
This approach will establish a cellular disease model using the end-point mature 
GABAergic MSNs to investigate molecular and cellular pathogenesis of HD and 
subsequently develop a new therapeutic intervention.  
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Table 6.1: Biomarkers to identify neuron cells and GABAergic striatal MSNs. 
Biomarker / 
Target gene Biomarker for 
β-Tubulin III Neurons 
DARPP-32 Striatal MSNs 
CTIP2 Striatal MSNs 
EBF1 Striatal neuron (LGE SVZ and MZ) 
FOXP1 Striatal neuron (LGE SVZ and MZ) 
DRD1 Striatonigral neurons type of MSN 
DRD2 Striatopallidal neurons type of MSN 
GAD2 GABAergic neurons 
CALBIN-1 GABAergic neuron 
 
6.2 Aims 
 
The objective of this chapter was to establishing a successful protocol for directly 
differentiating ventral telencephalon-like progenitor cells (described in Chapter 5) into 
the mature GABAergic MSN-like phenotype using novel differentiation media plus 
different TFs constructs. In addition, the maturity and functionality of GABAergic MSNs 
generated in in vitro was investigated using different means of assessment. 
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6.3 Experimental design 
 
 The protocol used for characterisation of TFs in the previous chapter (Chapter 5) 
was also used here. The experimental design conducted to maintain cells is illustrated in 
Figure 6.1. This method is described in greater detail in the Materials and Methods 
chapter (Chapter 3) (see section 3.11, 3.12 & 3.13).  
 
Figure 6.1: Experimental design.  
The experimental protocol used in this chapter to maintain the human pluripotent stem cells 
(hPSCs) stage (D0) to naïve rosette stage neural progenitors (nrNPCs) at PD 20.  
Abbreviations: D: Day, P/S: Pen/Strep, nrNPC: Naïve rosettes stage neural progenitors, EB: 
Embryonic body, EBD: embryonic body day, MD: Monolayer differentiation, MDD: Monolayer 
differentiation day; PdD8: Platting down Day 8. 
 
The nucleofection of H9 or 34D6 nrNPCs with different TF expression vectors 
was initiated at PdD18. The cells were checked for GFP expression 48 hours after 
nucleofection; then selection of nucleofected cells was initiated with G418 sulfate. Cells 
that survived selection were washed with PBS and cultured in ADF medium for one day 
in order to recover. These cells were then re-plated onto treated cover slips in 24-well 
     hPSCs Embryonic Bodies/ Monolayer 
Differentiation    
Naïve rosettes stage neural progenitors  (nrNPC) 
Nucleofection on PdD16-20 
H9 spheres 
34D6 spheres 
34D6 on matrigel 10cm nuc 
plate: 
 
mTeSR1+ 1%P/S+ 5% 
supplement 
H9 ESCs on Mefi 6cm nuc 
plate: 
 
H9 medium + FGF (10ng/ml) 
 
Embryonic Bodies “EB” on 10cm 
steriline plate: 
 
ADF medium + LDN193189 (0.5µM) + 
SB431542 till EBD4 (10µM)  
D0                                            D3 
EBD0                       EBD4                           EBD8/PdD8                                                                                                
MDD0                      MDD4                          MDD8/PdD8 
 
H9 and 34D6 rosettes cells: 
 
ADF medium  
At EBD8, the spheres were plating 
down into 24 well PLL/Laminin 
plate  “PdD8 rosettes cells”. 
 
ADF +1.5µM IWR-1+ 0.25µMLDN 
At MDD8, the spheres were re-
plating down into 24 well PDL/
Laminin plate  “PdD8 rosettes 
cells”. 
 
34D6 
H9  
Monolayer  differentiation “MD” on 10cm 
nuc plate: 
 
ADF medium + LDN193189 (1µM) + 
SB431542 till MDD4 (10µM)  
10µM SB431542 
 0.5-1µM LDN 
PdD20 
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plates for differentiation experiments (described in Section 3.2.7.1). Cover slips were 
subjected to specific treatment, as described in the Materials and Methods chapter 
(Section 3.2.7), to ensure strong adherence and subsequent growth on the cover slips 
for downstream applications.  
The nucleofected H9 or 34D6 nrNPCs were maintained in differentiation medium 
and allowed to differentiate for varying time periods. Three differentiation experiments 
were performed in this chapter, which are described briefly in Table 6.2. In each 
experiment, there were slight differences in the neural induction protocol, G418 
selection, coating of cover slips and differentiation medium.  
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Table 6.2: The summary of the experimental design. 
Experiment 
number 
Human cell 
lines 
Neural 
induction 
protocol 
G418 
selection 
Coating on 
cover slips in 
24-well 
plates 
Differentiation medium 
1 
H9-derived 
nrNPCs 
(Nucleofected 
with pCAGG-
DLX2/GSX2 
and the control 
pCAGG) Embryonic bodies (EB) 
(0.5µm 
LDN193189 + 
10µM 
SB431542) 
400µg/ml 
for 1 week PLL/Laminin 
ADF medium, 2% B27+A, 
1% P/S, 1% L-G and 1% 
FBS. 
2 
34D6-derived 
nrNPCs 
(Nucleofected 
with one of five 
expression 
vectors or the 
control 
pCAGG) 
800µg/ml 
for 1 day 
Cover slips 
treated with 
nitric acids, 
washed and 
coated with 
PDL/Matrigel 
(see section 
3.2.7). 
Week 1: ADF medium, 2% 
B27+A, 1% P/S, 1% L-G, 
10ng/ml BDNF, 200µM AA, 
0.5µM dbcAMP, 5µM DAPT 
and 0.5µM VPA. 
 
Week2: Addition of ACM to 
give an ADF:ACM ratio of 
1:1, and 1mM Ca+Cl2. 
Only the nucleofected cells that were mature DARPP-32+ve neurons were used 
 
 
 
 
 
3 
34D6-derived 
nrNPCs 
(Nucleofected 
with pCAGG-
DLX2/MASH1 
or the control 
pCAGG) 
Monolayer 
differentiation 
(MD) with IWR-
1 (WNT 
antagonist) 
(1µm 
LDN193189 + 
10µM 
SB431542) 
800µg/ml 
for 1 day 
Cover slips 
treated with 
nitric acids, 
washed and 
coated with 
PDL/Matrigel 
(see section 
3.2.7). 
Week 1: ADF medium, 2% 
B27+A, 1% P/S, 1% L-G, 
10ng/ml BDNF, 200µM AA, 
10µM DAPT, 1.8mM Ca+Cl2, 
2µM PD332991, 10µM 
Forskolin, 3µM CHIR99021, 
300µM GABA. 
Week 1: (1:1) ADF medium: 
Neurobasal A, 2% B27+A, 
1% P/S, 1% L-G, 10ng/ml 
BDNF, 200µM AA, 1.8mM 
Ca+Cl2, 3µM CHIR99021.  
Abbreviations: B27+A: Serum-free supplement with retinoic acid, P/S: Pen/Strep, L/G: L/Glutamate, 
FBS: Fetal bovine serum, ACML: Astrocyte conditioned media, BDNF: Brain-derived neurotrophic 
factor, AA: Ascorbic acid, dbcAMP: Dibutyryl cyclic adenosine 3’, 5’-monophosphate, DAPT: as Notch 
signaling inhibitor, chemical name is N-[(3,5-Difluorophenyl)acetyl]-L-alanyl-2-phenyl]glycine-1,1-
dimethylethyl ester, VPA: Valproic acid, Ca+Cl2: Calcium chloride, PD332991: CDK4/6 inhibitor, 
Forskolin: elevates cAMP; CHIR99021: Glycogen synthase kinase 3 (GSK3) inhibitor and WNT agonist. 
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6.3.1 Strategy for the analysis of mature MSNs 
 
The nucleofected nrNPCs were analysed at the following time points: week 0 
(W0), which is equivalent to Differentiation day 0 (Dd0), W3 (Dd21) and W6 (Dd42) for 
34D6 cell line and W0, W2, W4 and W6 for H9 cell line. RNA samples harvested at 
different time points and protein samples at Dd42 were analysed by qRT-PCR and 
western blotting, respectively. This was in order to examine DARRP-32 and CTIP2 
mRNA, and DARPP-32 protein expression levels.  
For the mRNA expression of DARPP-32, two-way ANOVA was used to test the 
following hypotheses: 
H0: Nucleofection of cells with different constructs has no significant effect on the 
expression of DARPP-32. 
H0: Incubation time with differentiation media has no significant effect on the expression 
of DARPP-32. 
H0: Nucleofection of cells with different constructs and the incubation time with 
differentiation media together have no significant effect on the expression of DARPP-32. 
Cells expressing DARPP-32 and CTIP2 were then subjected to further analysis by 
qRT-PCR. The expression of some of the mature striatum markers, such as FOXPI and 
EBF1, dopamine receptors, such as DRD1 and DRD2 (Garel et al. 1999; Tamura et al. 
2004; Martín-Ibáñez et al. 2012; Lobo et al. 2006), and markers of GABAergic neurons, 
such as GAD2 and CALBIN-1 (Kiyama et al. 1990; Gerfen 1992; Pickel and Heras 1996; 
Pinal and Tobin 1998; Pan 2012; Lin et al. 2015), was examined at different time points. 
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6.4 Results 
 
6.4.1 Nucleofection of H9 nrNPCs with pCAGG-DLX2/GSX2 or the 
control pCAGG vector. 
 
6.4.1.1 Increased expression of β-Tubulin III from W0 to W2 in pCAGG-
DLX2/GSX2 nucleofected H9 nrNPCs. 
 
H9 nrNPCs at PdD18 were nucleofected with pCAGG-DLX2/GSX2 or pCAGG, 
and maintained in differentiation media. These were then analysed for expression of 
the neuron specific marker, β-Tubulin III, by ICC at W0 and W2. 
At W0, β-Tubulin III was expressed at low levels in both pCAGG and pCAGG-
DLX2/GSX2 nucleofected H9 nrNPCs (Figure 6.2). At W2, β-Tubulin III was highly 
expressed in both of pCAGG and pCAGG-DLX2/GSX2 nucleofected H9 nrNPCs 
(Figure 6.2). In addition, the development of neuron morphology in both populations of 
H9 nucleofected cells was more advanced at W2 than W0, indicating that β-Tubulin 
III+ve neuron cells are generated upon nucleofection of H9 nrNPCs (Figure 6.2). The 
negative control for β-Tubulin III and GFP is shown in Appendix 5.1. 
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6.4.1.2 Failure of pCAGG-DLX2/GSX2 nucleofected H9 nrNPCs to generate 
mature MSNs despite increased expression of DARPP-32. 
 
DARPP-32 expression in both pCAGG and pCAGG-DLX2/GSX2 nucleofected 
H9 nrNPCs increased dramatically and significantly from W2 to W6 at transcriptome 
level (Figure 6.3 A). This gene expression corresponded with the increased DARPP-
32+ve immunoreactivity in ICC (Figure 6.3 B and C) and western blotting (Figure 6.4) 
at W6 relative to negative control (HEK293) and/or pCAGG. These results confirm the 
generation of MSNs, as evidenced by DARPP-32+ve immunoreactivity at the 
transcriptome and protein levels. 
Next, the electrophysiological characterisation was carried out to assess the 
functionality of the differentiated neurons. This was undertaken by Dr. Vsevalod 
Telezhkin, as described in the Materials and Methods chapter. Unfortunately, 
electrophysiological analysis of the pCAGG-DLX2/GSX2 nucleofected H9 nrNPCs 
indicated that DARPP-32+ve MSNs were not functionally mature MSNs (data not 
shown). As a result, hPSC-derived nrNPCs were nucleofected with all the TF 
expression vectors (pCAGG-DLX2, pCAGG-DLX2/GSX2, pCAGG-DLX2/MASH1, 
pCAGG-DLX2/GSX2/MASH1, pCAGG-MASH1 plus the control pCAGG) in parallel in 
order to determine if any of them would differentiate into functionally mature DARPP-
32+ve MSNs. An iPSCs line, 34D6, was used for these experiments. This was 
performed in order to determine and obtain HD-iPSC lines, which consequently 
differentiate into mature MSNs for future experiments.  
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Figure 6.4: DARPP-32 protein expression in pCAGG and pCAGG-DLX2/GSX2 
nucleofected H9 nrNPCs at W6.  
Western blotting analysis of pCAGG and pCAGG-DLX2/GSX2 nucleofected H9 nrNPC along 
with negative control lysates (A). HEK293 cells were used as a negative control for DARPP-32 
gene expression. DARPP-32 gene expression was normalised to β-ACTIN for each 
nucleofection and quantified as determined by densitometric analysis (N = 2, p < 0.0001) (B). 
Micrographs of pCAGG-DLX2/GSX2 nucleofected H9 nrNPCs stained with anti-DARPP-32 
antibodies were captured at 50µm (C). The two panels show focusing on different areas (white 
circles) of the same image, to highlight morphology. Yellow scale bar indicates 50µm.  
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6.4.2 Nucleofection of 34D6 nrNPCs with different transcription factor 
expressing vectors. 
 
34D6 nrNPCs were nucleofected at PdD18 with one of the following five 
constructs (pCAGG-DLX2, pCAGG-DLX2/MASH1, pCAGG-DLX2/GSX2, pCAGG-
DLX2/MASH1/GSX2, pCAGG-MASH1) or a control vector (pCAGG). A large number of 
studies have used β-Tubulin III to detect neuron cells and double DARPP-32 and 
CTIP2 to confirm the presence of MSNs (Arlotta et al. 2008; Carri et al. 2013; Ding et 
al. 2014). Therefore, in this study, the nucleofected cells were maintained in the 
differentiation media (as described in Table 6.2) and examined for the expression of 
neuron specific marker, i.e. β-Tubulin III, and MSNs specific markers, i.e. DARPP-32 
and CTIP2 at molecular and gene levels.  
 
6.4.2.1 Ectopic expression of DLX2 and MASH1 promotes differentiation of 
iPSCs into DARPP-32+ve and CTIP2+ve functional MSNs. 
 
All differently nucleofected vectors, including control, are expressing β-Tubulin 
III at W3(Dd21), confirming their neuronal identity as demonstrated in Figure 6.5. 
Expression of DARPP-32 and CTIP2, at the transcriptional level, was statistically 
significant in all the nucleofected 34D6 nrNPCs from W0(Dd0) to W6(Dd42) (Figure 
6.6 A and B). Also, DARPP-32 gene expression correlated well to protein expression 
data obtained by Western blotting in all nucleofected 34D6 nrNPCs at W6(Dd42) 
(Figure 6.7 A and B).  
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Figure 6.5: β-Tubulin III and GFP expression in differently nucleofected 34D6 nrNPCs at 
W3. 
ICC images of 34D6 nrNPCs nucleofected with the indicated transcription factor expressing 
vectors (left column) and stained with antinuclear antibody (Dapi: Blue), and anti-β-Tubulin III 
(Red). GFP expression (Green) was also shown and the micrographs were superimposed to 
visualize co-localisation of the different proteins. Scale bar indicates 100µm. 
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Figure 6.6: Expression of DARPP-32 and CTIP2 mRNA in nucleofected 34D6 nrNPCs at 
different time points. 
Expression of DARPP-32 (A) and CTIP2 (B) in nucleofected 34D6 nrNPCs was assessed by 
qRT-PCR at various time points and normalised to GAPDH (2-delta ct). p-value was calculated 
using Two-way ANOVA with Bonferroni correction. Summary of p-value: * = 0.01, ** = 0.0029, 
*** = 0.0001 and **** < 0.0001.  
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Figure 6.7: DARPP-32 protein expression at W6 in the nucleofected 34D6 nrNPCs. 
DARPP-32 expression in the nucleofected cells was assessed at W6(D42) by Western blotting 
(A). This was quantified and normalized to β-ACTIN for each nucleofection and quantified as 
determined by densitometric analysis (N = 2; p < 0.0001) (B).  
 
 
Ectopic expression of different TFs in 34D6 nrNPCs resulted in expression of 
DARPP-32 and CTIP2. This effect, however, differed on a time dependent manner in 
differentiation medium. The expression level of DARPP-32 and CTIP2 in the different 
groups of nucleofected cells incubated for varying lengths of time in differentiation 
medium, was subjected to ANOVA analysis. There was a significant difference in the 
expression level of DARPP-32 and CTIP2 among different groups of nucleofected 
34D6 nrNPCs (p-value for DARPP-32 = 0.0029 and p-value for Ctip2 = 0.0001), and 
between cells incubated for different lengths of time (p < 0.0001 for both markers). 
Moreover, the interaction of 34D6 nrNPC nucleofection group and incubation time was 
significant for both DARPP-32 and Ctip2 (p ≤ 0.0001). 
The expression level of DARPP-32 and CTIP2 increased noticeably in all 
nucleofected 34D6 nrNPCs from W0(Dd0) to W6(Dd42) (p < 0.0001) compared to 
pCAGG nucleofected 34D6 nrNPCs (Figure 6.6 A and B). The expression of DARPP-
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32 was increased in the 34D6 nrNPCs nucleofected with pCAGG-MASH1, pCAGG-
DLX2 and pCAGG-DLX2/MASH1 at W6(Dd42). The pCAGG-DLX2/MASH1 
nucleofected 34D6 nrNPCs were the only group that showed the highest dramatic 
increase in DARPP-32 expression compared with the control (pCAGG) nucleofected 
cells at W6(Dd42) (p = 0.01). It was also shown that there was a significant increase in 
DARPP-32 expression between Dd21 and Dd42 (p < 0.0001) (Figure 6.6 A). Similarly, 
CTIP2 expression was significantly increased at W6 (Dd42) in the pCAGG-MASH1, 
pCAGG-DLX2 and pCAGG-DLX2/MASH1 nucleofected cells, but only when compared 
to the other nucleofected 34D6 nrNPCs (p < 0.0001) (Figure 6.6 B). In addition, 
electrophysiological studies showed that only the pCAGG-DLX2/MASH1 nucleofected 
cells differentiated into more neuron-like cells that generated spontaneous action 
potentials from W3 (Dd21) (Experiment conducted by Dr. Vsevolod Telezhkin, a 
postdoc in the neuroscience physiology group at Cardiff University) (Figure 6.8 A and 
B). The electrophysiology showed the development of the resting membrane potential, 
which dropped from -30 to -40 over time, indicating the progression towards more 
neuron-like cells (Figure 6.8 A and B). In vivo, the resting membrane potential is -70, 
and hence the neurons were not fully mature. However, they were progressing in the 
right direction. 
Together, these results indicate that among all the vectors tested, only pCAGG-
DLX2/MASH1 nucleofected 34D6 nrNPCs are associated with increased DARPP-32 
and CTIP2 expression at the molecular and protein levels. Furthermore, the 
DLX2/MASH1 combination generated functional and mature MSNs that elicited trains 
of action potentials (Figure 6.8 A and B). Therefore, the pCAGG-DLX2/MASH1 
nucleofected cells were subjected to further analysis for studies of mature striatal 
MSNs. 
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Figure 6.8: Development of membrane potential in 34D6 nrNPCs expressing different 
combinations of TFs 
The membrane potential of TF expressing (or control) vector nucleofected 34D6 cells incubated 
for varying lengths of time in differentiation media (A). In pCAGG-DLX2/MASH1 nucleofected 
cells, the development of the resting membrane potential over time is dropping from -30 to -40. 
pCAGG-DLX2/MASH1 nucleofected cells show spontaneous activity at week 3 and week 6 (B). 
 
6.4.2.2 Increased DARPP-32 and CTIP2 immunoreactivity in pCAGG-
DLX2/MASH1 nucleofected 34D6 nrNPCs  
 
pCAGG and pCAGG-DLX2/MASH1 nucleofected 34D6 nrNPCs, at W6(Dd42), 
were double stained with anti-DARPP-32 and anti-CTIP2 and analysed using ICC 
(Figure 6.9 A and B). Around 80% of the pCAGG-DLX2/MASH1 nucleofected cells 
were DARPP-32+ve; however, only 12% of the control (pCAGG) nucleofected cells were 
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DARPP-32+ve (Figure 6.9 C). Meanwhile, 85% of the pCAGG-DLX2/MASH1 
nucleofected cells, and 69% of the pCAGG nucleofected cells, were CTIP2+ve (Figure 
6.9 B). Most of the pCAGG-DLX2/MASH1 nucleofected cells were both DARPP-32+ve 
and CTIP2+ve as shown in the confocal microscope images of DARPP-32 and CTIP2 
double staining (Figure 6.9 B). This result support MSNs phenotype in concordance to 
previous results in section 6.4.2.1.  
 
Figure 6.9: Expression of DARPP-32 and CTIP2 at W6 in pCAGG and pCAGG-
DLX2/MASH1 nucleofected cells.  
pCAGG and pCAGG-DLX2/MASH1 nucleofected 34D6 nrNPCs were labelled with anti-DARPP-
32 antibodies (primary dilution; 1:100, Santa Cruz) and detected with an Alexa Fluor® 594 
labelled anti-rabbit IgG secondary antibody (red), and anti-CTIP2 antibody (primary dilution; 
1:500, Abcam) and detected with an Alexa Fluor® 350 anti-Rat IgG secondary antibody (blue) 
and Nuclear staining with SYTOX green fluorescent counterstain (primary dilution; 1:300, 
Invitrogen. Cat. No. S33025) (A). Confocal microscopy images of pCAGG-DLX2/MASH1 
nucleofected cells double stained against anti-DARPP-32 antibody (red) and anti-CTIP2 
antibody (blue) (B). Green scale bar indicates 36µm. The quantification of DARPP-32 and 
CTIP2 expression in pCAGG and pCAGG-DLX2/MASH1 nucleofected cells was measured by 
cell profiler program (N = 3) (C).  
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6.4.2.3 Increased gene expression of FOXP1, EBF1, DRD1 and DRD2 in 
pCAGG-DLX2/MASH1 nucleofected 34D6 nrNPCs provides an 
evidence of mature striatal MSNs. 
 
In the terminal differentiation phase, FOXP1 and EBF1 are TFs that are 
expressed by MSNs (Arlotta et al. 2008). These were used as markers to identify LGE 
determinants, as they are expressed in the SVZ and MZ of the LGE (Long et al. 
2009b), and are also known as markers for striatal projection neurons (Martín-Ibáñez 
et al. 2012). Therefore, these markers were to assess the maturity of the MSNs. There 
was a gradual increase in FOXP1 and EBF1 mRNA expression from Dd0 to Dd21 and 
from Dd0 to Dd42 in pCAGG-DLX2/MASH1 nucleofected cells when compared to 
control (pCAGG) (Figures 6.10 and 6.11). This increase was statistically significant for 
FOXP1 expression (p < 0.01) and for EBF1 expression (p < 0.001). No differences 
between the expression of FOXP1 and EBF1 from Dd21 to Dd42 were observed. The 
expression of both FOXP1 and EBF1 in pCAGG-DLX2/MASH1 nucleofected cells is 
indicative of mature MSNs. 
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Figure 6.10 FOXP1 mRNA expression in pCAGG-DLX2/MASH1 
and pCAGG nucleofected 34D6 nrNPCs at different time 
points. 
Expression of FOXP1, relative to GAPDH (2-delta ct), in pCAGG and 
pCAGG-DLX2/MASH1 nucleofected cells, was measured by qRT-
PCR. The start at Dd21 indicates the significance differences 
between pCAGG-DLX2/MASH1 nucleofected cells and the control 
at this time point. Statistical test was performed using Two-way 
ANOVA with Bonferroni correction. p-value summary: * = 0.01. 
 
 
Figure 6.11: EBF1 mRNA expression in pCAGG-DLX2/MASH1 
and pCAGG nucleofected 34D6 nrNPCs at different time 
points. 
Expression of EBF1, relative to GAPDH (2-delta ct), in pCAGG and 
pCAGG-DLX2/MASH1 nucleofected cells, was measured by qRT-
PCR. Statistical test was performed using Two-way ANOVA with 
Bonferroni correction. p-value summary: ** = 0.001.  
Dd
0
Dd
21
Dd
42
0
2
4
6
8
10
Time points ( Differentiation Days )
FO
XP
1 
re
la
tiv
e 
ex
pr
es
si
on
 to
 G
AP
DH
 ( 
2 
-d
el
ta
 c
t  )
pCAGG
pCAGG-DLX2/MASH1
* 
* 
* 
Dd
0
Dd
21
Dd
42
0
10
20
30
Time points ( Differentiation Days )
EB
F1
 re
la
tiv
e 
ex
pr
es
si
on
 to
 G
AP
DH
 ( 
2 
-d
el
ta
 c
t  )
pCAGG
pCAGG-DLX2/MASH1
** 
** 
                                                                                                                           Chapter 6: Results 
232 
 
pCAGG-DLX2/MASH1 nucleofected 34D6 nrNPCs expressed DRD1 and DRD2 
(Figure 6.12 A and B). Compared to control (pCAGG) nucleofected cells, there was a 
significant increase in the expression of both of DRD1 (p = 0.0282) and DRD2 (p < 
0.0001) in pCAGG-DLX2/MASH1 nucleofected cells. The difference in DRD1 and 
DRD2 expression at different time points was also significant (p =0.0073 and p < 
0.0001, respectively). In addition, the interaction between nucleofection of cells and 
incubation time had a significant effect on DRD1 and DRD2 expression (p = 0.0367 
and p < 0.0001, respectively). Moreover, expression of both of DRD1 and DRD2 in 
pCAGG-DLX2/MASH1 nucleofected 34D6 nrNPCs, relative to GAPDH (2-delta ct), 
increased sharply from W0(Dd0) to W3(Dd21), and these increases were statistically 
significant (p = 0.001 and p < 0.001 for DRD1 and DRD2 respectively) (Figure 6.12 A 
and B). This was followed by a gradual decrease in DRD1 and DRD2 expression from 
W3(Dd21) to W6(Dd42) (Figure 6.12 A and B). However, compared to W0(Dd0), the 
expression of both DRD1 and DRD2, at W6(Dd42), was increased. This increase was 
statistically significant for DRD2 (p = 0.01) (Figure 6.12 A and B). At Dd21, the 
expression of both of DRD1 and DRD2 was significantly elevated in pCAGG-
DLX2/MASH1 nucleofected 34D6 nrNPCs compared to control (pCAGG) nucleofected 
34D6 nrNPCs (p = 0.001 and p < 0.001 for DRD1 and DRD2 respectively) (Figure 6.12 
A and B). Data also showed that the expression of DRD2, at Dd21, was higher than 
the expression of DRD1 in the pCAGG-DLX2/MASH1 nucleofected 34D6 nrNPCs 
(Figure 6.12 A and B). The expression of DRD1 and DRD2 appears when neuron 
cells become mature striatum as it is known as neurochemical characteristic of 
endogenous MSNs (Lobo et al. 2006; Carri et al. 2013). This expression is mediated by 
DLX2 as evident in Dlx1/2-/- mutant mice (Long et al. 2009a). Together, these data 
indicate that the overexpression of DLX2 and MASH1 in 34D6 nrNPCs generates 
DRD1+ve and DRD2+ve mature MSNs by W3 (Dd21) via increased expression of FOXP1 
and EBF1.  
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Figure 6.12: DRD1 and DRD2 mRNA expression in pCAGG-DLX2/MASH1 and pCAGG 
nucleofected 34D6 nrNPCs, at different time points. 
Expression of DRD1 (A) and DRD2 (B) dopamine receptors, relative to GAPDH (2-delta ct), in 
pCAGG and pCAGG-DLX2/MASH1 nucleofected cells. Statistical test was performed using 
Two-way ANOVA with Bonferroni correction. p-value summary: * = 0.01, ** = 0.001, and **** < 
0.0001. 
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6.4.2.4 Characterisation of mature GABAergic MSNs through the CALBIN-1 
and GAD2 expression 
 
The development of GABAergic neuron, which is the major cell type in the 
striatum, is induced by glutamic acid decarboxylases enzyme (GADs). Hence, its 
expression is a specific calibrate of GABAergic neuron (Pinal and Tobin 1998; Pan 
2012). Another widely used marker for GABAergic neuron is CALBIN-1 (Kiyama et al. 
1990; Gerfen 1992; Pickel and Heras 1996; Lin et al. 2015). In this study, pCAGG-
DLX2/MASH1 nucleofected 34D6 nrNPCs exhibited GABAergic properties, such as 
expression GAD2 and CALBIN-1 (Figures 6.13 and 6.14). This effect was influenced 
by the incubation time in differentiation medium. The ANOVA analysis of variance 
tested the significance of differences between the expression level of both of GAD2 
and CALBIN-1 in pCAGG-DLX2/MASH1 and pCAGG nucleofected cells harvested 
after different incubation times in differentiation media. There was a significant 
difference in the expression level of GAD2 and CALBIN-1 between pCAGG and 
pCAGG-DLX2/MASH1 nucleofected 34D6 nrNPCs (p = 0.0005 and p = 0.036 
respectively), and between the incubation times (p = 0.0002 and p = 0.0308 
respectively). Moreover, the interaction of nucleofected 34D6 nrNPCs and incubation 
time was significant only for GAD2 expression (p = 0.0013).  
Expression of both GAD2 and CALBIN-1 was elevated from Dd0 to Dd21 (p = 
0.0001). Their expression declined gradually from Dd21 to Dd42. However, compared 
to Dd0, the increase in expression of both GAD2 and CALBIN-1, at Dd42, was 
statistically significant (p = 0.001) (Figures 6.13 and 6.14). The increase in expression 
of GAD2, in pCAGG-DLX2/MASH1 nucleofected 34D6 nrNPCs, compared to control 
cells, at Dd21 and at Dd42, was statistically significant (p = 0.0001 and p = 0.01 
respectively) (Figure 6.13). CALBIN-1 expression in pCAGG-DLX2/MASH1 
nucleofected 34D6 nrNPCs was significantly increased when compared to control cells, 
at Dd21 (p = 0.0001) (Figure 6.14). 
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Interestingly, dopamine receptor expression in pCAGG-DLX2/MASH1 and pCAGG 
nucleofected cells, at different incubation times, correlated with GABAergic phenotypic 
expression. Therefore, it can be concluded that co-expression of DLX2 with MASH1 in 
34D6 nrNPCs at Pd18 has the ability to differentiate progenitor neurons into functional 
and mature GABAergic MSNs that express all the relevant markers (i.e. DARPP-32, 
CTIP2, FOXP1, EBF1, DRD1, DRD2, GAD2 and CALBIN-1), from Dd21 onward. 
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Figure 6.13: GAD2 mRNA expression in pCAGG-DLX2/MASH1 
and pCAGG nucleofected 34D6 nrNPCs at different time points. 
Expression of GAD2, relative to GAPDH (2-delta ct), in pCAGG and 
pCAGG-DLX2/MASH1 nucleofected cells was measured by qRT-
PCR. Statistical test was performed using Two-way ANOVA with 
Bonferroni correction. p-value summary: * = 0.01, ** = 0.001, and *** = 
0.0001. 
 
 
Figure 6.14: CALBIN-1 mRNA expression in pCAGG-DLX2/MASH1 
and pCAGG nucleofected 34D6 nrNPCs at different time points. 
Expression of CALBIN-1, relative to GAPDH (2-delta ct), in pCAGG and 
pCAGG-DLX2/MASH1 nucleofected cells was measured by qRT-PCR. 
Statistical test was performed using Two-way ANOVA with Bonferroni 
correction. p-value summary: * = 0.01, ** = 0.001, and *** = 0.0001. 
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6.4.3 IWR-1 pre-treated 34D6 nrNPCs induced GSX2 upon 
nucleofection of pCAGG-DLX2/MASH1 leads to direct 
programming of functional striatal GABAergic MSN-like cells. 
 
It had been observed previously that treatment of iPSCs with the small 
molecule IWR-1 at PdD8 resulted in expression of GSX2 in the iPSC-derived nrNPCs 
(unpublished data from the Allen lab, Cardiff University, Cardiff, UK). Having 
demonstrated that ectopic expression of DLX2 and MASH1 in 34D6 nrNPCs leads to 
their differentiation into mature MSNs; as illustrated earlier, it is investigated further 
whether adding and external GSX2 in these cells would affect cell differentiation.  
 34D6 nrNPCs were initially treated with IWR-1, followed by combined 
DLX2/MASH1 and control (pCAGG) nucleofection. These pCAGG-DLX2/MASH1 and 
pCAGG nucleofected 34D6 nrNPCs were maintained in differentiation media 
containing PD332991, a CDK4/6 inhibitor, to inhibit cell proliferation (Table 6.1), in 
order to sustain the expression of GFP+ve in 34D6 nrNPCs. A GFP+ve population was 
clearly observed after G418 selection in both, pCAGG-DLX2/MASH1 and pCAGG 
nucleofected 34D6 nrNPCs at week two differentiation (Figure 6.15), indicating the 
ectopic expression of integrated DLX2 and MASH1 in 34D6 nrNPCs at W2(Dd14). The 
differentiated cells were then examined for functionality (electrophysiology) and the 
presence of neuronal and its maturation markers, as described previously. 
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Ectopic expression of DLX2 and MASH1 directed the differentiation of IWR-1-
treated 34D6 nrNPCs towards MSN phenotype expressing DARPP-32 and CTIP2 at 
molecular level (Figures 6.16 and 6.17). In addition, ICC analysis showed that the 
differentiated cells were both DARPP-32+ve and CTIP2+ve (Figure 6.17 A). DARPP-32 
was expressed in 20% of pCAGG-DLX2/MASH1 nucleofected cells compared to 12% 
of pCAGG nucleofected cells. CTIP2 was expressed in 48% of pCAGG-DLX2/MASH1 
nucleofected cells and in 52% of pCAGG nucleofected cells (Figure 6.17 B). 
Importantly, IWR-1-treated, pCAGG-DLX2/MASH1 nucleofected 34D6 nrNPCs 
showed increased expression of LGE-derived mature striatal GABAergic MSNs 
markers at Dd21, i.e. FOXP1 and EBF1 compared to the control (pCAGG nucleofected 
cells) group as demonstrated in Figures 6.18 and 6.19. In addition, the phenotype of 
LGE-derived mature striatal GABAergic MSNs was also supported through the 
expression of other specific markers including DRD1, DRD2 (Figure 6.20 A and B), 
GAD2 (Figure 6.21) and CALBIN-1 (Figure 6.22). The functionality and maturity of 
these GABAergic MSNs was also validated through the electrophysiological analysis, 
which showed a high percentage of functional neurons (Figure 6.23). The expression 
of GSX2 was observed in IWR-1-treated 34D6 cells (data not shown). It was found that 
expression of GSX2 in pCAGG or pCAGG-DLX2/MASH1 nucleofected 34D6 nrNPCs 
re-programmed their differentiation such that 100% of these differentiated cells were 
capable of generating spontaneous action potentials starting at week 4 (Figure 6.23). 
The IWR-1-containing differentiation media improved neuronal maturation dramatically 
in pCAGG-DLX2/MASH1 nucleofected 34D6 nrNPCs. A higher proportion of pCAGG-
DLX2/MASH1 nucleofected 34D6 nrNPCs (68.4%), compared to control (pCAGG) 
nucleofected 34D6 nrNPCs (46.2%), had differentiated into functionally active neurons, 
capable of generating spontaneous action potentials, at week 3 (Figure 6.23). In 
pCAGG-DLX2/MASH1 nucleofected cells, nearly 70% fire action potentials, and 20% 
attempt to generate spontaneous action potential; while in pCAGG nucleofected cells, 
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46% fire action potential, and 46% are not generating spontaneous action potential, 
and hence are not being active neurons (Figure 6.23). 
These data together suggest that the GSX2-induced expression by IWR-1 pre-
treatment in pCAGG-DLX2/MASH1 nucleofected cells were direct differentiated into 
functional and mature MSN-like neurons with striatal GABAergic phenotypes 
expressing the above genes (EBF1, FOXP1, DRD1/2, GAD2, and CALBIN-1). The 
induction of GSX2 using IWR-1 pre-treatment has effectively differentiated 34D6 
nrNPCs into GABAergic neurons. 
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Figure 6.16: DARPP-32 and CTIP2 mRNA expression in IWR-1-pretreated pCAGG-
DLX2/MASH1 and pCAGG nucleofected 34D6 nrNPCs at different time points. 
DARP32 (A) and CTIP2 (B) expression, relative to GAPDH (2-delta ct), in pCAGG and pCAGG-
DLX2/MASH1 nucleofected cells was measured by qRT-PCR. Statistical test was performed 
using Two-way ANOVA with Bonferroni correction. p-value summary: * = 0.01, ** = 0.001, 
and *** = 0.0001. 
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Figure 6.17: Expression of DARPP-32 and CTIP2 at W6 in IWR-1-pretreated pCAGG and 
pCAGG-DLX2/MASH1 nucleofected 34D6 nrNPCs.  
IWR-1-treated, pCAGG and pCAGG-DLX2/MASH1 nucleofected cells were labeled with 
antibodies against DARPP-32 (primary dilution; 1:100, Santa Cruz) with an Alexa Fluor® 594 
labelled anti-rabbit IgG secondary antibody (red), and CTIP2 (primary dilution; 1:500, Abcam) 
with an Alexa Fluor® 350 anti-Rat IgG secondary antibody (blue). Nuclear staining was done 
with SYTOX green fluorescent counterstain (primary dilution; 1:300, Invitrogen. Cat. No. 
S33025) (A). DARPP-32 and CTIP2 gene expression in pCAGG and pCAGG-DLX2/MASH1 
nucleofected cells was measured by cell profiler program (N = 3) (B). pCAGG-DLX2/MASH1 
nucleofected cells expressed the neuronal marker β-Tubulin III (C).  
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Figure 6.18: FOXP1 mRNA expression in IWR-1-treated pCAGG-
DLX2/MASH1 and pCAGG nucleofected 34D6 nrNPCs at different 
time points. 
Expression of FOXP1, relative to GAPDH (2-delta ct), in IWR-1-treated 
pCAGG and pCAGG-DLX2/MASH1 nucleofected cells was measured 
by qRT-PCR. The expression of FOXP1 in IWR-1-treated pCAGG-
DLX2/MASH1 nucleofected cells was increased from Dd0 to Dd21. 
Also, at Dd21 and Dd42, the expression of FOXP1 was increased in 
these cells compared to the control. 
 
Figure 6.19: EBF1 mRNA expression in IWR-1-treated pCAGG-
DLX2/MASH1 and pCAGG nucleofected 34D6 nrNPCs at different 
time points. 
Expression of EBF1, relative to GAPDH (2-delta ct), in IWR-1-treated 
pCAGG and pCAGG-DLX2/MASH1 nucleofected cells, was measured 
by qRT-PCR. The expression of EBF1 in IWR-1-treated pCAGG-
DLX2/MASH1 nucleofected cells was increased from Dd0 to Dd42. 
Also, at Dd21 and Dd42, the expression of EBF1 was increased in 
these cells compared to the control.  
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Figure 6.20: DRD1 and DRD2 mRNA expression in IWR-1-treated pCAGG-
DLX2/MASH1 and pCAGG nucleofected 34D6 nrNPCs at different time points. 
Expression of DRD1 (A) and DRD2 (B) dopamine receptors, relative to GAPDH (2-delta ct), 
in IWR-1-treated pCAGG and pCAGG-DLX2/MASH1 nucleofected cells, was measured 
by qRT-PCR. The expression of DRD1 and DRD2 in IWR-1-treated pCAGG-
DLX2/MASH1 nucleofected cells was increased significantly from Dd0 to Dd21. 
Compared to the control, the expression of DRD1 and DRD2 was increased significantly 
in treated pCAGG-DLX2/MASH1 cells at Dd21. Statistical test was performed using Two-
way ANOVA with Bonferroni correction. p-value summary: * = 0.01, ** = 0.001, and *** = 
0.0001. 
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Figure 6.21: GAD2 mRNA expression in IWR-1-treated pCAGG-
DLX2/MASH1 and pCAGG nucleofected 34D6 nrNPCs at different time 
points. 
Expression of GAD2, relative to GAPDH (2-delta ct), in IWR-1-treated pCAGG 
and pCAGG-DLX2/MASH1 nucleofected cells, was measured by qRT-PCR. 
The expression of GAD2 in IWR-1-treated pCAGG-DLX2/MASH1 
nucleofected cells was increased significantly from Dd0 to Dd21. Compared 
with the control, the expression of GAD2 was increased significantly in IWR-
1-treated pCAGG-DLX2/MASH1 cells. Statistical test was performed using 
Two-way ANOVA with Bonferroni correction. p-value summary: **** < 
0.0001. 
 
Figure 6.22: CALBIN-1 mRNA expression in IWR-1-treated pCAGG-
DLX2/MASH1 and pCAGG nucleofected 34D6 nrNPCs at different time 
points. 
Expression of CALBIN-1, relative to GAPDH (2-delta ct), in IWR-1-treated 
pCAGG and pCAGG-DLX2/MASH1 nucleofected cells, was measured by 
qRT-PCR. The expression of CALBIN-1 in IWR-1-treated pCAGG-
DLX2/MASH1 nucleofected cells was increased significantly from Dd0 to 
Dd21. Compared with the control, the expression of CALBIN-1 was increased 
in IWR-1-treated pCAGG-DLX2/MASH1 cells at Dd21 and Dd42. Statistical 
test was performed using Two-way ANOVA with Bonferroni correction. p-value 
summary: * = 0.01, and ** = 0.001.  
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Figure 6.23: Percentage of spontaneously active IWR-1-treated pCAGG-DLX2/MASH1 and 
pCAGG nucleofected 34D6 nrNPCs after several weeks of differentiation in culture 
media. 
The pie charts above show the percentage of cells generating spontaneous action potentials, 
attempting to generate spontaneous action potentials or not generating any spontaneous action 
potentials, in nucleofected IWR-1-treated cells from week 3 to week 6. Overexpression of DLX2 
and MASH1 in IWR-1-treated cells resulted in an increase in the proportion of cells generating 
spontaneous action potentials at week 3 (20%) and at week 6 (4%). 
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6.5 Discussion 
 
The present study has established a novel and highly effective in vitro protocol 
to generate a high yield of functional GABAergic MSN-like cells via forced co-
expression of DLX2 and MASH1 in 34D6 nrNPCs. These GABAergic neurons were 
FOXP1+ve / EBF1+ve / GAD2+ve / CALBIN-1+ve / DRD1+ve / DRD2+ve / DARPP-32+ve and 
CTIP2+ve. We have demonstrated that the remaining combinations of TFs (DLX2, 
MASH1, DLX2/GSX2, and DLX2/MASH1/GSX2) in H9 nrNPCs led to differentiation 
into DARPP-32+ve/CTIP+ve MSNs, but not functionally active. In addition, pre-treatment 
of 34D6 nrNPCs with IWR-1 prior to nucleofection with pCAGG-DLX2/MASH1 also 
caused differentiation into mature and functional GABAergic MSN-like cells.  
The data presented here shows that all of the differently nucleofected cells were 
undergoing neurogenesis, as evidenced by expression of neuronal biomarker, β-
Tubulin III+ve at W3. These β-Tubulin III+ve neurons gained the striatal MSN phenotype 
by expressing DARPP-32+ve and CTIP2+ve at W3. The results are consistent with 
previous studies that employed the widely used biomarkers β-Tubulin III, Darpp-32, 
Ctip2 and Darpp-32/Ctip2 co-expression to detect striatal MSNs (Ouimet and 
Greengard 1990; Ouimet et al. 1984; Arlotta et al. 2008; Carri et al. 2013; Ding et al. 
2014) The data also clearly shows that single MASH1, DLX2 and DLX2/MASH1 
nucleofection in H9 nrNPCs are associated with the highest increase in the DARPP-32 
and CTIP2 biomarkers at W6. Interestingly, of all the nucleofected constructs, only 
pCAGG-DLX2/MASH1 showed action potential firing starting at W3 in both, H9 and 
34D6 nrNPCs. In addition, DLX2/MASH1 co-expression in 34D6 nrNPCs was 
associated with a high yield of pure MSN-like cells and approximately 85% of these 
cells were CTIP2+ve and DARPP-32+ve. These findings suggest that the TF combination 
of DLX2/MASH1 is the most efficient for inducing the expression of neuron-related 
biomarkers and subsequently generating a higher yield of functional MSN-like cells.   
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At the stage of neurogenesis, increased expression of CTIP2 and DARPP-32 in 
pCAGG-DLX2/MASH1 nucleofected 34D6 nrNPCs has a functional impact in MSNs. 
Previous studies have shown increased expression of Ctip2 during embryogenesis at 
E12.5 through to adulthood, and MSN neurogenesis occurs at E13.5, revealing 
importance of Ctip2 in striatal development (Arlotta et al. 2008). In addition, expression 
of Ctip2 increases during MSN migration in the mantle zone (MZ) and in post-mitotic 
neurons (Arlotta et al. 2008). Ctip2 is exclusively expressed in the striatum and plays a 
fundamental role in MSN differentiation and striatal architecture (Arlotta et al. 2008). 
DARPP-32 acts as an integrator at dopaminoceptive neurons and is a regulator of 
neuronal excitability, electrophysiology, and transcriptional as well as behavioral 
responses to physiological plus pharmacological stimuli, as evidenced by profound 
functional deficits in mice lacking the Darpp-32 gene (Fienberg et al. 1998; Bibb et al. 
1999; Svenningsson et al. 2004). Many studies have also shown that Darpp-32 acts via 
phosphorylation and dephosphorylation of its various threonine and serine locations, 
which in turn regulate phosphatase and kinase function (Nishi et al. 1997; Hemmings 
et al. 1984; Bibb et al. 1999; Svenningsson et al. 2004; Fernandez et al. 2006). For 
example, phosphorylation of threonine 34 (thr34) on Darpp-32 by cAMP-dependent 
protein kinase (PKA), upon activation of DRD1, results in the conversion into potent 
protein phosphatase-1 inhibitor (PP1) (Hemmings et al. 1984; Nishi et al. 1997). 
Subsequently, PP1 inhibitors dephosphorylates many downstream physiological 
effectors, including NMDA glutamate receptors, voltage-gated ion channels, kinases 
and transcription factors (Greengard et al. 1999; Bibb et al. 1999; Svenningsson et al. 
2004). However, phosphorylation of thr75 by cell division protein kinase 5 (CDK5) 
modulates PP1’s inhibitory effect through inhibition of PKA (Bibb et al. 1999; Nishi et al. 
2000). These functions may have aided in both, the characterisation of GABAergic 
MSN function and the successful differentiation in the current in vitro models.  
Following successful generation of functional neurons, the striatal MSN 
phenotype was assessed by examining the FOXP1, EBF1 and DRD1/2 biomarkers. 
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Many studies have demonstrated the expression of these biomarkers in striatal MSNs 
in the supraventricular zone (SVZ) and the MZ (Garel et al. 1999; Yun et al. 2002; 
Garcia-Dominguez et al. 2003; Tamura et al. 2004; Long et al. 2009b). Hence, they 
were used to detect striatal MSNs in many mutant mouse models when studying the 
role of TFs in neurogenesis. FOXP1 has a key role in up-regulating glutamate and 
GABA receptor signaling genes, which are required in order for striatal MSNs to 
receive glutamatergic input from the cortex (Jones et al. 1977; Royce 1982; Ferino et 
al. 1987; Wilson 1987; Tang et al. 2012). In addition, FOXP1 is highly expressed in 
striatal projection neuron development (Tamura et al. 2004; Martín-Ibáñez et al. 2012). 
Similarly, EBF1 has been found to play a role in striatal projection neuron development 
and differentiation (Garel et al. 1999; Tamura et al. 2004; Martín-Ibáñez et al. 2012; 
Lobo et al. 2006). Consistent with the previous findings, this study has showed 
significantly increased expression of FOXP1 and EBF1 at W3, confirming a striatal 
MSN phenotype in neurons derived from pCAGG-DLX2/MASH1 nucleofected nrNPCs. 
The expression of these biomarkers also suggests the important role in the 
development of the striatum and MSNs. Therefore, both FOXP1 and EBF1 are 
principal biomarkers for striatal projection neurons. 
The importance of the striatum in controlling motor and cognitive functions has 
been documented extensively (Albin et al. 1989; Moyer et al. 2007). This role is 
accomplished, either direct or indirect pathways through dopaminergic action via 
Drd1/2. Drd1 provides direct neuronal projections to the substantia nigra (SNr) and 
entopeduncular nucleus. Conversely, Drd2 provides indirect projections to the external 
segment of the globus pallidus (GPe) and subthalamic nucleus (STN) (Albin et al. 
1989; Moyer et al. 2007). The counterbalance between Drd1 and Drd2 modulates the 
responsiveness of the direct and indirect pathways to cortical signals that is the key 
model of basal ganglia (Albin et al. 1989). In addition, several lines of evidence have 
demonstrated that Drd1 and Drd2 receptors have opposing effects on cAMP and PKA 
activity in neostriatal neurons, thus regulating dendritic excitability and glutamatergic 
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signaling in MSNs (Nishi et al. 1997). Activation of Drd1 receptors increases cAMP and 
PKA phosphorylation and, subsequently, increases Darpp-32 phosphorylation of thr34. 
Drd2 receptor activation, on the other hand, decreases cAMP and PKA activity and 
dephosphorylates Darpp-32 at thr34 (Stoof and Kebabian 1981). A number of studies 
have demonstrated increased expression of both Drd1 and Drd2 in the striatum, with 
Drd2 expression being higher than Drd1 in mice and rat (Schambra et al. 1994; Jung 
and Bennett 1996; Sillivan and Konradi 2011). This pattern is observed in the striatum 
during neurogenesis, in embryogenesis through adulthood (Jung and Bennett 1996; 
Araki et al. 2007; Sillivan and Konradi 2011). However, the predominance of Drd2 over 
Drd1 is reversed in the cortex (Araki et al. 2007; Sillivan and Konradi 2011). Many 
studies have shown the presence of two types of MSNs that are segregated based on 
location: Drd1-dominated (striatonigral) and Drd2-dominated (striatopallidal) (Gerfen et 
al. 1990). In line with these studies, current study demonstrates increased expression 
of both the DRD1 and DRD2 genes in pCAGG-DLX2/MASH1 nucleofected 34D6 
nrNPCs compared to control group. Interestingly, the results also reveal greater up-
regulation of DRD2 over DRD1. Therefore, these findings confirm the generation of 
striatal MSNs from iPSCs in our in vitro model.  
Moreover, the data demonstrate that functional MSNs derived from pCAGG-
DLX2/MASH1 nucleofected 34D6 nrNPCs gain the GABAergic phenotype, as seen 
through increased CALBIN-1 and GAD2 expression at W3. A growing number of 
studies are utilizing these two biomarkers to detect GABAergic MSNs (Kiyama et al. 
1990; Gerfen 1992; Pickel and Heras 1996; Pinal and Tobin 1998; Pan 2012; Lin et al. 
2015). In mice studies, Calbin-1 is known to be localised in GABA-dominant regions of 
the brain (e.g. dorsal striatum and caudate-putamen nuclei) (Kiyama et al. 1990; 
Gerfen 1992; Pickel and Heras 1996; Lin et al. 2015). The Gad2 gene encodes the 
glutamic acid decarboxylase enzyme, which decarboxylates glutamate into GABA 
(Pinal and Tobin 1998; Pan 2012). The distinct role of Gad2 is supported by its 
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restricted expression in nerve terminals and synapses, where GABA acts as a 
neurotransmitter (Pinal and Tobin 1998). 
Many mutant mice models have been established to understand the role of 
different TFs in neurogenesis in the ventral telencephalon (Casarosa et al. 1999; 
Stühmer et al. 2002b; Yun et al. 2002; Cobos et al. 2007; Poitras et al. 2007; Long et 
al. 2009b; Castro et al. 2011). Double and triple TF mutant mice, such as Mash1-/-
;Dlx1/2-/- and Gsx2-/-;Mash1-/- have been associated with severe defects in striatal 
development, unlike single TF mutant mice models such as Mash1-/- and Gsx2 -/-. The 
exception was the single Dlx2 mutant mouse model, where severe defects were 
observed in the dLGE, with the vLGE and septum preserved. These findings shed light 
on the importance of TFs interaction in regulating and driving the consecutive 
processes of neurogenesis. Therefore, the use of a combination of TFs to generate 
GABAergic MSN-like cells in this work was the fundamental objective. In fact, the 
results of the current study clearly demonstrated the successful use of TFs 
combination (i.e. DLX/MASH1) to generate functional GABAergic MSN-like cells in 
vitro.  
The expression of endogenous DLX2 and MASH1 in in vitro has initiated 
proliferation and differentiation of stem cells into functional GABAergic MSNs via 
induction of target and effector genes. Many studies have shown the significance of 
both DLX2 and MASH1 and their target genes in neuronal differentiation and 
development. DLX2 plays an essential role in promoting the differentiation of striatal 
projection neurons in the BG (Long et al. 2009b; Lobo et al. 2006). Its importance was 
revealed through the Dlx1/2-/- mutant mouse model, where the expression of striatal 
differentiation markers such as Drd1/2 and Gad1/2 was reduced in the striatum (Yun et 
al. 2002; Long et al. 2009b). These striatal differentiation genes were linked to the 
dLGE; hence it was suggested that the function of Dlx1/2 was critical for the dLGE 
regions (olfactory bulb and striatum interneurons) (Long et al. 2009b). Dlx2 partially 
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supports the GABAergic phenotype and differentiation phases during the late stage of 
neurogenesis via repression of Mash1 and Notch signaling (Casarosa et al. 1999; Yun 
et al. 2002; Poitras et al. 2007; Long et al. 2009b). In addition, Dlx2 triggers GABAergic 
neuron differentiation through up-regulation of Gad1/2 expression and vGat (Long et al. 
2009b; Stühmer et al. 2002b). Dlx2 also plays a role in neurite maturation by 
repressing the p21-activated serine/threonine kinase, PAK3, and migration of 
GABAergic neurons to the neocortex by promoting Arx expression (Colasante et al. 
2008; Cobos et al. 2007). Impaired neuronal migration was evident in Arx mutant mice 
and Dlx1/2 double homozygous mutants (Long et al. 2009b; Colombo et al. 2007; 
Colasante et al. 2008). Furthermore, Dlx2 has a role in specification of progenitors in 
the SVZ of LGE by repressing some TFs, such as MGE TFs (Gsx1, Gbx1/2), a 
diencephalon TFs (Otp) and ventral cortical TFs (such as Ebf3) (Long et al. 
2009b).These knowledge have indicated that Dlx2 was required at later steps in the 
development of LGE to regulate differentiation, migration and maturation of LGE (Yun 
et al. 2002).   
Mash1 is believed to exhibit a parallel and overlapping role with Dlx2. In other 
words, Mash1 plays several roles at both the early and late stages of neurogenesis 
including (i) promoting the expression of neural markers such as Map2 and Sox1, 
which are not expressed by TF Dlx2 (Yun et al. 2002; Long et al. 2009b; Cobos et al. 
2007), (ii) repressing differentiation of adjacent progenitors through upregulation of 
Notch signaling, (iii) cell fate specification and (vi) cell proliferation (Castro et al. 2011; 
Yun et al. 2002). Overexpression of Mash1 was observed in the Dlx1/2-/- double 
homozygous mutant, which maintained some characteristics of striatal differentiation 
(Long et al. 2009b). Moreover, in Dlx1-/-;Dlx2-/-;Mash1-/- triple mutant, it was 
demonstrated that the majority of LGE differentiation relied on their combined function 
(Long et al. 2009b; Yun et al. 2002; Poitras et al. 2007). Consequently, it was 
suggested that both Dlx1/2 and Mash1 play a parallel role in regulating LGE 
differentiation and specification (Long et al. 2009b). However, it was found that the 
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development of dLGE was more reliant on Dlx1 and Dlx2 than Mash1, while the 
opposite was true for the development of vLGE and septum (Long et al. 2009b). This 
variation is due to their different expression levels in the dLGE and vLGE. For example, 
it was found that Dlx2 and Mash1 were mostly co-expressed in the VZ and SVZ 
progenitors of dLGE. However, Dlx2 was expressed to a lesser extent in the vLGE than 
the dLGE region (Yun et al. 2002). Hence, the function of Dlx2 was more critical in the 
dLGE rather than the vLGE, while the function of Mash1 was more critical in the vLGE 
and septum (Long et al. 2009b). Therefore, the interaction between Dlx2 and Mash1 
was identified to play a major role in the transcriptional hierarchies regulating LGE and 
GABAergic neuron differentiation and specification (Long et al. 2009b). This is further 
supported by current work showing that the combination of DLX2 and MASH1 was 
sufficient to direct the differentiation of iPSCs into functionally mature MSNs, unlike the 
other TFs constructs. 
In the past, while some progress had been made in disease modeling, the 
pathogenesis of neurodegenerative diseases was not yet fully understood, and hence 
treatments for such diseases were not developed. The recent establishment of iPSCs, 
by Takahashi and Yamanaka et al., in 2006, has opened new avenues for scientists to 
generate and develop more sophisticated cell models for investigating and developing 
treatments for diseases such as, Huntington’s, Parkinson’s and Alzheimer’s diseases. 
A recent study succeeded in grafting hPSCs-derived striatal precursors into the 
striatum of quinolinic acid (QA)-lesioned rats after they were treated with SHH/DKK1 
(Carri et al. 2013). In vivo, these precursor cells differentiated further into DARPP-32+ve 
MSNs (Carri et al. 2013). Subsequently, motor neuron deficit symptoms in these rats 
were improved (Carri et al. 2013). This study highlights the possibility that hPSC-
derived nrNPCs could, in the future, be used in regenerative medicine to cure 
neurological diseases. However, this study has demonstrated that ectopic expression 
of striatum-specific TFs such as DLX2 and MASH1, rather than morphogens (e.g. 
SHH), could efficiently drive the differentiation of iPSCs into a high yield of functionally 
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mature MSN-like cells. These iPSC-derived MSNs establish a foundation for the future 
differentiation of HD-specific patient iPSCs into mature and functional neurons, for use 
in HD disease modeling and in regenerative medicine or gene therapy. 
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To date, HD pathophysiology remains poorly understood. The use of human 
induced pluripotent stem cells (h-iPSCs) for disease modeling, affords an opportunity 
to understand disease pathophysiology. HD-specific cell-based models, derived by the 
differentiation of HD-related cell types such as MSN from HD-specific patient iPSCs 
(HD-iPSCs), offer an opportunity to gain a deeper understanding of HD 
pathophysiology. The main aim of this study was to develop an efficient and 
reproducible protocol for direct programming of MSN differentiation from h-iPSCs. This 
is currently an important approach for disease modeling, drug screening and gene 
therapy. However, the best protocols available for direct programming of MSN 
differentiation from hPSCs have been unsatisfactory. Nevertheless, some innovative 
work has been achieved recently by Carri et al. (2013), Nicoleau et al. (2013) and 
Arber et al. (2014) in the generation of MSN from hPSCs using DKK1 & SHH (Carri et 
al. 2013; Nicoleau et al. 2013) or ACTIVIN A (Arber et al. 2014). Their approach was to 
use developmental signals to control and stimulate transcriptional networks that 
regulate sequential neuron progenitor fate.  
This thesis is the first to develop an alternative protocol, and it has been shown 
that this protocol can successfully, efficiently and reproducibly generate functional MSN 
by the ectopic expression of key fate defining TFs that play a role in subpallium and 
MSNs specification and differentiation. 
 
7.1 The three TFs DLX2, MASH1 and GSX2 were chosen for 
ectopic expression in hPSCs to direct differentiation into 
MSN. 
 
The TFs DLX2, MASH1 and GSX2 have been shown to be expressed in the ventral 
telencephalon and to have a role in the development of ventral telencephalon and 
striatum (Chapter 1) (Porteus et al. 1994; Horton et al. 1999; Anderson 1997b; 
Casarosa et al. 1999; Panganiban and Rubenstein 2002; Yun et al. 2002; Cobos et al. 
2007; Long et al. 2009b; Wang et al. 2013). Further, microarray analysis, detailed in 
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Chapter 2, has shown DLX2, MASH1 and GSX2 to be involved in subpallium 
development. Thus, microarray analysis is a valuable tool for validation and elucidation 
of the transcriptional network. Ventral telencephalon deficiency could be induced by 
knockout of these TFs (Anderson et al. 1997a; Toresson et al. 2000; Long et al. 2009b; 
Wang et al. 2009) and, therefore, combinations of the TFs DLX2, MASH1 and GSX2 
were chosen to be cloned and sub-cloned into the expression vector pCAGG. 
MASH1, DLX2 and GSX2 are similarly expressed in both mouse and human 
ventral telencephalon domains (Fode et al. 2000; Carri et al. 2013; Pauly et al. 2013). 
However, loss-of-function studies have demonstrated that each of DLX2, MASH1 and 
GSX2 has different functions in striatal neuron development, and they differ in their 
response to several signals (Anderson et al. 1997a; Anderson 1997b; Casarosa et al. 
1999; Toresson et al. 2000; Corbin et al. 2000; Stühmer et al. 2002a; Yun et al. 2002; 
Yun et al. 2003; Woltjen et al. 2009; Wang et al. 2013). Consequently, this raised the 
question: which gene targets of these TFs promote MSN differentiation? To address 
this question, different constructs of these TFs in the pCAGG vector (pCAGG-DLX2, 
pCAGG-MASH1, pCAGG-DLX2/MASH1, pCAGG-DLX2/GSX2 and pCAGG-
DLX2/MASH1/GSX2) were successfully produced and expressed in hPSCs. 
The successful and efficient cloning of expression vectors with the appropriate 
expression of each of the TFs and the self-cleavage of 2A peptides were achieved. 
Nucleofection of the expression constructs (pCAGG-DLX2, pCAGG-DLX2/MASH1, 
pCAGG-DLX2/GSX2, pCAGG-DLX2/GSX2/MASH1, pCAGG-MASH1 and pCAGG) 
into HEK293 have resulted in 80-90% GFP expression, and the 36, 35 and 34 kDa 
proteins (DLX2, MASH1 and GSX2 respectively) have been detected. These data 
confirm co-expression of TFs together from one vector (pCAGG polycistronic vector), 
essential for the efficient production of MSN. Thus, this vector can achieve efficient 
expression of multiple TFs and can be used for gene therapy. A similar outcome was 
reported by Szymczak et al. (2004), showing that a polycistronic vector with 2A 
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peptides produced an efficient translation of multiple CD3 genes that stimulated T-cell 
differentiation in CD3 knockout mice (Szymczak et al. 2004). 
GSX2 is enriched in the LGE (Carri et al. 2013) and is required for the up-regulation 
of ventral telencephalon genes that are essential for LGE specification and 
differentiation, such as MASH1 and DLX2 (Corbin et al. 2000; Wang and Steinbeisser 
2009; Wang et al. 2013). In Gsx2 knockout studies in mouse, it was shown that the 
expression of Mash1 and Dlx2 were reduced compared to the wild type, and the striatal 
neuronal phenotype that originates from LGE was lost while the cortical interneurons 
were unaffected (Toresson et al. 2000; Corbin et al. 2000; Yun et al. 2003; Wang et al. 
2013). It seems that Gsx2 is an upstream gene for Dlx2 and Mash1; hence Gsx2 was 
chosen as a TF to direct differentiation in vitro in this study.   
DLX2 is located in the two domains of ventral telencephalon: the LGE and to some 
extent in MGE (Pauly et al. 2013). Fate-mapping studies showed that DLX2 was 
expressed in cells co-expressing GABA (Stühmer et al. 2002a). Dlx2 contributes 
profoundly in different stages of neurogenesis: proliferation and differentiation (Lobo et 
al. 2006; Long, Swan, et al. 2009). Dlx2 is required to inhibit Mash1 and Notch 
signaling to repress proliferation and initiate differentiation (Casarosa et al. 1999; Yun 
et al. 2002; Poitras et al. 2007; Long et al. 2009b). In addition, Dlx2 up-regulates Arx 
and suppresses Pax3 to induce migration of striatal neurons (Cobos et al. 2007; 
Colasante et al. 2008). These are supported further by Dlx2-/- mice, where both cortical 
interneurons and striatal matrix GABAergic neurons were decreased (Anderson 1997a; 
Anderson et al. 1997b). Another TF of importance in ventral telencephalon is MASH1. 
Its expressing cells are also located in the LGE and MGE (Fode et al. 2000). In the 
studies of mice lacking Mash1, there was a reduction in the expression of cortical 
interneurons. There was also a reduction in the expression of Foxp1, Darpp-32, and 
Calbindin, which are expressed in striatal neuronal progenitors, MSN and striatal matrix 
neurons respectively (Casarosa et al. 1999; Wang et al. 2009). The loss-of-function 
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model provides evidence of role of Mash1 in neurogenesis. A growing number of 
studies have revealed that Mash1 exhibits its function through Notch-dependent (in 
LGE) and independent (in MGE and septum) mechanisms (Horton et al. 1999; 
Casarosa et al. 1999; Yun et al. 2002).  
Together, the demonstrated roles of GSX2, DLX2 and MASH1 encourage use of 
these key TFs to direct stem cell programming in vitro. In fact, triple and double mutant 
mice model: MASH1;DLX1/2 and GSX2;MASH1, respectively, have further drawn the 
line of importance of these key TFs in striatal development (Wang and Steinbeisser 
2009; Long et al. 2009). Therefore, these Key TFs were selected to conduct the aims 
and objectives of this thesis.   
 
7.2 Ectopic expression of different combinations of MASH1, 
DLX2 and GSX2 in hPSCs induced direct programming 
of sequential LGE fate specification and eventual 
differentiation into mature MSNs. 
 
Ectopic expression of different combinations of DLX2, MASH1 and GSX2 in 
34D6 nrNPCs has been shown to induce direct LGE fate specification, the striatum 
primordium (Chapter 5). All combinations of TF nucleofected into 34D6 nrNPCs, with 
the exception of individual MASH1 or DLX2 constructs, reduced expression of PAX6 
from ND3 to ND42. In addition, different combinations of TF reduced the expression of 
MGE NKX2.1 from ND3 in all nucleofected 34D6 cells. In this study, the reduction of 
PAX6 and NKX2.1 excludes formation of MGE and dorsal neuronal phenotype, which 
is mediated by different combinations of DLX2, MASH1 and GSX2. The endogenous 
expression of these TFs were efficient to drive hPSC-derived nrNPCs into LGE 
neuronal phenotype. Determination of LGE phenotype mediated by DLX2, MASH1 and 
GSX2 has been explored in many studies. It has been reported that when the 
subpallium markers, such as Dlx2, Mash1 and Gsx2, were mutated within 
telencephalon, the pallium markers, such as Pax6, were increased and expanded into 
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LGE (Casarosa et al. 1999; Wilson and Rubenstein 2000; Yun et al. 2001; Yun et al. 
2003). In the Gsx2-/- study, a reduction in the striatal projection neurons, originating 
from LGE, and misspecification of ventral and dorsal LGE was observed (Yun et al. 
2001; Yun et al. 2003). In the Mash1-/- the differentiation of the early stages of LGE was 
obstructed (Casarosa et al. 1999). In the Dlx2-/-, the differentiation of subpallium was 
deficient (Wang et al. 2013), and the number of differentiations of late born LGE 
neurons was reduced (Anderson et al. 1997; Marin et al. 2000; Cobos et al. 2007). 
Also, in the mice lacking Dlx2, Nkx2.1 accumulated in the mutant MGE and expanded 
dorsally into the LGE region and PSB (Marin et al. 2000). These data, taken together 
with the findings of this study and the literature, confirm the importance of DLX2 and 
MASH1 co-expression or/and GSX2 in the development of LGE, and provide 
evidences of the function of these genes in the development of LGE within 
telencephalon.  
Based on the positive results reported in Chapter 5, further work was carried out 
to determine if the 34D6-derived LGE fate specific cells could differentiate further into 
mature MSN-like neurons. It was demonstrated that 34D6 nrNPCs expressing different 
combinations of TFs expressed the MSN marker DARPP-32 as well as the striatal 
MSN marker CTIP2. However, whole cell-patch clamp analysis showed that only the 
pCAGG-DLX2/MASH1 nucleofected cells were functional and mature MSNs as evident 
by electrophysiology. These outcomes indicate that ectopic expression of DLX2, 
MASH1 and GSX2 in 34D6 nrNPCs induced direct programming of differentiation into 
MSNs. However, in iPS34D6 cells, ectopic expression of DLX2 and MASH1 only was 
sufficient to direct differentiation to functional MSNs.  
DARPP-32 is the most commonly used marker for detection of terminally 
differentiated striatal GABAergic MSNs (Aubry et al. 2008). There are two destinations 
for striatal projection neurons, which are related to the embryonic stages. The early-
born neurons are destined to the patch compartment of striatum, which forms 15% of 
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striatum, while the mid-late neurons migrate to the matrix compartment of striatum, 
which forms 85% of striatum (Kooy and Fishell 1987). Consequently, the MSNs locate 
in the two striatum compartments and are combinations of early, mid and late born 
neurons. DARPP-32 is only expressed in the late born neurons. In this study a large 
percentage of pCAGG-DLX2/MASH1 nucleofected 34D6nrNPCs expressed DARPP-
32, and hence, it indicates the differentiation of late-born MSNs. In fact, DLX2 and 
MASH1 ectopic expression in 34D6-nrNPCs resulted in an increase of DARPP-32 from 
around 12% to 85% and CTIP2 from around 69% to 85%. In concordance, the 
association of DARP-32 expression and late-born neuron generation mediated by 
DLX2 and MASH1 was illustrated in many mice mutant models. In the mice lacking 
DLX2, the late-born striatal neurons accumulated in LGE, and the migration from LGE 
to the striatal MZ was obstructed and DARPP-32 was not expressed (Anderson et al. 
1997). Moreover, in mice lacking MASH1, the expression of DARPP-32 was reduced 
(Wang et al. 2009). Also, it was reported that ectopic co-expression of Dlx2 and Mash1 
differentiates a higher percentage of cortical astroglia cells into GABAergic neurons 
than sole ectopic expression of Dlx2 (Berninger, Costa, et al. 2007; Heinrich et al. 
2010). These findings indicate that DLX2 and MASH1 provide a greater regulator of 
genes related to late-born neuron production in the development of striatal MSNs. 
This project provides the first example of the use of ectopic delivery or 
expression of TFs (such as DLX2 and MASH1) in h-iPSCs to direct the reprogramming 
of terminal differentiation of functional MSNs expressing a variety of TFs markers for 
striatal GABAergic MSNs. Overexpression of MASH1 and DLX2 in 34D6 nrNPCs, 
generated GFP+ve / DARPP-32+ve / CTIP+ve / FOXP1+ve / EBF1+ve / DRD1&2+ve / GAD2+ve / 
CALBIN-1+ve MSNs. The direct differentiated MSNs, in this study, show dopaminergic 
markers (DRD1 and DRD2), GABAergic markers (GAD2 and CALBIN-1), LGE 
determinants (FOXP1, EBF1 and CTIP2) and terminal differentiation of striatal MSN 
(DARPP-32 and CTIP2) similar to those seen in developing human subpallium MSNs 
(Carri et al. 2013). In addition, co-expression of CTIP2 with the MSN marker DARPP-
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32 was observed both in this study and in vivo human studies (Carri et al. 2013). In the 
caudate nucleus, CTIP2 was co-expressed with the majority of MSN (95%) and was 
not co-expressed with other cell types (Arlotta et al. 2008; Carri et al. 2013). Co-
expression of DARPP-32 with CTIP2 in cells expressing both of MASH1 and DLX2 
suggests that ectopic co-expression of these two genes is able to drive neurons 
towards a striatal MSN type. Moreover, it was found that FOXP1 and FOXP2 were 
expressed in LGE of both an 11 week old human fetus (Carri et al. 2013) and 50-54 
days post fertilization and that FOXP1 and FOXP2 identified striatal progenitors and 
differentiated MSN (Pauly et al. 2013). FOXP2, EBF1 and CTIP2 were reported to be 
expressed in the LGE SVZ and MZ but not in the MGE (Long et al. 2009a) while 
reduced expression of Calbindin was seen in mice lacking MASH1 (Wang et al. 2009), 
and the expression of GAD67 and DRD2 were also reduced (Casarosa et al. 1999). 
These outcomes support the hypothesis underpinning this thesis and demonstrate the 
ability of DLX2 and MASH1 to promote the conversion of h-iPSCs into striatal MSN. 
Also, the role of DLX2 and MASH1 is linked to the development of striatal MSN, 
dopaminergic receptors of MSN and GABAergic MSN phenotypes, and hence DLX2 
and MASH1 together drive the LGE progenitors towards striatal GABAergic MSN 
marker.  
LGE precursor cells induced to differentiate into DARPP-32+ve MSN through both 
overexpression of GSX2 and DLX2 in H9 nrNPCs and overexpression of DLX2 alone 
or DLX2, GSX2 and MASH1 in 34D6 nrNPCs. However, the MSNs did not elicit action 
potentials, and hence they were generated immature MSNs. Also, the co-expression of 
GSX2 with DLX2 and/or MASH1 was not able to push the DARPP-32+ve MSN into 
mature neurons. The constrained action of GSX2 on maturity has no definite 
explanation. However, It has been reported that in the Gsx2-/- mutant striatum the 
expression of Darpp-32 was reduced, while the expression of Calbindin, the marker for 
mature matrix striatal MSNs, was increased (Wang et al. 2009). These data speculate 
that overexpression of GSX2 has a role in the development of MSNs but these are not 
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of mature phenotype. Meanwhile, the co-expression of DLX2 and MASH1 was able to 
generate mature, yet functional DARPP-32+ve MSN. Therefore, IWR-1 (GSX2) pre-
treatment of stem cells was used to generate normal expression of GSX2 in cell culture 
and then the cells were nucleofected with MASH1 and DLX2 construct to investigate 
the effect of external GSX2-mediated expression on MSN differentiation and the 
neuronal maturation. 
34D6 cultured with or without IWR-1 differentiated into MSNs. IWR-1 cultures in 
34D6 nrNPCs induced the expression of GSX2 in cell culture (unpublished data from 
the Allen lab). The 34D6 cells cultured with IWR-1 were more mature as evident by 
fired action potential than those cultured without IWR-1. However, the generation of 
functional MSN-like cells upon IWR-1 pre-treated 34D6 nrNPCs was merely for a short 
time at W3. This was supported by a sharp decrease of biomarkers at W6. This 
phenomenon could be as a result of cell toxicity or conflict in exogenously induced 
GSX2 expression with endogenous DLX2/MASH1 expression. Therefore, an extra 
work is required to understand what causes hindered development of long lasting 
MSNs in this model.  
Neuronal maturation in the nucleofected 34D6 nrNPCs with DLX2 and MASH1 
construct was investigated through assessment of functional properties by the whole 
cell patch clamp. Via use of ectopic expression of DLX2 and MASH1 to mature 34D6-
derived MSNs generated cells is able to fire action potentials and having a depolarized 
resting membrane potential (mean -46 mV at week 6). Furthermore, it was observed 
that 68.4, 100 and 87.5% of patched neurons show spontaneous generating of action 
potentials at week 3, 4 and 6 respectively in the nucleofected 34D6 with DLX2 and 
MASH1 plus treatment of 34D6 with IWR-1. Also, the resting potential membrane was -
46.5±1.0 mV, -49.2±2.7 mV and -52.3±3.5 mV at week 3, 4 and 6. It was shown that 
the hESC-derived MSNs by using SHH and DKK1 have -43±4.9 mV of resting 
membrane potential (Carri et al. 2013). These data suggest that the DLX2 and MASH1 
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construct, with or without IWR-1 in the culture, has the ability to generate mature MSNs 
that can produce an action potential. 
The successive steps in differentiating hPSCs that generate GABAergic neurons 
are efficiently regulated by the dual action of MASH1 and DLX2 applying the current 
protocol as evident by the expression of various biomarkers and electrophysiology.   
 
7.3 An alternative protocol was performed in this study 
compared with morphogen strategy 
 
Developmental cues, such as WNT and SHH, to differentiate hPSCs directly 
towards MSN were previously performed (Carri et al. 2013; Nicoleau et al. 2013; Ma et 
al. 2012). However, this strategy generates a mixture of cell types (Review in Soldner 
and Jaenisch 2012). According to previous papers (Carri et al. 2013; Nicoleau et al. 
2013; Ma et al. 2012), their protocol could generates a mixture of LGE and MGE 
specific progenitors which was carried out for terminally differentiated into MSNs. It 
was found that 200 ng/ml of SHH promoted LGE-like neurons (Carri et al. 2013). 
Meanwhile, in a paper published by Nicoleau et al. (2013), it was shown that 50 ng/ml 
of SHH in hPSCs promoted the LGE-like neurons that expressed GSX2+ve/NKX2.1-ve, 
and that the expression level of NKX2.1 was increased when 200 ng/ml of SHH was 
used in culture (Nicoleau et al. 2013). Therefore, a more-defined and efficient route for 
neuron differentiation into MSNs is required. The requirements of a protocol for the 
induction of uniformed disease-specific cell types in vitro, that can be used for iPSCs-
disease modeling and cell replacement therapy, are to produce and highly specific 
iPSC-disease-specific cell types with high efficiency.  
In this study, the strategy of direct reprogramming by ectopic expression of TF 
was used to introduce multiple candidate genes into hPSC-derived nrNPCs and to 
allow the selection and reproducibility of a disease-specific cell type (MSN). This 
protocol also generated PAX6-ve/DLX2+ve/MASH1+ve/NKX2.1-ve LGE-specific progenitors 
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that differentiated further into mature MSNs. This is in line with Pauly et al. (2013) 
finding showing that the LGE domains, in vivo, were DLX2+ve/NKX2.1-ve/ PAX6-ve, while 
the MGE domains were DLX2+ve/NKX2.1+ve. These data indicate that the direct 
differentiated MSNs, in this study, was well-defined and efficient.  
In 2014, a paper by Victor et al. 2014 was published using essentially the same 
protocol as in this study, but with slight differences in the cell line, type and the genes 
that were ectopically expressed. MicroRNA (mRNA)-9/9 and mRNA-124 were used for 
direct programming, as they have a role, during neural development, in an ATP-
dependent chromatin-remodeling regulation process that is essential for functional 
neuronal differentiation (Wu et al. 2009; Yoo et al. 2009; Staahl et al. 2013). As the 
neuronal progenitors exit cell cycle, migrate and differentiate, the process of chromatin-
remodeling is taking place where the neural precursor Brg/Brm-associated factor 
switches through a change in conformation to neuron specific Brg/Brm-associated 
factor. This process typically is driven by mRNA-9/9 and mRNA-124 (Staahl et al. 
2013). TFs MASH1, NEUROD2 and MYT1L (MNM), used in conjunction with mRNA-
9/9 and mRNA-142 (mRNA9/9-142) can direct differentiation into neurons (Yoo et al. 
2011). However, the outcome of this procedure was a mixture of inhibitory and 
excitatory neurons. Victor et al. (2014) used mRNA9/9-142 with TFs CTIP2, DLX1, 
DLX2 (CDM) and MYT1L to replace the TFs with brain enriched genes that 
characterised the MSN so as to promote mRNA9/9-142 to mediate the neuronal 
differentiation into more specific cell types such as striatal MSNs (Victor et al. 2014). 
This work directly reprogrammed MSNs from human postnatal cells by lentiviral 
transduction (Victor et al. 2014). The differentiated cells expressed 70% of DARPP-32 
in this case, whereas in our study, 85% of DARPP-32 and CTIP2 were expressed. In 
addition, it was found that when TFs MNM and CDM were expressed individually in 
human postnatal cells without the mRNA-9/9-142, the cells were not direct 
differentiated into neurons and were immuno-negative to MAP2 (Yoo et al. 2011; Victor 
et al. 2014). However, the reprogramming of hPSCs by TFs DLX2 and MASH1 has 
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been shown in this work to convert cells successfully into LGE-like neurons that then 
terminally differentiate to mature MSN. 
 
7.4 Limitation of study 
 
It is generally known that the efficiency of neuronal nucleofection with plasmids is 
poor. In this study, it was shown that the efficiency of expression of vector 
nucleofection into hPSC-derived nrNPCs before G418 selection was around 26% that 
was increased to around 80% after selection. While a lentiviral system has advantages, 
screening of multiple constructs by creating them as plasmids is more straightforward. 
Promising candidates emerging from this primary test can then be cloned further to 
create the lentiviral constructs that can increase efficiency of transduction. Thus, 
lentiviral transduction, as used by Victor et al. (2014) to differentiate human postnatal 
cells, can be used to obtain high yield, stable TF transduction into hPSCs-derived 
nrNPCs.  
 
7.5 Future work 
 
The successful development of a protocol to direct the differentiation of iPSCs 
into functionally mature MSNs opens new avenues for future research. Future work will 
include establishing a disease model for HD using the following methods. Skin 
fibroblasts from HD patients can be collected to generate stable iPSCs derived using 
established methods from Takahashi, Yamanaka and their colleagues, who used the 
retroviral introduction of ESC TFs, such as, OCT3/4, SOX2, KLF4 and c-MYC 
(Takahashi et al. 2007; Takahashi and Yamanaka 2006). Other options for generating 
HD patient-derived iPSCs involve using non-retroviral vectors such as polycistronic 
vectors (Sommer et al. 2009), piggyBac transposons (Woltjen et al. 2009), transient 
episomal delivery (Okita et al. 2008), RNA (Warren et al. 2010) and even protein 
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delivery (Kim et al. 2009). These HD patient-derived iPSCs can then be differentiated 
into neural progenitor cells to generate NSC that characterised by self-renewal and 
proliferation. Finally, these NSC can be differentiated into specific neuron types, such 
as mature MSNs, using the protocol described in this thesis, which is the ectopic 
expression of DLX2 and MASH1. Future successful generation of MSN-like cells from 
HD-patient specific iPSCs, that recapitulate the phenotype of HD neuropathology, can 
facilitate HD disease modeling in vitro to understand HD progression, cell replacement 
therapy for human medical trials and therapeutic drug screening (Figure 7.1). In 
addition, generating HD-iPSCs with different CAG repeat lengths is recommended as it 
was reported that HD cell lines with longer CAG repeats were most vulnerable to 
BDNF withdrawal and cellular stressors (Consortium 2012). 
In addition, the use of an isogenic genetically modified iPSCs model could be 
used to replace the mutated HTT gene with a healthy sequence gene using zinc finger-
mediated gene transfer or BAC-mediated homologous recombination. According to An 
et al. (2012), the BAC technique was used to correct the mutated HTT in iPSCs 
derived from an HD patient, and the characterisation of iPSCs were maintained (An et 
al. 2012). Therefore, this technique could be used to generate an isogenic control 
model from HD-iPSCs, and then this study protocol could be used to direct 
differentiation into MSNs. The generation of successful MSNs from genetically modified 
iPSCs would be used for HD disease modeling and hence for cell replacement therapy 
(Figure 7.1). 
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Over the last 4 years, there have been several studies that differentiated hPSCs 
into MSN-like cells and used these for cell replacement therapy in the rodent brain. 
However, functional studies, such as the motor and cognitive roles as well as 
electrophysiological connectivity, were not fully carried out. Consequently, functional 
effectiveness in further complex screening is required, such as the characterisation of 
motor and cognitive roles as well as electrophysiological connectivity in more detail. 
Examples of some tests for functional studies include: IntelliCage (Krackow et al. 
2010), Giant Analysis System that includes Trendmill and GaintScan software (Malone 
et al. 1998), Conditioned Place Preference (CPP) (Rosecrans et al. 2009) and 
Ultrasonic Vocalisation Analysis System (UVAS) (Branchi et al. 2001).  
 
7.6 Weakness and strength of the thesis 
 
7.6.1 Weakness of the thesis 
 
All combinations of TFs with the exception of MASH1 and GSX2 (pcagg-
MASH1/GSX2), and each TF alone apart from GSX2 (pCAGG-GSX2) were sub-cloned 
to the expression vector pCAGG. The overexpression of MASH1 and GSX2 in hPSCs, 
and their effects on MSN reprogramming should be investigated. It was shown that 
GSX2 (Méndez-Gómez and Vicario-Abejón 2012) and MASH1 (Fode et al. 2000) 
antagonize cortical fates, and they are both essential in determining the genetic 
network for the development of post mitotic MSNs, since cells migrate and differentiate 
in the MZ. In addition, overexpression of GSX2 in hPSCs and its role in gene 
expression of dorso-ventral markers, especially the ventral markers such as DLX2 and 
MASH1, in comparison with other expression vectors such as pCAGG-DLX2, pCAGG-
MASH1, pCAGG-DLX2/MASH1, PCAGG-DLX2/GSX2 and pCAGG-
DLX2/MASH1/GSX2 should be considered since the expression of ventral markers 
was up-regulated by GSX2. However, the sub-cloning of GSX2 in pCAGG-MASH1 to 
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construct (pCAGG-MASH1/GSX2), or in pCAGG to construct (pCAGG-GSX2) was not 
finished on time. 
 
7.6.2 Strength of the thesis 
 
One of the strengths of this thesis is the use of hPSCs to differentiate into MSNs. 
The protocol achieved in this study will enable differentiation of HD-patient specific 
iPSCs into MSN. Generate of an HD-iPSCs disease model would lead to an improved 
understanding of the pathophysiology of HD. 
Two cell lines were used for direct differentiation into MSNs: hESCs (H9) and h-
iPSCs (34D6). Consequently, in this study it has been shown that the strategy for direct 
reprogramming of MSN by ectopic expression is effective in two different cell lines. The 
resulting hPS-derived MSNs are abundant, express the profile of several striatal 
GABAergic markers and most notably are able to generate spontaneous action 
potentials. Consequently the strategy used in this study has the potential to be 
transferred to HD-patient specific iPSCs and to produce diseased MSNs in vitro. 
 
In conclusion, this study provides the first example of ectopic expression of TFs 
(such as DLX2 and MASH1) in h-iPSCs to direct their differentiation into MSN-like 
cells. Overexpression of MASH1 and DLX2 in h-iPSCs-derived nrNPCs promoted 
generation of fully differentiated MSN that expresses FOXP2/EBF1/CTIP2/DARPP-
32/DRD1&2/GAD2 and CALBIN-1. These MSN can be used for HD-modeling to 
understand the mechanisms of neurodegeneration in human HD, facilitate the 
development of a potential cell-based therapy and aid in therapeutic drug screening. 
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2.1 Table show
s the dysregulated genes betw
een C
tip2
-/- hom
ozygous, C
tip2
-/+ heterozygous and w
ild-type: 
  
Probe set ID
 
p-value 
R
egulation 
FC
A
bsolute 
Fold change 
Log Fold change 
G
ene sym
bol 
1422860_at 
8.11E
-05 
up 
5.52421 
5.52421 
2.465768 
N
ts 
1425699_a_at 
9.05E
-05 
up 
3.433145 
3.433145 
1.7795308 
A
bhd14a 
1448293_at 
9.13E
-05 
up 
2.6417077 
2.6417077 
1.4014708 
E
bf1 
1417605_s_at 
9.20E
-05 
up 
5.183407 
5.183407 
2.3739007 
C
am
k1 
1424092_at 
9.41E
-05 
up 
10.151953 
10.151953 
3.3436854 
E
pb4.1 
1435311_s_at 
9.49E
-05 
up 
2.457243 
2.457243 
1.2970405 
 
1455469_at 
9.60E
-05 
up 
5.0760446 
5.0760446 
2.3437047 
S
lc6a7 
1438228_at 
1.03E
-04 
up 
2.405829 
2.405829 
1.2665341 
4930452B
06R
ik 
1456512_at 
1.04E
-04 
up 
3.8267944 
3.8267944 
1.9361364 
P
dzrn4 
1421679_a_at 
1.04E
-04 
up 
18.726233 
18.726233 
4.226989 
C
dkn1a 
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1460617_s_at 
1.08E
-04 
up 
1.6370419 
1.6370419 
0.7110913 
R
ab6b 
1456005_a_at 
1.09E
-04 
up 
7.3031363 
7.3031363 
2.8685162 
B
cl2l11 
1416361_a_at 
1.10E
-04 
up 
2.9430172 
2.9430172 
1.5572959 
D
ync1i1 
1428213_at 
1.13E
-04 
up 
1.5718087 
1.5718087 
0.65242565 
N
sm
ce4a 
1455064_at 
1.20E
-04 
up 
1.879241 
1.879241 
0.91015005 
R
ab36 
1440209_at 
1.27E
-04 
up 
5.260762 
5.260762 
2.3952718 
M
ar-01 
1454656_at 
1.28E
-04 
up 
1.7252355 
1.7252355 
0.7867933 
S
pata13 
1427122_at 
1.30E
-04 
up 
4.2831583 
4.2831583 
2.098675 
C
opg2as2 
1416561_at 
1.31E
-04 
up 
2.265817 
2.265817 
1.1800313 
G
ad1 
1430526_a_at 
1.38E
-04 
up 
1.7694229 
1.7694229 
0.8232789 
S
m
arca2 
1442379_at 
1.39E
-04 
up 
3.3677416 
3.3677416 
1.7517815 
E
G
574403 
1423495_at 
1.43E
-04 
up 
2.2837672 
2.2837672 
1.1914155 
D
ecr2 
1435486_at 
1.48E
-04 
up 
5.3985577 
5.3985577 
2.432574 
P
ak3 
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1421990_at 
1.65E
-04 
up 
1.8222594 
1.8222594 
0.8657284 
S
yt1 
1428136_at 
1.73E
-04 
up 
2.47847 
2.47847 
1.3094498 
S
frp1 
1438454_at 
1.75E
-04 
up 
3.063769 
3.063769 
1.6153076 
B
430203M
17R
ik 
1426929_at 
1.76E
-04 
up 
2.3975563 
2.3975563 
1.2615647 
B
runol4 
1441598_at 
1.85E
-04 
up 
1.6369637 
1.6369637 
0.7110223 
Tm
eff2 
1459861_s_at 
1.85E
-04 
up 
1.7437768 
1.7437768 
0.8022154 
K
dm
2b  
1456137_at 
1.89E
-04 
up 
3.8626266 
3.8626266 
1.9495822 
N
rxn3 
1416840_at 
2.01E
-04 
up 
2.1153219 
2.1153219 
1.0808772 
M
id1ip1 
1435404_at 
2.03E
-04 
up 
2.8292687 
2.8292687 
1.5004292 
D
isp2 
1454900_s_at 
2.10E
-04 
up 
1.3680533 
1.3680533 
0.45212445 
M
ycbp2 
1458842_at 
2.22E
-04 
up 
3.2285945 
3.2285945 
1.6909063 
O
dz1 
1421118_a_at 
2.31E
-04 
up 
2.002576 
2.002576 
1.001857 
G
pr56 
1442873_at 
2.32E
-04 
up 
25.567024 
25.567024 
4.6762123 
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1455298_at 
2.34E
-04 
up 
3.936704 
3.936704 
1.9769882 
 
1454672_at 
2.40E
-04 
up 
6.487682 
6.487682 
2.6977031 
 
1450051_at 
2.43E
-04 
up 
1.5632838 
1.5632838 
0.6445797 
A
trx 
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ak3 
1447139_at 
2.51E
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2.7812095 
2.7812095 
1.4757124 
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cl7c 
1430668_a_at 
2.52E
-04 
up 
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1.5340186 
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2.7305598 
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l 
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up 
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B
cl11a 
1438957_x_at 
2.78E
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up 
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C
ds2 
1451458_at 
2.83E
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up 
2.4060595 
2.4060595 
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Tm
em
2 
1416896_at 
2.84E
-04 
up 
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4.676809 
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2.85E
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2.0293076 
1.0209875 
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1458499_at 
1.25E
-04 
dow
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2.3589375 
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-1.2381371 
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de10a 
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A
rhgdib 
1423803_s_at 
1.97E
-04 
dow
n 
1.5766994 
-1.5766994 
-0.6569076 
G
ltscr2 
1419389_at 
2.02E
-04 
dow
n 
3.8294756 
-3.8294756 
-1.9371468 
P
de10a 
1416185_a_at 
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-0.4713381 
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P
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-1.9322833 
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Tom
m
7 
1448978_at 
2.61E
-04 
dow
n 
3.3793082 
-3.3793082 
-1.7567279 
N
gef 
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2.67E
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n 
1.4174502 
-1.4174502 
-0.50329804 
H
dhd2 
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2.71E
-04 
dow
n 
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-1.6305734 
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C
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2.87E
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n 
1.4123412 
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-0.4980887 
 N
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2.2 Table of the target genes that found to play fundamental roles in the 
development of forebrain and striatal medium spiny neuron fate: 
 
Gene Name Process 
achaete-scute complex homolog 1 (Drosophila)  
Neurogenesis. adhesion molecule with Ig like domain 1 
basic leucine zipper and W2 domains 2 
calcium/calmodulin-dependent protein kinase I 
cell adhesion molecule with homology to L1CAM 
dedicator of cytokinesis 7 
disabled homolog 1 (Drosophila) 
Doublecortin 
doublecortin-like kinase 1 
drebrin 1 
ELAV (embryonic lethal, abnormal vision, Drosophila)-like 3 (Hu 
antigen C) 
enabled homolog (Drosophila) 
ephrin B2 
ephrin B3 
G-protein signalling modulator 1 (AGS3-like, C. elegans) 
Gene Name 
growth arrest specific 7 
hairy and enhancer of split 5 (Drosophila) 
kinesin family member 2A 
L1 cell adhesion molecule 
LIM homeobox protein 6 
myelin transcription factor 1-like 
myocyte enhancer factor 2C 
myocyte enhancer factor 2D 
neurogenic differentiation 1; neurogenic differentiation 5 
neurogenic differentiation 2 
neuron navigator 1 
neuronal guanine nucleotide exchange factor 
neuropilin 1 
orthopedia homolog (Drosophila) 
PHD finger protein 10 
platelet-activating factor acetylhydrolase, isoform 1b, subunit 1 
roundabout homolog 1 (Drosophila) 
RUN and FYVE domain containing 3 
slit homolog 2 (Drosophila) 
spastin 
SRY-box containing gene 11 
achaete-scute complex homolog 1 (Drosophila)  
Activator transcription factor. activating transcription factor 2 
activating transcription factor 5 
activating transcription factor 7 interacting protein 
AF4/FMR2 family, member 3 
ataxin 7-like 3 
bromodomain and WD repeat domain containing 1 
BTB and CNC homology 2 
calmodulin binding transcription activator 1 
cAMP responsive element binding protein 3-like 1 
Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-
terminal domain, 4 
chromodomain helicase DNA binding protein 8 
churchill domain containing 1 
circadian locomoter output cycles kaput 
cone-rod homeobox containing gene 
CREB binding protein 
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cysteine-serine-rich nuclear protein 3 
D site albumin promoter binding protein 
dachshund 1 (Drosophila) 
DEAH (Asp-Glu-Ala-His) box polypeptide 9 
delta/notch-like EGF-related receptor 
DNA methyltransferase (cytosine-5) 1 
E2F transcription factor 1 
E74-like factor 2 
early B-cell factor 1 
endothelial PAS domain protein 1 
enhancer of yellow 2 homolog (Drosophila) 
ets variant gene 1 
eyes absent 2 homolog (Drosophila) 
family with sequence similarity 120, member B 
forkhead box D3 
forkhead box F2 
forkhead box H1 
forkhead box K1 
Friend leukemia integration 1 
heterogeneous nuclear ribonucleoprotein D-like 
IKAROS family zinc finger 2 
interferon activated gene 204 
interferon regulatory factor 3 
interleukin enhancer binding factor 2 
Kruppel-like factor 1 (erythroid) 
Kruppel-like factor 11 
Kruppel-like factor 17 
Kruppel-like factor 3 (basic) 
Kruppel-like factor 5 
Kruppel-like factor 6 
Kruppel-like factor 7 (ubiquitous) 
LIM domain containing preferred translocation partner in lipoma 
LIM homeobox protein 3 
mediator complex subunit 1 
mediator complex subunit 13 
mediator complex subunit 13-like 
mediator complex subunit 15 
mediator of RNA polymerase II transcription, subunit 11 homolog 
(S. cerevisiae) 
mediator of RNA polymerase II transcription, subunit 12 homolog 
(yeast)-like 
mediator of RNA polymerase II transcription, subunit 25 homolog 
(yeast) 
mediator of RNA polymerase II transcription, subunit 28 homolog 
(yeast) 
mediator of RNA polymerase II transcription, subunit 8 homolog 
(yeast) 
mediator of RNA polymerase II transcription, subunit 9 homolog 
(yeast) 
Meis homeobox 1 
membrane-bound transcription factor peptidase, site 2 
microphthalmia-associated transcription factor 
MYB binding protein (P160) 1a 
myeloblastosis oncogene-like 1 
myocyte enhancer factor 2C 
myocyte enhancer factor 2D 
MYST histone acetyltransferase monocytic leukemia 4 
N-acetyltransferase 14 
nascent polypeptide-associated complex alpha polypeptide 
neurogenic differentiation 1; neurogenic differentiation 5 
nuclear factor I/A 
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nuclear factor I/B 
nuclear factor of activated T-cells 5 
nuclear factor of activated T-cells, cytoplasmic, calcineurin-
dependent 2 
nuclear protein in the AT region 
nuclear receptor subfamily 2, group E, member 1 
nuclear receptor subfamily 5, group A, member 1 
nuclear respiratory factor 1 
nuclear transcription factor-Y alpha 
one cut domain, family member 2 
paraspeckle protein 1 
peroxisome proliferator activated receptor gamma 
POU domain, class 2, transcription factor 1 
POU domain, class 3, transcription factor 2 
pre B-cell leukemia transcription factor 1 
pre B-cell leukemia transcription factor 2 
RAR-related orphan receptor alpha 
ras responsive element binding protein 1 
recombination signal binding protein for immunoglobulin kappa J 
region 
regulatory factor X, 4 (influences HLA class II expression) 
RNA binding motif protein 39 
SET domain containing 1B 
Sp7 transcription factor 7 
Spi-B transcription factor (Spi-1/PU.1 related) 
splicing factor proline/glutamine rich  
SRY-box containing gene 19; SRY-box containing gene 4 
SRY-box containing gene 2 
SRY-box containing gene 6 
steroid receptor RNA activator 1 
sterol regulatory element binding transcription factor 1 
SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily a, member 1 
SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily a, member 2 
thyrotroph embryonic factor 
trans-acting transcription factor 1 
trans-acting transcription factor 3 
transcription factor 4 
transducin (beta)-like 1 X-linked 
transformation related protein 53 binding protein 1 
transformation/transcription domain-associated protein 
ubiquitin specific peptidase 49 
v-maf musculoaponeurotic fibrosarcoma oncogene family, protein 
B (avian) 
YY1 transcription factor 
zinc finger homeobox 3 
zinc finger protein 143 
zinc finger protein 326 
zinc finger protein 410 
zinc finger protein 521 
zinc finger protein, autosomal 
ZXD family zinc finger C 
 
AE binding protein 2  
Transcriptional repressor. B-cell CLL/lymphoma 11A (zinc finger protein) 
B-cell leukemia/lymphoma 11B 
BTB and CNC homology 2 
C-terminal binding protein 2 
CUG triplet repeat, RNA binding protein 2 
DNA methyltransferase (cytosine-5) 1 
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DNA methyltransferase 3A 
E4F transcription factor 1 
Ets2 repressor factor 
GATA-like 1 
Kruppel-like factor 11 
Kruppel-like factor 12 
Kruppel-like factor 17 
Kruppel-like factor 3 (basic); similar to BKLF 
Kv channel interacting protein 3, calsenilin 
MAF1 homolog (S. cerevisiae) 
MYB binding protein (P160) 1a 
MYST histone acetyltransferase monocytic leukemia 4 
Max dimerization protein 3 
Max interacting protein 1 
NF-kappaB repressing factor 
PHD finger protein 21A 
SAP30-like 
SET domain containing (lysine methyltransferase) 8; predicted 
gene 8590 
Sin3A associated protein 
TGFB-induced factor homeobox 1 
TSC22 domain family, member 1 
WT1-interacting protein 
YY1 transcription factor 
acidic (leucine-rich) nuclear phosphoprotein 32 family, member A 
activating transcription factor 7 interacting protein 
additional sex combs like 1 (Drosophila) 
additional sex combs like 3 (Drosophila) 
amine oxidase, flavin containing 1 
arginine glutamic acid dipeptide (RE) repeats 
chromobox homolog 4 (Drosophila Pc class) 
chromobox homolog 6; neuronal pentraxin receptor; Cbx6-Nptxr 
readthrough transcripts 
chromodomain helicase DNA binding protein 8 
cofactor of BRCA1 
cold shock domain protein A 
core-binding factor, runt domain, alpha subunit 2, translocated to, 
3 (human) 
cryptochrome 1 (photolyase-like) 
dachshund 1 (Drosophila) 
forkhead box D3 
forkhead box K1 
forkhead box P1 
forkhead box P2 
forkhead box P4 
hairy and enhancer of split 5 (Drosophila) 
hairy/enhancer-of-split related with YRPW motif 1 
heterogeneous nuclear ribonucleoprotein A/B 
heterogeneous nuclear ribonucleoprotein D-like 
histone deacetylase 11 
histone deacetylase 8 
homeobox, msh-like 1 
hypothetical protein LOC100046298; akirin 2 
interferon activated gene 204 
lysine (K)-specific demethylase 2B 
mediator complex subunit 13 
mediator complex subunit 13-like 
mediator of RNA polymerase II transcription, subunit 12 homolog 
(yeast)-like 
membrane-bound transcription factor peptidase, site 2; similar to 
zinc finger, X-linked, duplicated B; Yy2 transcription factor 
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mesoderm induction early response 1, family member 2 
methyl CpG binding protein 2 
myelin basic protein expression factor 2, repressor 
nuclear receptor co-repressor 1 
nuclear receptor co-repressor 2 
nuclear receptor coactivator 5 
nuclear receptor interacting protein 1 
nuclear receptor subfamily 1, group D, member 2; predicted gene 
5827 
nuclear receptor subfamily 2, group E, member 1 
nuclear receptor subfamily 5, group A, member 1 
paired box gene 4 
polycomb group ring finger 3 
predicted gene 13886; TAR DNA binding protein 
predicted gene 14457; predicted gene 14503; zinc finger protein 
161; predicted gene 14509 
prohibitin 2 
proliferation-associated 2G4; predicted gene 5297 
ras responsive element binding protein 1 
recombination signal binding protein for immunoglobulin kappa J 
region 
retinoblastoma 1 
retinoblastoma binding protein 7; predicted gene 6382 
ring finger protein 2 
scaffold attachment factor B2 
similar to MBD2 (methyl-CpG-binding protein)-interacting zinc 
finger protein; similar to MBD2-interacting zinc finger; histone H4 
transcription factor 
similar to NFkB interacting protein 1; protein phosphatase 1, 
regulatory (inhibitor) subunit 13 like 
similar to c-Maf long form; avian musculoaponeurotic fibrosarcoma 
(v-maf) AS42 oncogene homolog 
similar to transcriptional regulator protein; SAP30 binding protein 
sin3 associated polypeptide 
special AT-rich sequence binding protein 1 
splicing factor proline/glutamine rich (polypyrimidine tract binding 
protein associated); similar to PTB-associated splicing factor 
suppression of tumorigenicity 18 
suppressor of variegation 4-20 homolog 2 (Drosophila) 
trans-acting transcription factor 1 
transcription elongation regulator 1 (CA150) 
transcriptional regulator, SIN3B (yeast) 
transducin-like enhancer of split 1, homolog of Drosophila E(spl) 
transducin-like enhancer of split 3, homolog of Drosophila E(spl) 
tripartite motif-containing 24 
tripartite motif-containing 27 
v-maf musculoaponeurotic fibrosarcoma oncogene family, protein 
B (avian) 
zinc finger protein 148 
zinc finger protein 318 
zinc finger protein 503 
zinc finger protein 521 
zinc finger protein 639 
zinc finger, MYND domain containing 11 
zinc fingers and homeoboxes 3 
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B-cell leukemia/lymphoma 11B  
Neuron development. Eph receptor A4 
Eph receptor A7 
Eph receptor B2 
FIG4 homolog (S. cerevisiae) 
Kruppel-like factor 7 (ubiquitous) 
L1 cell adhesion molecule 
LIM homeobox protein 2 
LIM homeobox protein 3 
LIM homeobox protein 6 
MYC binding protein 2 
POU domain, class 4, transcription factor 3 
RAS protein-specific guanine nucleotide-releasing factor 1 
RAS-related C3 botulinum substrate 1 
RAS-related C3 botulinum substrate 3 
SLIT and NTRK-like family, member 4 
Unc-51 like kinase 2 (C. elegans) 
achaete-scute complex homolog 1 (Drosophila) 
activated leukocyte cell adhesion molecule 
adenosine A2a receptor 
adhesion molecule with Ig like domain 1 
amyloid beta (A4) precursor protein-binding, family B, member 2 
ankyrin 3, epithelial 
autophagy-related 7 (yeast); similar to AGP7 
biregional cell adhesion molecule-related/down-regulated by 
oncogenes (Cdon) binding protein 
cadherin 23 (otocadherin) 
cadherin 4 
calcium channel, voltage-dependent, P/Q type, alpha 1A subunit 
cell adhesion molecule with homology to L1CAM 
chemokine (C-X-C motif) ligand 12 
crumbs homolog 1 (Drosophila) 
deleted in colorectal carcinoma 
dihydropyrimidinase-like 5 
distal-less homeobox 5 
dopamine receptor D1A 
doublecortin 
doublecortin-like kinase 1 
dystonin; hypothetical protein LOC100047109 
enabled homolog (Drosophila) 
ephrin B3 
ets variant gene 1 
glutamate receptor ionotropic, NMDA3A 
growth arrest specific 1 
growth arrest specific 7 
guanine nucleotide binding protein, alpha q polypeptide 
guanine nucleotide binding protein, alpha transducing 1 
huntingtin 
kelch-like 1 (Drosophila) 
kinesin family member 5C 
leukemia inhibitory factor 
leukocyte specific transcript 1 
methyl CpG binding protein 2 
microtubule-associated protein 1B 
microtubule-associated protein 1S 
microtubule-associated protein 2 
myocardial infarction associated transcript (non-protein coding) 
netrin 3 
neurofilament, light polypeptide 
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ATP/GTP binding protein 1  
Neuron differentiation.  B-cell leukemia/lymphoma 11B 
BCL2-associated athanogene 1 
Eph receptor A4 
Eph receptor A7 
Eph receptor B2 
FIG4 homolog (S. cerevisiae) 
Kruppel-like factor 7 (ubiquitous) 
L1 cell adhesion molecule 
LIM domain binding 1 
LIM homeobox protein 2 
LIM homeobox protein 3 
LIM homeobox protein 6 
MYC binding protein 2 
POU domain, class 3, transcription factor 2 
POU domain, class 3, transcription factor 4 
POU domain, class 4, transcription factor 3 
RAR-related orphan receptor alpha 
RAS protein-specific guanine nucleotide-releasing factor 1 
neurogenic differentiation 2 
neuron-glia-CAM-related cell adhesion molecule 
neuropilin 1 
neurotrophin 3 
neurturin 
nuclear receptor subfamily 2, group E, member 1 
numb-like 
one cut domain, family member 2 
paired box gene 6 
phosphatase and tensin homolog 
plexin A3 
predicted gene 8566; superoxide dismutase 1, soluble; similar to 
Superoxide dismutase 
protein kinase C, iota 
protein kinase, cGMP-dependent, type I 
protein tyrosine phosphatase, receptor type Z, polypeptide 1 
reelin 
reticulon 4 receptor-like 1 
ribosomal protein L24; predicted gene 9385; predicted gene 7380 
roundabout homolog 1 (Drosophila) 
runt related transcription factor 1 
sema domain, seven thrombospondin repeats (type 1 and type 1-
like), transmembrane domain (TM) and short cytoplasmic domain, 
(semaphorin) 5A 
similar to Ena-VASP-like; Ena-vasodilator stimulated 
phosphoprotein 
similar to PBX3a; pre B-cell leukemia transcription factor 3 
similar to RIKEN cDNA 2610109H07 gene; RIKEN cDNA 
2610109H07 gene 
similar to clusterin; clusterin 
slit homolog 2 (Drosophila) 
sodium channel and clathrin linker 1 
superoxide dismutase 2, mitochondrial 
taurine upregulated gene 1 
thymus cell antigen 1, theta 
topoisomerase (DNA) II beta 
tyrosine hydroxylase 
v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, 
neuro/glioblastoma derived oncogene homolog (avian) 
ventral anterior homeobox containing gene 2 
wingless-related MMTV integration site 3A 
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RAS-related C3 botulinum substrate 1 
RAS-related C3 botulinum substrate 3 
SLIT and NTRK-like family, member 4 
SRY-box containing gene 2 
SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily a, member 1 
Unc-51 like kinase 2 (C. elegans) 
achaete-scute complex homolog 1 (Drosophila) 
activated leukocyte cell adhesion molecule 
activator of basal transcription 1 
adenosine A2a receptor 
adhesion molecule with Ig like domain 1 
amyloid beta (A4) precursor protein-binding, family B, member 2 
ankyrin 3, epithelial 
autophagy-related 7 (yeast); similar to AGP7 
biregional cell adhesion molecule-related/down-regulated by 
oncogenes (Cdon) binding protein 
cadherin 23 (otocadherin) 
cadherin 4 
calcium channel, voltage-dependent, P/Q type, alpha 1A subunit 
cell adhesion molecule with homology to L1CAM 
cell division cycle 42 homolog (S. cerevisiae); predicted gene 
7407 
ceroid-lipofuscinosis, neuronal 8 
chemokine (C-X-C motif) ligand 12 
crumbs homolog 1 (Drosophila) 
deleted in colorectal carcinoma 
delta-like 1 (Drosophila) 
dihydropyrimidinase-like 5 
distal-less homeobox 1 
distal-less homeobox 2 
distal-less homeobox 5 
dopamine receptor D1A 
doublecortin 
doublecortin-like kinase 1 
dystonin; hypothetical protein LOC100047109 
enabled homolog (Drosophila) 
ephrin B3 
ets variant gene 1 
glutamate receptor ionotropic, NMDA3A 
growth arrest specific 1 
growth arrest specific 7 
guanine nucleotide binding protein, alpha q polypeptide 
guanine nucleotide binding protein, alpha transducing 1 
hairy and enhancer of split 5 (Drosophila) 
huntingtin 
inhibitor of DNA binding 4 
kelch-like 1 (Drosophila) 
kinase non-catalytic C-lobe domain (KIND) containing 1 
kinesin family member 5C 
leukemia inhibitory factor 
leukocyte specific transcript 1 
methyl CpG binding protein 2 
microtubule-associated protein 1B 
microtubule-associated protein 1S 
microtubule-associated protein 2 
myocardial infarction associated transcript (non-protein coding) 
myotrophin 
netrin 3 
neurofilament, light polypeptide 
neurogenic differentiation 2 
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neuron-glia-CAM-related cell adhesion molecule 
neuropilin 1 
neurotrophin 3 
neurotrophin 5 
neurturin 
nuclear receptor subfamily 2, group E, member 1 
numb-like 
one cut domain, family member 2 
orthopedia homolog (Drosophila) 
paired box gene 6 
phosphatase and tensin homolog 
plexin A3 
predicted gene 8566; superoxide dismutase 1, soluble; similar to 
Superoxide dismutase 
proprotein convertase subtilisin/kexin type 9 
protein kinase C, iota 
protein kinase, cGMP-dependent, type I 
protein tyrosine phosphatase, receptor type Z, polypeptide 1 
recombination signal binding protein for immunoglobulin kappa J 
region 
reelin 
reticulon 4 receptor-like 1 
ribosomal protein L24; predicted gene 9385; predicted gene 7380 
roundabout homolog 1 (Drosophila) 
runt related transcription factor 1 
sema domain, seven thrombospondin repeats (type 1 and type 1-
like), transmembrane domain (TM) and short cytoplasmic domain, 
(semaphorin) 5A 
similar to Ena-VASP-like; Ena-vasodilator stimulated 
phosphoprotein 
similar to PBX3a; pre B-cell leukemia transcription factor 3 
similar to RIKEN cDNA 2610109H07 gene; RIKEN cDNA 
2610109H07 gene 
similar to Stat3B; signal transducer and activator of transcription 3 
similar to clusterin; clusterin 
slit homolog 2 (Drosophila) 
sodium channel and clathrin linker 1 
superoxide dismutase 2, mitochondrial 
taurine upregulated gene 1 
thymus cell antigen 1, theta 
topoisomerase (DNA) II beta 
transforming growth factor, beta receptor I 
tubby-like protein 3 
tyrosine hydroxylase 
v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, 
neuro/glioblastoma derived oncogene homolog (avian) 
ventral anterior homeobox containing gene 2 
wingless-related MMTV integration site 3A 
 
LIM homeobox protein 6  
Generation of neuron in 
forebrain.  
POU domain, class 3, transcription factor 4 
SRY-box containing gene 2 
asp (abnormal spindle)-like, microcephaly associated (Drosophila) 
autophagy-related 7 (yeast); similar to AGP7 
distal-less homeobox 1 
distal-less homeobox 2 
guanine nucleotide binding protein, alpha q polypeptide 
orthopedia homolog (Drosophila) 
paired box gene 6 
plexin A3 
wingless-related MMTV integration site 3A 
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LIM homeobox protein 6  
Forebrain in neuron 
differentiation. 
POU domain, class 3, transcription factor 4 
SRY-box containing gene 2 
autophagy-related 7 (yeast); similar to AGP7 
distal-less homeobox 1 
distal-less homeobox 2 
guanine nucleotide binding protein, alpha q polypeptide 
orthopedia homolog (Drosophila) 
paired box gene 6 
plexin A3 
E2F transcription factor 1  
Forebrain development. LIM homeobox protein 2 
LIM homeobox protein 3 
LIM homeobox protein 6 
N-deacetylase/N-sulfotransferase (heparan glucosaminyl) 1 
POU domain, class 3, transcription factor 2 
POU domain, class 3, transcription factor 4 
RAS-related C3 botulinum substrate 1 
SRY-box containing gene 2 
SRY-box containing gene 3 
achaete-scute complex homolog 1 (Drosophila) 
aldehyde dehydrogenase family 1, subfamily A3 
alpha thalassemia/mental retardation syndrome X-linked homolog 
(human) 
amyloid beta (A4) precursor-like protein 1 
apoptotic peptidase activating factor 1 
asp (abnormal spindle)-like, microcephaly associated (Drosophila) 
autophagy-related 7 (yeast); similar to AGP7 
bone morphogenetic protein receptor, type 1A 
centrosomal protein 120 
chordin 
deleted in liver cancer 1 
disabled homolog 1 (Drosophila) 
distal-less homeobox 1 
distal-less homeobox 2 
dopamine receptor D1A 
doublecortin-like kinase 1 
fibroblast growth factor receptor substrate 2 
forkhead box P2 
guanine nucleotide binding protein, alpha q polypeptide 
homeobox, msh-like 1 
huntingtin 
inhibitor of DNA binding 4 
neurofibromatosis 1 
nuclear factor I/B 
nuclear receptor co-repressor 1 
nuclear receptor co-repressor 2 
nuclear receptor subfamily 2, group E, member 1 
numb-like 
orthopedia homolog (Drosophila) 
paired box gene 6 
platelet-activating factor acetylhydrolase, isoform 1b, subunit 1 
plexin A3 
protein kinase, cGMP-dependent, type I 
recombination signal binding protein for immunoglobulin kappa J 
region 
reelin 
regulatory factor X, 4 (influences HLA class II expression) 
similar to RIKEN cDNA 2610109H07 gene; RIKEN cDNA 
2610109H07 gene 
sine oculis-related homeobox 3 homolog (Drosophila) 
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topoisomerase (DNA) II beta 
wingless-related MMTV integration site 3A 
LIM homeobox protein 2  
Telencephalon development. LIM homeobox protein 6 
POU domain, class 3, transcription factor 2 
RAS-related C3 botulinum substrate 1 
SRY-box containing gene 2 
achaete-scute complex homolog 1 (Drosophila) 
aldehyde dehydrogenase family 1, subfamily A3 
autophagy-related 7 (yeast); similar to AGP7  
centrosomal protein 120 
disabled homolog 1 (Drosophila) 
distal-less homeobox 1 
distal-less homeobox 2 
dopamine receptor D1A 
forkhead box P2 
huntingtin 
inhibitor of DNA binding 4 
neurofibromatosis 1 
nuclear receptor co-repressor 2 
nuclear receptor subfamily 2, group E, member 1 
paired box gene 6 
platelet-activating factor acetylhydrolase, isoform 1b, subunit 1 
plexin A3 
reelin 
sine oculis-related homeobox 3 homolog (Drosophila) 
wingless-related MMTV integration site 3A 
Eph receptor B2  
Regulation of neurogenesis. Meis homeobox 1 
POU domain, class 3, transcription factor 2 
SRY-box containing gene 2 
TGFB-induced factor homeobox 1 
Unc-51 like kinase 2 (C. elegans) 
X-ray repair complementing defective repair in Chinese hamster 
cells 6 
achaete-scute complex homolog 1 (Drosophila) 
adhesion molecule with Ig like domain 1 
asp (abnormal spindle)-like, microcephaly associated (Drosophila) 
bone morphogenetic protein receptor, type 1A 
cadherin 4 
calcium channel, voltage-dependent, P/Q type, alpha 1A subunit 
cone-rod homeobox containing gene 
delta-like 1 (Drosophila) 
distal-less homeobox 1 
distal-less homeobox 2 
hairy and enhancer of split 5 (Drosophila) 
homeo box D3 
hypothetical protein LOC100044170; X-ray repair complementing 
defective repair in Chinese hamster cells 4 
inhibitor of DNA binding 4 
kinase non-catalytic C-lobe domain (KIND) containing 1 
leucine rich repeat containing 4C 
microtubule-associated protein tau 
neurofibromatosis 1 
neurofilament, light polypeptide 
neurofilament, medium polypeptide 
neuroligin 1 
neuropilin 1 
neurotrophin 3 
nuclear receptor subfamily 2, group E, member 1 
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orthopedia homolog (Drosophila) 
paired box gene 6 
plexin A3 
pre B-cell leukemia transcription factor 1; region containing RIKEN 
cDNA 2310056B04 gene; pre B-cell leukemia transcription factor 1 
steroidogenic acute regulatory protein 
tetratricopeptide repeat domain 3 
thymus cell antigen 1, theta 
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase 
activation protein, eta polypeptide 
vascular endothelial growth factor C 
Eph receptor B2  
Positive regulation of 
neurogenesis. 
SRY-box containing gene 2 
X-ray repair complementing defective repair in Chinese hamster 
cells 6 
achaete-scute complex homolog 1 (Drosophila) 
adhesion molecule with Ig like domain 1 
cadherin 4 
hypothetical protein LOC100044170; X-ray repair complementing 
defective repair in Chinese hamster cells 4 
microtubule-associated protein tau 
neurofilament, light polypeptide 
neurotrophin 3 
orthopedia homolog (Drosophila) 
paired box gene 6 
steroidogenic acute regulatory protein 
vascular endothelial growth factor C 
Rac GTPase-activating protein 1; predicted gene 1859  
Neuroblast proliferation. achaete-scute complex homolog 1 (Drosophila) 
asp (abnormal spindle)-like, microcephaly associated (Drosophila) 
fibroblast growth factor receptor substrate 2 
inhibitor of DNA binding 4 
numb-like 
platelet-activating factor acetylhydrolase, isoform 1b, subunit 1 
wingless-related MMTV integration site 3A 
ADP-ribosylation factor-like 4A  
Fate cell differentiation. C-terminal binding protein 2 
SH2B adaptor protein 2 
chibby homolog 1 (Drosophila) 
cyclin D1 
glutathione peroxidase 1 
glycogen synthase kinase 3 beta 
integrin alpha 6 
mediator complex subunit 1 
methyltransferase like 8 
nuclear receptor co-repressor 2 
nudix (nucleoside diphosphate linked moiety X)-type motif 7 
peroxisome proliferator activated receptor gamma 
predicted gene 14506; BCL2/adenovirus E1B interacting protein 3; 
predicted gene 6532; similar to E1B 19K/Bcl-2-binding protein 
homolog 
regulator of G-protein signaling 2 
runt-related transcription factor 1; translocated to, 1 (cyclin D-
related) 
selenium binding protein 1; hypothetical protein LOC100044204 
solute carrier family 2 (facilitated glucose transporter), member 4 
stromal cell derived factor 4 
transducin (beta)-like 1 X-linked 
Eph receptor B2  
Regulation of neuron 
differentiation. 
Meis homeobox 1 
POU domain, class 3, transcription factor 2 
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SRY-box containing gene 2 
TGFB-induced factor homeobox 1 
Unc-51 like kinase 2 (C. elegans) 
achaete-scute complex homolog 1 (Drosophila) 
adhesion molecule with Ig like domain 1 
asp (abnormal spindle)-like, microcephaly associated (Drosophila) 
cadherin 4 
calcium channel, voltage-dependent, P/Q type, alpha 1A subunit 
cone-rod homeobox containing gene 
delta-like 1 (Drosophila) 
hairy and enhancer of split 5 (Drosophila) 
homeo box D3 
inhibitor of DNA binding 4 
kinase non-catalytic C-lobe domain (KIND) containing 1 
leucine rich repeat containing 4C 
microtubule-associated protein tau 
neurofilament, light polypeptide 
neurofilament, medium polypeptide 
neuroligin 1 
neuropilin 1 
nuclear receptor subfamily 2, group E, member 1 
paired box gene 6 
plexin A3 
pre B-cell leukemia transcription factor 1; region containing RIKEN 
cDNA 2310056B04 gene; pre B-cell leukemia transcription factor 1 
tetratricopeptide repeat domain 3 
thymus cell antigen 1, theta 
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase 
activation protein, eta polypeptide 
LIM homeobox protein 6  
Forebrain neuron fate 
commitment. 
distal-less homeobox 1 
distal-less homeobox 2 
paired box gene 6 
Eph receptor A7 
achaete-scute complex homolog 1 (Drosophila) 
ataxia telangiectasia mutated homolog (human)  
Regulation of neuron 
apoptosis. 
leukocyte specific transcript 1 
lymphotoxin A 
neurofibromatosis 1 
nuclear receptor subfamily 3, group C, member 1 
proprotein convertase subtilisin/kexin type 9 
POU domain, class 4, transcription factor 3 
apoptotic peptidase activating factor 1 
ataxia telangiectasia mutated homolog (human)  
Neuron apoptosis. caspase 3 
huntingtin 
predicted gene 14506; BCL2/adenovirus E1B interacting protein 3; 
predicted gene 6532; similar to E1B 19K/Bcl-2-binding protein 
homolog 
tumor necrosis factor receptor superfamily, member 21 
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3.1 Testing the prim
er by Q
PC
R
: 
3.1.1 D
A
R
PP-32 prim
ers 
 
 
M
arker       cD
N
A
          -RT 
200bp   
100bp 
y = -3.1492x + 29.576; R
² = 0.98431; E = 2.08 
y = -3.5972x + 25.424; R
² = 0.90479; E = 1.93 
10#
15#
20#
25#
30#
35#
1#
1.5#
2#
2.5#
3#
3.5#
Mean Cq Values 
L
og cD
N
A
 Input (ng) 
C
alculation of D
A
R
PP-32 Prim
er  E
fficiency  
Linear (D
A
R
PP-32) 
Linear (G
A
PD
H
) 
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3.1.2 C
TIP2 prim
ers 
 
 
 
M
arker       cD
N
A
          -RT 
200bp   
100bp 
y = -3.5972x + 25.424; R
² = 0.90479; E
 = 1.93 
y = -3.3227x + 29.695; R
² = 0.9113; E
 = 2.00 
10#
12#
14#
16#
18#
20#
22#
24#
26#
28#
30#
1#
1.5#
2#
2.5#
3#
3.5#
Mean Cq Values 
L
og cD
N
A
 Input (ng) 
C
alculation of C
T
IP
2 P
rim
er  E
fficiency  
L
inear (G
A
PD
H
) 
L
inear (C
T
IP2) 
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3.1.3 A
R
X prim
ers 
 
 
 
M
arker       cD
N
A
          -RT 
200bp   
100bp 
y = -3.5972x + 24.932; R
² = 0.90479; E
 = 1.93 
y = -3.3662x + 29.262; R
² = 0.89537; E
 = 1.98 
10#
15#
20#
25#
30#
35#
1#
1.5#
2#
2.5#
3#
3.5#
Mean Cq Values 
L
og cD
N
A
 Input (ng) 
C
alculation of A
R
X
 Prim
er  E
fficiency  
L
inear (G
A
PD
H
) 
L
inear (A
R
X
) 
                                                                                                                                                                                                                                     A
ppendix 3.1 
 
323 
3.1.4 EN
D
O
-D
LX2 prim
ers 
 
 
 
M
arker       cD
N
A
          -RT 
200bp 
100bp 
y = -3.5972x + 24.932; R
² = 0.90479; E
 = 1.93 
y"="$3.1974x"+"32.247;"R²"="0.95204;"E"="2.05"
10"
15"
20"
25"
30"
1"
1.5"
2"
2.5"
3"
3.5"
Mean Cq Values 
L
og cD
N
A
 Input (ng) 
C
alculation of E
N
D
O
-D
L
X
2 P
rim
er  E
fficiency  
L
inear (G
A
PD
H
) 
L
inear (E
N
D
O
-D
L
X
2) 
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3.1.5 EN
D
O
-M
A
SH
1 prim
ers 
 
 
 
M
arker         cD
N
A
        -RT 
200bp 
100bp 
y = -3.5972x + 24.932; R
² = 0.90479; E
 = 1.93 
y = -3.261x + 29.391; R
² = 0.92666; E
 = 2.03 
10#
15#
20#
25#
30#
1#
1.5#
2#
2.5#
3#
3.5#
Mean Cq Values 
L
og cD
N
A
 Input (ng) 
C
alculation of E
N
D
O
-M
A
SH
1P
rim
er  E
fficiency  
L
inear (G
A
PD
H
) 
L
inear (E
N
D
O
-M
A
SH
1) 
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3.1.6 EN
D
O
-G
SX2 prim
ers 
 
 
 
M
arker       cD
N
A
          -RT 
200bp 
100bp 
y = -3.5972x + 24.932; R
² = 0.90479; E
 = 1.93 
y"="$3.1281x"+"34.889;"R²"="0.92383;"E"="2.09"
10"
15"
20"
25"
30"
35"
1"
1.5"
2"
2.5"
3"
3.5"
Mean Cq Values 
L
og cD
N
A
 Input (ng) 
C
alculation of E
N
D
O
-G
SX
2 P
rim
er  E
fficiency  
L
inear (G
A
PD
H
) 
L
inear (E
N
D
O
-G
SX
2) 
                                                                                                                                                                                                                                     A
ppendix 3.1 
 
326 
3.1.7 G
A
PD
H
 prim
ers 
 
 
 
M
arker       cD
N
A
          -RT 
200bp 
100bp 
y = -3.5972x + 24.932; R
² = 0.90479; E
 = 1.9 
10#
12#
14#
16#
18#
20#
22#
24#
1#
1.5#
2#
2.5#
3#
3.5#
Mean Cq Values 
L
og cD
N
A
 Input (ng) 
C
alculation of G
A
P
D
H
 P
rim
er  E
fficiency  
L
inear (G
A
PD
H
) 
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3.1.8 β-A
C
TIN
 prim
ers 
 
 
 
M
arker       cD
N
A
          -RT 
200bp 
100bp 
y = -3.2855x + 22.548; R
² = 0.99214; E
 = 2.01 
10#
12#
14#
16#
18#
20#
22#
24#
1#
1.5#
2#
2.5#
3#
3.5#
Mean Cq Values 
L
og cD
N
A
 Input (ng) 
C
alculation of β-A
C
T
IN
 P
rim
er  E
fficiency  
L
inear (β-A
C
T
IN
) 
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3.1.9 D
R
D
1 prim
ers 
 
 
 
y = -3.5972x + 24.932; R
² = 0.90479; E
 = 1.93 
y"="$3.3385x"+"32.852;"R²"="0.99733;"E"="1.99"
10"
15"
20"
25"
30"
1"
1.5"
2"
2.5"
3"
3.5"
Mean Cq Values 
L
og cD
N
A
 Input (ng) 
C
alculation of D
R
D
1 P
rim
er  E
fficiency  
L
inear (G
A
PD
H
) 
L
inear (D
R
D
1) 
S
canned by C
am
S
canner
200bp 
100bp 
M
arker         cD
N
A
        -RT 
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3.1.10 D
R
D
2 prim
ers 
 
 
 
y = -3.5972x + 24.932; R
² = 0.90479; E
 = 1.93 
y"="$3.4659x"+"32.071;"R²"="0.97545;"E"="1.94"
10"
15"
20"
25"
30"
1"
1.5"
2"
2.5"
3"
3.5"
Mean Cq Values 
L
og cD
N
A
 Input (ng) 
C
alculation of D
R
D
2 P
rim
er  E
fficiency  
L
inear (G
A
PD
H
) 
L
inear (D
R
D
2) 
S
canned by C
am
S
canner
200bp 
100bp 
M
arker         cD
N
A
        -RT 
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3.1.11 G
A
D
2 prim
ers 
 
 
 
S
canned by C
am
S
canner
200bp 
100bp 
M
arker         cD
N
A
        -RT 
y = -3.5972x + 24.932; R
² = 0.90479; E
 = 1.93 
y"="$3.5295x"+"32.143;"R²"="0.99879;"E"="1.92"
10"
15"
20"
25"
30"
1"
1.5"
2"
2.5"
3"
3.5"
Mean Cq Values 
L
og cD
N
A
 Input (ng) 
C
alculation of G
A
D
2 P
rim
er  E
fficiency  
L
inear (G
A
PD
H
) 
L
inear (G
A
D
2) 
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3.1.12 C
A
LB
IN
-1 prim
ers 
 
 
 
Scanned by C
am
Scanner
200bp 
100bp 
M
arker         cD
N
A
        -RT 
y = -3.5972x + 24.932; R
² = 0.90479; E
 = 1.93 
y"="$3.1226x"+"31.916;"R²"="0.99973;"E"="2.09"
10"
15"
20"
25"
30"
1"
1.5"
2"
2.5"
3"
3.5"
Mean Cq Values 
L
og cD
N
A
 Input (ng) 
C
alculation of C
A
L
B
IN
-1 P
rim
er  E
fficiency  
L
inear (G
A
PD
H
) 
L
inear (C
A
L
B
IN
-1) 
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3.1.13 EXO
-G
SX2  
 
 
 
y = -3.5972x + 24.932; R
² = 0.90479; E
 = 1.93 
y"="$3.4595x"+"23.976;"R²"="0.99826;"E"="1.95"
14"
15"
16"
17"
18"
19"
20"
21"
22"1.2"
1.7"
2.2"
2.7"
3.2"
Mean Cq Values 
L
og cD
N
A
 Input (ng) 
C
alculation of E
X
O
-G
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2P
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er  E
fficiency  
L
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A
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H
) 
L
inear (E
X
O
-G
SX
2) 
M
arker     cD
N
A
      -RT 
200bp  
100bp 
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3.1.14 EXO
-M
A
SH
1 
 
 
 
y = -3.5972x + 24.932; R
² = 0.90479; E
 = 1.93 
y"="$3.2721x"+"29.424;"R²"="0.96071;"E"="2.02"
10"
15"
20"
25"
30"
1"
1.5"
2"
2.5"
3"
3.5"
Mean Cq Values 
L
og cD
N
A
 Input (ng) 
C
alculation of E
X
O
-M
A
SH
1 P
rim
er  E
fficiency  
L
inear (G
A
PD
H
) 
L
inear (E
X
O
-M
A
SH
1) 
M
arker    cD
N
A
     -RT 
200bp  
100bp 
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3.1.15 EXO
-D
LX2 
 
 
 
y = -3.5972x + 24.932; R
² = 0.90479; E
 = 1.93 
y"="$3.3126x"+"23.665;"R²"="0.99498;"E"="2.0"
14"
15"
16"
17"
18"
19"
20"
21"
22"1.2"
1.7"
2.2"
2.7"
3.2"
Mean Cq Values 
L
og cD
N
A
 Input (ng) 
C
alculation of E
X
O
-D
L
X
2 P
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er  E
fficiency  
L
inear (G
A
PD
H
) 
L
inear (E
X
O
-D
L
X
2) 
200bp  
100bp M
arker        cD
N
A
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3.1.16 EB
F1 (The efficiency of EB
F1 prim
ers has been tested before in A
llen lab. Therefore, the ct value, m
elting 
curve and m
elt peak of EB
F1 and –R
T w
as show
n below
): 
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3.1.17 EM
X2 (The efficiency of EM
X2 prim
ers has been tested before in A
llen lab. Therefore, the ct value, m
elting 
curve and m
elt peak of EM
X2 and –R
T w
as show
n below
): 
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3.1.18 FO
XP1 (The efficiency of FO
XP1 prim
ers has been tested before in A
llen lab. Therefore, the ct value, m
elting 
curve and m
elt peak of FO
XP1 and –R
T w
as show
n below
): 
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3.1.19 PA
X6 (The efficiency of PA
X6 prim
ers has been tested before in A
llen lab. Therefore, the ct value, m
elting 
curve and m
elt peak of PA
X6 and –R
T w
as show
n below
): 
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3.1.20 N
K
X2.1 (The efficiency of N
K
X2.1 prim
ers has been tested before in A
llen lab. Therefore, the ct value, m
elting 
curve and m
elt peak of N
K
X2.1 and –R
T w
as show
n below
): 
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4.1 DNA Sequencing: 
 
4.1.1 P3X-2A-DLX2 (3,595 bp) 
 
CTAAATTGTAAGCGTTAATATTTTGTTAAAATTCGCGTTAAATTTTTGTTAAATCAGCTCATTTTTTAACCAA
TAGGCCGAAATCGGCAAAATCCCTTATAAATCAAAAGAATAGACCGAGATAGGGTTGAGTGGCCGCTACAGGG
CGCTCCCATTCGCCATTCAGGCTGCGCAACTGTTGGGAAGGGCGTTTCGGTGCGGGCCTCTTCGCTATTACGC
CAGCTGGCGAAAGGGGGATGTGCTGCAAGGCGATTAAGTTGGGTAACGCCAGGGTTTTCCCAGTCACGACGTT
GTAAAACGACGGCCAGTGAGCGCGACGTAATACGACTCACTATAGGGCGAATTGGCGGAAGGCCGTCAAGGCC
ACGTGTCTTGTCCAGAGCTCGTCGACGAATTCAGCGCTCTCGAGACCGGTGCCGCCATGGGAGGATCCCAGTG
TACTAATTATGCTCTCTTGAAATTGGCTGGAGATGTTGAGAGCAACCCAGGTCCCAGATCTGAGGGCAGAGGA
AGTCTTCTAACATGCGGTGACGTGGAGGAGAATCCCGGCCCTTCTAGAGCCACGAAGCAAGCAGGAGATGTTG
AAGAAAACCCCGGTCCT 
gct agc ATG act gga gtc ttt gac agt cta gtg gct gat atg cac tcg acc cag 
atc gcc gcc tcc agc acg tac cac cag cac cag cag ccc ccg agc ggc ggc ggc 
gcc ggc ccg ggt ggc aac agc agc agc agc agc agc ctc cac aag ccc cag gag 
tcg ccc acc ctt ccg gtg tcc acc gcc acc gac agc agc tac tac acc aac cag 
cag cac ccg gcg ggc ggc ggc ggc ggc ggg ggc tcg ccc tac gcg cac atg ggt 
tcc tac cag tac caa gcc agc ggc ctc aac aac gtc cct tac tcc gcc aag agc 
agc tat gac ctg ggc tac acc gcc gcc tac acc tcc tac gct ccc tat gga acc 
agt tcg tcc cca gcc aac aac gag cct gag aag gag gac ctt gag cct gaa att 
cgg ata gtg aac ggg aag cca aag aaa gtc cgg aaa ccc cgc acc atc tac tcc 
agt ttc cag ctg gcg gct ctt cag cgg cgt ttc caa aag act caa tac ttg gcc 
ttg ccg gag cga gcc gag ctg gcg gcc tct ctg ggc ctc acc cag act cag gtc 
aaa atc tgg ttc cag aac cgc cgg tcc aag ttc aag aag atg tgg aaa agt ggt 
gag atc ccc tcg gag cag cac cct ggg gcc agc gct tct cca cct tgt gct tcg 
ccg cca gtc tca gcg ccg gcc tcc tgg gac ttt ggt gtg ccg cag cgg atg gcg 
ggc ggc ggt ggt ccg ggc agt ggc ggc agc ggc gcc ggc agc tcg ggc tcc agc 
ccg agc agc gcg gcc tcg gct ttt ctg ggc aac tac ccc tgg tac cac cag acc 
tcg gga tcc gcc tca cac ctg cag gcc acg gcg ccg ctg ctg cac ccc act cag 
acc ccg cag ccg cat cac cac cac cac cat cac ggc ggc ggg ggc gcc ccg gtg 
agc gcg ggg acg att ttc gct agc 
TAAGTCGACGGTACCTGGAGCACAAGACTGGCCTCATGGGCCTTCCGCTCACTGCCCGCTTTCCAGTCGGGAA
ACCTGTCGTGCCAGCTGCATTAACATGGTCATAGCTGTTTCCTTGCGTATTGGGCGCTCTCCGCTTCCTCGCT
CACTGACTCGCTGCGCTCGGTCGTTCGGGTAAAGCCTGGGGTGCCTAATGAGCAAAAGGCCAGCAAAAGGCCA
GGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCG
ACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTC
GTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGC
TTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGA
ACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGAC
TTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCT
TGAAGTGGTGGCCTAACTACGGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTAC
CTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGC
AAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTC
AGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTT
AAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTA
ATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTCGTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGA
TAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGAACCACGCTCACCGGC
TCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCTGCAACTTTATCCGCC
TCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTG
TTGCCATTGCTACAGGCATCGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACG
ATCAAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGATCGTTGTC
AGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGCACTGCATAATTCTCTTACTGTCATGCCAT
CCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGCGACCGAG
TTGCTCTTGCCCGGCGTCAATACGGGATAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCATTGGA
AAACGTTCTTCGGGGCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTG
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CACCCAACTGATCTTCAGCATCTTTTACTTTCACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGC
CGCAAAAAAGGGAATAAGGGCGACACGGAAATGTTGAATACTCATACTCTTCCTTTTTCAATATTATTGAAGC
ATTTATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAAACAAATAGGGGTTC
CGCGCACATTTCCCCGAAAAGTGCCAC 
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4.1.2 P3X-2A-MASH1 (3,319 bp) 
 
CTAAATTGTAAGCGTTAATATTTTGTTAAAATTCGCGTTAAATTTTTGTTAAATCAGCTCATTTTTTAACCAA
TAGGCCGAAATCGGCAAAATCCCTTATAAATCAAAAGAATAGACCGAGATAGGGTTGAGTGGCCGCTACAGGG
CGCTCCCATTCGCCATTCAGGCTGCGCAACTGTTGGGAAGGGCGTTTCGGTGCGGGCCTCTTCGCTATTACGC
CAGCTGGCGAAAGGGGGATGTGCTGCAAGGCGATTAAGTTGGGTAACGCCAGGGTTTTCCCAGTCACGACGTT
GTAAAACGACGGCCAGTGAGCGCGACGTAATACGACTCACTATAGGGCGAATTGGCGGAAGGCCGTCAAGGCC
ACGTGTCTTGTCCAGAGCTCGTCGACGAATTCAGCGCTCTCGAGACCGGTGCCGCCATGGGA  
gga tcc ATG gaa agc tct gcc aag atg gag agc ggc ggc gcc ggc cag cag ccc 
cag ccg cag ccc cag cag ccc ttc ctg ccg ccc gca gcc tgt ttc ttt gcc acg 
gcc gca gcc gcg gcg gcc gca gcc gcc gca gcg gca gcg cag agc gcg cag cag 
cag cag cag cag cag cag cag cag cag cag gcg ccg cag ctg aga ccg gcg gcc 
gac ggc cag ccc tca ggg ggc ggt cac aag tca gcg ccc aag caa gtc aag cga 
cag cgc tcg tct tcg ccc gaa ctg atg cgc tgc aaa cgc cgg ctc aac ttc agc 
ggc ttt ggc tac agc ctg ccg cag cag cag ccg gcc gcc gtg gcg cgc cgc aac 
gag cgc gag cgc aac cgc gtc aag ttg gtc aac ctg ggc ttt gcc acc ctt cgg 
gag cac gtc ccc aac ggc gcg gcc aac aag aag atg agt aag gtg gag aca ctg 
cgc tcg gcg gtc gag tac atc cgc gcg ctg cag cag ctg ctg gac gag cat gac 
gcg gtg agc gcc gcc ttc cag gca ggc gtc ctg tcg ccc acc atc tcc ccc aac 
tac tcc aac gac ttg aac tcc atg gcc ggc tcg ccg gtc tca tcc tac tcg tcg 
gac gag ggc tct tac gac ccg ctc agc ccc gag gag cag gag ctt ctc gac ttc 
acc aac tgg ttc gGA TCC 
CAGTGTACTAATTATGCTCTCTTGAAATTGGCTGGAGATGTTGAGAGCAACCCAGGTCCCAGATCTGAGGGCA
GAGGAAGTCTTCTAACATGCGGTGACGTGGAGGAGAATCCCGGCCCTTCTAGAGCCACGAAGCAAGCAGGAGA
TGTTGAAGAAAACCCCGGTCCTGCTAGCTAAGTCGACGGTACCTGGAGCACAAGACTGGCCTCATGGGCCTTC
CGCTCACTGCCCGCTTTCCAGTCGGGAAACCTGTCGTGCCAGCTGCATTAACATGGTCATAGCTGTTTCCTTG
CGTATTGGGCGCTCTCCGCTTCCTCGCTCACTGACTCGCTGCGCTCGGTCGTTCGGGTAAAGCCTGGGGTGCC
TAATGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCC
GCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATA
CCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCC
GCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCG
TTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCG
TCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCG
AGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGAACAGTATTTG
GTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCAC
CGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCT
TTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGAGATTAT
CAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTA
AACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTCGTTCATCC
ATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAA
TGATACCGCGAGAACCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCG
CAGAAGTGGTCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGT
TCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTACAGGCATCGTGGTGTCACGCTCGTCGTTTGGTA
TGGCTTCATTCAGCTCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGT
TAGCTCCTTCGGTCCTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGCA
CTGCATAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCAT
TCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATACGGGATAATACCGCGCCACATAG
CAGAACTTTAAAAGTGCTCATCATTGGAAAACGTTCTTCGGGGCGAAAACTCTCAAGGATCTTACCGCTGTTG
AGATCCAGTTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGCATCTTTTACTTTCACCAGCGTTTCTG
GGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAAATGTTGAATACTCAT
ACTCTTCCTTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGT
ATTTAGAAAAATAAACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCAC 
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4.1.3 P3X-2A-DLX2/MASH1 (4,309 bp) 
 
CTAAATTGTAAGCGTTAATATTTTGTTAAAATTCGCGTTAAATTTTTGTTAAATCAGCTCATTTTTTAACCAA
TAGGCCGAAATCGGCAAAATCCCTTATAAATCAAAAGAATAGACCGAGATAGGGTTGAGTGGCCGCTACAGGG
CGCTCCCATTCGCCATTCAGGCTGCGCAACTGTTGGGAAGGGCGTTTCGGTGCGGGCCTCTTCGCTATTACGC
CAGCTGGCGAAAGGGGGATGTGCTGCAAGGCGATTAAGTTGGGTAACGCCAGGGTTTTCCCAGTCACGACGTT
GTAAAACGACGGCCAGTGAGCGCGACGTAATACGACTCACTATAGGGCGAATTGGCGGAAGGCCGTCAAGGCC
ACGTGTCTTGTCCAGAGCTCGTCGACGAATTCAGCGCTCTCGAGACCGGTGCCGCCATGGGA  
gga tcc ATG gaa agc tct gcc aag atg gag agc ggc ggc gcc ggc cag cag ccc 
cag ccg cag ccc cag cag ccc ttc ctg ccg ccc gca gcc tgt ttc ttt gcc acg 
gcc gca gcc gcg gcg gcc gca gcc gcc gca gcg gca gcg cag agc gcg cag cag 
cag cag cag cag cag cag cag cag cag cag gcg ccg cag ctg aga ccg gcg gcc 
gac ggc cag ccc tca ggg ggc ggt cac aag tca gcg ccc aag caa gtc aag cga 
cag cgc tcg tct tcg ccc gaa ctg atg cgc tgc aaa cgc cgg ctc aac ttc agc 
ggc ttt ggc tac agc ctg ccg cag cag cag ccg gcc gcc gtg gcg cgc cgc aac 
gag cgc gag cgc aac cgc gtc aag ttg gtc aac ctg ggc ttt gcc acc ctt cgg 
gag cac gtc ccc aac ggc gcg gcc aac aag aag atg agt aag gtg gag aca ctg 
cgc tcg gcg gtc gag tac atc cgc gcg ctg cag cag ctg ctg gac gag cat gac 
gcg gtg agc gcc gcc ttc cag gca ggc gtc ctg tcg ccc acc atc tcc ccc aac 
tac tcc aac gac ttg aac tcc atg gcc ggc tcg ccg gtc tca tcc tac tcg tcg 
gac gag ggc tct tac gac ccg ctc agc ccc gag gag cag gag ctt ctc gac ttc 
acc aac tgg ttc gga tcc  
CAGTGTACTAATTATGCTCTCTTGAAATTGGCTGGAGATGTTGAGAGCAACCCAGGTCCCAGATCTGAGGGCA
GAGGAAGTCTTCTAACATGCGGTGACGTGGAGGAGAATCCCGGCCCTTCTAGAGCCACGAAGCAAGCAGGAGA
TGTTGAAGAAAACCCCGGTCCT  
gct agc ATG act gga gtc ttt gac agt cta gtg gct gat atg cac tcg acc cag 
atc gcc gcc tcc agc acg tac cac cag cac cag cag ccc ccg agc ggc ggc ggc 
gcc ggc ccg ggt ggc aac agc agc agc agc agc agc ctc cac aag ccc cag gag 
tcg ccc acc ctt ccg gtg tcc acc gcc acc gac agc agc tac tac acc aac cag 
cag cac ccg gcg ggc ggc ggc ggc ggc ggg ggc tcg ccc tac gcg cac atg ggt 
tcc tac cag tac caa gcc agc ggc ctc aac aac gtc cct tac tcc gcc aag agc 
agc tat gac ctg ggc tac acc gcc gcc tac acc tcc tac gct ccc tat gga acc 
agt tcg tcc cca gcc aac aac gag cct gag aag gag gac ctt gag cct gaa att 
cgg ata gtg aac ggg aag cca aag aaa gtc cgg aaa ccc cgc acc atc tac tcc 
agt ttc cag ctg gcg gct ctt cag cgg cgt ttc caa aag act caa tac ttg gcc 
ttg ccg gag cga gcc gag ctg gcg gcc tct ctg ggc ctc acc cag act cag gtc 
aaa atc tgg ttc cag aac cgc cgg tcc aag ttc aag aag atg tgg aaa agt ggt 
gag atc ccc tcg gag cag cac cct ggg gcc agc gct tct cca cct tgt gct tcg 
ccg cca gtc tca gcg ccg gcc tcc tgg gac ttt ggt gtg ccg cag cgg atg gcg 
ggc ggc ggt ggt ccg ggc agt ggc ggc agc ggc gcc ggc agc tcg ggc tcc agc 
ccg agc agc gcg gcc tcg gct ttt ctg ggc aac tac ccc tgg tac cac cag acc 
tcg gga tcc gcc tca cac ctg cag gcc acg gcg ccg ctg ctg cac ccc act cag 
acc ccg cag ccg cat cac cac cac cac cat cac ggc ggc ggg ggc gcc ccg gtg 
agc gcg ggg acg att ttc gct agc 
TAAGTCGACGGTACCTGGAGCACAAGACTGGCCTCATGGGCCTTCCGCTCACTGCCCGCTTTCCAGTCGGGAA
ACCTGTCGTGCCAGCTGCATTAACATGGTCATAGCTGTTTCCTTGCGTATTGGGCGCTCTCCGCTTCCTCGCT
CACTGACTCGCTGCGCTCGGTCGTTCGGGTAAAGCCTGGGGTGCCTAATGAGCAAAAGGCCAGCAAAAGGCCA
GGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCG
ACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTC
GTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGC
TTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGA
ACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGAC
TTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCT
TGAAGTGGTGGCCTAACTACGGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTAC
CTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGC
AAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTC
AGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTT
AAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTA
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ATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTCGTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGA
TAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGAACCACGCTCACCGGC
TCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCTGCAACTTTATCCGCC
TCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTG
TTGCCATTGCTACAGGCATCGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACG
ATCAAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGATCGTTGTC
AGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGCACTGCATAATTCTCTTACTGTCATGCCAT
CCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGCGACCGAG
TTGCTCTTGCCCGGCGTCAATACGGGATAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCATTGGA
AAACGTTCTTCGGGGCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTG
CACCCAACTGATCTTCAGCATCTTTTACTTTCACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGC
CGCAAAAAAGGGAATAAGGGCGACACGGAAATGTTGAATACTCATACTCTTCCTTTTTCAATATTATTGAAGC
ATTTATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAAACAAATAGGGGTTC
CGCGCACATTTCCCCGAAAAGTGCCAC 
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4.1.4 pCAGG (6,407 bp) 
 
TAGTTATTTCTCGACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCC
ATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCA
TTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGACT
ATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAA
TGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATC
TACGTATTAGTCATCGCTATTACCATGGGTCGAGGTGAGCCCCACGTTCTGCTTCACTCTCCCCATCTCCCCC
CCCTCCCCACCCCCAATTTTGTATTTATTTATTTTTTAATTATTTTGTGCAGCGATGGGGGCGGGGGGGGGGG
GGGCGCGCGCCAGGCGGGGCGGGGCGGGGCGAGGGGCGGGGCGGGGCGAGGCGGAGAGGTGCGGCGGCAGCCA
ATCAGAGCGGCGCGCTCCGAAAGTTTCCTTTTATGGCGAGGCGGCGGCGGCGGCGGCCCTATAAAAAGCGAAG
CGCGCGGCGGGCGGGAGTCGCTGCGTTGCCTTCGCCCCGTGCCCCGCTCCGCGCCGCCTCGCGCCGCCCGCCC
CGGCTCTGACTGACCGCGTTACTCCCACAGGTGAGCGGGCGGGACGGCCCTTCTCCTCCGGGCTGTAATTAGC
GCTTGGTTTAATGACGGCTCGTTTCTTTTCTGTGGCTGCGTGAAAGCCTTAAAGGGCTCCGGGAGGGCCCTTT
GTGCGGGGGGGAGCGGCTCGGGGGGTGCGTGCGTGTGTGTGTGCGTGGGGAGCGCCGCGTGCGGCCCGCGCTG
CCCGGCGGCTGTGAGCGCTGCGGGCGCGGCGCGGGGCTTTGTGCGCTCCGCGTGTGCGCGAGGGGAGCGCGGC
CGGGGGCGGTGCCCCGCGGTGCGGGGGGGCTGCGAGGGGAACAAAGGCTGCGTGCGGGGTGTGTGCGTGGGGG
GGTGAGCAGGGGGTGTGGGCGCGGCGGTCGGGCTGTAACCCCCCCCTGCACCCCCCTCCCCGAGTTGCTGAGC
ACGGCCCGGCTTCGGGTGCGGGGCTCCGTGCGGGGCGTGGCGCGGGGCTCGCCGTGCCGGGCGGGGGGTGGCG
GCAGGTGGGGGTGCCGGGCGGGGCGGGGCCGCCTCGGGCCGGGGAGGGCTCGGGGGAGGGGCGCGGCGGCCCC
GGAGCGCCGGCGGCTGTCGAGGCGCGGCGAGCCGCAGCCATTGCCTTTTATGGTAATCGTGCGAGAGGGCGCA
GGGACTTCCTTTGTCCCAAATCTGGCGGAGCCGAAATCTGGGAGGCGCCGCCGCACCCCCTCTAGCGGGCGCG
GGCGAAGCGGTGCGGCGCCGGCAGGAAGGAAATGGGCGGGGAGGGCCTTCGTGCGTCGCCGCGCCGCCGTCCC
CTTCTCCATCTCCAGCCTCGGGGCTGCCGCAGGGGGACGGCTGCCTTCGGGGGGGACGGGGCAGGGCGGGGTT
CGGCTTCTGGCGTGTGACCGGCGGCTCTAGAGCCTCTGCTAACCATGTTCATGCCTTCTTCTTTTTCCTACAG
CTCCTGGGCAACGTGCTGGTTGTTGTGCTGTCTCATCATTTTGGCAAAGAATTCTGCAGTCGACGGTACCGCG
GGCCCGGGATCCGCCCCTCTCCCTCCCCCCCCCCTAACGTTACTGGCCGAAGCCGCTTGGAATAAGGCCGGTG
TGCGTTTGTCTATATGTTATTTTCCACCATATTGCCGTCTTTTGGCAATGTGAGGGCCCGGAAACCTGGCCCT
GTCTTCTTGACGAGCATTCCTAGGGGTCTTTCCCCTCTCGCCAAAGGAATGCAAGGTCTGTTGAATGTCGTGA
AGGAAGCAGTTCCTCTGGAAGCTTCTTGAAGACAAACAACGTCTGTAGCGACCCTTTGCAGGCAGCGGAACCC
CCCACCTGGCGACAGGTGCCTCTGCGGCCAAAAGCCACGTGTATAAGATACACCTGCAAAGGCGGCACAACCC
CAGTGCCACGTTGTGAGTTGGATAGTTGTGGAAAGAGTCAAATGGCTCTCCTCAAGCGTATTCAACAAGGGGC
TGAAGGATGCCCAGAAGGTACCCCATTGTATGGGATCTGATCTGGGGCCTCGGTGCACATGCTTTACATGTGT
TTAGTCGAGGTTAAAAAAACGTCTAGGCCCCCCGAACCACGGGGACGTGGTTTTCCTTTGAAAAACACGATGA
TAATATGGCCACAACCATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTG
GACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGA
CCCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTACGG
CGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGC
TACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGG
GCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAA
GCTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAAC
TTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCCATCG
GCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCACCCAGTCCGCCCTGAGCAAAGACCCCAACGA
GAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTAC
AAGTAAAGCGGCCGCGACTCTAGATCATAATCAGCCATACCACATTTGTAGAGGTTTTACTTGCTTTAAAAAA
CCTCCCACACCTCCCCCTGAACCTGAAACATAAAATGAATGCAATTGTTGTTGTTAACTTGTTTATTGCAGCT
TATAATGGTTACAAATAAAGCAATAGCATCACAAATTTCACAAATAAAGCATTTTTTTCACTGCATTCTAGTT
GTGGTTTGTCCAAACTCATCAATGTATCTTAAGGCGTAAATTGTAAGCGTTAATATTTTGTTAAAATTCGCGT
TAAATTTTTGTTAAATCAGCTCATTTTTTAACCAATAGGCCGAAATCGGCAAAATCCCTTATAAATCAAAAGA
ATAGACCGAGATAGGGTTGAGTGTTGTTCCAGTTTGGAACAAGAGTCCACTATTAAAGAACGTGGACTCCAAC
GTCAAAGGGCGAAAAACCGTCTATCAGGGCGATGGCCCACTACGTGAACCATCACCCTAATCAAGTTTTTTGG
GGTCGAGGTGCCGTAAAGCACTAAATCGGAACCCTAAAGGGAGCCCCCGATTTAGAGCTTGACGGGGAAAGCC
GGCGAACGTGGCGAGAAAGGAAGGGAAGAAAGCGAAAGGAGCGGGCGCTAGGGCGCTGGCAAGTGTAGCGGTC
ACGCTGCGCGTAACCACCACACCCGCCGCGCTTAATGCGCCGCTACAGGGCGCGTCAGGTGGCACTTTTCGGG
GAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATA
ACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTCCTGAGGCGGAAAGAACCAGCTGTGGAATGTGT
GTCAGTTAGGGTGTGGAAAGTCCCCAGGCTCCCCAGCAGGCAGAAGTATGCAAAGCATGCATCTCAATTAGTC
AGCAACCAGGTGTGGAAAGTCCCCAGGCTCCCCAGCAGGCAGAAGTATGCAAAGCATGCATCTCAATTAGTCA
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GCAACCATAGTCCCGCCCCTAACTCCGCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCC
ATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTATTCCAGAAGTAGTG
AGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAGATCGATCAAGAGACAGGATGAGGATCGTTTCGCATGAT
TGAACAAGATGGATTGCACGCAGGTTCTCCGGCCGCTTGGGTGGAGAGGCTATTCGGCTATGACTGGGCACAA
CAGACAATCGGCTGCTCTGATGCCGCCGTGTTCCGGCTGTCAGCGCAGGGGCGCCCGGTTCTTTTTGTCAAGA
CCGACCTGTCCGGTGCCCTGAATGAACTGCAAGACGAGGCAGCGCGGCTATCGTGGCTGGCCACGACGGGCGT
TCCTTGCGCAGCTGTGCTCGACGTTGTCACTGAAGCGGGAAGGGACTGGCTGCTATTGGGCGAAGTGCCGGGG
CAGGATCTCCTGTCATCTCACCTTGCTCCTGCCGAGAAAGTATCCATCATGGCTGATGCAATGCGGCGGCTGC
ATACGCTTGATCCGGCTACCTGCCCATTCGACCACCAAGCGAAACATCGCATCGAGCGAGCACGTACTCGGAT
GGAAGCCGGTCTTGTCGATCAGGATGATCTGGACGAAGAGCATCAGGGGCTCGCGCCAGCCGAACTGTTCGCC
AGGCTCAAGGCGAGCATGCCCGACGGCGAGGATCTCGTCGTGACCCATGGCGATGCCTGCTTGCCGAATATCA
TGGTGGAAAATGGCCGCTTTTCTGGATTCATCGACTGTGGCCGGCTGGGTGTGGCGGACCGCTATCAGGACAT
AGCGTTGGCTACCCGTGATATTGCTGAAGAGCTTGGCGGCGAATGGGCTGACCGCTTCCTCGTGCTTTACGGT
ATCGCCGCTCCCGATTCGCAGCGCATCGCCTTCTATCGCCTTCTTGACGAGTTCTTCTGAGCGGGACTCTGGG
GTTCGAAATGACCGACCAAGCGACGCCCAACCTGCCATCACGAGATTTCGATTCCACCGCCGCCTTCTATGAA
AGGTTGGGCTTCGGAATCGTTTTCCGGGACGCCGGCTGGATGATCCTCCAGCGCGGGGATCTCATGCTGGAGT
TCTTCGCCCACCCTAGGGGGAGGCTAACTGAAACACGGAAGGAGACAATACCGGAAGGAACCCGCGCTATGAC
GGCAATAAAAAGACAGAATAAAACGCACGGTGTTGGGTCGTTTGTTCATAAACGCGGGGTTCGGTCCCAGGGC
TGGCACTCTGTCGATACCCCACCGAGACCCCATTGGGGCCAATACGCCCGCGTTTCTTCCTTTTCCCCACCCC
ACCCCCCAAGTTCGGGTGAAGGCCCAGGGCTCGCAGCCAACGTCGGGGCGGCAGGCCCTGCCATAGCCTCAGG
TTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTTAATTTAAAAGGATCTAGGTGAAGATCCTTTTT
GATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCA
AAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGC
GGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATA
CCAAATACTGTCCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACC
TCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAG
ACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGA
ACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGG
CGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTG
GTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGG
CGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACA
TGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACCGCCATGCAT 
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4.1.5 pCAGG-DLX2 (7,622 bp) 
 
TAGTTATTTCTCGACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATT
AGTTCATAGCCCATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGC
TGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGC
CAATAGGGACTTTCCATTGACGTCAATGGGTGGACTATTTACGGTAAACTGCCCACTTGGC
AGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGG
CCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCT
ACGTATTAGTCATCGCTATTACCATGGGTCGAGGTGAGCCCCACGTTCTGCTTCACTCTCC
CCATCTCCCCCCCCTCCCCACCCCCAATTTTGTATTTATTTATTTTTTAATTATTTTGTGC
AGCGATGGGGGCGGGGGGGGGGGGGGCGCGCGCCAGGCGGGGCGGGGCGGGGCGAGGGGCG
GGGCGGGGCGAGGCGGAGAGGTGCGGCGGCAGCCAATCAGAGCGGCGCGCTCCGAAAGTTT
CCTTTTATGGCGAGGCGGCGGCGGCGGCGGCCCTATAAAAAGCGAAGCGCGCGGCGGGCGG
GAGTCGCTGCGTTGCCTTCGCCCCGTGCCCCGCTCCGCGCCGCCTCGCGCCGCCCGCCCCG
GCTCTGACTGACCGCGTTACTCCCACAGGTGAGCGGGCGGGACGGCCCTTCTCCTCCGGGC
TGTAATTAGCGCTTGGTTTAATGACGGCTCGTTTCTTTTCTGTGGCTGCGTGAAAGCCTTA
AAGGGCTCCGGGAGGGCCCTTTGTGCGGGGGGGAGCGGCTCGGGGGGTGCGTGCGTGTGTG
TGTGCGTGGGGAGCGCCGCGTGCGGCCCGCGCTGCCCGGCGGCTGTGAGCGCTGCGGGCGC
GGCGCGGGGCTTTGTGCGCTCCGCGTGTGCGCGAGGGGAGCGCGGCCGGGGGCGGTGCCCC
GCGGTGCGGGGGGGCTGCGAGGGGAACAAAGGCTGCGTGCGGGGTGTGTGCGTGGGGGGGT
GAGCAGGGGGTGTGGGCGCGGCGGTCGGGCTGTAACCCCCCCCTGCACCCCCCTCCCCGAG
TTGCTGAGCACGGCCCGGCTTCGGGTGCGGGGCTCCGTGCGGGGCGTGGCGCGGGGCTCGC
CGTGCCGGGCGGGGGGTGGCGGCAGGTGGGGGTGCCGGGCGGGGCGGGGCCGCCTCGGGCC
GGGGAGGGCTCGGGGGAGGGGCGCGGCGGCCCCGGAGCGCCGGCGGCTGTCGAGGCGCGGC
GAGCCGCAGCCATTGCCTTTTATGGTAATCGTGCGAGAGGGCGCAGGGACTTCCTTTGTCC
CAAATCTGGCGGAGCCGAAATCTGGGAGGCGCCGCCGCACCCCCTCTAGCGGGCGCGGGCG
AAGCGGTGCGGCGCCGGCAGGAAGGAAATGGGCGGGGAGGGCCTTCGTGCGTCGCCGCGCC
GCCGTCCCCTTCTCCATCTCCAGCCTCGGGGCTGCCGCAGGGGGACGGCTGCCTTCGGGGG
GGACGGGGCAGGGCGGGGTTCGGCTTCTGGCGTGTGACCGGCGGCTCTAGAGCCTCTGCTA
ACCATGTTCATGCCTTCTTCTTTTTCCTACAGCTCCTGGGCAACGTGCTGGTTGTTGTGCT
GTCTCATCATTTTGGCAAAGAATTCTGCAGTCGACGAATTCAGCGCTCTCGAGACCGGTGC
CGCCATGGGAGGATCCCAGTGTACTAATTATGCTCTCTTGAAATTGGCTGGAGATGTTGAG
AGCAACCCAGGTCCCAGATCTGAGGGCAGAGGAAGTCTTCTAACATGCGGTGACGTGGAGG
AGAATCCCGGCCCTTCTAGAGCCACGAAGCAAGCAGGAGATGTTGAAGAAAACCCCGGTCC
T 
gct agc ATG act gga gtc ttt gac agt cta gtg gct gat atg cac 
tcg acc cag atc gcc gcc tcc agc acg tac cac cag cac cag cag 
ccc ccg agc ggc ggc ggc gcc ggc ccg ggt ggc aac agc agc agc 
agc agc agc ctc cac aag ccc cag gag tcg ccc acc ctt ccg gtg 
tcc acc gcc acc gac agc agc tac tac acc aac cag cag cac ccg 
gcg ggc ggc ggc ggc ggc ggg ggc tcg ccc tac gcg cac atg ggt 
tcc tac cag tac caa gcc agc ggc ctc aac aac gtc cct tac tcc 
gcc aag agc agc tat gac ctg ggc tac acc gcc gcc tac acc tcc 
tac gct ccc tat gga acc agt tcg tcc cca gcc aac aac gag cct 
gag aag gag gac ctt gag cct gaa att cgg ata gtg aac ggg aag 
cca aag aaa gtc cgg aaa ccc cgc acc atc tac tcc agt ttc cag 
ctg gcg gct ctt cag cgg cgt ttc caa aag act caa tac ttg gcc 
ttg ccg gag cga gcc gag ctg gcg gcc tct ctg ggc ctc acc cag 
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act cag gtc aaa atc tgg ttc cag aac cgc cgg tcc aag ttc aag 
aag atg tgg aaa agt ggt gag atc ccc tcg gag cag cac cct ggg 
gcc agc gct tct cca cct tgt gct tcg ccg cca gtc tca gcg ccg 
gcc tcc tgg gac ttt ggt gtg ccg cag cgg atg gcg ggc ggc ggt 
ggt ccg ggc agt ggc ggc agc ggc gcc ggc agc tcg ggc tcc agc 
ccg agc agc gcg gcc tcg gct ttt ctg ggc aac tac ccc tgg tac 
cac cag acc tcg gga tcc gcc tca cac ctg cag gcc acg gcg ccg 
ctg ctg cac ccc act cag acc ccg cag ccg cat cac cac cac cac 
cat cac ggc ggc ggg ggc gcc ccg gtg agc gcg ggg acg att ttc 
gct agc 
TAAGTCGACGGTACCGCGGGCCCGGGATCCGCCCCTCTCCCTCCCCCCCCCCTAACGTTAC
TGGCCGAAGCCGCTTGGAATAAGGCCGGTGTGCGTTTGTCTATATGTTATTTTCCACCATA
TTGCCGTCTTTTGGCAATGTGAGGGCCCGGAAACCTGGCCCTGTCTTCTTGACGAGCATTC
CTAGGGGTCTTTCCCCTCTCGCCAAAGGAATGCAAGGTCTGTTGAATGTCGTGAAGGAAGC
AGTTCCTCTGGAAGCTTCTTGAAGACAAACAACGTCTGTAGCGACCCTTTGCAGGCAGCGG
AACCCCCCACCTGGCGACAGGTGCCTCTGCGGCCAAAAGCCACGTGTATAAGATACACCTG
CAAAGGCGGCACAACCCCAGTGCCACGTTGTGAGTTGGATAGTTGTGGAAAGAGTCAAATG
GCTCTCCTCAAGCGTATTCAACAAGGGGCTGAAGGATGCCCAGAAGGTACCCCATTGTATG
GGATCTGATCTGGGGCCTCGGTGCACATGCTTTACATGTGTTTAGTCGAGGTTAAAAAAAC
GTCTAGGCCCCCCGAACCACGGGGACGTGGTTTTCCTTTGAAAAACACGATGATAATATGG
CCACAACCATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGA
GCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCC
ACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGC
CCACCCTCGTGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACAT
GAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATC
TTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCC
TGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCA
CAAGCTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAAC
GGCATCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCG
ACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTA
CCTGAGCACCCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTG
CTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGTAAAGCG
GCCGCGACTCTAGATCATAATCAGCCATACCACATTTGTAGAGGTTTTACTTGCTTTAAAA
AACCTCCCACACCTCCCCCTGAACCTGAAACATAAAATGAATGCAATTGTTGTTGTTAACT
TGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCATCACAAATTTCACAAATAA
AGCATTTTTTTCACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAATGTATCTTAAGGC
GTAAATTGTAAGCGTTAATATTTTGTTAAAATTCGCGTTAAATTTTTGTTAAATCAGCTCA
TTTTTTAACCAATAGGCCGAAATCGGCAAAATCCCTTATAAATCAAAAGAATAGACCGAGA
TAGGGTTGAGTGTTGTTCCAGTTTGGAACAAGAGTCCACTATTAAAGAACGTGGACTCCAA
CGTCAAAGGGCGAAAAACCGTCTATCAGGGCGATGGCCCACTACGTGAACCATCACCCTAA
TCAAGTTTTTTGGGGTCGAGGTGCCGTAAAGCACTAAATCGGAACCCTAAAGGGAGCCCCC
GATTTAGAGCTTGACGGGGAAAGCCGGCGAACGTGGCGAGAAAGGAAGGGAAGAAAGCGAA
AGGAGCGGGCGCTAGGGCGCTGGCAAGTGTAGCGGTCACGCTGCGCGTAACCACCACACCC
GCCGCGCTTAATGCGCCGCTACAGGGCGCGTCAGGTGGCACTTTTCGGGGAAATGTGCGCG
GAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATA
ACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTCCTGAGGCGGAAAGAACCAGC
TGTGGAATGTGTGTCAGTTAGGGTGTGGAAAGTCCCCAGGCTCCCCAGCAGGCAGAAGTAT
GCAAAGCATGCATCTCAATTAGTCAGCAACCAGGTGTGGAAAGTCCCCAGGCTCCCCAGCA
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GGCAGAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCTAACTC
CGCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGACTAAT
TTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTATTCCAGAAGTAGTGA
GGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAGATCGATCAAGAGACAGGATGAGGATCG
TTTCGCATGATTGAACAAGATGGATTGCACGCAGGTTCTCCGGCCGCTTGGGTGGAGAGGC
TATTCGGCTATGACTGGGCACAACAGACAATCGGCTGCTCTGATGCCGCCGTGTTCCGGCT
GTCAGCGCAGGGGCGCCCGGTTCTTTTTGTCAAGACCGACCTGTCCGGTGCCCTGAATGAA
CTGCAAGACGAGGCAGCGCGGCTATCGTGGCTGGCCACGACGGGCGTTCCTTGCGCAGCTG
TGCTCGACGTTGTCACTGAAGCGGGAAGGGACTGGCTGCTATTGGGCGAAGTGCCGGGGCA
GGATCTCCTGTCATCTCACCTTGCTCCTGCCGAGAAAGTATCCATCATGGCTGATGCAATG
CGGCGGCTGCATACGCTTGATCCGGCTACCTGCCCATTCGACCACCAAGCGAAACATCGCA
TCGAGCGAGCACGTACTCGGATGGAAGCCGGTCTTGTCGATCAGGATGATCTGGACGAAGA
GCATCAGGGGCTCGCGCCAGCCGAACTGTTCGCCAGGCTCAAGGCGAGCATGCCCGACGGC
GAGGATCTCGTCGTGACCCATGGCGATGCCTGCTTGCCGAATATCATGGTGGAAAATGGCC
GCTTTTCTGGATTCATCGACTGTGGCCGGCTGGGTGTGGCGGACCGCTATCAGGACATAGC
GTTGGCTACCCGTGATATTGCTGAAGAGCTTGGCGGCGAATGGGCTGACCGCTTCCTCGTG
CTTTACGGTATCGCCGCTCCCGATTCGCAGCGCATCGCCTTCTATCGCCTTCTTGACGAGT
TCTTCTGAGCGGGACTCTGGGGTTCGAAATGACCGACCAAGCGACGCCCAACCTGCCATCA
CGAGATTTCGATTCCACCGCCGCCTTCTATGAAAGGTTGGGCTTCGGAATCGTTTTCCGGG
ACGCCGGCTGGATGATCCTCCAGCGCGGGGATCTCATGCTGGAGTTCTTCGCCCACCCTAG
GGGGAGGCTAACTGAAACACGGAAGGAGACAATACCGGAAGGAACCCGCGCTATGACGGCA
ATAAAAAGACAGAATAAAACGCACGGTGTTGGGTCGTTTGTTCATAAACGCGGGGTTCGGT
CCCAGGGCTGGCACTCTGTCGATACCCCACCGAGACCCCATTGGGGCCAATACGCCCGCGT
TTCTTCCTTTTCCCCACCCCACCCCCCAAGTTCGGGTGAAGGCCCAGGGCTCGCAGCCAAC
GTCGGGGCGGCAGGCCCTGCCATAGCCTCAGGTTACTCATATATACTTTAGATTGATTTAA
AACTTCATTTTTAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAA
AATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGA
TCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGC
TACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACTGG
CTTCAGCAGAGCGCAGATACCAAATACTGTCCTTCTAGTGTAGCCGTAGTTAGGCCACCAC
TTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTG
CTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAA
GGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACC
TACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGA
GAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCT
TCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAG
CGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGG
CCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGTTCTTTCCTGCGTTATC
CCCTGATTCTGTGGATAACCGTATTACCGCCATGCAT 
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4.1.6 pCAGG-MASH1 (7,346 bp) 
 
TAGTTATTTCTCGACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATT
AGTTCATAGCCCATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGC
TGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGC
CAATAGGGACTTTCCATTGACGTCAATGGGTGGACTATTTACGGTAAACTGCCCACTTGGC
AGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGG
CCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCT
ACGTATTAGTCATCGCTATTACCATGGGTCGAGGTGAGCCCCACGTTCTGCTTCACTCTCC
CCATCTCCCCCCCCTCCCCACCCCCAATTTTGTATTTATTTATTTTTTAATTATTTTGTGC
AGCGATGGGGGCGGGGGGGGGGGGGGCGCGCGCCAGGCGGGGCGGGGCGGGGCGAGGGGCG
GGGCGGGGCGAGGCGGAGAGGTGCGGCGGCAGCCAATCAGAGCGGCGCGCTCCGAAAGTTT
CCTTTTATGGCGAGGCGGCGGCGGCGGCGGCCCTATAAAAAGCGAAGCGCGCGGCGGGCGG
GAGTCGCTGCGTTGCCTTCGCCCCGTGCCCCGCTCCGCGCCGCCTCGCGCCGCCCGCCCCG
GCTCTGACTGACCGCGTTACTCCCACAGGTGAGCGGGCGGGACGGCCCTTCTCCTCCGGGC
TGTAATTAGCGCTTGGTTTAATGACGGCTCGTTTCTTTTCTGTGGCTGCGTGAAAGCCTTA
AAGGGCTCCGGGAGGGCCCTTTGTGCGGGGGGGAGCGGCTCGGGGGGTGCGTGCGTGTGTG
TGTGCGTGGGGAGCGCCGCGTGCGGCCCGCGCTGCCCGGCGGCTGTGAGCGCTGCGGGCGC
GGCGCGGGGCTTTGTGCGCTCCGCGTGTGCGCGAGGGGAGCGCGGCCGGGGGCGGTGCCCC
GCGGTGCGGGGGGGCTGCGAGGGGAACAAAGGCTGCGTGCGGGGTGTGTGCGTGGGGGGGT
GAGCAGGGGGTGTGGGCGCGGCGGTCGGGCTGTAACCCCCCCCTGCACCCCCCTCCCCGAG
TTGCTGAGCACGGCCCGGCTTCGGGTGCGGGGCTCCGTGCGGGGCGTGGCGCGGGGCTCGC
CGTGCCGGGCGGGGGGTGGCGGCAGGTGGGGGTGCCGGGCGGGGCGGGGCCGCCTCGGGCC
GGGGAGGGCTCGGGGGAGGGGCGCGGCGGCCCCGGAGCGCCGGCGGCTGTCGAGGCGCGGC
GAGCCGCAGCCATTGCCTTTTATGGTAATCGTGCGAGAGGGCGCAGGGACTTCCTTTGTCC
CAAATCTGGCGGAGCCGAAATCTGGGAGGCGCCGCCGCACCCCCTCTAGCGGGCGCGGGCG
AAGCGGTGCGGCGCCGGCAGGAAGGAAATGGGCGGGGAGGGCCTTCGTGCGTCGCCGCGCC
GCCGTCCCCTTCTCCATCTCCAGCCTCGGGGCTGCCGCAGGGGGACGGCTGCCTTCGGGGG
GGACGGGGCAGGGCGGGGTTCGGCTTCTGGCGTGTGACCGGCGGCTCTAGAGCCTCTGCTA
ACCATGTTCATGCCTTCTTCTTTTTCCTACAGCTCCTGGGCAACGTGCTGGTTGTTGTGCT
GTCTCATCATTTTGGCAAAGAATTCTGCAGTCGACGAATTCAGCGCTCTCGAGACCGGTGC
CGCCATGGGA  
gga tcc ATG gaa agc tct gcc aag atg gag agc ggc ggc gcc ggc 
cag cag ccc cag ccg cag ccc cag cag ccc ttc ctg ccg ccc gca 
gcc tgt ttc ttt gcc acg gcc gca gcc gcg gcg gcc gca gcc gcc 
gca gcg gca gcg cag agc gcg cag cag cag cag cag cag cag cag 
cag cag cag cag gcg ccg cag ctg aga ccg gcg gcc gac ggc cag 
ccc tca ggg ggc ggt cac aag tca gcg ccc aag caa gtc aag cga 
cag cgc tcg tct tcg ccc gaa ctg atg cgc tgc aaa cgc cgg ctc 
aac ttc agc ggc ttt ggc tac agc ctg ccg cag cag cag ccg gcc 
gcc gtg gcg cgc cgc aac gag cgc gag cgc aac cgc gtc aag ttg 
gtc aac ctg ggc ttt gcc acc ctt cgg gag cac gtc ccc aac ggc 
gcg gcc aac aag aag atg agt aag gtg gag aca ctg cgc tcg gcg 
gtc gag tac atc cgc gcg ctg cag cag ctg ctg gac gag cat gac 
gcg gtg agc gcc gcc ttc cag gca ggc gtc ctg tcg ccc acc atc 
tcc ccc aac tac tcc aac gac ttg aac tcc atg gcc ggc tcg ccg 
gtc tca tcc tac tcg tcg gac gag ggc tct tac gac ccg ctc agc 
ccc gag gag cag gag ctt ctc gac ttc acc aac tgg ttc gga tcc 
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CAGTGTACTAATTATGCTCTCTTGAAATTGGCTGGAGATGTTGAGAGCAACCCAGGTCCCA
GATCTGAGGGCAGAGGAAGTCTTCTAACATGCGGTGACGTGGAGGAGAATCCCGGCCCTTC
TAGAGCCACGAAGCAAGCAGGAGATGTTGAAGAAAACCCCGGTCCTGCTAGCTAAGTCGAC
GGTACCGCGGGCCCGGGATCCGCCCCTCTCCCTCCCCCCCCCCTAACGTTACTGGCCGAAG
CCGCTTGGAATAAGGCCGGTGTGCGTTTGTCTATATGTTATTTTCCACCATATTGCCGTCT
TTTGGCAATGTGAGGGCCCGGAAACCTGGCCCTGTCTTCTTGACGAGCATTCCTAGGGGTC
TTTCCCCTCTCGCCAAAGGAATGCAAGGTCTGTTGAATGTCGTGAAGGAAGCAGTTCCTCT
GGAAGCTTCTTGAAGACAAACAACGTCTGTAGCGACCCTTTGCAGGCAGCGGAACCCCCCA
CCTGGCGACAGGTGCCTCTGCGGCCAAAAGCCACGTGTATAAGATACACCTGCAAAGGCGG
CACAACCCCAGTGCCACGTTGTGAGTTGGATAGTTGTGGAAAGAGTCAAATGGCTCTCCTC
AAGCGTATTCAACAAGGGGCTGAAGGATGCCCAGAAGGTACCCCATTGTATGGGATCTGAT
CTGGGGCCTCGGTGCACATGCTTTACATGTGTTTAGTCGAGGTTAAAAAAACGTCTAGGCC
CCCCGAACCACGGGGACGTGGTTTTCCTTTGAAAAACACGATGATAATATGGCCACAACCA
TGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGG
CGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGC
AAGCTGACCCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCG
TGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCA
CGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAG
GACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACC
GCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGA
GTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAG
GTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACC
AGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCAC
CCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTC
GTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGTAAAGCGGCCGCGACT
CTAGATCATAATCAGCCATACCACATTTGTAGAGGTTTTACTTGCTTTAAAAAACCTCCCA
CACCTCCCCCTGAACCTGAAACATAAAATGAATGCAATTGTTGTTGTTAACTTGTTTATTG
CAGCTTATAATGGTTACAAATAAAGCAATAGCATCACAAATTTCACAAATAAAGCATTTTT
TTCACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAATGTATCTTAAGGCGTAAATTGT
AAGCGTTAATATTTTGTTAAAATTCGCGTTAAATTTTTGTTAAATCAGCTCATTTTTTAAC
CAATAGGCCGAAATCGGCAAAATCCCTTATAAATCAAAAGAATAGACCGAGATAGGGTTGA
GTGTTGTTCCAGTTTGGAACAAGAGTCCACTATTAAAGAACGTGGACTCCAACGTCAAAGG
GCGAAAAACCGTCTATCAGGGCGATGGCCCACTACGTGAACCATCACCCTAATCAAGTTTT
TTGGGGTCGAGGTGCCGTAAAGCACTAAATCGGAACCCTAAAGGGAGCCCCCGATTTAGAG
CTTGACGGGGAAAGCCGGCGAACGTGGCGAGAAAGGAAGGGAAGAAAGCGAAAGGAGCGGG
CGCTAGGGCGCTGGCAAGTGTAGCGGTCACGCTGCGCGTAACCACCACACCCGCCGCGCTT
AATGCGCCGCTACAGGGCGCGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTA
TTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATA
AATGCTTCAATAATATTGAAAAAGGAAGAGTCCTGAGGCGGAAAGAACCAGCTGTGGAATG
TGTGTCAGTTAGGGTGTGGAAAGTCCCCAGGCTCCCCAGCAGGCAGAAGTATGCAAAGCAT
GCATCTCAATTAGTCAGCAACCAGGTGTGGAAAGTCCCCAGGCTCCCCAGCAGGCAGAAGT
ATGCAAAGCATGCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCTAACTCCGCCCATCC
CGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGACTAATTTTTTTTAT
TTATGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTT
TTTGGAGGCCTAGGCTTTTGCAAAGATCGATCAAGAGACAGGATGAGGATCGTTTCGCATG
ATTGAACAAGATGGATTGCACGCAGGTTCTCCGGCCGCTTGGGTGGAGAGGCTATTCGGCT
ATGACTGGGCACAACAGACAATCGGCTGCTCTGATGCCGCCGTGTTCCGGCTGTCAGCGCA
GGGGCGCCCGGTTCTTTTTGTCAAGACCGACCTGTCCGGTGCCCTGAATGAACTGCAAGAC
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GAGGCAGCGCGGCTATCGTGGCTGGCCACGACGGGCGTTCCTTGCGCAGCTGTGCTCGACG
TTGTCACTGAAGCGGGAAGGGACTGGCTGCTATTGGGCGAAGTGCCGGGGCAGGATCTCCT
GTCATCTCACCTTGCTCCTGCCGAGAAAGTATCCATCATGGCTGATGCAATGCGGCGGCTG
CATACGCTTGATCCGGCTACCTGCCCATTCGACCACCAAGCGAAACATCGCATCGAGCGAG
CACGTACTCGGATGGAAGCCGGTCTTGTCGATCAGGATGATCTGGACGAAGAGCATCAGGG
GCTCGCGCCAGCCGAACTGTTCGCCAGGCTCAAGGCGAGCATGCCCGACGGCGAGGATCTC
GTCGTGACCCATGGCGATGCCTGCTTGCCGAATATCATGGTGGAAAATGGCCGCTTTTCTG
GATTCATCGACTGTGGCCGGCTGGGTGTGGCGGACCGCTATCAGGACATAGCGTTGGCTAC
CCGTGATATTGCTGAAGAGCTTGGCGGCGAATGGGCTGACCGCTTCCTCGTGCTTTACGGT
ATCGCCGCTCCCGATTCGCAGCGCATCGCCTTCTATCGCCTTCTTGACGAGTTCTTCTGAG
CGGGACTCTGGGGTTCGAAATGACCGACCAAGCGACGCCCAACCTGCCATCACGAGATTTC
GATTCCACCGCCGCCTTCTATGAAAGGTTGGGCTTCGGAATCGTTTTCCGGGACGCCGGCT
GGATGATCCTCCAGCGCGGGGATCTCATGCTGGAGTTCTTCGCCCACCCTAGGGGGAGGCT
AACTGAAACACGGAAGGAGACAATACCGGAAGGAACCCGCGCTATGACGGCAATAAAAAGA
CAGAATAAAACGCACGGTGTTGGGTCGTTTGTTCATAAACGCGGGGTTCGGTCCCAGGGCT
GGCACTCTGTCGATACCCCACCGAGACCCCATTGGGGCCAATACGCCCGCGTTTCTTCCTT
TTCCCCACCCCACCCCCCAAGTTCGGGTGAAGGCCCAGGGCTCGCAGCCAACGTCGGGGCG
GCAGGCCCTGCCATAGCCTCAGGTTACTCATATATACTTTAGATTGATTTAAAACTTCATT
TTTAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTTA
ACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGA
GATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGG
TGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACTGGCTTCAGCAG
AGCGCAGATACCAAATACTGTCCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAAC
TCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTG
GCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCG
GTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAA
CTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGG
ACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGG
AAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTT
TTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTAC
GGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGTTCTTTCCTGCGTTATCCCCTGATTC
TGTGGATAACCGTATTACCGCCATGCAT 
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4.1.7 pCAGG-DLX2/MASH1 (8,336 bp) 
 
TAGTTATTTCTCGACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATT
AGTTCATAGCCCATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGC
TGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGC
CAATAGGGACTTTCCATTGACGTCAATGGGTGGACTATTTACGGTAAACTGCCCACTTGGC
AGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGG
CCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCT
ACGTATTAGTCATCGCTATTACCATGGGTCGAGGTGAGCCCCACGTTCTGCTTCACTCTCC
CCATCTCCCCCCCCTCCCCACCCCCAATTTTGTATTTATTTATTTTTTAATTATTTTGTGC
AGCGATGGGGGCGGGGGGGGGGGGGGCGCGCGCCAGGCGGGGCGGGGCGGGGCGAGGGGCG
GGGCGGGGCGAGGCGGAGAGGTGCGGCGGCAGCCAATCAGAGCGGCGCGCTCCGAAAGTTT
CCTTTTATGGCGAGGCGGCGGCGGCGGCGGCCCTATAAAAAGCGAAGCGCGCGGCGGGCGG
GAGTCGCTGCGTTGCCTTCGCCCCGTGCCCCGCTCCGCGCCGCCTCGCGCCGCCCGCCCCG
GCTCTGACTGACCGCGTTACTCCCACAGGTGAGCGGGCGGGACGGCCCTTCTCCTCCGGGC
TGTAATTAGCGCTTGGTTTAATGACGGCTCGTTTCTTTTCTGTGGCTGCGTGAAAGCCTTA
AAGGGCTCCGGGAGGGCCCTTTGTGCGGGGGGGAGCGGCTCGGGGGGTGCGTGCGTGTGTG
TGTGCGTGGGGAGCGCCGCGTGCGGCCCGCGCTGCCCGGCGGCTGTGAGCGCTGCGGGCGC
GGCGCGGGGCTTTGTGCGCTCCGCGTGTGCGCGAGGGGAGCGCGGCCGGGGGCGGTGCCCC
GCGGTGCGGGGGGGCTGCGAGGGGAACAAAGGCTGCGTGCGGGGTGTGTGCGTGGGGGGGT
GAGCAGGGGGTGTGGGCGCGGCGGTCGGGCTGTAACCCCCCCCTGCACCCCCCTCCCCGAG
TTGCTGAGCACGGCCCGGCTTCGGGTGCGGGGCTCCGTGCGGGGCGTGGCGCGGGGCTCGC
CGTGCCGGGCGGGGGGTGGCGGCAGGTGGGGGTGCCGGGCGGGGCGGGGCCGCCTCGGGCC
GGGGAGGGCTCGGGGGAGGGGCGCGGCGGCCCCGGAGCGCCGGCGGCTGTCGAGGCGCGGC
GAGCCGCAGCCATTGCCTTTTATGGTAATCGTGCGAGAGGGCGCAGGGACTTCCTTTGTCC
CAAATCTGGCGGAGCCGAAATCTGGGAGGCGCCGCCGCACCCCCTCTAGCGGGCGCGGGCG
AAGCGGTGCGGCGCCGGCAGGAAGGAAATGGGCGGGGAGGGCCTTCGTGCGTCGCCGCGCC
GCCGTCCCCTTCTCCATCTCCAGCCTCGGGGCTGCCGCAGGGGGACGGCTGCCTTCGGGGG
GGACGGGGCAGGGCGGGGTTCGGCTTCTGGCGTGTGACCGGCGGCTCTAGAGCCTCTGCTA
ACCATGTTCATGCCTTCTTCTTTTTCCTACAGCTCCTGGGCAACGTGCTGGTTGTTGTGCT
GTCTCATCATTTTGGCAAAGAATTCTGCAGTCGACGAATTCAGCGCTCTCGAGACCGGTGC
CGCCATGGGA  
gga tcc ATG gaa agc tct gcc aag atg gag agc ggc ggc gcc ggc 
cag cag ccc cag ccg cag ccc cag cag ccc ttc ctg ccg ccc gca 
gcc tgt ttc ttt gcc acg gcc gca gcc gcg gcg gcc gca gcc gcc 
gca gcg gca gcg cag agc gcg cag cag cag cag cag cag cag cag 
cag cag cag cag gcg ccg cag ctg aga ccg gcg gcc gac ggc cag 
ccc tca ggg ggc ggt cac aag tca gcg ccc aag caa gtc aag cga 
cag cgc tcg tct tcg ccc gaa ctg atg cgc tgc aaa cgc cgg ctc 
aac ttc agc ggc ttt ggc tac agc ctg ccg cag cag cag ccg gcc 
gcc gtg gcg cgc cgc aac gag cgc gag cgc aac cgc gtc aag ttg 
gtc aac ctg ggc ttt gcc acc ctt cgg gag cac gtc ccc aac ggc 
gcg gcc aac aag aag atg agt aag gtg gag aca ctg cgc tcg gcg 
gtc gag tac atc cgc gcg ctg cag cag ctg ctg gac gag cat gac 
gcg gtg agc gcc gcc ttc cag gca ggc gtc ctg tcg ccc acc atc 
tcc ccc aac tac tcc aac gac ttg aac tcc atg gcc ggc tcg ccg 
gtc tca tcc tac tcg tcg gac gag ggc tct tac gac ccg ctc agc 
ccc gag gag cag gag ctt ctc gac ttc acc aac tgg ttc gga tcc 
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CAGTGTACTAATTATGCTCTCTTGAAATTGGCTGGAGATGTTGAGAGCAACCCAGGTCCCA
GATCTGAGGGCAGAGGAAGTCTTCTAACATGCGGTGACGTGGAGGAGAATCCCGGCCCTTC
TAGAGCCACGAAGCAAGCAGGAGATGTTGAAGAAAACCCCGGTCCT 
gct agc ATG act gga gtc ttt gac agt cta gtg gct gat atg cac 
tcg acc cag atc gcc gcc tcc agc acg tac cac cag cac cag cag 
ccc ccg agc ggc ggc ggc gcc ggc ccg ggt ggc aac agc agc agc 
agc agc agc ctc cac aag ccc cag gag tcg ccc acc ctt ccg gtg 
tcc acc gcc acc gac agc agc tac tac acc aac cag cag cac ccg 
gcg ggc ggc ggc ggc ggc ggg ggc tcg ccc tac gcg cac atg ggt 
tcc tac cag tac caa gcc agc ggc ctc aac aac gtc cct tac tcc 
gcc aag agc agc tat gac ctg ggc tac acc gcc gcc tac acc tcc 
tac gct ccc tat gga acc agt tcg tcc cca gcc aac aac gag cct 
gag aag gag gac ctt gag cct gaa att cgg ata gtg aac ggg aag 
cca aag aaa gtc cgg aaa ccc cgc acc atc tac tcc agt ttc cag 
ctg gcg gct ctt cag cgg cgt ttc caa aag act caa tac ttg gcc 
ttg ccg gag cga gcc gag ctg gcg gcc tct ctg ggc ctc acc cag 
act cag gtc aaa atc tgg ttc cag aac cgc cgg tcc aag ttc aag 
aag atg tgg aaa agt ggt gag atc ccc tcg gag cag cac cct ggg 
gcc agc gct tct cca cct tgt gct tcg ccg cca gtc tca gcg ccg 
gcc tcc tgg gac ttt ggt gtg ccg cag cgg atg gcg ggc ggc ggt 
ggt ccg ggc agt ggc ggc agc ggc gcc ggc agc tcg ggc tcc agc 
ccg agc agc gcg gcc tcg gct ttt ctg ggc aac tac ccc tgg tac 
cac cag acc tcg gga tcc gcc tca cac ctg cag gcc acg gcg ccg 
ctg ctg cac ccc act cag acc ccg cag ccg cat cac cac cac cac 
cat cac ggc ggc ggg ggc gcc ccg gtg agc gcg ggg acg att ttc 
gct agc 
TAAGTCGACGGTACCGCGGGCCCGGGATCCGCCCCTCTCCCTCCCCCCCCCCTAACGTTAC
TGGCCGAAGCCGCTTGGAATAAGGCCGGTGTGCGTTTGTCTATATGTTATTTTCCACCATA
TTGCCGTCTTTTGGCAATGTGAGGGCCCGGAAACCTGGCCCTGTCTTCTTGACGAGCATTC
CTAGGGGTCTTTCCCCTCTCGCCAAAGGAATGCAAGGTCTGTTGAATGTCGTGAAGGAAGC
AGTTCCTCTGGAAGCTTCTTGAAGACAAACAACGTCTGTAGCGACCCTTTGCAGGCAGCGG
AACCCCCCACCTGGCGACAGGTGCCTCTGCGGCCAAAAGCCACGTGTATAAGATACACCTG
CAAAGGCGGCACAACCCCAGTGCCACGTTGTGAGTTGGATAGTTGTGGAAAGAGTCAAATG
GCTCTCCTCAAGCGTATTCAACAAGGGGCTGAAGGATGCCCAGAAGGTACCCCATTGTATG
GGATCTGATCTGGGGCCTCGGTGCACATGCTTTACATGTGTTTAGTCGAGGTTAAAAAAAC
GTCTAGGCCCCCCGAACCACGGGGACGTGGTTTTCCTTTGAAAAACACGATGATAATATGG
CCACAACCATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGA
GCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCC
ACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGC
CCACCCTCGTGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACAT
GAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATC
TTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCC
TGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCA
CAAGCTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAAC
GGCATCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCG
ACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTA
CCTGAGCACCCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTG
CTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGTAAAGCG
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GCCGCGACTCTAGATCATAATCAGCCATACCACATTTGTAGAGGTTTTACTTGCTTTAAAA
AACCTCCCACACCTCCCCCTGAACCTGAAACATAAAATGAATGCAATTGTTGTTGTTAACT
TGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCATCACAAATTTCACAAATAA
AGCATTTTTTTCACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAATGTATCTTAAGGC
GTAAATTGTAAGCGTTAATATTTTGTTAAAATTCGCGTTAAATTTTTGTTAAATCAGCTCA
TTTTTTAACCAATAGGCCGAAATCGGCAAAATCCCTTATAAATCAAAAGAATAGACCGAGA
TAGGGTTGAGTGTTGTTCCAGTTTGGAACAAGAGTCCACTATTAAAGAACGTGGACTCCAA
CGTCAAAGGGCGAAAAACCGTCTATCAGGGCGATGGCCCACTACGTGAACCATCACCCTAA
TCAAGTTTTTTGGGGTCGAGGTGCCGTAAAGCACTAAATCGGAACCCTAAAGGGAGCCCCC
GATTTAGAGCTTGACGGGGAAAGCCGGCGAACGTGGCGAGAAAGGAAGGGAAGAAAGCGAA
AGGAGCGGGCGCTAGGGCGCTGGCAAGTGTAGCGGTCACGCTGCGCGTAACCACCACACCC
GCCGCGCTTAATGCGCCGCTACAGGGCGCGTCAGGTGGCACTTTTCGGGGAAATGTGCGCG
GAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATA
ACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTCCTGAGGCGGAAAGAACCAGC
TGTGGAATGTGTGTCAGTTAGGGTGTGGAAAGTCCCCAGGCTCCCCAGCAGGCAGAAGTAT
GCAAAGCATGCATCTCAATTAGTCAGCAACCAGGTGTGGAAAGTCCCCAGGCTCCCCAGCA
GGCAGAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCTAACTC
CGCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGACTAAT
TTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTATTCCAGAAGTAGTGA
GGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAGATCGATCAAGAGACAGGATGAGGATCG
TTTCGCATGATTGAACAAGATGGATTGCACGCAGGTTCTCCGGCCGCTTGGGTGGAGAGGC
TATTCGGCTATGACTGGGCACAACAGACAATCGGCTGCTCTGATGCCGCCGTGTTCCGGCT
GTCAGCGCAGGGGCGCCCGGTTCTTTTTGTCAAGACCGACCTGTCCGGTGCCCTGAATGAA
CTGCAAGACGAGGCAGCGCGGCTATCGTGGCTGGCCACGACGGGCGTTCCTTGCGCAGCTG
TGCTCGACGTTGTCACTGAAGCGGGAAGGGACTGGCTGCTATTGGGCGAAGTGCCGGGGCA
GGATCTCCTGTCATCTCACCTTGCTCCTGCCGAGAAAGTATCCATCATGGCTGATGCAATG
CGGCGGCTGCATACGCTTGATCCGGCTACCTGCCCATTCGACCACCAAGCGAAACATCGCA
TCGAGCGAGCACGTACTCGGATGGAAGCCGGTCTTGTCGATCAGGATGATCTGGACGAAGA
GCATCAGGGGCTCGCGCCAGCCGAACTGTTCGCCAGGCTCAAGGCGAGCATGCCCGACGGC
GAGGATCTCGTCGTGACCCATGGCGATGCCTGCTTGCCGAATATCATGGTGGAAAATGGCC
GCTTTTCTGGATTCATCGACTGTGGCCGGCTGGGTGTGGCGGACCGCTATCAGGACATAGC
GTTGGCTACCCGTGATATTGCTGAAGAGCTTGGCGGCGAATGGGCTGACCGCTTCCTCGTG
CTTTACGGTATCGCCGCTCCCGATTCGCAGCGCATCGCCTTCTATCGCCTTCTTGACGAGT
TCTTCTGAGCGGGACTCTGGGGTTCGAAATGACCGACCAAGCGACGCCCAACCTGCCATCA
CGAGATTTCGATTCCACCGCCGCCTTCTATGAAAGGTTGGGCTTCGGAATCGTTTTCCGGG
ACGCCGGCTGGATGATCCTCCAGCGCGGGGATCTCATGCTGGAGTTCTTCGCCCACCCTAG
GGGGAGGCTAACTGAAACACGGAAGGAGACAATACCGGAAGGAACCCGCGCTATGACGGCA
ATAAAAAGACAGAATAAAACGCACGGTGTTGGGTCGTTTGTTCATAAACGCGGGGTTCGGT
CCCAGGGCTGGCACTCTGTCGATACCCCACCGAGACCCCATTGGGGCCAATACGCCCGCGT
TTCTTCCTTTTCCCCACCCCACCCCCCAAGTTCGGGTGAAGGCCCAGGGCTCGCAGCCAAC
GTCGGGGCGGCAGGCCCTGCCATAGCCTCAGGTTACTCATATATACTTTAGATTGATTTAA
AACTTCATTTTTAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAA
AATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGA
TCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGC
TACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACTGG
CTTCAGCAGAGCGCAGATACCAAATACTGTCCTTCTAGTGTAGCCGTAGTTAGGCCACCAC
TTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTG
CTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAA
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GGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACC
TACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGA
GAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCT
TCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAG
CGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGG
CCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGTTCTTTCCTGCGTTATC
CCCTGATTCTGTGGATAACCGTATTACCGCCATGCAT 
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4.1.8 pCAGG-DLX2/GSX2 (8,540 bp) 
 
TAGTTATTTCTCGACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATT
AGTTCATAGCCCATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGC
TGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGC
CAATAGGGACTTTCCATTGACGTCAATGGGTGGACTATTTACGGTAAACTGCCCACTTGGC
AGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGG
CCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCT
ACGTATTAGTCATCGCTATTACCATGGGTCGAGGTGAGCCCCACGTTCTGCTTCACTCTCC
CCATCTCCCCCCCCTCCCCACCCCCAATTTTGTATTTATTTATTTTTTAATTATTTTGTGC
AGCGATGGGGGCGGGGGGGGGGGGGGCGCGCGCCAGGCGGGGCGGGGCGGGGCGAGGGGCG
GGGCGGGGCGAGGCGGAGAGGTGCGGCGGCAGCCAATCAGAGCGGCGCGCTCCGAAAGTTT
CCTTTTATGGCGAGGCGGCGGCGGCGGCGGCCCTATAAAAAGCGAAGCGCGCGGCGGGCGG
GAGTCGCTGCGTTGCCTTCGCCCCGTGCCCCGCTCCGCGCCGCCTCGCGCCGCCCGCCCCG
GCTCTGACTGACCGCGTTACTCCCACAGGTGAGCGGGCGGGACGGCCCTTCTCCTCCGGGC
TGTAATTAGCGCTTGGTTTAATGACGGCTCGTTTCTTTTCTGTGGCTGCGTGAAAGCCTTA
AAGGGCTCCGGGAGGGCCCTTTGTGCGGGGGGGAGCGGCTCGGGGGGTGCGTGCGTGTGTG
TGTGCGTGGGGAGCGCCGCGTGCGGCCCGCGCTGCCCGGCGGCTGTGAGCGCTGCGGGCGC
GGCGCGGGGCTTTGTGCGCTCCGCGTGTGCGCGAGGGGAGCGCGGCCGGGGGCGGTGCCCC
GCGGTGCGGGGGGGCTGCGAGGGGAACAAAGGCTGCGTGCGGGGTGTGTGCGTGGGGGGGT
GAGCAGGGGGTGTGGGCGCGGCGGTCGGGCTGTAACCCCCCCCTGCACCCCCCTCCCCGAG
TTGCTGAGCACGGCCCGGCTTCGGGTGCGGGGCTCCGTGCGGGGCGTGGCGCGGGGCTCGC
CGTGCCGGGCGGGGGGTGGCGGCAGGTGGGGGTGCCGGGCGGGGCGGGGCCGCCTCGGGCC
GGGGAGGGCTCGGGGGAGGGGCGCGGCGGCCCCGGAGCGCCGGCGGCTGTCGAGGCGCGGC
GAGCCGCAGCCATTGCCTTTTATGGTAATCGTGCGAGAGGGCGCAGGGACTTCCTTTGTCC
CAAATCTGGCGGAGCCGAAATCTGGGAGGCGCCGCCGCACCCCCTCTAGCGGGCGCGGGCG
AAGCGGTGCGGCGCCGGCAGGAAGGAAATGGGCGGGGAGGGCCTTCGTGCGTCGCCGCGCC
GCCGTCCCCTTCTCCATCTCCAGCCTCGGGGCTGCCGCAGGGGGACGGCTGCCTTCGGGGG
GGACGGGGCAGGGCGGGGTTCGGCTTCTGGCGTGTGACCGGCGGCTCTAGAGCCTCTGCTA
ACCATGTTCATGCCTTCTTCTTTTTCCTACAGCTCCTGGGCAACGTGCTGGTTGTTGTGCT
GTCTCATCATTTTGGCAAAGAATTCTGCAGTCGACGAATTCAGCGCTCTCGAGACCGGTGC
CGCCATGGGAGGATCCCAGTGTACTAATTATGCTCTCTTGAAATTGGCTGGAGATGTTGAG
AGCAACCCAGGTCCC 
aga tct ATG tcg cgc tcc ttc tat gtc gac tcg ctc atc atc aag 
gac acc tca cgg cct gcg ccc tcg ctg cct gaa ccg cac ccc ggg 
ccg gat ttc ttc atc ccg ctt ggc atg ccg ccc cca ttg gtg atg 
tcc gtg tcc ggc ccc ggc tgc ccg tcc cgc aag agc ggc gcg ttc 
tgc gtg tgc cct ctc tgc gtc act tcg cac ctg cac tcc tct cgg 
ggg tct gtg ggc gcc ggc agc ggg ggc gca ggg gcc ggg gtt acc 
ggg gcc gga ggc agt ggg gtg gca ggg gcc gca ggg gca ctg cct 
ctg ctt aag agc cag ttc tct tcg gct cct ggg gac gcg cag ttt 
tgc ccg cgg gtg aac cat gcg cat cat cac cac cac ccg ccg cag 
cac cac cat cac cat cat cag ccc cag cag cct ggc tcg gcc gcg 
gcg gcg gca gca gca gca gcg gcg gcg gcg gcc gcg gcg gcc ttg 
ggg cac ccg cag cac cac gca cct gtc tgc acc gcc acc acc tac 
aac gtg gcg gac ccg cgg aga ttc cac tgc ctc acc atg gga ggc 
tct gac gcc agc cag gta ccc aat ggc aag agg atg agg acg gcg 
ttc act agc acg caa ctc ctg gag ctg gag aga gaa ttc tct tcc 
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aac atg tac ctg tct cga ctc cgg agg att gaa atc gcc act tac 
ctg aac ctg tcg gag aag cag gtg aaa atc tgg ttt cag aac cgc 
cga gtg aag cac aag aag gag ggg aag ggc acg cag agg aac agt 
cac gcg ggc tgc aag tgc gtc ggg agc cag gtg cac tac gcg cgc 
tcc gag gat gag gac tcc ctg tcg ccg gcc tca gcc aac gat gac 
aag gag att tcc ccc tta aga tct 
GAGGGCAGAGGAAGTCTTCTAACATGCGGTGACGTGGAGGAGAATCCCGGCCCTTCTAGAG
CCACGAAGCAAGCAGGAGATGTTGAAGAAAACCCCGGTCCT 
gct agc ATG act gga gtc ttt gac agt cta gtg gct gat atg cac 
tcg acc cag atc gcc gcc tcc agc acg tac cac cag cac cag cag 
ccc ccg agc ggc ggc ggc gcc ggc ccg ggt ggc aac agc agc agc 
agc agc agc ctc cac aag ccc cag gag tcg ccc acc ctt ccg gtg 
tcc acc gcc acc gac agc agc tac tac acc aac cag cag cac ccg 
gcg ggc ggc ggc ggc ggc ggg ggc tcg ccc tac gcg cac atg ggt 
tcc tac cag tac caa gcc agc ggc ctc aac aac gtc cct tac tcc 
gcc aag agc agc tat gac ctg ggc tac acc gcc gcc tac acc tcc 
tac gct ccc tat gga acc agt tcg tcc cca gcc aac aac gag cct 
gag aag gag gac ctt gag cct gaa att cgg ata gtg aac ggg aag 
cca aag aaa gtc cgg aaa ccc cgc acc atc tac tcc agt ttc cag 
ctg gcg gct ctt cag cgg cgt ttc caa aag act caa tac ttg gcc 
ttg ccg gag cga gcc gag ctg gcg gcc tct ctg ggc ctc acc cag 
act cag gtc aaa atc tgg ttc cag aac cgc cgg tcc aag ttc aag 
aag atg tgg aaa agt ggt gag atc ccc tcg gag cag cac cct ggg 
gcc agc gct tct cca cct tgt gct tcg ccg cca gtc tca gcg ccg 
gcc tcc tgg gac ttt ggt gtg ccg cag cgg atg gcg ggc ggc ggt 
ggt ccg ggc agt ggc ggc agc ggc gcc ggc agc tcg ggc tcc agc 
ccg agc agc gcg gcc tcg gct ttt ctg ggc aac tac ccc tgg tac 
cac cag acc tcg gga tcc gcc tca cac ctg cag gcc acg gcg ccg 
ctg ctg cac ccc act cag acc ccg cag ccg cat cac cac cac cac 
cat cac ggc ggc ggg ggc gcc ccg gtg agc gcg ggg acg att ttc 
gct agc 
TAAGTCGACGGTACCGCGGGCCCGGGATCCGCCCCTCTCCCTCCCCCCCCCCTAACGTTAC
TGGCCGAAGCCGCTTGGAATAAGGCCGGTGTGCGTTTGTCTATATGTTATTTTCCACCATA
TTGCCGTCTTTTGGCAATGTGAGGGCCCGGAAACCTGGCCCTGTCTTCTTGACGAGCATTC
CTAGGGGTCTTTCCCCTCTCGCCAAAGGAATGCAAGGTCTGTTGAATGTCGTGAAGGAAGC
AGTTCCTCTGGAAGCTTCTTGAAGACAAACAACGTCTGTAGCGACCCTTTGCAGGCAGCGG
AACCCCCCACCTGGCGACAGGTGCCTCTGCGGCCAAAAGCCACGTGTATAAGATACACCTG
CAAAGGCGGCACAACCCCAGTGCCACGTTGTGAGTTGGATAGTTGTGGAAAGAGTCAAATG
GCTCTCCTCAAGCGTATTCAACAAGGGGCTGAAGGATGCCCAGAAGGTACCCCATTGTATG
GGATCTGATCTGGGGCCTCGGTGCACATGCTTTACATGTGTTTAGTCGAGGTTAAAAAAAC
GTCTAGGCCCCCCGAACCACGGGGACGTGGTTTTCCTTTGAAAAACACGATGATAATATGG
CCACAACCATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGA
GCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCC
ACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGC
CCACCCTCGTGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACAT
GAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATC
TTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCC
TGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCA
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CAAGCTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAAC
GGCATCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCG
ACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTA
CCTGAGCACCCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTG
CTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGTAAAGCG
GCCGCGACTCTAGATCATAATCAGCCATACCACATTTGTAGAGGTTTTACTTGCTTTAAAA
AACCTCCCACACCTCCCCCTGAACCTGAAACATAAAATGAATGCAATTGTTGTTGTTAACT
TGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCATCACAAATTTCACAAATAA
AGCATTTTTTTCACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAATGTATCTTAAGGC
GTAAATTGTAAGCGTTAATATTTTGTTAAAATTCGCGTTAAATTTTTGTTAAATCAGCTCA
TTTTTTAACCAATAGGCCGAAATCGGCAAAATCCCTTATAAATCAAAAGAATAGACCGAGA
TAGGGTTGAGTGTTGTTCCAGTTTGGAACAAGAGTCCACTATTAAAGAACGTGGACTCCAA
CGTCAAAGGGCGAAAAACCGTCTATCAGGGCGATGGCCCACTACGTGAACCATCACCCTAA
TCAAGTTTTTTGGGGTCGAGGTGCCGTAAAGCACTAAATCGGAACCCTAAAGGGAGCCCCC
GATTTAGAGCTTGACGGGGAAAGCCGGCGAACGTGGCGAGAAAGGAAGGGAAGAAAGCGAA
AGGAGCGGGCGCTAGGGCGCTGGCAAGTGTAGCGGTCACGCTGCGCGTAACCACCACACCC
GCCGCGCTTAATGCGCCGCTACAGGGCGCGTCAGGTGGCACTTTTCGGGGAAATGTGCGCG
GAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATA
ACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTCCTGAGGCGGAAAGAACCAGC
TGTGGAATGTGTGTCAGTTAGGGTGTGGAAAGTCCCCAGGCTCCCCAGCAGGCAGAAGTAT
GCAAAGCATGCATCTCAATTAGTCAGCAACCAGGTGTGGAAAGTCCCCAGGCTCCCCAGCA
GGCAGAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCTAACTC
CGCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGACTAAT
TTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTATTCCAGAAGTAGTGA
GGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAGATCGATCAAGAGACAGGATGAGGATCG
TTTCGCATGATTGAACAAGATGGATTGCACGCAGGTTCTCCGGCCGCTTGGGTGGAGAGGC
TATTCGGCTATGACTGGGCACAACAGACAATCGGCTGCTCTGATGCCGCCGTGTTCCGGCT
GTCAGCGCAGGGGCGCCCGGTTCTTTTTGTCAAGACCGACCTGTCCGGTGCCCTGAATGAA
CTGCAAGACGAGGCAGCGCGGCTATCGTGGCTGGCCACGACGGGCGTTCCTTGCGCAGCTG
TGCTCGACGTTGTCACTGAAGCGGGAAGGGACTGGCTGCTATTGGGCGAAGTGCCGGGGCA
GGATCTCCTGTCATCTCACCTTGCTCCTGCCGAGAAAGTATCCATCATGGCTGATGCAATG
CGGCGGCTGCATACGCTTGATCCGGCTACCTGCCCATTCGACCACCAAGCGAAACATCGCA
TCGAGCGAGCACGTACTCGGATGGAAGCCGGTCTTGTCGATCAGGATGATCTGGACGAAGA
GCATCAGGGGCTCGCGCCAGCCGAACTGTTCGCCAGGCTCAAGGCGAGCATGCCCGACGGC
GAGGATCTCGTCGTGACCCATGGCGATGCCTGCTTGCCGAATATCATGGTGGAAAATGGCC
GCTTTTCTGGATTCATCGACTGTGGCCGGCTGGGTGTGGCGGACCGCTATCAGGACATAGC
GTTGGCTACCCGTGATATTGCTGAAGAGCTTGGCGGCGAATGGGCTGACCGCTTCCTCGTG
CTTTACGGTATCGCCGCTCCCGATTCGCAGCGCATCGCCTTCTATCGCCTTCTTGACGAGT
TCTTCTGAGCGGGACTCTGGGGTTCGAAATGACCGACCAAGCGACGCCCAACCTGCCATCA
CGAGATTTCGATTCCACCGCCGCCTTCTATGAAAGGTTGGGCTTCGGAATCGTTTTCCGGG
ACGCCGGCTGGATGATCCTCCAGCGCGGGGATCTCATGCTGGAGTTCTTCGCCCACCCTAG
GGGGAGGCTAACTGAAACACGGAAGGAGACAATACCGGAAGGAACCCGCGCTATGACGGCA
ATAAAAAGACAGAATAAAACGCACGGTGTTGGGTCGTTTGTTCATAAACGCGGGGTTCGGT
CCCAGGGCTGGCACTCTGTCGATACCCCACCGAGACCCCATTGGGGCCAATACGCCCGCGT
TTCTTCCTTTTCCCCACCCCACCCCCCAAGTTCGGGTGAAGGCCCAGGGCTCGCAGCCAAC
GTCGGGGCGGCAGGCCCTGCCATAGCCTCAGGTTACTCATATATACTTTAGATTGATTTAA
AACTTCATTTTTAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAA
AATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGA
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TCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGC
TACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACTGG
CTTCAGCAGAGCGCAGATACCAAATACTGTCCTTCTAGTGTAGCCGTAGTTAGGCCACCAC
TTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTG
CTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAA
GGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACC
TACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGA
GAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCT
TCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAG
CGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGG
CCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGTTCTTTCCTGCGTTATC
CCCTGATTCTGTGGATAACCGTATTACCGCCATGCAT 
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4.1.9 pCAGG-DLX2/MASH1/GSX2 (9,254 bp) 
 
TAGTTATTTCTCGACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATT
AGTTCATAGCCCATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGC
TGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGC
CAATAGGGACTTTCCATTGACGTCAATGGGTGGACTATTTACGGTAAACTGCCCACTTGGC
AGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGG
CCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCT
ACGTATTAGTCATCGCTATTACCATGGGTCGAGGTGAGCCCCACGTTCTGCTTCACTCTCC
CCATCTCCCCCCCCTCCCCACCCCCAATTTTGTATTTATTTATTTTTTAATTATTTTGTGC
AGCGATGGGGGCGGGGGGGGGGGGGGCGCGCGCCAGGCGGGGCGGGGCGGGGCGAGGGGCG
GGGCGGGGCGAGGCGGAGAGGTGCGGCGGCAGCCAATCAGAGCGGCGCGCTCCGAAAGTTT
CCTTTTATGGCGAGGCGGCGGCGGCGGCGGCCCTATAAAAAGCGAAGCGCGCGGCGGGCGG
GAGTCGCTGCGTTGCCTTCGCCCCGTGCCCCGCTCCGCGCCGCCTCGCGCCGCCCGCCCCG
GCTCTGACTGACCGCGTTACTCCCACAGGTGAGCGGGCGGGACGGCCCTTCTCCTCCGGGC
TGTAATTAGCGCTTGGTTTAATGACGGCTCGTTTCTTTTCTGTGGCTGCGTGAAAGCCTTA
AAGGGCTCCGGGAGGGCCCTTTGTGCGGGGGGGAGCGGCTCGGGGGGTGCGTGCGTGTGTG
TGTGCGTGGGGAGCGCCGCGTGCGGCCCGCGCTGCCCGGCGGCTGTGAGCGCTGCGGGCGC
GGCGCGGGGCTTTGTGCGCTCCGCGTGTGCGCGAGGGGAGCGCGGCCGGGGGCGGTGCCCC
GCGGTGCGGGGGGGCTGCGAGGGGAACAAAGGCTGCGTGCGGGGTGTGTGCGTGGGGGGGT
GAGCAGGGGGTGTGGGCGCGGCGGTCGGGCTGTAACCCCCCCCTGCACCCCCCTCCCCGAG
TTGCTGAGCACGGCCCGGCTTCGGGTGCGGGGCTCCGTGCGGGGCGTGGCGCGGGGCTCGC
CGTGCCGGGCGGGGGGTGGCGGCAGGTGGGGGTGCCGGGCGGGGCGGGGCCGCCTCGGGCC
GGGGAGGGCTCGGGGGAGGGGCGCGGCGGCCCCGGAGCGCCGGCGGCTGTCGAGGCGCGGC
GAGCCGCAGCCATTGCCTTTTATGGTAATCGTGCGAGAGGGCGCAGGGACTTCCTTTGTCC
CAAATCTGGCGGAGCCGAAATCTGGGAGGCGCCGCCGCACCCCCTCTAGCGGGCGCGGGCG
AAGCGGTGCGGCGCCGGCAGGAAGGAAATGGGCGGGGAGGGCCTTCGTGCGTCGCCGCGCC
GCCGTCCCCTTCTCCATCTCCAGCCTCGGGGCTGCCGCAGGGGGACGGCTGCCTTCGGGGG
GGACGGGGCAGGGCGGGGTTCGGCTTCTGGCGTGTGACCGGCGGCTCTAGAGCCTCTGCTA
ACCATGTTCATGCCTTCTTCTTTTTCCTACAGCTCCTGGGCAACGTGCTGGTTGTTGTGCT
GTCTCATCATTTTGGCAAAGAATTCTGCAGTCGACGAATTCAGCGCTCTCGAGACCGGTGC
CGCCATGGGA  
gga tcc ATG gaa agc tct gcc aag atg gag agc ggc ggc gcc ggc 
cag cag ccc cag ccg cag ccc cag cag ccc ttc ctg ccg ccc gca 
gcc tgt ttc ttt gcc acg gcc gca gcc gcg gcg gcc gca gcc gcc 
gca gcg gca gcg cag agc gcg cag cag cag cag cag cag cag cag 
cag cag cag cag gcg ccg cag ctg aga ccg gcg gcc gac ggc cag 
ccc tca ggg ggc ggt cac aag tca gcg ccc aag caa gtc aag cga 
cag cgc tcg tct tcg ccc gaa ctg atg cgc tgc aaa cgc cgg ctc 
aac ttc agc ggc ttt ggc tac agc ctg ccg cag cag cag ccg gcc 
gcc gtg gcg cgc cgc aac gag cgc gag cgc aac cgc gtc aag ttg 
gtc aac ctg ggc ttt gcc acc ctt cgg gag cac gtc ccc aac ggc 
gcg gcc aac aag aag atg agt aag gtg gag aca ctg cgc tcg gcg 
gtc gag tac atc cgc gcg ctg cag cag ctg ctg gac gag cat gac 
gcg gtg agc gcc gcc ttc cag gca ggc gtc ctg tcg ccc acc atc 
tcc ccc aac tac tcc aac gac ttg aac tcc atg gcc ggc tcg ccg 
gtc tca tcc tac tcg tcg gac gag ggc tct tac gac ccg ctc agc 
ccc gag gag cag gag ctt ctc gac ttc acc aac tgg ttc gga tcc 
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CAGTGTACTAATTATGCTCTCTTGAAATTGGCTGGAGATGTTGAGAGCAACCCAGGTCCC 
aga tct ATG tcg cgc tcc ttc tat gtc gac tcg ctc atc atc aag 
gac acc tca cgg cct gcg ccc tcg ctg cct gaa ccg cac ccc ggg 
ccg gat ttc ttc atc ccg ctt ggc atg ccg ccc cca ttg gtg atg 
tcc gtg tcc ggc ccc ggc tgc ccg tcc cgc aag agc ggc gcg ttc 
tgc gtg tgc cct ctc tgc gtc act tcg cac ctg cac tcc tct cgg 
ggg tct gtg ggc gcc ggc agc ggg ggc gca ggg gcc ggg gtt acc 
ggg gcc gga ggc agt ggg gtg gca ggg gcc gca ggg gca ctg cct 
ctg ctt aag agc cag ttc tct tcg gct cct ggg gac gcg cag ttt 
tgc ccg cgg gtg aac cat gcg cat cat cac cac cac ccg ccg cag 
cac cac cat cac cat cat cag ccc cag cag cct ggc tcg gcc gcg 
gcg gcg gca gca gca gca gcg gcg gcg gcg gcc gcg gcg gcc ttg 
ggg cac ccg cag cac cac gca cct gtc tgc acc gcc acc acc tac 
aac gtg gcg gac ccg cgg aga ttc cac tgc ctc acc atg gga ggc 
tct gac gcc agc cag gta ccc aat ggc aag agg atg agg acg gcg 
ttc act agc acg caa ctc ctg gag ctg gag aga gaa ttc tct tcc 
aac atg tac ctg tct cga ctc cgg agg att gaa atc gcc act tac 
ctg aac ctg tcg gag aag cag gtg aaa atc tgg ttt cag aac cgc 
cga gtg aag cac aag aag gag ggg aag ggc acg cag agg aac agt 
cac gcg ggc tgc aag tgc gtc ggg agc cag gtg cac tac gcg cgc 
tcc gag gat gag gac tcc ctg tcg ccg gcc tca gcc aac gat gac 
aag gag att tcc ccc tta aga tct 
GAGGGCAGAGGAAGTCTTCTAACATGCGGTGACGTGGAGGAGAATCCCGGCCCTTCTAGAG
CCACGAAGCAAGCAGGAGATGTTGAAGAAAACCCCGGTCCT  
gct agc atg act gga gtc ttt gac agt cta gtg gct gat atg cac tcg acc cag 
atc gcc gcc tcc agc acg tac cac cag cac cag cag ccc ccg agc ggc ggc ggc 
gcc ggc ccg ggt ggc aac agc agc agc agc agc agc ctc cac aag ccc cag gag 
tcg ccc acc ctt ccg gtg tcc acc gcc acc gac agc agc tac tac acc aac cag 
cag cac ccg gcg ggc ggc ggc ggc ggc ggg ggc tcg ccc tac gcg cac atg ggt 
tcc tac cag tac caa gcc agc ggc ctc aac aac gtc cct tac tcc gcc aag agc 
agc tat gac ctg ggc tac acc gcc gcc tac acc tcc tac gct ccc tat gga acc 
agt tcg tcc cca gcc aac aac gag cct gag aag gag gac ctt gag cct gaa att 
cgg ata gtg aac ggg aag cca aag aaa gtc cgg aaa ccc cgc acc atc tac tcc 
agt ttc cag ctg gcg gct ctt cag cgg cgt ttc caa aag act caa tac ttg gcc 
ttg ccg gag cga gcc gag ctg gcg gcc tct ctg ggc ctc acc cag act cag gtc 
aaa atc tgg ttc cag aac cgc cgg tcc aag ttc aag aag atg tgg aaa agt ggt 
gag atc ccc tcg gag cag cac cct ggg gcc agc gct tct cca cct tgt gct tcg 
ccg cca gtc tca gcg ccg gcc tcc tgg gac ttt ggt gtg ccg cag cgg atg gcg 
ggc ggc ggt ggt ccg ggc agt ggc ggc agc ggc gcc ggc agc tcg ggc tcc agc 
ccg agc agc gcg gcc tcg gct ttt ctg ggc aac tac ccc tgg tac cac cag acc 
tcg gga tcc gcc tca cac ctg cag gcc acg gcg ccg ctg ctg cac ccc act cag 
acc ccg cag ccg cat cac cac cac cac cat cac ggc ggc ggg ggc gcc ccg gtg 
agc gcg ggg acg att ttc gct agc 
TAAGTCGACGGTACCGCGGGCCCGGGATCCGCCCCTCTCCCTCCCCCCCCCCTAACGTTACTGGCCGAAGCCG
CTTGGAATAAGGCCGGTGTGCGTTTGTCTATATGTTATTTTCCACCATATTGCCGTCTTTTGGCAATGTGAGG
GCCCGGAAACCTGGCCCTGTCTTCTTGACGAGCATTCCTAGGGGTCTTTCCCCTCTCGCCAAAGGAATGCAAG
GTCTGTTGAATGTCGTGAAGGAAGCAGTTCCTCTGGAAGCTTCTTGAAGACAAACAACGTCTGTAGCGACCCT
TTGCAGGCAGCGGAACCCCCCACCTGGCGACAGGTGCCTCTGCGGCCAAAAGCCACGTGTATAAGATACACCT
GCAAAGGCGGCACAACCCCAGTGCCACGTTGTGAGTTGGATAGTTGTGGAAAGAGTCAAATGGCTCTCCTCAA
GCGTATTCAACAAGGGGCTGAAGGATGCCCAGAAGGTACCCCATTGTATGGGATCTGATCTGGGGCCTCGGTG
CACATGCTTTACATGTGTTTAGTCGAGGTTAAAAAAACGTCTAGGCCCCCCGAACCACGGGGACGTGGTTTTC
CTTTGAAAAACACGATGATAATATGGCCACAACCATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTG
CCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATG
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CCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGT
GACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAG
TCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCG
CCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGG
CAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAG
AACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACC
AGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCACCCAGTCCGCCCT
GAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTC
GGCATGGACGAGCTGTACAAGTAAAGCGGCCGCGACTCTAGATCATAATCAGCCATACCACATTTGTAGAGGT
TTTACTTGCTTTAAAAAACCTCCCACACCTCCCCCTGAACCTGAAACATAAAATGAATGCAATTGTTGTTGTT
AACTTGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCATCACAAATTTCACAAATAAAGCATTTT
TTTCACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAATGTATCTTAAGGCGTAAATTGTAAGCGTTAATA
TTTTGTTAAAATTCGCGTTAAATTTTTGTTAAATCAGCTCATTTTTTAACCAATAGGCCGAAATCGGCAAAAT
CCCTTATAAATCAAAAGAATAGACCGAGATAGGGTTGAGTGTTGTTCCAGTTTGGAACAAGAGTCCACTATTA
AAGAACGTGGACTCCAACGTCAAAGGGCGAAAAACCGTCTATCAGGGCGATGGCCCACTACGTGAACCATCAC
CCTAATCAAGTTTTTTGGGGTCGAGGTGCCGTAAAGCACTAAATCGGAACCCTAAAGGGAGCCCCCGATTTAG
AGCTTGACGGGGAAAGCCGGCGAACGTGGCGAGAAAGGAAGGGAAGAAAGCGAAAGGAGCGGGCGCTAGGGCG
CTGGCAAGTGTAGCGGTCACGCTGCGCGTAACCACCACACCCGCCGCGCTTAATGCGCCGCTACAGGGCGCGT
CAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTA
TCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTCCTGAGGCGGAAAGA
ACCAGCTGTGGAATGTGTGTCAGTTAGGGTGTGGAAAGTCCCCAGGCTCCCCAGCAGGCAGAAGTATGCAAAG
CATGCATCTCAATTAGTCAGCAACCAGGTGTGGAAAGTCCCCAGGCTCCCCAGCAGGCAGAAGTATGCAAAGC
ATGCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCTAACTCCGCCCATCCCGCCCCTAACTCCGCCCAGTT
CCGCCCATTCTCCGCCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGCCTCTGA
GCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAGATCGATCAAGAGACAGGATG
AGGATCGTTTCGCATGATTGAACAAGATGGATTGCACGCAGGTTCTCCGGCCGCTTGGGTGGAGAGGCTATTC
GGCTATGACTGGGCACAACAGACAATCGGCTGCTCTGATGCCGCCGTGTTCCGGCTGTCAGCGCAGGGGCGCC
CGGTTCTTTTTGTCAAGACCGACCTGTCCGGTGCCCTGAATGAACTGCAAGACGAGGCAGCGCGGCTATCGTG
GCTGGCCACGACGGGCGTTCCTTGCGCAGCTGTGCTCGACGTTGTCACTGAAGCGGGAAGGGACTGGCTGCTA
TTGGGCGAAGTGCCGGGGCAGGATCTCCTGTCATCTCACCTTGCTCCTGCCGAGAAAGTATCCATCATGGCTG
ATGCAATGCGGCGGCTGCATACGCTTGATCCGGCTACCTGCCCATTCGACCACCAAGCGAAACATCGCATCGA
GCGAGCACGTACTCGGATGGAAGCCGGTCTTGTCGATCAGGATGATCTGGACGAAGAGCATCAGGGGCTCGCG
CCAGCCGAACTGTTCGCCAGGCTCAAGGCGAGCATGCCCGACGGCGAGGATCTCGTCGTGACCCATGGCGATG
CCTGCTTGCCGAATATCATGGTGGAAAATGGCCGCTTTTCTGGATTCATCGACTGTGGCCGGCTGGGTGTGGC
GGACCGCTATCAGGACATAGCGTTGGCTACCCGTGATATTGCTGAAGAGCTTGGCGGCGAATGGGCTGACCGC
TTCCTCGTGCTTTACGGTATCGCCGCTCCCGATTCGCAGCGCATCGCCTTCTATCGCCTTCTTGACGAGTTCT
TCTGAGCGGGACTCTGGGGTTCGAAATGACCGACCAAGCGACGCCCAACCTGCCATCACGAGATTTCGATTCC
ACCGCCGCCTTCTATGAAAGGTTGGGCTTCGGAATCGTTTTCCGGGACGCCGGCTGGATGATCCTCCAGCGCG
GGGATCTCATGCTGGAGTTCTTCGCCCACCCTAGGGGGAGGCTAACTGAAACACGGAAGGAGACAATACCGGA
AGGAACCCGCGCTATGACGGCAATAAAAAGACAGAATAAAACGCACGGTGTTGGGTCGTTTGTTCATAAACGC
GGGGTTCGGTCCCAGGGCTGGCACTCTGTCGATACCCCACCGAGACCCCATTGGGGCCAATACGCCCGCGTTT
CTTCCTTTTCCCCACCCCACCCCCCAAGTTCGGGTGAAGGCCCAGGGCTCGCAGCCAACGTCGGGGCGGCAGG
CCCTGCCATAGCCTCAGGTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTTAATTTAAAAGGATC
TAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAG
ACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAA
AAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACTGGC
TTCAGCAGAGCGCAGATACCAAATACTGTCCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTG
TAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCT
TACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACA
CAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGC
TTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCT
TCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTG
TGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTT
GCTGGCCTTTTGCTCACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACCGCCATGCA
T 
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5.1 Negative and background control for immunocytochemistry 
A) Negative control: 
 
 
 
Β-TUBULIN III DAPI 
DAPI 
DAPI 
DARPP-32 
CTIP2 Nuclear Staining 
hESCs (H9): 
GFP MASH1 DAPI 
DLX2 DAPI 
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B) Background control (secondary antibodies only): 
 
 
 
FOXG1 DAPI 
hESC derived nrNPCs at PdD10: 
GSX2 DAPI 
Primary cells: MIidbrain 
DAPI Anti-mouse 594  Anti-rabbit 488 
Anti-rabbit 594  Anti-rat 350 Nuclear Staining  
